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Abstract 
Despite the considerable progress in cancer research which has been translated into 
better cancer care and decreased overall mortality rates in the last decade for  
numerous cancers, colorectal carcinoma (CRC) and leukaemia remain still one of the 
commonest malignancies worldwide. The compounds with improved anti-cancer 
activity that circumvent limitations of conventional chemotherapeutic agents are 
urgently searched. Artesunate (ART) and dihydroartemisinin (DHA) are the most 
active compounds of all semisynthetic derivatives of artemisinin (a natural extract of 
the Chinase plant, Artemisia annua L.) that have been proven to exert potent       
anti-cancer activity in vitro, in vivo and under human clinical trials.  
ART and DHA contain a labile ring system, an endoperoxide bridge, which reductive 
cleavage by iron is a necessary prerequisite in their cytotoxicity. With ample evidence 
showing that the cytotoxicity of ART and DHA against cancer cells is linked with 
targeting a number of cellular proteins promoting tumorigenesis, the aim of this study 
was to provide additional molecular basis of ART and DHA activities in CRC          
HT-29-AK and leukaemia HL-60 cells in vitro.  
Since the interior of most solid tumours are hypoxic (~1% O2), which has implications 
for cancer metastasis and resistance to anti-cancer agents clinically, the anti-cancer 
effects of ART and DHA were performed under laboratory standard normoxic 
condition (20% O2) and low oxygen tension (1% O2), which mimics the tumour 
microenvironment. With reported ability of aspirin (acetylsalicylic acid; ASA) to 
enhance the cytotoxicity of other anti-cancer agents, we postulated that ASA would 
equally enhance the cytotoxic effects of ART and DHA. The mechanistic basis of this 
interaction was evaluated in cultured HT-29-AK and HL-60 cells in normoxia       
(20% O2) and hypoxia (1% O2).  
This study shows that ART and DHA treatment of HT-29-AK and HL-60 cells in 
normoxia effectively inhibited the growth of both cell lines and this inhibition was 
affected by oxygen availability. Upon combination, ART and DHA with ASA could 
reverse decreased susceptibility of HT-29-AK cells under hypoxic conditions to ART 
and DHA alone.  
In conclusion, these data illustrate the importance of modeling the tumour 
microenvironment when developing novel therapeutic drug applications. We also 
show that ART and DHA co-treated with ASA might be effective combination regimen 
to enhance efficacy of chemotherapy in cancer cells. Given the broad spectrum of 
mediators involved in ART and DHA anti-cancer effects (alone and in combination 
with ASA), further studies are required to validate our observations and translate 
them into significance for cancer therapy.  
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1.1. Artemisinin and its derivatives 
The genus Artemisia L., (Asteraceae) compromises about 180 species of herbs, 
including some important medical plants, such as Artemisia annua L. being native to 
East and Southeastern Europe, the Caucasus, and Western and Middle Asia (GRIN 
Taxonomy Databases, 2015). Artemisinin (qinghaosu, sweet wormwood or armoise 
annuelle), is a pharmaco-dynamically active 15-carbon sesquiterpene trioxane        
6-lactone endoperoxide isolated in 1971 from the Chinese herb  Artemisia annua L. 
(Efferth et al. 2004; Krungkrai et al. 2010; Sertel et al. 2010). Though it has been 
used for over 2000 years particularly in China as a folk remedy against fever and 
haemorrhoids, it is mostly readily known as a treatment against the malaria parasite 
(Meshnick et al. 1996; Laman et al. 2014).  
To overcome the solubility limitations of artemisinin (in water and oil), limited routes 
of administration (oral and rectal), its poor bioavailability (30% rectal relative to oral) 
and a short elimination half-life in vivo (~2.59+/-0.55h) having all impact on 
decreased effectiveness as an anti-malarial, semi-synthetic derivatives of artemisinin 
were developed (Duc et al. 1994; de Vries and Dien 1996; Ashton et al. 1998). A 
more water-soluble active metabolite of artemisinin, dihydroartemisinin                    
(β-dihydroartemisinin, artenimol, DHA) is the chemical intermediate in production of 
water-soluble artesunate (ART) (de Vries and Dien 1996). Other semi-synthetic 
artemisinin derivatives include artemether and arteether (artemotil), which are both 
fat-soluble and around twice as active as artemisinin (de Vries and Dien 1996). 
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Today, artemisinin-compounds are not used in monotherapy against malaria as it is 
associated with comparatively high recrudescence rates of infections after 5-day 
treatments of ~10% (de Vries and Dien 1996). In fact, with the World Health 
Organization (WHO) policy guidelines artemisinin and its derivatives should be only 
used in combination with other not failing anti-malarial compounds in a malaria 
treatment regimen, artemisinin-based combination therapy (ACT) (Cui and Su 2009). 
ACT with conventional anti-malarial agents, such as amodiaquine, mefloquine, 
piperaquine, lumefantrine are at present widely used drugs to treat severe and 
multidrug-resistant strains of Plasmodium falciparum (P. falciparum) clinically 
because of their lack of severe side effects and rapid parasite clearance within 
approximately 48h (de Vries and Dien 1996; Tran et al. 2004; Nosten and White 
2007). However, parasite resistance to ACT has emerged recently in seven 
provinces along Thai-Cambodia border (Southeast Asia) (Noedl et al. 2010; Satimai 
et al. 2012; Ashley et al. 2014). The threat of malaria resistance to ACT globally 
prompts an urgent need to design and develop novel treatments regimens that will 
overcome the increasing burden caused by P. falciparum. 
1.2. The mechanism of action of artemisinin and its derivatives against malaria 
parasites 
The active moiety of artemisinin and its derivatives is the endoperoxide in a labile 
1,2,4-trioxane heterocyclic ring system (Meshick et al. 1996; Kaiser et al. 2007; 
Antoine et al. 2014). In Plasmodium parasite, artemisinin and its derivatives          
(for simplification hereafter the 1,2,4-trioxanes) are bio-activated by high 
intraparasetic-haem-iron content leading to cleavage of the endoperoxide bridge   
(C-O-O-C) in the two seqentional steps: activation followed by alkylation, resulting in 
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the formation of toxic molecules which kill parasite (Meshick et al. 1996; O’Neill et al. 
2010; Antoine et al. 2014; Gopalakrishnan and Kumar 2015). 
1.2.1. Activation of endoperoxide bridge 
In the activation step, the 1,2,4-trioxane bond requires reductive cleavage by haem-
derived iron (Fe) through two mechanisms including reductive scission and open 
peroxide model, resulting in formation of carbon centred free radicals (CCR) and/or 
reactive oxygen species (ROS)  (Efferth et al. 2004; Mercer et al. 2007; Cui and Su 
2009; O'Neill et al. 2010; Antoine et al. 2014; Gopalakrishnan and Kumar 2015).       
In the reductive scission model, Drew et al. (2007), Cui and Su (2009),  and O'Neill   
et al. (2010) propose that formation of a bond between low-valent transition irons 
(ferrous haem or non-haem, exogenous Fe2+) and either oxygen-(O)1 or O2 within 
peroxide skeleton of 1,2,4-trioxanes results in its reductive scission and the 
formation of an unstable O-centred radical. The un-symmetrical structure of the 
peroxide group triggers further rapid intra-molecular re-arrangements to produce    
O-centred radical and the formation of more stable primary or secondary C-centred 
radicals (Cui and Su 2009; O'Neill et al. 2010). In alternative open peroxide model, 
the peroxide bond cleavage involves protonation or complexation with ferrous Fe2+ 
(Cui and Su 2009; O'Neill et al. 2010). In the Fenton reaction, created 
hydroperoxides (H2O2) during cleavage of the 1,2,4-trioxane bond are catalysed by 
Fe2+ to form ROS, such as hydroxyl radicals (•HO), peroxyl radicals and (protonated) 
superoxide anions within Plasmodium-infected erythrocytes (O'Neill et al. 2010; 
Antoine et al. 2014). 
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1.2.2. Alkylation of Plasmodium-specific proteins and lipids 
The haem(II)-iron mediated reductive decomposition of 1,2,4-trioxane results in the 
release of highly reactive alkylating CCR and ROS, which target pivotal Plasmodium-
specific macromolecules including proteins and lipids, leading to DNA damage and 
eradication of the parasite (Cui and Su 2009; Krungkrai et al. 2010;O'Neill et al. 
2010; Gopalakrishnan and Kumar 2015). Iron-activated 1,2,4-trioxanes may target 
membrane containing organelles, such as the mitochondria, endoplastic reticulum, 
nuclear envelope and the food vacuole membranes (Cui and Su 2009). Other 
primary targets of 1,2,4-trioxanes in Plasmodium include haem alkylation, inhibition 
of endocytosis, inhibition of inosine monophosphate dehydrogenase and succinic 
acid dehydrogenase resulting in loss of mitochondrial potential, inhibition of 
cytochrome oxidase activity and inhibiting alkylation of membrane associated 
Plasmodium-specific proteins (Krungkrai et al. 2010; Antoine et al. 2014). These 
include translationally controlled tumour protein (TCTP; 25kDa), histidine-rich protein 
(42 kDa), and pfATP6, the sarco/endoplasmatic reticulum Ca2+ ATPase (SERCA) 
(Eckstein-Ludwig et al. 2003; Kaiser et al. 2007; Nagamune et al. 2007; Cui and Su 
2009; Krungkrai et al. 2010; O'Neill et al. 2010).  
1.3. Pharmacological activity of 1,2,4-trioxanes against malaria parasites in 
vitro  
1,2,4-trioxanes-family of anti-malarial agents are active against sensitive and 
multidrug resistant isolates of Plasmodium species at low (nM) concentrations in 
vitro (Krishna et al. 2004; Jones et al. 2009; Nsobya et al. 2010). In a chloroquine 
sensitive 3D7 strain of P. falciparum, DHA and artemether treatment for 24h 
displayed high activity, resulting in IC50 values (the 50% growth-inhibition 
concentrations) of 2.30 ± 1.50nM and 3.53 ± 1.91nM, respectively (Jones et al. 
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2009). After 72h incubation, in P. falciparum strains resistant to chloroquine         
(IC50 value of 101.1nM) and monodesethylamodiaquine (IC50 value of 66.4nM) being 
above standard cutoffs for resistance for both compounds (100nM and 60nM, 
respectively), DHA was shown to effectively kill parasites with mean IC50 value at 
subnanomolar concentration (0.55nM) with narrow concentration range across all 
212 samples of IC50 values <5nM (Nsobya et al. 2010). More recently, P.falciparum 
(3D7 strain) parasites treated in vitro with a panel of 1,2,4-trioxanes showed growth 
inhibition IC50 values of 7.50 ± 0.2nM, 3.48 ± 0.60nM, 1.60 ± 0.40nM and               
4.46 ± 0.75nM for artemisinin, DHA, ART and artemether, respectively (Antoine et al. 
2014). The growth of parasites was not inhibited (IC50 value of >10 000nM) when 
using deooxyartemisinin, a compound without endoperoxide bridge (Antoine et al. 
2014). Additionally, deooxyartemisinin showed no effect on parasite membrane 
potential, thus confirming the importance of the endoperoxide bond in the activation 
of 1,2,4-trioxanes (Antoine et al. 2014). During the single-cell assays (<6mins), 
depolarisation of the parasite membrane potential was abolished when artemisinin 
(100nM) was co-treated with iron chelators, desferrioxamide (100µM) and 
deferiprone (DFO, 100µM), which are selective for non-haem Fe3+ (Antoine et al. 
2014). Because artemisinin alone has been reported previously to induce membrane 
depolarisation of the malaria parasite, the findings of Antoine et al. (2014) indicate 
the role of Fe3+ in the cleavage of 1,2,4-trioxanes’ endoperoxide bond. 
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1.4. Anti-cancer effects of 1,2,4-trioxanes are linked with anti-malarial 
mechanisms 
1.4.1. Regulatory mechanisms of iron homeostasis in cells 
Interestingly, the same way that iron plays a central role in the mechanisms of action 
of 1,2,4-trioxanes against malaria parasites, the mode of action of these agents 
against cancer cells has been reported to be iron-dependent (Efferth 2005;       
O’Neill et al. 2010). Malignant cells are characterised by rapid proliferation where 
high intracellular iron content is needed as a cofactor of haem synthesis and DNA 
metabolism to help promote continued cell proliferation (O'Donnell et al. 2006; 
Mercer et al. 2007; Oh et al. 2009; O’Neill et al. 2010). Synthesized in hepatocytes, 
human serum transferrin (an 80kDa bilobal glycoprotein) is secreted into the 
bloodstream where is responsible for binding iron from diet (Eckenroth et al. 2011). 
Iron-loaded transferrin is subsequently internalised into cells through type II 
transmembrane proteins, transferrin receptors (TfR1, CD71), which are expressed 
on the cell surface (Dautry-Varsat et al. 1983; Eckenroth et al. 2011). The low pH 
(~5.6 or below) of the endocytic vesicle facilitates the release of iron within the cell 
from the transferrin-receptor complex (Dautry-Varsat et al. 1983; Eckenroth et al. 
2011). The apotransferrin (iron-free transferrin)-receptor complex is recycled to the 
cell surface and apotransferrin upon increased pH dissociates from the cell and is 
ready to bind iron again (Dautry-Varsat et al. 1983; Eckenroth et al. 2011). Iron 
homeostasis is tightly controlled by transferrin, TfRs and regulatory iron proteins, 
including hypoxia inducible factor (HIF)-1α (Lok and Ponka 1999; Takami and 
Sakaida 2011). Imbalanced iron homeostasis may contribute to excess reactive iron, 
which produces toxic free radicals causing cellular damage via Fenton reaction 
(Fe2+/hydrogen peroxide H2O2) or Haber-Weiss reaction, where a large amount of 
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highly reactive hydroxyl radicals (•OH) can be generated from an interaction 
between H2O2 and superoxide (O2•-) (Kehrer 2000; Takami and Sakaida 2011). 
1.4.2. Selective targeting of cancer cells by 1,2,4-trixanes  
The expression of TfR1 in cancer cells is higher compared to normal cells, which is 
required for increased iron up-take to maintain robust cell proliferation (O'Donnell et 
al. 2006). It has been reported that cancer cells may possess up to five times more 
TfR1 than normal cells, and its expression varies between different cell lines (Efferth 
2005; Cheung et al. 2010). For example, the expression of TfR1 at the plasma 
membrane in retinoblastoma cancer (RB) cells reached ~70% and it was more than 
2 times higher than in normal retina cells (Zhao et al. 2013). Therefore, the high 
requirement on iron by tumour cells makes them more susceptible to selective 
targeting by 1,2,4-trioxanes. It was confirmed by Zhao et al. 2013 where ART-
mediated toxic effects to cells (reffered as cytotoxicity) at 24h and 48h treatment was 
selective towards highly proliferating RB cells, whereas minimal cell death with the 
same ART concentrations (12.5-200µg/ml) was observed against normal retina cell 
lines. Similarly, a potent and selective cytotoxicity of DHA following 48h incubation 
was observed towards a panel of ovarian cancer cells with the highest inhibition 
observed against ovarian OVCA-439 cells (IC50 value of  3.83 ± 0.14µM; 14.33-
folds), as compared with normal HOSE642 ovarian epithelial cells (IC50 value of 54.9 
± 1.67µM) (Jiao et al. 2007). The use of compounds without the endoperoxide 
bridge, such as deoxy-10-(p-fluorophenoxy)DHA demonstrated low levels of 
cytotoxicity against human promyelogenous leukaemic HL-60 cells (50-fold less 
active) and human  T lymphocyte Jurkat cells (130-fold less active), as compared to 
its parent drug, DHA (Mercer et al. 2007). These observations further confirm the 
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importance of iron in the activation of 1,2,4-trioxanes’  endoperoxide bridge and their 
anti-cancer effects. 
1.4.3. TfR1s as an indicator of malignant phenotype 
The density of TfR1s was reported to be a useful prognostic marker and an indicator 
of malignant phenotype in several tumours, including pancreatic and colorectal 
cancers (Ryschich et al. 2004; Prutki et al. 2006). In contrast to normal pancreatic 
tissue, the immunohistochemical analysis of specimens derived from patients with 
primary pancreatic cancer showed a positive expression of TfR1 (more than 80% of 
cells stained) in 82 % of tumour cell samples, 11% of samples had heterogenous 
expression (25-80% of cells positively stained) and 7% of samples were negative 
(staining of <5% of cells) (Ryschich et al. 2004). In pancreatic specimens with distant 
metastasis, 75% of samples showed positive expression of TfR1, 8% of samples had 
heterogenous TfR1 expression, whereas negative staining was observed in 17% of 
analysed samples (Ryschich et al. 2004). Additionally, the flow cytometric analysis 
showed that the expression of TfR1 in highly proliferating pancreatic cell lines in vitro 
was very low, and was ranging from 2% in Capan1 to 19% in KCIMOH1 pancreatic 
cancer cells (Ryschich et al. 2004). The differences arising between the observations 
in vivo and in cultured pancreatic cancer cells could be linked with the tumour local 
microenvironment. A high-iron supply in vitro does not necessitate the up-regulation 
of TfR1 cell surface levels (Ryschich et al. 2004). However, samples derived from 
patients during surgery could be characterised by tumour heterogeneity (Ryschich et 
al. 2004; Fisher et al. 2013). The heterogeneity of a tumour mass refers to the 
existence of subpopulations of cells within a tumour characterised by the presence of 
distinct genotypes and phenotypes (Fisher et al. 2013). This results in adaptation of 
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different subpopulations of cells to a fluctuating tumour microenvironment and 
competing for iron under limited supply (Ryschich et al. 2004; Fisher et al. 2013). 
In the immunohistochemical analysis, the expression of TfR1 was positively 
correlated with the grandular formation (tumour grading) of colorectal carcinoma 
(CRC) samples derived from sixty-three patients (Prutki et al. 2006).                     
Well-differentiated CRC cells (>95% of the tumour is gland forming) and CRC 
samples of Duke A and B grade had significantly higher levels of TfR1 expression 
than those with poorly-differentiated characteristics (<50% gland formation) and 
samples of Dukes C and D grade (Prutki et al. 2006; Fleming et al. 2012).  In CRC 
patients with lymph node infiltration and distant metastasis, TfR1 staining was 
categorised as absent-weak (Prutki et al. 2006). A high expression of TfR1 on        
well-differentiated cells which were associated with decreased bowel penetration 
could be linked with adaptation to the local tumour microenvironment with limited 
supply of iron (Prutki et al. 2006). The presence of increased bowel well penetration, 
which is often characterised with higher number of blood vessels and distant 
metastasis in poorly-differentiated malignant samples, support the spread of cancer 
cells to a different microenvironment (Prutki et al. 2006). It is suggested by Prutki et 
al. (2006) that cancer cells within a new tumour microenvironment have increased 
supply of oxygen and are exposed to oxygen stress partly linked with an overload of 
reactive iron acting as a pro-oxidant, which result in decreased TfR1 levels on CRC 
samples. From the reports of Ryschich et al. (2004) and Prutki et al. (2006) it can be 
summarised that the density of TfR1s can be a useful prognostic marker and an 
indicator of malignant phenotype. The reports further provide evidence for targeting 
TfR1 in cancer therapy.  
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1.4.4. Anti-cancer effects of 1,2,4-trioxanes are associated with a decrease in TfR1 
levels 
There are increasing reports describing that the cytotoxicity of ART and DHA against 
cancer cells is mediated by inhibition of the normal function and expression of TfR1.  
DHA inhibited the growth of leukaemic HL-60 cells in a dose-dependent (0.25-
8µmol/l) and time-dependent (12-72h) manner, which was associated with 
decreasing TfR1 content on cell surface, reduced mRNA and protein expression of  
intracellular TfR1 (Zhou et al. 2008). In human hepatoma HepG2 cell line, DHA (5-
25µM) decreased cell-surface TfR1 levels in concentration and time-dependent 
manners with concomitant decreasing levels of internal plasma glycoprotein 
transferrin levels observed with DHA at 10 and 25µM after 24h incubation (Ba et al. 
2012). DHA (5-25µM) for 24h caused TfR1 internalisation in HepG2 cells with similar 
observations when cells were treated with DHA 25µM for different times, resulting in 
disruption of iron uptake and in a cell death due to overall inhibition of iron 
endocytosis needed by cancer cells to proliferate (Ba et al. 2012). The pretreatment 
of breast cancer MCF7 cells for 30mins with 20mM NAC, an antioxidant which was 
used to mimic the inhibition of DHA-mediated ROS production at 20µM after 24h 
incubation in the cells, showed that DHA disturbed intracellular iron homeostasis 
possibly through an alternative mechanism independent of oxidation damage (Ba et 
al. 2012). In similar investigations, Zhao et al. (2013) showed increased ART 
internalisation in RB cells upon treating the cells with increasing ART concentrations 
(15-40µg/ml) for 24h, which was partly linked with the decreased expression of the 
membrane TfR1. The findings indicate that ART is transported into the cell through 
an endocytic pathway together with its receptor CD71. The hypothesis arising from 
these reports could be that 1,2,4-trioxanes after activation by iron released from 
TfR1-transferrin complex within the cell inhibit recycling of apotransferrin-receptor 
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complex to the cell surface. Thus, only TfR1 which were not earlier activated by 
1,2,4-trioxanes facilitate agents transport onto cells, and these TfR1 once within the 
cells are not used again. The proposed effects of 1,2,4-trioxanes on TfR1-transferrin 
complex upon activation by iron is presented in figure 1. 




Figure 1: The proposed mechanism of the iron-mediated activation of ART and DHA within cancer cells. Iron loaded 
transferrin (holotransferrin) with 1,2,4-trioxanes (ART, DHA) binds cell surface TfR1. Holotransferrin-TfR1-drug complex is 
internalised into the cell through endocytosis. Within an endosome, a low 5.6pH facilitate the release of iron and drug from the 
complex. Iron catalyses the cleavage of 1,2,4-trioxanes’  endoperoxide bridge resulting in the generation of free radicals  which  
contribute to the inhibition of recycling of apotransferrin (iron-free transferrin)-receptor complex to the cell surface. 
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1.4.5. Enhanced delivery of 1,2,4-trioxanes into cancer cells through TfR1 
The iron-binding ability of TfR1 has been used to enhance the delivery of            
1,2,4-trioxanes into malignant cells since they require iron for their activation (figure 
1). Artemisinin covalently attached to iron-carrying transferrin was transported onto 
human leukaemia Molt-4 cancer cells through endocytosis where released iron from 
transferrin package activated artemisinin and resulted in a more potent and selective 
killing of cancer cells, as compared to artemisinin alone (Lai et al. 2005). The pre-
treatment of Molt-4 cells with 12µM holotransferrin (i.e., iron loaded transferrin) for 1h  
resulted in enhanced cytotoxicity of DHA (200µM) by ~10-fold, as compared to DHA 
alone after 8h incubation (Singh and Lai 2004). Enhanced killing of cancer cells was 
reported also with synthesized covalent conjugates of artemisinin and a transferrin-
receptor targeting peptide (Oh et al. 2009). Iron (II) glycine sulphate (Ferrosanol®, 
10µg/ml) increased the cytotoxicity of ART, artemisinin and ART-maltosyl-β-
cyclodextrin (a compound with the endoperoxide bridge) in the dose range 0.001 to 
30µg/ml against human CCRF-CEM leukaemia and human astrocytoma U373 cells 
following 7 days treatment (Efferth et al. 2004). Similar studies in a panel of 36  cell 
lines showed that Ferrosanol® (10µg/ml) increased the cytotoxicity of ART in most of 
cell lines, including colon HT-29 cells (23.91% enhancement; ART IC50 value of 
1.38µM vs. ART+Ferrosanol IC50 value of 1.06µM), whereas some cell lines, 
including breast cancer MCF7 cells showed decreased efficacy to ART when co-
treated with Ferrosanol® (10µg/ml) (17.66-fold inhibition; ART IC50 value of 1.68µM 
vs. ART+Ferrosanol  IC50 value of 29.67µM) (Kelter et al. 2007). The cytotoxicity of 
1,2,4-trioxanes have been shown to be further increased by the addition of free 
ferrous haeme (Fe2+ protoporphyrin-IX) (Efferth et al. 2004; Zhang and Gerhard 
2008; Zhang and Gerhard 2009). However, there are conflicting reports on the 
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activation of artemisinin by haemin (ferric haeme; Fe3+ protoporphyrin-IX) (Haynes 
and Vonwiller 1995; Zhang and Gerhard 2008; Zhang and Gerhard 2009). For 
example, Zhang and Gerhard (2008) using spectrophotometry to measure the 
absorption spectra have shown that haemin (20µM) has not enhanced the activity of 
artemisinin, whereas haeme (20µM) more effectively potentiated the inhibitory effect 
of artemisinin. In contrast, the concentration of haemin at 2µM which had no 
significant inhibitory effect on neurite outgrowth alone, has shown to enhance 
effectively the inhibition of neurite outgrowth in the neuroblastoma cell line NB2a 
when co-administrated with DHA and artemether, as compared to single drugs 
treatments (at 100, 200 and 300nM) (Smith et al. 1997). There was no effect on 
neurite outgrowth when haemin (2µM) was co-administrated with desoxyarteether (at 
100, 200 and 300nM), a compound without the endoperoxide bridge (Smith et al. 
1997). The observations of Smith et al. (1997) indicate that haemin is involved in 
1,2,4-trioxanes activation and their enhanced neurotoxicity. However, the differences 
arising between the effects of Ferrosanol® in combination with ART against various 
cancer cell lines and conflicting effects of haemin in drugs-mediated activity in 
different experimental settings show the need of  testing these mediators further in 
vitro and in vivo before use in clinical therapy. 
Further evidence that iron is central to the cytotoxicity of 1,2,4-trioxanes stemmed 
from the observation that chelation of cellular iron using deferoxamine (20µM and 
100µM) antagonised the cytotoxic activity of DHA (0.50µM and 0.80µM, respectively) 
in HL-60 cells after 24h incubation through inhibition of caspase-3 dependent 
apoptosis (Lu et al. 2008; Zhao et al. 2015). 
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1.5. Colorectal carcinoma and inflammation 
Drug regimens with mode of action targeting multiple aspects of cancer development 
are needed for CRC. This is important because despite of considerable decrease in 
overall mortality rates in the last decade due to improvements in CRC therapy 
regimens, CRC still remains the third commonest malignancy worldwide. It is 
responsible for 9.67% of all new cancer cases and caused 694 000 deaths in 2012, 
with nearly 317 525 new cases estimated to be diagnosed by 2020 (Ferlay et al. 
2016).  
The same as other cancers, CRC is a multistage genetic and epigenetic disease 
arising from a single replication-competent cell (stem cell or proliferative progenitor 
cell) (Greenhough et al. 2009). CRC is characterised by dysregulation of the normal 
mechanisms controlling cell survival, proliferation, migration, invasion and the cell-
cell interactions (Greenhough et al. 2009). These distinct characteristics developed 
by cancer cells have been linked to the inflammatory response, with the first 
inflammation-cancer connection reported in 1863 by German pathologist Rudolf 
Virchow and was observed as the presence of leukocytes within tumours (Heidland 
et al. 2006). The inflammatory response is sub-divived into acute inflammation that 
leads to therapeutic recovery or chronic  inflammation, which is a predisposing factor 
for the development of pro-cancerous dysplastic lesions and promoting cancer 
progression (Nesaretnam and Meganathan 2011; Cooks et al. 2013). The presence 
of inflammatory cells witin injured intenstinal cells initiate cancer development 
through promoting complex interactions between cytokines, chemokines, growth 
factors, reactive nitrogen intermediates (RNI) and ROS (Grivennikov et al. 2010; 
Qiao and Li 2014). RNI and ROS are capable of inducing oxidative stress, which 
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causes DNA mutations and genomic instability (Nishikawa et al. 2005; Grivennikov 
et al. 2010). 
In CRC mucosa samples derived from patients with ulcerative colitis (UC) there was 
a higher incidence of the mutation of mitochondrial DNA elicited by chronic 
inflammation and oxidative stress than that from control samples (Nishikawa et al. 
2005). The results indicate the strong relationship between chronic inflammation and 
precancerous status in UC patients (Nishikawa et al. 2005). In addition, as presented 
in table 1, chronic inflammation associated with infection is extensively reported as a 
predisposing factor to many cancers, including CRC in patients suffering 
inflammatory bowel diseases (IBDs), such as UC, Crohn’s disease and chronic 
subclinical bowel inflammation in obese people (Dambacher et al. 2007; John et al. 
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1.5.1. Molecular mechanisms governing the development of inflammation-associated 
CRC 
Chronic inflammation in the intestine can be promoted by intrinsic factors (host 
mutations), which include accumulation of mutations in specific genes, including 
tumour suppressor p53, Kirsten-ras (K-ras), adenomatous polyposis coli (APC) and 
NOD-like receptor protein Nlp3 (Xie and Itzkowitz 2007; Zaki et al. 2010; Cooks et al. 
2013). There are many environmental factors which promote chronic inflammation 
within the gut, such as viral or bacterial infections, obesity and dietary products 
(Gunter and Leitzmann 2006; Bonnett et al. 2013; Li. et al. 2015). The inflammatory 
process is driven by growth factors, cytokines and chemokines, which are secreted 
by immune cells recruited to the local microenvironment, or can be secreted by the 
tumour cells themselves (Grivennikov et al. 2010; Qiao and Li 2014). The 
proinflammatory cytokine IL-31, which is primary expressed in activated 
lymphocytes, increased the expression of cytokine IL-8 in CRC derived intestinal 
epithelial cell (IEC) lines (Dambacher et al. 2007). The IL-31 cytokine in IEC lines 
activated a network of signaling mediatos, including extracellular signal-regulated 
kinase (ERK)-1/2, serine-threonine protein kinase (Akt), the signal transducers and 
activators of transcription (STAT) 1/3), which resulted in enhanced migration of the 
cells (Dambacher et al. 2007). Later work by Cooks et al. (2013) showed that mutant 
p53 prolonged the activation of a key regulator of inflammation and a modulator of 
inflammation-associated cancer, nuclear factor (NF)-κβ which was induced by pro-
inflammatory cytokine tumour necrosis factor (TNF)-α in cultured cells and intestinal 
organoid cultures. A germline p53 mutation in mice was responsible for the 
development of severe chronic inflammation and persistent tissue damage (Cooks et 
al. 2013).  
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It is documented that augumented activation of NF-κβ, STAT-1/3 and mitogen-
activated protein kinase (MAPK) transcriptional modulators create a network 
interaction that enhance the synthesis and secretion of pro-inflammatory cytokines, 
which all together promote CRC through the growth of adenomatous polyps (non-
malignant disease) in sporadic carcinoma, or by dysplasia sequence in colitis and 
IBD (Dambacher et al. 2007; Xie and Itzkowitz 2007; Harpaz and Polydorides 2010; 
Zaki et al. 2010; Cooks et al. 2013; Rokavec et al. 2014). Cytokines, such as IL-6, IL-
8, IL-18, IL-31 and TNF-α have been extensively reported to increase ulceration, and 
hyperplasia in inflammed colon (Dambacher et al. 2007; Harpaz and Polydorides 
2010; Wang et al. 2013). Over-expressed cytokine levels are reported in CRC tissue 
samples and further contribute to cancer progression throuth a negative loop system 
enhancing and activating other factors (Dambacher et al. 2007; Szkaradkiewicz et al. 
2009; Harpaz and Polydorides 2010; Wang et al. 2013). These include up-regulation 
of pro-angiogenic vascular endothelial growth factor (VEGF) and pro-invasive and 
pro-matastatic matrix metalloproteinases (MMP), dysregulation of cell-cell adhesion 
molecules, including E-cadherin, activation of pro-survival PI3K/AKT 
(phosphoinosine 3-kinase/serine-threonine protein kinase) pathway, thus 
contributing to CRC tumour progression, invasion, angiogenesis and metastasis 
(Waldner et al. 2010; Zaki et al. 2010; Cooks et al. 2013; Wang et al. 2013; Rokavec 
et al. 2014). Mechanisms promoting carcinogenesis in CRC are reported to be 
complex with not completely defined first trigger leading to disease. Recent study of 
Li. et al. 2015 confirms complexity of CRC development by introducing Human 
Papillomavirus (HPV) as important high-risk infection in CRC patients (reported in 46 
out of 95 CRC patients; 48.4%). HPV infection in CRC tissues strongly correlated 
with poorer clinical stages (III and IV) of cancer and higher Stat3 activities (P<0.01) 
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and IL-17 levels (P<0.01), as compared to adjacent healthy tissues, which together 
may promote accumulation of other tumour-promoting downstream cytokines and 
activate other signaling mediators within gut microenvironment (Li et al. 2015).  
1.5.2. Importance of cytokine IL-6 in CRC 
Especially, a multifunctional pro-tumourigenic IL-6 cytokine is extensively reported to 
have a broad range of biological functions, including in CRC tumour cell proliferation, 
survival, invasiveness and metastasis of cancer through various mediators, such as 
the oncogenic STAT-3 transcription factor activation (Grivennkov et al. 2009; 
Nagasaki et al. 2014; Rokavec et al. 2014). In a study of Sasaki et al. (2012) of 118 
male individuals with colorectal adenoma, serum IL-6 concentrations in samples of 
venous blood were significantly (1.24 vs. 1.04 pg/mL, p=0.01) higher as compared to 
samples from 218 age-matched control patients. Uchiyama et al. (2012) documented 
higher levels of IL-6 in sporadic CRC patients and an increased expression of IL-6 in 
CRC tissues, as compared with the levels in a control group and in patients with 
adenoma. Uchiyama et al. (2012) suggest that IL-6 promotes JAK/STAT signaling 
through the phosphorylation of membrane-associated gp130 subunit in sporadic 
CRC, but not in adenoma or normal colorectal tissues. In addition, higher levels of 
IL-6 in patients might be mediated through increased expressions of chemokine 
CXCL7 and its receptor CXCR2 (Uchiyama et al. 2012). Lu et al. (2015) reported 
that elevated concentrations of IL-6 (p=0.002) and IL-8 (p=0.038) in CRC patients 
when compared to healthy volunteers correlated with a higher risk of recurrence. 
Gene expression of members of Toll-like receptors (TLRs) family including TLR-1, 
TLR2, TLR4 and TLR8 (mediators of innate and adaptive immune responses) were 
reported to induce the release of IL-6 and IL-8 mRNA levels and detection of these 
levels can be used as a marker in CRC (Lu et al. 2015). Groblewska et al. (2008) 
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reported a high-level of IL-6 serum concentrations in CRC patients, as compared to 
samples from adenoma and healthy patients, which contributed to suggestion of the 
usefulness of IL-6 in the diagnosis of CRC.  
1.5.3. Inflammation promotes carcinogenesis through high TfR1 in cells  
 The mucosal TfR1 expression was increased in samples from patients with IBD and 
in the colonic epithelium of rats induced with experimental colitis, as compared to 
normal colonic mucosa (Harel et al. 2011). The study of Harel et al. (2011) showed 
also that TfR1 expression in the normal colonic mucosa had basolateral localisation, 
wherase the samples derived from IBD patients had apical TfR1 expression. These 
observations indicate that chronic inflammation might not only increase the 
expression of TfR1 but also changes its localisation. The pretreatment of human 
colorectal Caco-2 cells with a pro-inflammatory cytokine TNF-α increased the iron 
uptake by the cells, suggesting the role of TNF-α in increasing the expression of 
TfR1 on cell surface (Harel et al. 2011). Similar observations were reported earlier by 
Han et al. (2010) where incubation of Caco-2 cells with a mixture of cytokines (TNF-
α, IL-1β and IL-6) increased transferrin-iron absorption by 70%. The observations 
indicate that pro-inflammatory cytokines are capable of modulating iron metabolism 
in gut epithelial cells and might contribute to CRC progression, through increasing 
iron up-take by cells and possibly increasing TfR1 expression. There are several 
reports describing that the cytotoxicity of ART and DHA against cancer cells is 
mediated by inhibition of the normal function and expression of TfR1 (Zhou et al. 
2008; Ba et al. 2012). Therefore, the involvement of TfR1 in the activity of ART and 
DHA is not limited only to drug transport. ART and DHA by selective decresing TfR1 
levels might inhibit the intiation and progression of CRC.  
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1.6. Leukaemia and inflammation 
Leukaemia, the most common white blood cell malignancy is the 11th leading cause 
of cancer-related deaths globally, accounting for 2.5% of all new cancer cases and 
265 461 deaths in 2012 (Ferlay et al. 2016). More commonly leukaemia is reported 
as secondary cancer after treatment for metastatic colorectal or breast cancer 
(Shapiro et al. 2007; Valentini et al. 2011). The highest proportion of adult leukaemia 
dignosed clinically constitute acute leukaemia, which is sub-classified into two main 
types: acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) 
(Meenaghan et al. 2012). Acute leukaemia is a clonal malignancy of haematopoietic 
stem cells maturation failure, leading to accumulation of immature cells in the bone 
marrow, referred as blasts, which prevent the normal production of healthy red cells, 
white cells and platelets (Meenaghan et al. 2012). Acute promyelocytic leukaemia 
(APL), constitutes around 10-15% of all AML and is characterised by the 
translocation between chromosomes 15 and 17 and promyelocytic leukaemia (PML)-
retinoic acid receptor (RAR)-α fusion transcript (de Botton et al. 2006; Mohamed et 
al. 2013). Other features include increase in abnormal promyelocytes, large blasts, 
pancytopenia and coagulopathy which can lead to serious bleeding manifestations, 
including fatal intracranial haemorrhage (Mohamed et al. 2013). At early APL 
diagnosis and treatment with standard regimen of all-trans retinoic acid (ATRA) 
combined with anthracycline or other chemotherapeutic agens, including idarubicin 
there is a high cure rate of ~90% (Tsimberidou et al. 2004; Mohamed et al. 2013). 
However, higher mortality is observed in refractory (chemo-resistant) and in relapsed 
APL patients who constitute up to ~23% of cases (de Botton et al. 2006; Gallagher et 
al. 2012; Zhu et al. 2014). High-relapse incidence of bone marrow (BM) and 
extramedullary disease involving the central nervous system, leukaemia cutis and 
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retinoic acid syndrome indicates of urgent need for more effective and safer 
chemotherapeutic agents for APL treatment, which provide improvements of long-
term outcomes (Chang et al. 1999; de Botton et al. 2006). 
1.6.1. Molecular mechanisms promoting the development of inflammation-associated 
leukaemia 
A functional link between inflammation and cancer development in solid tumours, 
especially CRC is broadly investigated and reported (Zaki et al. 2010; Cooks et al. 
2013; Rokavec et al. 2014). However, the role of different molecular pathways and 
mediators governing the development of leukaemia in relation with inflammation has 
scarcely been documented. In human chronic myelocytic leukaemia (CML) K562 
cells, the numbers of TfR1 increased when the cells were incubated with TNF-α for 
24h (Nezu et al. 1994). A high expression of TfR1 was concomitant with increased 
cell proliferation (higher G2/M phase ratio), thus suggesting a key role of 
inflammation in leukaemogenesis (Nezu et al. 1994). Once initiated, leukaemia 
progression implicates new factors, including the activation of NF-κβ, which is a 
critical survival factor of B-cell chronic lymphocytic leukaemia (B-CLL) cells 
(Ringshausen et al. 2004). Additional factors, such as the activation of MAPK p38, 
STAT-3/5 and ERK 1/2 pathways and their down-stream proteins, including high 
levels of angiogenic factors VEGF-α and MMP-9 (92-kDa gelatinase) have been 
reported to promote leukaemia progression (Kolonics et al. 2001; Ringshausen et al. 
2004; Ueda et al. 2005). Frequent methylation of SHP1, a negative regulator of 
Jak/STAT signaling pathway was also shown to be important in AML pathogenesis 
(Chim et al. 2004). In adult T-cell leukaemia, cytokine IL-21 activated 
phosphorylation of STAT -3 and -5, thus contributing to leukaemia progression 
(Ueda et al. 2005). Uncontrolled and rapid growth of leukaemia cells results in 
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hypoxic microenvironment within blast cells.  A key regulator of hypoxia, hypoxia 
inducible factor-(HIF)-α was shown to enhance aggressiveness of leukaemia by 
over-expressing TfR1 on cell surface through binding to iron-responsive elements in 
the 3’-untranslated region of TfR1 (Lok and Ponka 1999). Interestingly, investigations 
of Luger and colleagues in 1989 on cultured human peripheral blood mononuclear 
cells (PBMCs) showed for the first time potential positive role of IL-6 in destroying of 
malignant cells, through IL-6-mediated enhancement of the cytolytic activity of CD3-
natural killer (CD3-NK) cells via IL-2 production. Enhanced NK cell activity was 
further reported by Ress et al. (1990) in a patient during the course of 13-year 
disease-free survival after therapy for acute non-lymphoblastic leukaemia and with 
concurrent tuberculosis. Ress et al. (1990) suggested that chronic inflammation 
caused by tuberculosis may have augumented the cytotoxicity of NK cells, thus 
changed clinical and haematological course of malignancy and resulted in a 
prolonged survival. From combined results of Luger et al. (1989) and Ress et al. 
(1990) it can be hypothesized that IL-6 over-production triggered by stimuli, such as 
some chronic infections (e.g. tuberculosis) or acute inflammation from cytotoxic 
agents (e.g. anti-cancer drugs) may lead to spontaneous cytolytic activity of NK cells 
against tumour cells, resulting in a better therapeutic outcome. With conflicting 
differences in IL-6 functions observed in CRC and leukaemia, it is crucial to 
undertake subsequent research studies investigating the anti-cancer effects of 
cytotoxic agents, including 1,2,4-trioxanes on IL-6 expression and their possible 
implications for cancer treatment. 
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1.7. Inflammation as an anti-cancer therapeutic opportunity: use of NSAIDs 
With increasing evidence of inflammation being associated with carcinogenesis, the 
most known anti-inflammatory drugs, NSAIDs (non-steroidal anti-inflammatory 
drugs) are more commonly investigated for their anti-cancer effects.                      
The first suggestions that NSAIDs might have beneficial therapeutic implications in 
cancer were developed in the 1970s when Jaffe (1974) and Bennett et al. (1977) 
showed that human colon cancer cells in tissue culture had often more 
prostaglandins (PGs) E2 than in the surrounding non-tumourigenic mucosa. Recent 
studies have shown that an NSAID and a selective cyclooxygenase (COX)-2 
inhibitor, celecoxib (400mg twice daily for 7 days) in patients with hereditary colon 
cancer syndrome, familial adenomatous polyposis (FAP), effectively reduced tumour 
progression (Dovizio et al. 2012). The administration of celecoxib in FAP patients 
resulted in PGE2 suppression via COX-2 inhibition, thus further confirming 
inflammation-colon cancer association (Dovizio et al. 2012). One of the most used 
NSAIDs, aspirin (acetylsalicylic acid; ASA) being used traditionally as an analgesic, 
antipyretic and anti-inflammatory agent has been showed to significantly suppress 
CRC mucosal PGE2 at daily doses of 40.5, 81, 162, 324 or 648mg for 14 days 
(Ruffin et al. 1997). The measured lowest effective doses of ASA causing colorectal 
mucosal PGE2  suppression  were 81mg and 40.5mg, respectively and daily dose of 
81mg ASA was recommended to be used as a chemo-preventative (reducing the 
development of cancer) (Ruffin et al. 1997).  In clinical studies, long-term use of ASA 
and other NSAIDs showed that the reduced risk of tumour formation is not limited 
only to CRC (Martinez et al. 1995; Din et al. 2010). Similar chemo-preventative 
effects of ASA and other NSAIDs were observed in variety of other cancers including 
breast (Johnson et al. 2002), oesophageal (Farrow et al. 1998), lung (Moysich et al. 
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2002) and ovarian (Moysich et al. 2001). A population-based case-control study on 
the chemo-preventative effects of ASA indicated that doses as low as 75mg/day (>4 
tablets/week) effectively decreased the risk of CRC after only 1 year, and that these 
benefits increased with the duration of ASA use (Din et al. 2010). In addition, ASA 
(80mg/day and 30mg/day in 95% and 5% of patients, respectively) in initiated or 
continued use after colon cancer diagnosis in patients (chosen between 1998 and 
2007) was associated with decreased mortality (survival gain with adjusted rate ratio 
(RR) 0.65; P=0.001), but ASA regimen was not associated with increased survival in 
rectal patients (adjusted RR 1.10; P=0.6) (Bastiaannet et al. 2012). Encouragingly, a 
few studies indicate a chemo-preventative activity of ASA in haematologic cancer, an 
adult leukaemia. In epidemiological study of Kasum et al. (2003) in over 28,000 
postmenopausal woman (55-69 years of age) during the 8-year follow-up period, it 
was reported that multivariate-adjusted RR of leukaemia was decreased to 0.45 
(95% confidence interval; 0.27-0.75) for woman using ASA two or more times per 
week (doses not stated) when compared to nonusers. Similar inverse associations 
were observed for AML (RR of 0.30, 95% confidence interval = 0.11-0.84; P=0.02) 
and CLL (RR of 0.38, 95% confidence interval = 0.18-0.81; P=0.009) when sub-
categorised from main leukaemia (Kasum et al. 2003). In contrast, woman being 
reported to use non-aspirin NSAIDs (ibuprofen, naproxen, sulindac and piroxicam)  
for at least two times a week were 1.31 times (95% confidence interval: 0.77-2.22) 
as likely to develop leukaemia as those being non-users, but these differences were 
not significant (Kasum et al. 2003). These arising differences between ASA and 
other NSAIDs in their effectiveness in cancer prevention were reported further in 
other studies. Weiss et al. (2006) showed that ASA led to a modest decrease in adult 
acute leukaemia risk (adjusted odd ration 0.84; 95%CI, 0.59-1.21; 169 cases, 676 
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controls), whereas users of acetaminophen, also known as paracetamol were 1.53 
times (95%CI, 1.03-2.26) as likely to develop leukaemia as nonusers. 
Acetaminophen has an ability to decrease transiently DNA repair, and because 
lymphocytes may be more likely to undergo DNA damage, patients taking 
acetaminophen may have increased risk of acute leukaemia (Weiss et al. 2006). A 
population-base case-control study (420 AML, 186 CML and 701 controls aged 20-
79) performed by Ross et al. (2011) showed that ASA (325mg) was associated with 
a decreased risk of myeloid leukaemia in woman (odd ratio-(OR)=0.59, 95%=0.37-
0.93; 14% patients) but not man (OR=0.85, 95Cl=0.58-1.24; 21% patients). These 
differences were more prominent with increased ASA tablets per week (<7 for 
women OR=0.56, 95%=0.26-1.20; 4% patients, man OR=0.73, 95%=0.37-1.46; 4% 
patients; and ≥7 for women OR=0.60, 95%=0.35-1.02; 10% patients, man OR=0.89, 
95%=0.58-1.36; 16% patients) and duration of ASA use (<10 years and >10 years). 
Similarly to Weiss et al. 2006 results, Ross et al. (2011) demonstrated that 
acetaminophen was related with increased risk of myeloid leukaemia but this relation 
was observed only for women (OR=1.60, 95%=1.04-2.47; 23% patients) and was 
significantly higher with number of tablets (≥7 equal to OR=2.37, 95%=1.34-4.18; 
P=0.003 vs. <7 tablets/week). These studies show benefits of ASA chemo-
preventive therapy over other NSAIDs agents in CRC and leukaemia cancers. At the 
same time, however, the same studies show the importance to study further 
molecular mechanisms of NSAIDs actions due to extensive reports of severe 
adverse effects in patients undertaking ASA therapy. For example, low-dose 
prophylactic ASA regimens for cardiovascular disease of 75mg-300mg daily for at 
least a month were reported to be associated with a dose-dependent increased risk 
(compared with controls: 75mg with  OR: 2.3; 150mg, with OR; 3.2; and 300mg with 
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OR: 3.9) of severe side-effects, such as gastrointestinal bleeding from peptic ulcer 
(Weil et al. 1995). More currently, García Rodríguez et al. (2011) showed that ASA 
low-dose (75 to 325mg/day) in patients within 40 to 84 years of age resulted in an 
almost 2-fold increase in the risk of upper gastrointenstinal bleeding when compared 
with nonuse. This bleeding risk was observed to be similar across duration of time 
studied (>1year and for ≤1 year) and higher with concurrent use of clopidogrel and 
some other medications being known to increase gastrointestinal bleeding (García 
Rodríguez et al. 2011). Therefore, despite widely reported benefits of low-dose ASA 
use in cancer prevention, the toxicity observed within gastrointestinal tract limit ASA 
high-dose regimen for cancer treatment. These reports also provide a rationale to 
combine ASA with current chemo-therapeutic agents to improve their therapeutic 
effectiveness and decrease side effects for the treatment of human cancers.  
1.8. Molecular mechanisms of ASA anti-cancer effects  
1.8.1. COX-1 and COX-2 enzymes 
The mechanism of action responsible for the effects of ASA on cancer cells is 
associated with its ability to non-specifically suppress the COX enzymes (COX-1 and 
-2, known as prostaglandin endoperoxide synthase (Dovizio et al. 2012; Rahman et 
al. 2012). These COX enzymes are membrane-bound haemo- and glycol-proteins 
with a molecular weight of 72kDa which catalyze the conversion of arachidonic acid 
(a 20-carbon, 4-double bond fatty acid) to prostanoids (Vane and Botting 2003). 
COX-1 is expressed constitutively in many normal tissues and mediates the release 
of thromboxanes (TXs) and PGs, which are mainly involved in platelet aggregation 
(TXA2) (Patrono 2015), gastric cytoprotection (PGE2) (Takeuchi et al. 2001) and ASA 
induced gastrointestinal bleedings (TXA2) (Patrono 2015). Additionally, increasing 
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experimental studies indicate a key role of COX-1 in carcinogenesis (Rossiello et al. 
2007; Dovizio et al. 2012; Yang et al. 2014). In contrast, COX-2 is found in greatest 
amounts in the human kidney and spinal cord and induces the release of PGs (e.g. 
PGE2 and PGI2) and TXA2 involved in inflammatory, cell proliferation and 
angiogenesis processes correlated with the development of cancer (Pai et al. 2003; 
Holla et al. 2005; Holla et al. 2006; Kim et al. 2011; Dovizio et al. 2012; Yang et al. 
2014). COX-2-dependent inhibition of its primary metabolite, PGE2 has been 
reported to reduce tumour progression in patients with FAP and inhibit the 
invasiveness of colon cancer cells (Pai et al. 2003; Dovizio et al. 2012). COX-2 is 
over-expressed in various cancer cell lines, mainly CRC, breast, endometrial, 
ovarian, bladder, pancreatic and Kaposi’s sarcoma (Johnson et al. 2002; Din et al. 
2004; Banović et al. 2005; Rossiello et al. 2007; Dhawan et al. 2010; Rahman et al. 
2012). Most prominently, higher basal levels of COX-2 gene expression were 
observed in CRC, including cells being chemo-resistant to 5-fluorouracil (5-FU) and 
irinotecan, as compared with their respective sensitive cells, which clinically was 
linked with a 68% enhanced risk of mortality (Rahman et al. 2012; Roelofs et al. 
2014). The pre-treatment of sensitive and chemo-resistant MIP101 and RKO  
colorectal cell lines in vitro  with 1.8mM ASA or 30µM celecoxib (selective COX-2 
inhibitor) for 48h followed by addition of 5-FU (5 µM) for additional 24h resulted in 
greater inhibition of cell growth, as compared to 5-FU alone (Rahman et al. 2012). 
Those reports show that the more potent inhibitory effects of 5-FU when co-treated 
with ASA against cancer cells might indicate the possibility to use of ASA in cancer 
therapy in combination with other currently used chemo-therapeutic agents to 
enhance their anti-cancer effects. The observations can be further supported by the 
fact that the use of ASA (25mg/kg) in children suffering from autoimmune diseases 
30 | P a g e  
 
resulted in average serum concentrations of 5.2mM, ranging from 0.38 to 10.26mM 
ASA (Juárez Olguin et al. 2004). At this therapeutic dose, ASA reached safely 
systemic levels in patients with a concentration as high as 10.26mM (Juárez Olguin 
et al. 2004).  
1.8.2. Molecular targets of ASA in cancer cells  
Growing reports from in vitro and in vivo studies indicate that ASA mediated anti-
cancer effects are not limited only to COX-2 inhibition and involve other targets (see 
figure 2). ASA has been reported to inhibit cell growth and induce apoptosis in 
several cancer cell lines, namely CRC, leukaemic, prostate and oral squamous 
carcinoma cells (Bellosillo et al. 1998; Din et al. 2004; Yoo and Lee 2007; Iglesias-
Serret et al. 2010; Xiang et al. 2010; Park et al. 2010; Im and Jang 2012; Pathi et al. 
2012). ASA at different concentrations (2.5-10mM) inhibited the growth of four cell 
lines of CRC (SW480, RKO, HT-29 and HCT116 cell lines) over a period of 3 days 
with IC50 values ranging from 2.5 to 5mM, which are within the range of clinically safe 
ASA serum levels  (Juárez Olguin et al. 2004; Pathi et al. 2012). These inhibitory 
effects of ASA were accompanied by the inhibition of pro-survival survivin, anti-
apoptotic Bcl-2 and induction of pro-apoptotic Poly(ADP-ribose) polymerase (PARP) 
proteins cleavage in all four cell lines (Pathi et al. 2012). The authors further reported 
that following 48h incubation, ASA (0-10mM) induced the production of multiple 
caspases (-3.-7,-8, and -9) in colorectal RKO and SW480 cells (Pathi et al. 2012). 
Similarly, after 24h incubation with ASA (0-10mM), the IC50 values for a panel of 
human CRC cells (HRT-18, SW480, HT-29, DLD-1, LoVo and HCT116) were 
ranging from 1.48 to 3.12mM ASA (mean 2.38mM ASA) (Din et al. 2004). These 
inhibitory effects of ASA against a panel of CRC cell lines were accompanied by the 
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induction of apoptosis, which was dependent on IκBα degradation and NF-κB 
nuclear translocation (Din et al. 2004).  
In addition, the cytotoxic effects of ASA were reported to differ between CRC and 
other cancer types (breast, endometrial and ovarian) and were most likely to be 
linked with molecular mechanisms other than apoptosis dependent (Din et al. 2004). 
More recent study has shown that ASA (0.25-1mmol/L) following 48h incubation 
inhibited the growth of human ovarian cancer OVCAR-3 cells, which was COX-1-
dependent and correlated with blocking  Epidermal Growth Factor (EGF)-activated 
the phosphorylation levels of Akt and Erk (Cho et al. 2013). Other mechanisms 
contributing to ASA (0-10mM) cytotoxicty against colorectal cells were attributed to 
the inhibition of Sp transcriptional factors (Sp 1, Sp 3 and Sp 4) and their 
downstream molecules, including pro-angiogenic VEGF-α and its receptor, pro-
inflammatory NFκB-p50, NFκB-p65 and pro-invasive β-catenin, which is down-
stream product of Wnt (wingless-type MMTV integration site family) signaling 
pathway (Pathi et al. 2012). Such multifaceted activities of ASA towards cancer cells 
which are attributed to targeting many distinct molecular molecules, makes ASA an 
attractive therapeutic agent for numerous cancers, including CRC and leukaemia. 
These reports provide a rationale to combine ASA with current chemotherapeutic 
agents to improve their therapeutic effectiveness and decrease side effects.  
 
 




Figure 2: COX- dependent and independent mechanisms of action of ASA in cancer cells. ASA is able to induce caspase-
dependent tumour cell death (apoptosis) by inhibiting the expression of key transcription factors, including Sp transcription factor, 
Wnt pathway, EGF pathway and NFκB pathway and its main down-stream mediators such as Akt, Erk, VEGF-α, survivin and 
increasing Bcl2/Bax ration in a way dependent and independent of inhibition of COX enzymes. Caspases (-3, -7, -8, -9) induced 
apoptosis lead to inhibition of proliferation and growth of cancer cells, suppressed inflammation, invasion, angiogenesis and inhibit  
the spread to distinct organs by decreasing cell metastasis. Red arrows indicate inhibition while black induction. The suggested 
mechanism of survivin impact on the inhibition of apoptosis is marked with ‘?’ symbol. 
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1.8.3. ASA in combination with other therapeutic compounds shows increased 
activity against cancer cells 
Due to the anti-inflammatory properties of ASA and its ability to inhibit cancer cell 
growth and induce apoptosis, ASA has become an attractive agent to invastigate in 
combination with currently used chemo-therapeutic agents. ASA increased the 
cytotoxic effects of many anti-cancer agents, such as reversine, doxorubicin, 
cisplatin and valproic acid in several cancer cell lines, including gastric SGC7901 
cells, hepatoma (HepG2 and SMMC-7721) cells, cervical (HeLa, U14, Siha, Caski 
and C33A) cells and T cell lymphoma (Kumar and Singh 2012; Li et al. 2013, Qin et 
al. 2013; Dong et al. 2014). aYan and co-workers (2010) reported that ASA when co-
administered in combination with troglitazone (oral anti-type II diabetes drug with 
anti-cancer properties) resulted in a marked synergistic effect in growth inhibition and 
apoptosis (programmed cell death) induction of lung cancer CL1-0 and A549 cells. In 
human hepatoma HepG2 cells, ASA (5µmol/ml) when co-administrated with 
doxorubicin (0.25nmol/ml) for 48h significantly enhanced cell death (by 13%; 
P<0.05), as compared to doxorubicin alone (Hossain et al. 2012). This was 
concomitant with augumented release of pro-apoptotic caspases (-3,-8 and -9), 
increased Bax/Bcl-2 ratio and more prominent DNA damage (Hossain et al. 2012). 
After 72h incubation, combination of ASA (1mM), curcumin (10µM) and sulforaphane 
(5µM) showed a synergistic effect on the reduction of pancreatic Panc-1 cancer cells 
cell viability, which was associated with the activation of caspase-3-dependent 
apoptosis (Thakkar et al. 2013).  
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1.9. Anti-inflammatory effects of 1,2,4-trioxanes 
1.9.1. Activities of 1,2,4-trioxanes in non-cancerous models 
ART and DHA have demonstrated to display potent anti-inflammatory effects in 
many immune-related diseases, including human rheumatoid arthritis, bacterial 
sepsis, allergic asthma and cancer (Cheng et al. 2011; He et al. 2011; Jiang et al. 
2011; Zuo et al. 2014). For more detailed anti-inflammatory and immune-regulatory 
activities of 1,2,4-trioxanes refer to recent article reviews (Ho et al. 2014;               
Shi et al. 2015). Unlike ASA and other NSAIDs, treatment with 1,2,4-trioxanes 
against malaria, cancer and other diseases is associated with high efficacious and 
safety, and no serious adverse effects resulting in growing interest in 1,2,4-trioxanes 
as therapeutic regimen against diseases associated with chronic inflammation    
(Weil et al. 1995; Tran et al. 2004; García Rodríguez et al. 2011; Ross et al. 2011; 
Hakacova et al. 2013; Krishna et al. 2015). For example, in a 14-month-old child with 
severe herpesvirus 6B myocarditis where previous treatment was unsuccessful (with 
inotropics, diuretics, immunoglobulin and ganciclovir), ART treatment (5mg/kg/day 
intravenously for 10 days and subsequent oral therapy with ART 2x5mg/kg for        
10 days) resulted in a full recovery evidenced by lack of CD3+ T lymphocytes and no 
serious adverse effects (Hakacova et al. 2013). However, the exact molecular 
mechanisms underlying ant-inflammatory activities of 1,2,4-trioxanes are not 
completely defined. Ng et al. (2014) showed the utility of ART against chronic 
obstructive pulmonary disease (COPD) in cigarette smokers. The molecular 
mechanisms of action of ART in COPD were linked mainly with the inhibition of pro-
inflammatory PI3K/Akt and p44/42 MAPK signaling pathways, and inhibition of pro-
inflammatory cytokines, including IL-1β and TNF-1α (Ng et al. 2014). A high anti-
inflammatory properties of 1,2,4-trioxanes in non-cancer settings, such as COPD 
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may show their preventative benefits against the development of lung cancer. This 
hypothesis is based on the COPD-lung cancer association reported extensively and 
the cytotoxic effects of 1,2,4-trioxanes shown against both diseases. Other examples 
may include utility of 1,2,4-trioxanes against chronic oesteomyelitis, pelvic 
inflammatory disease, chronic pancreatitis, ulcerative colitis as their potent           
anti-cancer activities were demonstrated against osteosarcoma, ovarian, pancreatic 
and colorectal tumours, respectively  (Jiao et al. 2007; Li et al. 2008; Wang et al. 
2011; Xu et al. 2011; Kong et al. 2012).    
1.9.2. Activities of 1,2,4-trioxanes in cancer models 
Similarly with non-cancer studies (Wu et al. 2010), in experimental cancer settings, 
ART and DHA were capable to exert potent anti-inflammatory activities mainly 
through suppression of the signaling pathways NF-κB, ERK and STAT, the 
expression of COX-2 and pro-inflammatory cytokines, including IL-8 and IL-1β 
(Wang et al. 2008; Wang et al. 2011; Li et al. 2014). In CML xenograft mouse model 
(ART 50-200mg/kg thrice/week for 4 weeks) and in human myeloid leukaemia KBM-
5 cells in vitro, ART (50-100µM) following 4h incubation suppressed phosphorylation 
of  STAT-5 pathway, protein levels of ERK, JAK-2 and p-38, which were activated by 
MAPK pathway being strongly linked with inflammation and cancer progression (Kim 
et al. 2015). It can be hypothesized that the ability of ART to inhibit STAT-5 and ERK 
pathways in leukaemia could find therapeutic benefits to treat myelodysplastic 
syndrome (MS). MS is a condition characterised by abnormal activation of innate 
immunity mediators, where both pathways were documented to be key modulators in 
phenotypic transformation to acute leukaemia (Kolonics et al. 2001, Wei et al. 2013). 
First initial in vitro reports of ART effects against MS were published recently (Wang 
et al. 2014). Zuo et al. 2014 showed that the suppression of COX-2 (mRNA and 
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protein levels) and its product PGE2 in ART- treated (20, 100, 200mg/kg) bladder 
T24 and RT4 cancer cells for 24h correlated with miR-16 expression (reported 
tumour suppressor). Together with observation that exogenous PGE2 inhibited ART-
mediated caspase-3-dependent apoptosis in these cells (Zuo et al. 2014). The 
growth inhibition of human gastric HGC-27 cancer cells by ART (20, 40, 80mg/l) for 
48h was associated with COX-2 inhibition and induction of caspase-3 and -9-
dependent apoptosis (Zhang et al. 2015). ART-induced apoptosis in HGC-27 cells 
was further associated with increased levels of pro-apoptotic Bax, decreased levels 
of anti-apoptotic Bcl-2, and the loss of mitochondrial membrane potential via 
rhodamine 123 fluorescence inhibition (Zhang et al. 2015). The anti-inflammatory 
effects of DHA against pancreatic BxPC-3 cancer cells in vitro and in nude BALB/c 
mice were through NF-κB-mediated inhibition of COX-2, cytokine IL-8, as well as 
pro-angiogenic VEGF-α and MMP-9 gene levels (Wang et al. 2011). In addition, 
artemisinin (and MAPKp38 inhibitor SB-203580) in Lewis lung carcinoma (LLC) 
mediated down-regulation of IL-1β-induced p38 MAPK activation and decreased 
high levels of pro-angiogenic VEGF-C, thus reducing tumour lymphangiogenesis 
(Wang et al. 2008). With increasing reports of the anti-inflammatory effects of ART 
and DHA due to COX-2 down-regulation in solid tumours, there is limited 
experimental data showing their anti-inflammatory effects in human leukaemia 
cancer cells, thus future studies are needed. 
Bachmeier et al. (2011) documented the development of resistance and induced 
invasion and metastasis in ART-treated highly metastatic human breast MDA-MB-
231 cancer cells. These effects of ART in MDA-MB-231 cancer cells were attributed 
with the activation of the transcription factor activator protein (AP)-2, which is 
involved in cell proliferation (Bachmeier et al. 2011). Moreover, augumented 
37 | P a g e  
 
activation of NF-κB resulted in increased levels of bcl-2 and reduced levels of bax 
(Bachmeier et al. 2011). Induced resistance in MDA-MB-231 cancer cells upon 
activation of AP-2 and NF-κB resulted in increased transcription, expression and 
activity of matrix-degrading enzyme MMP-1 (collagenase-1), which promote invasion 
and migration of cancer cells (Bachmeier et al. 2011). Therefore, the threat of 
resistance development in cancer cells to 1,2,4-trioxanes monotherapy emphasize 
the need to investigate better therapeutic regimens against cancer. Given that 
available evidence suggest that COX inhibitors enhance the cytotoxic effects of anti-
cancer agents, it can be postulated that ASA would equally enhance the cytotoxic 
effects of ART and DHA. The mechanistic basis of the interaction of ASA with these 
cytotoxic agents warrants to be evaluated. 
1.10. Inflammatory cytokines promote epithelial-mesenchymal transition  
1.10.1. Loss of function of cell adhesion molecules supports invasive characteristics 
of cancer cells  
Increasing invasive and the migratory potential of cells in cancer progression is 
facilitated by epithelial-mesenchymal transition (EMT) (Jang et al. 2009; Gu et al. 
2015). EMT process converts immotile, epithelial cells into mesenchymal derivatives, 
which are characterised by a spindle-like or fibroblastoid morphology and the loss of 
cell-cell interactions and polarity (Imbert et al. 2012; Yao et al. 2014; Gu et al. 2015). 
The mesenchymal properties of epithelial cells initiate malignant transformation by 
allowing the mesenchymal cells to migrate, invade and promoting the acquisition of 
metastatic potential (Imbert et al. 2012; Yao et al. 2014; Gu et al. 2015). EMT 
initiation and progression requires the vast majority of distinct signaling molecules, 
including pro-inflammatory mediator COX-2, and cytokines IL-6, IL-17 and TNF-1α 
(Jang et al. 2009; Yadav et al. 2011; Rokavec et al. 2014; Saito et al. 2014; Gu et al. 
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2015). Multiple transcriptional repressors have been reported to induce EMT, 
including vimentin, ZEB1, the zinc finger protein Snail 1, Slug and the basic helix-
loop-helix factor Twist1 (Chen et al. 2010; Yadav et al. 2011; Xiong et al. 2012; Deep 
et al. 2014). A variety of signal transduction pathways, such as the NF-κB, Wnt/β-
catenin, and JAK-STAT-3 signaling pathways have been implicated in EMT process 
(Chen et al. 2010; Yadav et al. 2011; Xiong et al. 2012 Rokavec et al. 2014; Gu et al. 
2015). Even more remarkable, it has been documented that micro-environmental 
stressors, including tumour hypoxia represent a key contributor to EMT initiation and 
progression (Chen et al. 2010). The culture of human breast cancer cells under 
hypoxic conditions (1% O2) resulted in enhanced activation of Notch signaling 
pathway and increased migratory and invasive abilities of cells, as compared to 
standard normoxic conditions (21% O2) (Chen et al. 2010). A considerable number 
of experimental reports have demonstrated that many of these signaling factors 
down-regulate the expression of EMT pre-requisite, E-cadherin (Jang et al. 2009; 
Chen et al. 2010; Yadav et al. 2011; Xiong et al. 2012; Deep et al. 2014; Saito et al. 
2014).  E-cadherin (CDH1 gene), is a 120kDa cell-cell adhesion type I cadherin 
belonging to the family of transmembrane glycoproteins (Pećina-Šlaus 2003).         
E-cadherin is located at the baso-lateral membrane of epithelial cells and regulates 
their Ca2+-dependent intracellular adhesion, being critical for the maintaining of 
tissue structure and morphogenesis (Pećina-Šlaus 2003; Fujii et al. 2014).               
E-cadherin is frequently reported to be absent or down-regulated in diverse 
metastatic and invasive human tumours of epithelial origin, including CRC, breast, 
pancreatic, hepatocellular carcinoma, ovarian and endometrial cancers  (Deep et al. 
2014; He et al. 2013; Zhou et al. 2013; Kashiwagi et al. 2010; Jang et al. 2009; 
Sawada et al. 2008;  Mell et al. 2003). Clinically, down-regulated expression of        
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E-cadherin was reported to be associated with worse survival rate in patients with 
CRC (Elzagheid et al. 2012; He et al. 2013).  
Conversely, the up-regulation of E-cadherin was partialy involved in the inhibition of 
doxorubicin chemo-resistance in cultured breast cancer cells through microRNA-
200c (regulator of cancer chemoresistance) induced inhibition of Akt signaling 
pathway (Chen et al. 2013).  In HepG2 liver carcinoma, E-cadherin inhibited nuclear 
accumulation of Nrft2 (promoter of cancer chemoresistance), indicating that 
chemoresistance in cancer cells upon the loss of E-cadherin might be linked with 
Nrft2 (Kim et al. 2012). These reports further suggest that anti-cancer agents which 
increase expression of E-cadherin may decrease the risk of chemo-resistance and 
offer effective therapeutic strategy for epithelial cancers. Besides E-cadherin, a tight 
junction integral membrane protein CLDN-1 (member of claudin family) also plays a 
fundamental role in maintaining cell-cell contacts (Bezdekova et al. 2012). CLDNs 
contribute to the formation of ion selective pores or barriers that regulate the flow of 
ions and small molecules, together with a role in maintaining epithelial cell polarity 
(Bezdekova et al. 2012). Conflicting reports have been published with respect of 
CLDN-1 expression in human cancers and its clinical outcome. Shibutani et al. 
(2013) reported that low expression of CLDN-1 in stage II and III colorectal cancer 
was correlated with poor survival. In contrast, other studies demonstrated that up-
regulation of CLDN-1 expression in colon cancer was linked with the tumour growth 
and disease progression (Dhawan et al. 2005). Increased CLDN-1 expression has 
been reported in several other malignancies, including breast, ductal 
adenocarcinoma and squamous lung and esophagus cell carcinomas (Dhawan et al. 
2005; Gyõrffy et al. 2005; Borka et al. 2007; Paschoud et al. 2007; Blanchard et al. 
2013). Loss of CLDN-1 function through its up-regulation was observed to be 
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associated with the alteration of expression of EMT molecules (e.g. SNAIL-2), 
increasing cellular transformation and metastatic potential of cancer cells (Dhawan et 
al. 2005; Blanchard et al. 2013; Huang et al. 2015). There is some evidence that 
CLDN-1 up-regulates the repressor Zeb-1, thereby suppressing E-cadherin levels in 
colon carcinoma, which was demonstrated to be associated with poor survival (Singh 
et al. 2011). This data suggest that CLDN-1 has a key role in modulating other 
proteins/signaling pathways during tumorigenesis. The role of E-cadherin and CLDN-
1 is extensively studied in epithelial cancers whereas their role in haematological 
malignancies is limited and emphasize the need of urgent further work. Experimental 
studies with 1,2,4-trioxanes may also provide additional molecular mechanisms of 
action to understand better their role in carcinogenesis. 
1.10.2. Restored adhesion of cancer cells through 1,2,4-trioxanes activities 
Recently, some research studies reported that anti-cancer activities of 1,2,4-
trioxanes correlate with their effects on EMT mediators. The inhibitory effect of ART 
(40µg/ml) in human endometrial carcinoma HEC-1B cells as investigated by RT-PCR 
demonstrated lower expression of COX-2 mRNA, increased expressions of             
E-cadherin and caspase-3 mRNA when compared to respective controls (Lijuan et 
al. 2010). Experimental studies of Weifeng et al. (2011) showed that artemisinin 
(50µM) increased adhesion of human hepatocarcinoma HepG2 cells by β-catenin 
down-regulation and concomitant increase in Cdc42-mediated activation of              
E-cadherin. In human cultured CRC cell lines (CLY, HT-29 and Lovo), ART 
treatment (0-100µM for 24-72h) led to the inhibition of cell growth in concentration 
and time-dependent manners and simultaneously ART modulated the expressions of 
E-cadherin and β-catenin, which was linked with differentiation state of these cells (Li 
et al. 2008). It was confirmed using a Western blotting analysis where ART treatment 
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at 0-200µM for 72h in well-differentiated HT-29 cells showed a decreasing               
E-cadherin protein expression with concomitant no significant changes in β-catenin 
protein levels (Li et al. 2008). In contrast, poorly-differentiated CLY and moderately-
differentiated Lovo cells showed higher E-cadherin expression and reduction in        
β-catenin protein levels (at 200µM ART) (Li et al. 2008). Immunofluorescence 
detection of E-cadherin and β-catenin upon ART treatment (50µM) for 72h showed 
membranous localisation of E-cadherin and β-catenin proteins, loss of E-cadherin 
and nuclear β-catenin accumulation in CLY cells and Lovo cells with cytoplasmic 
staining of both proteins (Li et al. 2008). The corresponding differences in E-cadherin 
and β-catenin expression and localisation levels in ART-treated CLY and Lovo cells 
were indicated to correspond with the suppression of hyperactive Wnt signaling 
pathway, thus showing the importance of ART in the reversion of EMT in cancer 
cells. Much of these research studies with 1,2,4-trioxanes on EMT mediators have 
been performed in regards of E-cadherin alone. However due to reported inverse 
relationship between E-cadherin and CLDN-1, it is challenging to further investigate 
how ART and DHA affect the expression and cellular localisation of these proteins 
evaluated simultaneously.  
1.11. Inhibition of cell migration, invasion and metastasis by 1,2,4-trioxanes. 
Activated by cytokines and signaling modulators, MMP-2 (72-kDa gelatinase) and 
MMP-9 proteins are members of Zn2+ metalloendopeptidases matrix family, which 
have been shown to enhance migration, invasion, metastasis and promote 
angiogenesis in many human solid cancers, including gastric, lung, ovarian and 
neuroblastoma (Jodale et al. 2005; Hung et al. 2010; Kumar et al. 2010; Yan et al. 
2010; bKim et al. 2012; Ji et al. 2014). In addition, the mRNA expression of MMP-2 
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and MMP-9 proteins as analysed by RT-PCR was demonstrated in CML, indicating 
the role of MMPs in haematological malignancies (de Bont et al. 2001). MMP-2 and 
MMP-9 are responsible for disorganising highly regulated cell-cell interactions, 
degradation of extracellular matrix (EM) and disabling normal functions of other 
molecules, including cleavage of growth factor β-induced protein and E-cadherin 
loss, thus contributing to cell invasion and decreased cell-EM interactions (bKim et al. 
2012). The potential of the primary malignant cells to metastasize and establish 
secondary tumours in other organs, such as leukaemia as a result of CRC has been 
related with high mortality (Steeg et al. 2006; Shapiro et al. 2007). Therefore, 
inhibition of any of these MMPs may increase the efficacy of current cancer 
therapies, reduce mortality and improve of life of patients.  
Studies reveal that 1,2,4-trioxanes (artemisinin, ART and DHA) inhibit cell migration, 
invasion and metastasis in vitro and in vivo by altering the expression of MMP gene 
family and other factors (Buommino et al. 2009; Rasheed et al. 2010; Wang et al. 
2011; Weifeng et al. 2011). The inhibitory effects of artemisinin against melanoma 
A375M cell line was shown by reducing the production of MMP-2 and decreasing 
αvβ3 integrin expression (Buommino et al. 2009). In PMA (30nm) pretreated human 
fibrosarcoma HT-1080 cells, DHA at increasing concentrations ranging between 0-
50µM for 24h reduced the levels of MMP-2 and MMP-9 through decreased AP-1 and 
NF-κβ expression, and induced low levels of membrane-type 1 MMP (MT1-MMP) (at 
50µM DHA) (Hwang et al. 2010). A low concentration of ART (at 2.5µM and 5µM) for 
24h in human non-small cell lung cancer effectively decreased transcriptional 
expressions of MMP-2 and MMP-7 (small uterine metalloproteinase), together with 
down-regulation of mRNA and protein expression of urokinase-type plasminogen 
activator (uPA), which is involved in  promoting degradation of extracellular matrix 
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(Rasheed et al. 2010). In human HCC hepatoma cells, ART (0-75µM) for 48h 
treatment showed a concentration-dependent decrease in MMP-2 levels and 
increase of tissue inhibitor of metalloproteinase (TIMP)-2 (suppressor of metastasis) 
as evaluated with Western blotting analysis (Weifeng et al. 2011). Similar results in 
both proteins were observed by gelatinase zymography analysis with hepatoma 
HepG2 cells upon treting the cells with ART (0-50µM) for 24h (Weifeng et al. 2011). 
Additionally, ART, DHA and artemisinin have demonstrated to inhibit cell migration 
and invasion in other experimental settings including 2D wound healing assays, 3D 
transwell chamber invasion assays and in vivo metastasis assays in several cancer 
types, including lung and hepatoma cancers (Hwang et al. 2010; Rasheed et al. 
2010; Weifeng et al. 2011; aChen et  al. 2013). For example, inhibited migration and 
invasion of hepatoma cells (HepG2 and SMMC-7721) in 2D wound-healing assay 
upon artemisinin treatment (0-75µM) for 24-48-72h was observed in concentration- 
and time- dependent manners and was characterised by blocking the ability of cells 
to close the wound gap (Weifeng et al. 2011). Chen et al. (2013) have demonstrated 
that ART treatment (10-40mg/kg) in lung adenocarcinoma A549 cell xenograft 
tumour decreased dose-dependently the protein expressions of MMP-9 and ICAM-1 
(intracellular adhesion molecule-1), suppressed tumour growth with concomitant 
inhibition of cell invasion in vitro (at ART 1.25µg/L) as evaluated with 3D transwell 
chamber invasion assay. In human cervical cancer (Hela and Caski) cells, DHA at 
20µmol/L for 48h treatment up-regulated mRNA and protein levels of metastatic 
inhibitor, RKIP in vitro, which was accompanied by significant (P<0.001) reduction in 
tumour volume in Balb/c nude mice xenografts by ~5.25-folds in Hela and ~5.95-
folds in Caski cells when compared to controls (Hu et al. 2014). These reports 
indicate that 1,2,4-trioxanes are potent anti-cancer agents, with the ability to inhibit 
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cell metastasis by blocking migratory and invasive abilities of cells through changes 
on several signaling mediators, especially MMPs. However, in literature there are no 
reports on ART and DHA effects to block the ability of the cells to re-growth post 
drug treatment, which may have significant meaning for patient survival outcome and 
the development of secondary cancers. Therefore, new studies designed to evaluate 
this concept are needed. In addition, the effects of ART and DHA on MMPs in 
human colorectal and leukaemia cancer cells are not completely defined and require 
further investigations.    
1.12. Angiogenesis as a anti-cancer target of 1,2,4-trioxanes 
The rapid and uncontrolled growth of malignant tissues causes inefficient tissue 
oxygenation (hypoxia) leading to angiogenesis (Duffy et al. 2003). Angiogenesis is 
an active process of the outgrowth of new structurally and functionally abnormal 
blood micro-vessels from pre-existing vessels being characterised by dilated, chaotic 
and hyperpermeable vasculature (Aguayo et al. 2000; Goel et al. 2011). In more 
invasive rectal cancers (T- and N-stages), high micro-vessel density correlates with 
poor prognosis in patients (Rasheed et al. 2009). Significantly increased number of 
blood vessels was widely reported in the leukaemogenic processes of several 
leukaemias, including AML (median: 16.1, range 1.2-32.8; P<0.02) and CML 
(median: 21.4, range 4.7-41.7; P<0.03), as compared to control BM (median: 11.2; 
range 1.2-24), which could be linked with a high risk of poor prognosis for these 
patients (Aguayo et al. 2000). 
1.12.1. Inhibition of the VEGF gene family by 1,2,4-trioxanes 
The human VEGFs are encoded by three separate genes which include VEGF-α, 
VEGF-β and VEGF-C (Anfosso et al. 2006). The secretion of the main cancer pro-
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angiogenic factor VEGF-α is enhanced during angiogenesis and occurs via multiple 
processes, including hypoxia-mediated activation of HIF-1α (Faderl et al. 2005; 
Yoshioka et al. 2012; Li et al. 2014). Human VEGF-α is a homodimeric glycoprotein 
which form five main isoforms: VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206 
(Panoilia et al. 2015). The VEGF165 isoform is most abundant and enhances 
angiogenesis and vascular permeability by binding to vascular endothelial cells 
through interaction with tyrosine kinase receptor-2 (VEGFR-2 or KDR/Flk-1) and 1 
(VEGFR-1 or Flt-1) (Cohen et al. 1996; Schneider et al. 2011; Yoshioka et al. 2012; 
Panoilia et al. 2015). The expression of VEGF-α in cancer cells is up-regulated by 
oxygen radicals within hypoxic tumours, directly by hypoxia-mediated HIF-1α over-
expression, and indirectly by inflammatory cytokines such as TNF-α, IL-1β, IL-6 and 
IL-8 via activation of PI3K/Akt signaling pathway (Cohen et al. 1996; Neufeld et al. 
1999; Faderl et al. 2005; Huang et al. 2008; Li et al. 2012). The expression of VEGF-
α has been reported to be quite low under normoxic conditions (~20% O2) but high in 
hypoxia (~1% O2) (Yoshioka et al. 2012). Elevated levels of VEGF-α are reported to 
play a critical role in the tumour progression, disease stage and poor survival 
prognosis not only in solid tumours, including colorectal, osteosarcoma and cervical 
cancers but also in haematological malignances, including leukaemia (Aguayo et al. 
2000; Koomagi et al. 2001; Faderl et al. 2005; Des Guetz et al. 2006; Lyu et al. 
2007; Zhou et al. 2011; Katanyoo et al. 2013).   
1,2,4-trioxanes (ART, DHA, artemisinin) were reported to elicit potent anti-
antigenesis properties  through  in several experimental settings in vitro, and in vivo 
(Aung et al. 2011;  Wang et al. 2008;  Wang et al. 2011). The anti-angiogenic effects 
of ART (at 7.20µM) in Dell’Eva et al. (2004) research study were linked with strongly 
reduced vascularization of Matrigel plugs pretreated earlier with angiogenic stimuli 
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mix (VEGF-α of 100ng/ml; TNF-α of 2ng/ml and heparin (24-26U/ml) and injected 
subcutaneously into syngenic mice, or when ART (100mg/kg/day) was administrated 
with water of the animals for 4 days. In addition, orally administrated artemisinin 
(50mg/kg/day) in mouse Lewis lung carcinoma study reduced VEGF-C mediated 
lymphangiogenesis (Wang et al. 2008). Conditioned media analysed by ELISA from 
chronic myelogenous leukaemia K562 cells upon treatment with ART (2µmol/) for 
48h, showed that the VEGF-α secretion and mRNA levels were significantly (P<0.01) 
inhibited (by 25.7% and 27.1%, respectively) (Zhou et al. 2007). The VEGF-α 
secretion and mRNA levels were decreased accordingly with increasing ART 
concentrations (5 and 10µmol/L), as compared to control cells (Zhou et al. 2007). 
Interestingly, in the same study of  Zhou et al. 2007, the inhibitory effect of ART 
(1.2µmol/100µl per egg for 48h) on angiogenesis in chicken charioallantoic 
membrane (CAM) in vivo model was associated with the presence of an 
inflammation of cells infiltration (Zhou et al. 2007). It can be hypothesized that ART 
(1.2µmol/100µl per egg for 48h) in CAM induced transient inflammatory response, 
which led to IL-6-mediated activation of NK cells, thus potent anti-angiogenic effects 
of ART, as compared to untreated CAM.   
1.12.2. Regulation of HIF-1α transcription activator protein by 1,2,4-trioxanes 
Besides the VEGF gene family, new mutations taking place as tumour grows 
facilitate the over-expression of other pro-angiogenic proteins including HIF-1. HIF-1 
is a heterodimer which belongs to the basic helix-loop-helix family of transcription 
activator proteins (Duffy et al. 2003). HIF-1 is responsible for transcription of several 
genes associated with key cellular functions including cell adhesion, cell-extracellular 
matrix interactions, inflammation, iron homeostasis, angiogenesis and inhibition of 
apoptosis (Duffy et al. 2003; Harada et al. 2005; Jeong et al. 2005). HIF-1 consists of 
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two subunits: the β/ aryl hydrocarbon receptor nuclear translocator subunit which is 
constitutively present, and α subunit which in the presence of iron and oxygen is 
rapidly degraded (t1/2 of 5 mins) by ubiquitin-mediated proteolysis in normoxia but 
becomes stable in hypoxia (Harada et al. 2005; Duffy et al. 2003; Romney et al. 
2011).  
Recent studies have shown that HIF-1α increases the transcription of TfR by binding 
to its hypoxia-responsive elements which promote tumour growth and tumour 
aggressiveness by enhancing cell proliferation and activation of other factors, 
including IL-6, MMP-2 and -9 (Tacchini et al. 1999; Jeong et al. 2005; Choi et al. 
2011). Using a microarray-based approach, Anfosso et al. (2006) showed that the 
cytotoxic effects of 1,2,4-trioxanes (e.g. ART, arteether, artemisetene)  in 60 human 
cancer cell lines, including leukaemic HL-60 and colorectal HT-29 cells correlated 
with the expression of  30 genes  being regulated actively by angiogenesis. For 
example, high mRNA expression of MMP-9 correlated significantly (P<0.01) with low 
IC50 values (inverse correlation) for ART, arteether and artemisetene (Anfosso et al. 
2006). In direct correlation, high mRNA expression of MMP-11 correlated 
significantly (P<0.05) with high IC50 values for ART, arteether and artemisinin 
(Anfosso et al. 2006). In addition, the high expression of VEGF-C and HIF-1α 
correlated with ART and arteether at a significance level of P<0.01 (Anfosso et al. 
2006). Interestingly, high IC50 values for ART, arteether correlated with high IL-6 
signal transducer expression (P<0.05) indicating potential role of IL-6 in 1,2,4-
trioxanes’ activities (Anfosso et al. 2006).  
There are also some inconsistent reports regarding the effect of DHA on HIF-1α 
production. The generation of ROS in rat C6 glioma cells when treated with DHA    
(5-25µM) resulted in inhibited HIF-1α expression and cell-growth inhibition (Huang et 
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al. 2007). In contrast, as measured in Western blotting analysis, the protein 
expression of HIF-1α in human hepatoma cell line HepG2 increased in a DHA 
concentration-dependent manner (1-25µM) for 24h and with DHA at 25µM in 
increasing incubation times from 0h to 24h, which was shown to be independent of 
ROS production but induced by cellular iron depletion (Ba et al. 2012). As the effects 
of 1,2,4-trioxanes on HIF-1α  expression are not completely defined, we aimed to 
examine in this study the effect of ART and DHA against cultured HT-29-AK and  
HL-60 cells. Based on the above reports, the simplified postulated mechanisms of 
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Figure 3: Schematic representation of the mechanisms by which 1, 2,4-trioxanes inhibit spread of cancer cells to distant 
parts in the body. 
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1.13. 1,2,4-trioxanes as a hypoxia selective agents  
Hypoxia is a condition of decreased availability of oxygen in the interior of most, if not all 
solid tumours (Suzuki et al. 1998; Ke and Costa 2006; Brahimi-Horn et al. 2007). It occurs 
due to robust tumour growth with resulting long distances (~100-150µm) to local blood 
vessels (diffusion-limited hypoxia) (Brahimi-Horn et al. 2007; Vordermark 2010). Hypoxia is 
associated with poor vasculature of tumour vessels leading to inadequate oxygen and 
nutrient supply in certain tumour areas (perfusion-limited hypoxia) (Brahimi-Horn et al. 2007; 
Vordermark 2010). Thus, the resultant cellular hypoxia and metabolic stress leads to the 
recruitment of additional abnormal blood vessels through the process of angiogenesis 
(Faderl et al. 2005; Rustum et al. 2010). The disproportional and incomplete vasculature in 
hypoxic tumours often is linked with the development of resistance to non-surgical cancer 
therapies, mainly radiation and chemo-therapy (Bhattacharya et al. 2004; Goel et al. 2011; 
Milosevic et al. 2012). Radiation is insufficient in enhancing the cytotoxicity of agents 
because of low oxygen levels in highly hypoxic areas (Milosevic et al. 2012). The transport 
of anti-cancer agents at therapeutically meaningful concentrations via blood flow to hypoxic 
cells is inadequate by limited convection and diffusion (Bhattacharya et al. 2004; Rustum et 
al. 2010; Goel et al. 2011). The effectiveness of some chemotherapeutic drugs which target 
highly proliferating cancer cells is also decreased at high cell density hypoxic, well-
differentiated regions of tumour due to slower cell proliferation rate (Bhattacharya et al. 
2004; Rustum et al. 2010). Remaining alive hypoxic cells enhance tumour aggressiveness 
through inhibition of cancer cell death and increasing the expression of pro-angiogenic and 
metastatic factors, especially activated HIF-1α mediated over-expression of Mad1 (MAX 
dimerization protein 1), which has been shown experimentally to be associated with 
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treatment failure, therapeutic resistance and cancer recurrence (Milosevic et al. 2012; bCho 
et al. 2013; Chen et al. 2014; Dekervel et al. 2014).  
Other regulatory activities of HIF-1α in hypoxic niches include activation of carbonic 
anhydrase IX (CA-9), a glycotransmembrane protein of zinc metalloenzymes responsible for 
acid-base balance and intracellular interactions (Saarnio et al. 1998; Rasheed et al. 2009). 
A high protein expression and staining of CA-9 were shown to be usefull in diagnosis and 
survival prognosis in many carcinomas, including CRC, bladder, breast and non-small cell 
lung cancer (Saarnio et al. 1998; Rasheed et al. 2009; IIie et al. 2010; Lock et al. 2012; Li et 
al. 2014; Cheng et al. 2015; de Martino et al. 2015). Over-expression of CA-9 was reported 
to enhance EMT transformation and metastaic potential in cancer cells through reducining 
cell adhesion capacity linked with modulation of E-cadherin localisation (from membrane to 
cytoplasm) via β-catenin (Švastová et al. 2003). Therefore, there is currently much ongoing 
research focused on targeting tumour hypoxic microenvironment and its regulators, which 
could represent promising therapeutic approach (Chen et al. 2009; bCho et al. 2013; Chen 
et al. 2014).  
Recently, there are some reports showing that 1,2,4-trioxanes target cancer cells with 
similar potency profiles in normoxic and hypoxic experiments and are able to modulate the 
expression of important signaling mediators, such as VEGF-α and HIF-α under both 
conditions. For example, DHA (0-80µM) for 48h in human CRC cell lines (HCT15, HCT116, 
and Coco 205) effectively inhibited the growth of cells under normoxic (21% O2) and 
strongly hypoxic (0.2% O2) conditions (Ontikatze et al. 2014). Hypoxia was induced in CRC 
cells for 2h prior DHA treatment and was associated with DHA-induced cell apoptosis and 
necrosis (Ontikatze et al. 2014). In BxPc3-RFP pancreatic cancer cell line, cytotoxic effects 
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of DHA in normoxia increased with higher DHA concentrations (0-80µM) over a period of 
time (24-48-72h) in vitro, whereas DHA (25mg/kg for 4 weeks) reduced the tumour growth 
in nude mice models (Aung et al. 2011). Subsequent mechanistic basis of DHA (0-80µM) 
anti-cancer effects in cultured pancreatic BxPc3-RFP cells following 18h incubation showed 
increasing down-regulation of VEGF-α protein expression with increasing DHA 
concentrations under standard normoxic conditions (20% O2), whereas unchanged 
expression levels of VEGF-α under hypoxic conditions (1% O2) (Aung et al. 2011). More 
prominent results were obtained for HIF-1α were its levels were not detected in all DHA-
untreated and treated samples under normoxic conditions but decreased in hypoxia, as 
compared to control (Aung et al. 2011). These evidence indicate potential applications of 
1,2,4-trioxanes for cancer therapies especially for highly aggressive and resistant tumours 
to current chemotherapies, thus becoming first anti-malarial agents selectively targeting 
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Figure 4: Tumour hypoxic mass features and their effect on inhibited responsiveness 
to standard radio- and chemo-therapy treatments. Poor vasculature of tumour blood 
vessels leads to inadequate oxygen and nutrient supply resulting in highly hypoxic areas 
dominated by HIF-α factor linked with treatment failure, therapeutic resistance and cancer 
recurrence. Low levels of oxygen within hypoxia interior restricts radiation and transport of 
chemo-therapeutic agents due to their limited convection, diffusion and being inactive 
towards slowly proliferating highly hypoxic cells. Increasing reports indicate high potency of 
1,2,4-trioxanes (ART and DHA) towards highly hypoxic cells, thus showing potential benefits 
in cancer treatment. 
 
However, above studies concentrated only on the evaluation of DHA effects under both 
conditions without testing other 1,2,4-trioxanes, such as ART. In addition, the effects of ART 
and DHA under both conditions were not explored against cancers of different phenotypic 
state, including adherent human colorectal HT-29-AK cells and suspension human 
leukaemic HL-60 cells, investigated alone and in combination with other chemotherapeutic 
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agents, such as ASA, which could additionally enhance the effects of the agents. Other 
study design are also needed, including longer pre-incubation of cells under hypoxic 
conditions, thus allowing the low oxygen microenvironment in cell culture to induce changes 
in expression of signaling factors such as VEGF-α and HIF-1α which normally are taking 
place in tumour hypoxia. 
1.14. Induction of the apoptosis of cancer cells by 1,2,4-trioxanes 
In principle, the major aim of current chemotherapy approaches is to selectively induce the 
apoptosis of cancer cells. Apoptosis, or programmed cell death is a highly regulated 
mechanism used to regulate tissue homeostasis, including in gut mucosal and leukaemic 
mast cells microenvironment through removal of superfluous, damaged or potentially 
deleterious cells (Zhang et al. 2004; Greenhough et al. 2009; Hassan et al. 2014). 
Apoptosis signaling that leads to caspase activation is mediated through two major 
pathways, the death receptor pathway (extrinsic) and the mitochondrial pathway (intrinsic) 
(Hector and Prehn 2009; Sanmartin et al. 2012). Caspases are cysteine-dependent, 
aspartate-specific proteases, which belong to the familily of more than 14 enzymes where 
only seven actively participate in the apoptosis program (Herr and Debatin 2001). Of these, 
caspases -2, -8, -9 and -10 constitute initiator caspases, which activation leads to proteolytic 
activation of the downstream effector or executioner caspases-3,-6, and -7 (Herr and 
Debatin 2001). Especially, caspase-3 (known as CPP32, Yama and apopain) is reported to 
be required for the execution of apoptosis by cleaving a number of key cellular proteins, 
including other caspases -6 and -7 (Yang et al. 2001; Devarajan et al. 2002). Caspase-3 
activity induces the classical morphological and biochemical of apoptosis, such as 
internucleosomal DNA fragmentation, membrane damage, chromatin condensation and 
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hypodiploid DNA content (Coalho et al. 2000; Bestwick et al. 2006; Sanmartin et al. 2012). 
Escape from cell death being associated with dysfunction, down-regulation or loss of 
caspase-3 has been shown in several cancer types, including acute myeloid leukaemia, 
colorectal, breast and non-small cell lung carcinoma and has been linked with therapy 
failure and the development of resistance to standard chemotherapies (Joseph et al. 2001; 
Yang et al. 2001; Devarajan et al. 2002; Zhang et al. 2004; Hector et al. 2012). For 
example, a breast cancer MCF-7 cell line, deficient of caspase-3 and resistant to many 
chemothatapeutic agents was shown to be sensitive towards doxorubicin and etoposide 
when caspase-3 was reconstituted, which led to enhanced cancer cells death (Yang et al. 
2001). The proposed mechanism of the defective apoptosis in cancer progression and 
potential responses to cancer therapy is presented in figure 5. Therefore, there is great 
therapeutic potential to investigate the mechanistic role of current chemotherapeutic agents 
on caspase-3-dependent apoptosis.  
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Figure 5: Non-tumorigenic cells with damaged DNA can be self repair or be utilized 
by self-destruct mechanism, an apoptosis. Escape from the apoptosis by cells with 
dysfunctional apoptotic genes may lead to therapy failure and the development of 
resistance to standard chemotherapies (re-drawn from Kelly et al. 1999). 
 
As presented in figure 6, the primary mechanism by which 1,2,4-trioxanes exert their anti-
tumour activities is through the induction of caspase-dependent apoptotic cell death via the 
extrinsic (He et al. 2010; Kong et al. 2012) or the intrinsic effector mechanisms (Mercer et 
al. 2007; Lu et al. 2008; Hamacher-Brady et al. 2010; Xu et al. 2011; Kim et al. 2015; Zhang 
et al. 2015; Zhao et al. 2015). In pancreatic BxPC-3 and PANC-1 cancer cells, DHA (0-
100µM/L) following 48h incubation increased the ROS- and Apo2L/TRAIL (Apo2 ligand or 
tumour necrosis factor-related apoptosis-inducing ligand) mediated protein expression of 
Death Receptor (DR)-5 (initiator of the extrinsic pathway), which led to cleavage of initiator 
caspase-8 and its downstream effector caspases -9 and -3 (Kong et al. 2012).  A reductive 
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cleavage of DHA by CCR in leukaemic HL-60 cells induced a time- (for up to 24h) and 
concentration-dependent (0.1-10µM) mitochondrial membrane depolarisation, which is 
characteristic for the intrinsic pathway, and the cell cycle arrest at the Go/G1 phase with 
degraded DNA as investigated by flow cytometric analyses (Mercer et al. 2007). By 
employing Western blotting analysis, it was shown that DHA in HL-60 cells was responsible 
for activation of caspases- 3 and -7, which was time- (for up to 24h) and concentration-
dependent (0.1-10µM) (Mercer et al. 2007). Partialy ROS-dependent induced apoptosis by 
DHA (2.5 to 40µM/L) for up to 24h in Jurkat T-lymphoma cells resulted in the release of 
cytochrome c from damaged mitochondria, activation of caspases (-3 and -8), cleavage and 
up-regulation of the DNA repair enzyme PARP and induction of pivotal characteristics of 
apoptotic cell death, including chromatin condensation, hypodiploid nuclei or nuclear 
fragmentation (Handrick et al. 2010). The genotoxicity (DNA damage) directly induced by 
DHA and ART was also evidence with DNA gel electrophoresis in some cell lines, including 
leukaemia and ovarian cancers (Jiao et al. 2007; Li et al. 2009; Yang et al. 2009).  
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Figure 6: Simplified proposed mechanisms of DHA and ART-mediated cell death in 
cancer cells. The apoptosis signaling pathway induced by ART and DHA includes the cell 
extrinsic mechanisms triggered by Apo2L/TRAIL/DR5 activation and cell-intrinsic 
mechanisms linked with induced cell mitochondria damage and results in DNA 
fragmentation. Crosstalk between both pathways involves activation of Bid, Bax, Bak 
proteins and the inhibition of the cell proliferation survival pathways (PI3K/AKT, ERK and 
NFκβ pathways).  
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Survivin is an oncofetal protein (16.5-kDa) implicated in inhibition of apoptosis (binds 
directly to caspase-3 and caspase-7) and has a role in enhancement of motility and 
metastatic abilities of CRC (Shin et al. 2001; Ye et al. 2014). Together with stimulating 
angiogenesis, survivin has prognostic implications in cancer patients and promotes 
resistance to chemo-therapy, thus making survivin an attractive target in cancer therapy   
(Ko et al. 2010; Ye et al. 2014). The inhibitory effects of DHA against colorectal SW480 cells 
were linked with survivin inhibition whereas in other experimental study with DHA (25-
100µM/L) in BxPC-3 and PANC-1 pancreatic cells for 72h incubation, it was observed that 
survivin levels were unchanged (Shao et al. 2008; Kong et al. 2012). In leukaemic KBM-5 
cells in vitro and in CML xenograft model, ART (at 50-100µM for 4h and 50-200mg/kg 
thrice/week for 4 weeks, respectively) down-regulated survivin mRNA and protein levels as 
evaluated by Western blotting (Kim et al. 2015). In osteosarcoma HOS cells, ART (10-
80µmol/L) following 48h treatment decreased in a concentration-dependent manner protein 
survivin as measured by Western blotting (Xu et al. 2011). Therefore, the investigation and 
understanding of the differences arising in the effects of 1,2,4-trioxanes on survivin 
expression in various cancers could provide additional knowledge on their mode of action.  
In addition, in cultured human prostate malignant cells have shown that DHA (30µM for   
PC-3 and DU145, 50µM LNCaP cells) for 24h inhibited the PI3-kinase/Akt and 
ERKsurvival/proliferation pathways with concomitant cleavage of caspases (-3, -8, -9) at 
50µM for 24h due to TRAIL/DR5 activation (He et al. 2010). Similar inhibitory effects of ART 
and DHA against phosho-Akt were observed in some other in vitro and in vivo studies      
(Ma et al. 2011; Thanaketpaisarn et al. 2011; Lee et al. 2013; Odaka et al. 2014). Akt is 
reported to promote resistance to 5-FU and inhibition of apoptosis through numerous 
mechanisms, such as direct inhibition of caspase-3 and the inactivation of some other      
60 | P a g e  
 
pro-apoptotic proteins (e.g. Bad, caspase-9) and up-regulation of anti-apoptotic proteins 
(e.g. survivin, Bcl-2, Mcl-1), thus preventing caspases cascade activation (Bortul et al. 2003; 
Zhang et al. 2004; Zhang et al. 2014; Ye et al. 2014). Elevated Akt protein levels have been 
reported in haematological malignancies, including HL-60 cells which correlated with 
decreased sensitivity induced by TRIAL (Bortul et al. 2003). In colorectal HCT116 cells, 
TNF-α activated Akt pathway contributed to inflammation-induced EMT, enhanced invasion 
and metastasis of cells (Wang et al. 2013). Due to broad-spectrum functions of Akt in 
cancer development it is important to further explore its function in ART- and DHA- 
mediated anti-cancer effects to better understand their molecular basis of action. Other key 
mechanisms of ART- and DHA- induced apoptosis in cancer cells are associated with the 
regulation of BcL-2 family proteins, including inhibition of anti-apoptotic Bcl-2 and up-
regulation of pro-apoptotic Bax, Bim and Bak proteins, activation of p53 and inhibition of 
NFκβ signaling pathways (Hou et al. 2008; Li et al. 2009; Handrick et al. 2010; Xu et al. 
2011; Kong et al. 2012; Du et al. 2013; Zhao et al. 2015). 
1.15. Combination therapy for cancer with 1,2,4-trioxanes and future prospectives 
Major shortcomings of many current chemotherapeutic agents, such as cisplatin, 
doxorubicin, 5-FU, irinotecan, oxaliplatin, oral fluoropyrimidines and raltitrexed (given either 
alone or in combination) include lack of specificity resulting in unfavourable side effects 
(such as hypotrophy, leukopenia or stomatitis) and the development of drug resistance 
(Shahrokni et al. 2009; Rasheed et al. 2010; Feng et al. 2014). Complete remission of 
cancer without toxic effects to healthy cells in the rest of the body is the main aim in the 
clinical anticancer treatment. 1,2,4-trioxanes are broad-spectrum natural Artemisia annua 
L.-derived compounds that have been proven to elicit potent cytotoxic activities towards 
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rapidly dividing cancer cells in vitro  and in vivo. Additionally, ART and DHA have been 
shown to be effective towards cancer cell lines being resistant to current chemo-therapeutic 
agents. ART (1µg/ml) following 24h incubation has been shown to be effective against 
doxorubicin (0.5µg/ml)-resistant T leukaemia cells through induction of apoptosis and DNA 
fragmentation (Efferth et al. 2007). Other study showed that DHA inhibited the growth of 
imatinib-resistant CML (Lee et al. 2013). Encourangingly, increasing reports are describing 
that 1,2,4-trioxanes (ART, artemether) are effective to combat cancer clinically where are 
well tolerated without causing serious side effects (Singh and Verma 2002; Singh and 
Panwar 2006; Jansen et al. 2011; Krishna et al. 2015). This include a pilot study of ART-
treated patients with advanced cervical cancer led to disease remission of about 6 months 
(after 28-day treatment), prolonged survival for about 12 months, improved clinical 
symptoms (reduced vaginal discharge and pain) and was well tolerated  (Jansen et al. 
2011). Recently, in double-blinded pilot study, Krishna et al. (2015) reported higher 
recurrence-free survival probability at 3 years of follow-up after ART treatment at daily dose 
of 200mg orally for 2 weeks in CRC. Treatment was well tolerated with some adverse 
effects, including leucopenia but no reports of nausea (Krishna et al. 2015). Despite these 
promising reports there is a global  threat that relatively short half-life of 1,2,4-trioxanes 
linked with repeated administrations and high drug doses could eventually lead to the 
development of drug resistance in cancer cells due to their metabolic adaptation. Therefore, 
there is pressing need for undertaking additional molecular investigations enhancing current 
understanding of 1,2,4-trioxanes anti-cancer actions. Additional molecular mechanisms 
governing the anti-cancer effects of 1,2,4-trioxanes could provide a solid background for 
novel drug combinations for the cancer treatment. The combination therapies are attractive 
because they could overcome drug resistance and possibly yield even better therapeutic 
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effects than monotherapy. There are several reports of the ability of ART and DHA to 
enhance therapeutic effectiveness in vitro and animal settings of other anti-cancer agents, 
including cisplatin  (Efferth et al. 2007; Wang et al. 2010; Thanaketpaisarn et al. 2011; 
Krusche et al. 2013; Liu and Cui 2013; Zhang et al. 2013; Feng et al. 2014). Most recently, 
in human myeloid leukaemic KBM-5 cells, combination of ART (10µM) with either, 
doxorubicin (30µM), paclitaxel (1.50nM) or docetaxel (1.50nM) for 24h significantly 
(P<0.001) potentiated the cytotoxicity of all drugs through enhanced down-regulation of 
survivin and augumented cleavage of PARP (Kim et al. 2015). Clinically, ART in 
combination with decarbazine was successfully used in the treatment of stage IV uveal 
melanoma (median survival of 2-5 months) where subject was alive after 47 months of 
diagnosis with progressive decline of splenic and lung metastases (Berger et al. 2005). A 
randomized open-controlled trial in patients with advanced lung cancer showed that ART 
(120 mg/day intravenously for 8 days) combined with vinorelbine (25 mg reconstituted in 
2ml H2O m(2) and used once-a-day intravenously, at the 1st and 8th day) and cisplatin (25 
mg/m(2), once-a day intravenously, at the 2nd to 4th day) used for at least two three-week 
cycles significantly improved disease control, prolonged time to progression with no 
additional toxic effects as those observed in control vinorelbine/cisplatin group 
(myelosuppression and digestion reaction) (Zhang et al. 2008). Reports from pre-clinical 
and clinical studies make the point evident that cancer monotherapy is not enough and 
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1.16. Aim of the study  
The main aim of the current study was to evaluate anti-cancer effects of ART and DHA    
(figure 7) against human promyelocytic leukaemia HL-60, human colorectal carcinoma HT-
29-AK and Caco-2 human epithelial colorectal adenocarcinoma cell lines. Of particular 
interest was to elucidate the mechanism of action of ART and DHA in both cell lines. For 
that purposes following objectives were established: 
1. Using the MTT assay, to evaluate the cytotoxicity of ART and DHA against both cell 
lines at increasing incubation time points (24-48-72h) under standard normoxic 
condition (20% O2) and to compare the results with the drugs cytotoxicity determined 
under low oxygen tension  (1% O2). 
2. To determine the role of iron in drugs-mediated cytotoxicity against cancer cells 
through incubation of ART and DHA for 24h with iron carrying molecule, haemin 
(1µM and 3µM) and iron chelator deferiprone (DFO) (60µM) at concentrations of 
these modulators having no toxic impact on cells. 
3. To evaluate the effects of ART and DHA on sTfR1 needed for drug and iron 
endocytosis. 
4. Using basis wound scratch and growth irreversibility assays to study anti-invasive 
and anti-metastatic effects of ART and DHA against cancer cells. 
5. To provide characteristics of the proliferation kinetics of both cell lines under different 
tumour microenvironments (20% vs. 1% O2). 
6. Using ELISA, qPCR, immunocytochemical staining, gel electrophoresis, flow 
cytometric and Western blotting analyses to indicate the role of pivotal signaling 
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molecules involved in inflammatory responses (COX-2, IL-6), proliferation and 
survival mechanisms (survivin, Akt), cell-cell interactions, pro-invasive and metastatic 
abilities (E-cadherin, CLDN-1, MMP-2 and MMP-9), functions in angiogenesis  
(VEGF-α, HIF-1α and CA-9) and apoptotic cell death mechanisms (caspase-3, BrDu 
assay, DNA fragmentation assay).  
7. Employing experimental techniques listed above, to elucidate the anti-cancer 
activities and underlying mechanisms of action of ART and DHA alone and in 
combination with ASA as a chemo-sensitising agent, in cultured HL-60 and HT-29-
AK cells under different oxygen tensions (20% vs. 1% O2). Because the primary 
mechanisms of action of ART and DHA and ASA are linked with the inhibition of 
COX-2 and induction of caspase-dependent apoptosis it was hypothesized that ASA 
would enhance the cytotoxic effects of ART and DHA. 
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CHAPTER 2 
MATERIALS & METHODS 
2.1. REAGENTS AND CHEMICALS 
ART and DHA were purchased from Dafra-Pharma (Turnhout, Belgium). All the ELISA kits 
which include human IL-6, human VEGF-α165, human sTfR1 and human total survivin were 
purchased from R&D Systems (Abingdon, Oxfordshire, UK). The primers for qPCR include 
CLDN-1, E-cadherin, VEGF-α, survivin and HIF-1α were purchased from Invitrogen 
(Paisley, Renfrewshire, UK). Monoclonal antibodies against phospho-Akt (Ser473), total-
Akt, HIF1-α (anti-human/mouse), MMP-9 (human/mouse) and polyclonal antibody against 
catalytically active cleaved caspase-3 were obtained from Cell Signaling Technology 
(Hitchin, Hertfordshire, UK). Primary antibody against CLND-1 (anti-human/mouse) was 
purchased from Invitrogen (Paisley, Renfrewshire, UK). Anti-hCA9 mouse monoclonal 
IgG2A and fluorescein conjugated mouse monoclonal IgG E-cadherin antibodies were 
purchased from R&D Systems (Abingdon, Oxfordshire, UK). Alexa-conjugated secondary 
antibody (Alexa Fluor 488 goat anti-mouse IgG H+L) was purchased from Molecular Probes 
(UK). Stabilised goat anti-rabbit and anti-biotin HRP-conjugated secondary antibodies were 
purchased from Thermo Scientific Pierce (Rockford, USA).  APO-BrdUTM TUNEL Assay Kit 
was supplied by Life Technologies (Paisley, Renfrewshire, UK). Deferiprone (3-hydroxy-1,2-
dimethyl-4(1H)-pyridone, DFO), 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide 
(MTT), saponin, sodium azide and all other chemicals  and reagents, unless otherwise 
stated, were from Sigma-Aldrich (Poole, Dorset, UK). Culture plastics were purchased from 
Thermo Fisher Scientific (Loughborough, UK). 
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2.2. PROPAGATION OF CANCER CELLS 
2.2.1. Cell lines and culture 
The cell lines HL-60 (human promyelogenous leukaemic), HT-29-AK (human colorectal 
carcinoma) and Caco-2 (human epithelial colorectal adenocarcinoma) were obtained from 
the European Collection of Cell Cultures (ECACC). HL-60 cells were grown in suspension 
and cultured in RPMI 1640 medium obtained through PAA Cell Culture Company 
(Cambridge, UK). HT-29-AK and Caco-2 cell lines were maintained as monolayer cultures 
in MEM (Eagle's, with Earle's salts) medium supplied from PAA Cell Culture Company 
(Cambridge, UK). All media were supplemented with 10% fetal bovine serum (FBS) 
(Biosera, Ringmer, UK), 2mM L-glutamine (PAA Cell Culture Company, Cambridge, UK) 
and 1% antibiotic solution (100 U/ml penicillin, 0.1mg/ml streptomycin) purchased from PAA 
Cell Culture Company (Cambridge, UK). Caco-2 cells were additionally supplied with 1% 
MEM non Essential Amino Acids (Bosera, Ringmer, UK) and 1mM sodium pyruvate 
purchased from Sigma-Aldrich (Poole, Dorset, UK). All of the cells were maintained in the 
log phase of growth to avoid cell differentiation. For experiments performed under standard 
culture conditions, cells were grown at 37 °C in humidified atmosphere with the gas phase 
of 20% O2, 5% CO2, 75% N2 (subsequently reffered to as normoxia). The normoxic 
conditions were obtained by a humidified incubator NuAire NU-5510/E (Polymouth, USA). 
For experiments in low oxygen tension (hypoxia), cells were incubated in a humidified 
Galaxy 48R incubator (New Brunswick Scientific, Cambridge, Cambridgeshire, UK) and 
flushed with 1% O2, 5% CO2, 94% N2 at 37 °C. The hypoxic incubator was turned on one 
hour before the culture flasks with HL-60 and HT-29-AK cells were transferred from 
normoxic conditions (20% O2) to the experimental conditions of hypoxia (1% O2) and grown 
for 72h before any experiments were conducted. 
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2.2.2. Cell harvesting 
The harvesting/collection of cells from tissue culture flasks was performed prior routine 
passaging, experiment setting up or freezing when cells were pre-confluent (middle-late log 
phase) observed as 70-80% confluency. Adherent HT-29-AK and Caco-2 cells were 
harvested by trypsynisation where flasks with cells were removed from incubator and 
depleted in nutrients medium was discarded by aspiration. Cells were washed twice with 
5ml of PBS to remove remaining serum-containing medium and 1ml of proteinase trypsin-
(EDTA) (0.1% trypsin/0.04% EDTA in DPBS) was added to the flasks to cover adhering cell 
layer. Flasks were incubated for 3mins at 37ºC to allow cells to detach. Once sufficiently un-
attached, cells were dislodged by gently tapping the bottom of flask and 5ml of pre-warmed 
complete MEM medium was added to cells to neutralise trypsin. Re-suspended cells in 1:2 
or 1:3 dilutions were sub-cultured into new 75cm2 tissue culture flasks with added 10ml of 
fresh media and were returned to incubator. Optionally, re-suspended cells in complete 
MEM medium were transferred from flasks to universal bottles and used for the 
experimental set-up. Suspension HL-60 cells were harvested by transferring cells from 
flasks to universal bottles, centrifuged (1200 rpm, 2mins) and depleted in nutrients culture 
medium was discarded by aspiration. Cell pellets were re-suspended with 10ml of complete 
RPMI 1640 medium, transferred to fresh 75cm2 flasks and placed to incubator or cell pellets 
were used in experiments. 
2.2.3. Cell counting 
Cell counting involved the use of an electronic counter (NucleoCounter®, Chemometec, 
Allerod, Denmark). Total number of cells in a cell suspension was determined by preparing 
50µl medium-suspended cells, adding 50µl of lysis buffer to permeate the plasma 
membrane of cells, vortexing the mixture and adding 50µl of stabilising buffer to raise the 
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pH value of the mixture. Aliquot 50µl of the stabilised lysate was drawn into 
NucleoCassette® being impregnated with propidium iodine staining the nuclei of cells with 
impaired plasma membranes. The number of cells was automatically determined in the 
NucleoCounter® and multiplied by dilution factor of 3. 
2.2.4. Cryopreservation of cells 
The cell lines were stored in liquid nitrogen to keep stocks for long-term storage. Cells were 
transferred from culture flasks into universal bottles, pelleted by centrifugation (1200 rpm, 
2mins) and the supernatant was discarded without disturbing the cells. Pellets at a density 
of at least 106cells/ml were re-suspended in 1ml of ice-cold freezing solution containing 10% 
dimethyl sulfoxide (DMSO) in FBS. Re-suspended cells were transferred into labelled 1,8ml 
polypropylene cryogenic vials (Fisher Scientific, Loughborough, UK), placed on wet ice 
during the procedure and transferred to a -80ºC freezer overnight before liquid nitrogen 
storage at -190ºC.  
2.2.5. Recovery of cryopreserved cells 
Frozen cells were taken out carefully of the liquid nitrogen and thawed rapidly (<1 min) to 
decrease the toxic effect on cells by DMSO. Cryovials were first placed in a 37ºC water bath 
and gently agitated until the cell suspension was thawed. The content of the cryovials was 
transferred to universal bottles, re-suspended with 5ml of pre-warmed RPMI 1640 or MEM 
complete growth medium and centrifuged (1200 rpm, 2mins). The supernatant containing 
freezing solution was discarded and cell pellets were re-suspended in 10ml of appropriate 
fresh medium prior seeding in 75cm2 cell culture flasks. Flasks were incubated for 24h (at 
37°C, 20% O2, 5% CO2, 75% N2) before medium was exchanged or cells sub-cultured.  
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2.3. Drug solutions                                                                                                       
Stock solutions of ART and DHA were prepared at the concentrations of 0.1, 1.0 10 and 
100mM using sterile DMSO at >99% grade (Sigma-Aldrich, UK). ASA was dissolved in 
DMSO at stock concentrations of 1mM and 10mM. DFO was dissolved in DMSO as a 
10mM stock solution, whereas stock solution of 3.5mM haemin was prepared using 0.1M 
NaOH. The final concentration of DMSO in culture media was less than 0.5%, which 
excluded the toxic effect by DMSO on cell viability. 
2.4. MTT ASSAY 
2.4.1. Measurement of cytotoxicity of ART, DHA and ASA 
The anti-proliferative effects of ART, DHA against HL-60, Caco-2 and HT-29-AK cells were 
measured by the 3-(4,5-dimethyl-thizol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
colorimetric assay. As depicted in figure 8, this assay is based on the ability of viable cells to 
metabolise yellow MTT tetrazolium to form the black formazan crystals by the mitochondrial 
succinate dehydrogenase. Because it was hypothesized that incubation length has an effect 
on the potency of test agents, the MTT cytotoxicity assays were performed for 24, 48 and 
72h of incubation. All of the cell lines at a density of 1x104cells/well were seeded in 96-well 
flat-bottomed microtitre plates (Thermo Fisher Scientific, UK). HL-60 cells were treated with 
varying concentrations of ART or DHA ranging from 0 µM to 100 µM, whereas HT-29-AK 
and Caco-2 cells were exposed to each compound at concentrations ranging from 0 µM to 
750 µM. In similar MTT assay investigations, the cytotoxic effects of ASA (0-60mM) were 
evaluated against HL-60 and HT-29-AK cells and the results were used in subsequent 
combination studies. All of the plates were incubated for 24, 48, and 72h at 37°C either 
under normoxic (20% O2, 5% CO2, 75% N2) or hypoxic (1% O2, 5% CO2, 94% N2) 
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conditions. After incubation, the assays were terminated by adding 20µl of MTT solution at a 
working concentration of 5mg/ml to each well and the plates were incubated for additional 
2h (at 37°C). At the end of the incubation, 100µl of lysis buffer (15% sodium dodecyl sulfate 
in 50% N,N-dimethyl formamide) was added to each well. The plates were incubated 
overnight to dissolve formazan crystals before the optical densities (OD) of the plates were 




Figure 8: Simplified principle of MTT tetrazolium conversion into formazan crystals. 
MTT assay is a colorimetric technique where MTT tetrazolium is converted into black 
formazan crystals by the mitochondrial succinate dehydrogenase being present in highly 
respiring/living cells. The crystals are dissolved by adding lysis buffer to cells, which 
destroys their membranes. The absorbance read at 492nm using a plate reader is 
proportional with the numbers of living cells.  
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2.4.2. Data analysis 
Data were expressed as percentage of control cell growth determined from following a 
formula:  
Percentage of control cell growth = mean absorbance of drug treated wells/ average 
absorbance of control wells) x 100%. 
The IC50 values (the 50% growth-inhibition concentrations) of ART, DHA and ASA at each 
of the incubation periods were estimated from sigmoidal-concentration-response curves of 
the results by the 4-parametric logistic analysis (Grafit Software, Erithacus, Staines, UK). 
Based on the results obtained, HL-60 and HT-29-AK cells as being most susceptible to 
cytotoxic effects of the test agents were used in subsequent investigations. In many of the 
subsequent experiments described herein, fixed concentrations of the test agents were 
used based on previously estimated ½IC50, IC50 and 2xIC50 and etc.  
2.4.3. Cytotoxicity of ART and DHA against confluent HT-29-AK cells 
To investigate whether inoculums size has effect on the potency of test agents in normoxia 
(20% O2), similar MTT assays were performed against confluent HT-29-AK cells. Cells 
(1x104cells/well) were seeded in 96-well flat-bottomed microtitre plates and incubated for 
72h in normoxia as described above until ~80% confluency was reached. Thereafter, 
culture medium was discarded and replaced with fresh medium containing varying 
concentrations (0-750µM) of ART or DHA and incubated for 24h before the assays were 
terminated and analysed as described above.  
2.4.4. Effect of iron on the activity of ART and DHA 
The direct role of iron in the activity of ART and DHA against HL-60 and HT-29-AK cells was 
assessed by MTT assay in normoxia (20% O2) and hypoxia (1% O2). Cells were seeded at 
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1x104cells/well in 96-well flat bottomed microplates, and treated with varying concentrations 
(0-750µM) of ART or DHA in the absence or presence of 60µM (¼ the IC50 value of the iron 
chelator DFO measured) of DFO or iron haemin (at 1 µM or 3 µM) for 24h at 37°C. Following 
incubation, cells were terminated and analysed via Grafit Software as described above. The 
IC50 values for ART and DHA alone and agents in the presence of DFO or haemin were 
compared. 
2.4.5. Cell rate of growth measurements 
The proliferation rate of both cell lines under normoxic (20% O2) and hypoxic (1% O2) 
conditions were investigated using MTT assay. HL-60 and HT-29-AK cells (1x104/well) were 
seeded in 96-well flat-bottomed microtitre plates and incubated for 0, 24, 48, 72 and 96h at 
37°C in normoxia or hypoxia. After incubation, plates were terminated as described 
previously and the OD was measured at 492nm using a plate reader (Anthos Labtech 
Instruments, Anthos 2001, Salzburg, Austria). The mean OD values and standard 
deviations were estimated from at least 3 independent experiments. The mean absorbance 
values derived from both oxygen tensions were analysed and plotted as ordinate, with 
incubation period as abscissa via Grafit Software using a linear model. 
2.4.6. Irreversibility of cancer cell growth upon ART and DHA treatments  
To investigate wheather ART and DHA have the ability to inhibit the re-growth of cancer 
cells, MTT assay with some modifications was performed. Adherent HT-29-AK cells 
(1x104cells/well) were plated in 96-well flat-bottomed microtitre plates, and incubated for 
72h in normoxia (20% O2) without or with ART (at 0µM, 7.22µM, 14.44µM, and 28.88µM) or 
DHA (at 0µM, 9.88µM, 19.75µM and 39.50µM). Following incubation, some of the plates 
were terminated as described above. The other plates had their incubation medium 
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removed and the cells were washed three times in 50µl of drug-free fresh MEM medium. 
Drug-free fresh MEM medium (100µl) was subsequently added to each well and the plates 
were incubated for additional 72h before the assays were terminated as above. In the case 
of HL-60 cells (1x106 cells/5ml/well), the cells were plated in duplicate into 6-well flat 
bottomed plates (Thermo Fisher Scientific, UK) and incubated for 72h without or with ART 
(at 0µM, 0.30µM, 0.60µM and 1.20µM) or DHA (at 0µM, 0.25µM, 0.49µM and 0.98 µM). 
After incubation, an aliquot of cell suspension from the control or drug-treated samples was 
transferred into 96-well flat-bottomed microtitre plates and immediately terminated as 
described previously. The cell suspension remaining in 6-well plates from the drug-treated 
and control samples was accordingly pelleted by centrifugation (1200rpm, 2mins). The 
supernatant from each sample was discarded and the pelleted cells were washed three 
times in drug-free RPMI 1640 medium. Cells were re-suspended in a drug-free fresh RPMI 
1640 medium (100µl) and seeded in 6-well flat bottomed plates and left to grow for 
additional 72h. After incubation cells were plated in 96-well flat-bottomed microtitre plates, 
terminated and the absorbances read at 492nm as described above.  
2.4.7. Combination studies 
The microtitre MTT assay was performed to investigate whether ASA modulates the 
cytotoxicity of ART and DHA against cancer cells under different culture conditions. Cells 
(5x106 cells/75cm2 tissue culture flask) were incubated with a fixed concentration of ASA 
(HL-60 cells under normoxic and hypoxic conditions 2.50mM and 2.21mM, respectively; HT-
29-AK cells under normoxic and hypoxic conditions, 6.15mM and 8.47mM, respectively) and 
incubated for 72h under normoxic (20% O2) or hypoxic (1% O2) conditions, respectively. 
Cells were collected by centrifugation (1200 rpm, 2 mins) and re-suspended in 5ml of fresh 
culture medium. Cells (1x104 cells/well) were seeded in 96-well flat-bottomed microtitre 
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plates and treated without or with varying concentrations of ART or DHA (0-750µM) in the 
presence of fixed concentrations of ASA as stated above. The plates were incubated for 
72h and the assay terminated by adding 20µl of MTT (5mg/ml) followed by a 2 h incubation 
step at 37ºC. The resultant formazan crystals were solubilised by adding 100µl of lysis 
buffer to each well and incubating the plates overnight. OD was measured of each plate and 
data were analysed via Grafit Software as previously. 
2.5. ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAs) 
Enzyme-Linked Immunosorbent Assays (ELISAs) were used to determine the effects of the 
ART and DHA treatment on the cellular level of sTfR1, IL-6, VEGF-α165 and survivin 
according to the manufacturer’s instructions (www.rndsystems.com). HT-29-AK and HL-60 
cells (5x106cells/flask) were incubated for 72h without or with ART and DHA at 
concentrations determined for normoxic (20% O2) and hypoxic (1% O2) experiments. At the 
end of the incubation periods in both conditions, cells were harvested, washed twice in PBS 
(2ml) by centrifuged (1200 rpm, 2mins). Aliquot of the cell-free incubation media (1ml) was 
collected and stored at -20oC for batch analyses for secreted sTfR1, IL-6 and VEGF α165 
levels whereas pellets were used for survivin analysis. 
2.5.1. The Quantikine® Human sTfR1 immunoassay 
For sTfR1 measurements 100µl of sTfR1 assay diluent was loaded into each well of the 96-
well plate, followed by the addition of 20µl of standard or thawed culture media. The plate 
was then incubated at 37ºC for 1h before being washed three times in 400µl wash buffer. 
Then 100µl/well of sTfR1 conjugate was immediately added to each well and the plate 
incubated (1h, at 37ºC). The wash step was repeated and 100µl/well of substrate solution 
was added. The plate was covered in foil to avoid light and further incubated (30 mins, at 
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37ºC). Stop solution (100µl/well) was added and absorbances at 492nm were measured 
immediately using a plate reader (Anthos Labtech Instruments, Anthos 2001, Salzburg, 
Austria).    
2.5.2. The Quantikine® Human IL-6 immunoassay 
The IL-6 assay was performed by pre-coating each well of the 96-well plate with 100µl of 
assay diluent followed by the addition of 100µl of standard or thawed sample culture 
medium. Following incubation (2h, at 37ºC), the plate was washed six times with 400µl 
wash buffer followed by the addition of 200µl/well of IL-6 conjugate After incubation (2h, at 
37ºC), wash step was repeated before 50µl/well of substrate solution was added. The plate 
was incubated (1h, at 37ºC), followed by the addition of 50µl/well of amplifier solution and 
incubated (30mins, at 37ºC). Experiment was finished by addition of 50µl/well of stop 
solution and the plate was read at 492nm. 
2.5.3. The Quantikine® Human VEGF-α165 immunoassay 
Prior VEGF-α165 assay, frozen (at -20oC) aliquot of the cell-free incubation medium was 
defrosted at RT and spun (at 1200rpm, 3mins) to remove cell debris. Assay diluents of 50µl 
was added to each well of the 96 well plate followed by the addition of 200µl/well of 
standard or thawed sample culture medium and the plate was incubated for 2h at 37ºC. 
Plate was washed three times with 400µl wash buffer and 200µl of VEGF-α165 conjugate 
was added to each well before incubation (2h, at 37ºC). After washing plate three times, 
200µl of substrate solution (1:1 with colour reagents A and B) was added and plate was 
incubated in the dark for 25mins. Finally, 50µl of stop solution was added to each well and 
plate was read at 492nm. 
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2.5.4. The Quantikine® Human Survivin immunoassay 
Pellets (2x106 cells) were solubilised in 200µl of lysis buffer before the cell lysates were 
stored at -20ºC and assayed for cellular survivin levels. Thawed samples were centrifuged 
(2500rpm, 5mins) and the supernatant diluted 2-fold in reagent diluent and assay diluents of 
1:1. Standard or diluted sample (100µl/well) was loaded into a 96-well plate and incubated 
for 2h at 37ºC. After washing the plates three times, 100µl/well of diluted total survivin 
detection antibody (1:15 dilution with reagent diluent) was added and  incubated at 37ºC for 
2h. The wash step was repeated and 100µl/well of diluted streptavidin-HRP (1: 200 dilution 
with reagent diluent) was added and incubated (20mins, at 37ºC). After another wash step, 
100µl/well of substrate solution (1:1 with colour reagents A and B) was added and the plate 
was incubated (20mins, at 37ºC,) in the dark before 50µl/well of stop solution was added 
and the absorbance read at 492nm.  
2.5.5. Data analysis 
The absorbances were read within 30mins and the concentrations of sTfR1, IL-6,        
VEGF-α165 and survivin were measured from the standard curve via Grafit Software 
(Erithacus, Staines, UK). 
2.6. REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION (RT-qPCR) 
Real-time qPCR was used to determine the effects of the drug treatment on the cellular 
level of E-cadherin, CLDN-1, survivin, HIF-1α and VEGF-α. Cells, (1x106cells/well) were 
plated in 6-well sterile culture plates (Thermo Fisher Scientific, UK), treated without or with 
test agents alone or in combination with ASA at determined concentrations and incubated 
for 24h and 72h under normoxic  conditions (20% O2). At the end of the incubation periods, 
cells were harvested and washed twice in PBS.  
78 | P a g e  
 
2.6.1. RNA extraction 
Total RNA from cell samples was extracted using Direct-zol RNA MiniPrep kit™ (Zymo 
Reseach, UK) directly from TRI Isolation Reagent® (Zymo Reseach, UK) according to the 
manufacturer’s instructions (www.zymoresearch.com). Pelleted cells in 1,5 ml eppendorf 
tubes were homogenised by adding 800µl of the TRI Reagent® to each sample, mixing well 
by pipetting the mixture up and down and incubating for 5mins at RT. To remove 
particulates from cell lysates, samples were centrifuged (12000 rpm, 1 min, at 4ºC) and the 
supernatant (750µl) was carefully transferred into new eppendorf tubes for RNA purification. 
The same volume of ice-cold 100% ethanol (1:1 of sample homogenate and 100% ethanol) 
was added to each tube and vortexed. Cleared homogenate of 500µl was transferred into 
Zymo-Spin IIC Column™ in a Collection Tube, centrifuged (12000 rpm, 1 min, at 4ºC) and 
the flow-through was discarded. The loading of column with mixture (500µl) was repeated to 
process the volume of all samples. Samples were then washed with 400µl RNA Wash 
Buffer before centrifugation (12000 rpm, 1 min, at 4ºC) and the removal of the flow-through. 
Removal of any genomic DNA contamination was accomplished by adding 80µl of DNase I 
digestion mix (5µl DNase I (1U/µl), 8µl DNase I Reaction Buffer (10x), 3µl DNase/RNase-
Free Water, 64µl RNA Wash Buffer in 80% ethanol) to each column, incubating for 15mins 
at RT and centrifuged (12000 rpm, 30sec, at 4ºC). Columns were transferred into new 
Collection Tubes, washed twice with 400µl Direct-zol™ RNA PreWash by centrifugation 
(12000 rpm, 1 min, at 4ºC) and the flow-through was discarded. Columns were washed with 
700µl of RNA Wash Buffer, centrifuged (12000 rpm, 1 min, at 4ºC) and spun for an 
additional 2 mins in emptied Collection Tubes to ensure residual liquid removal. Columns 
were carefully transferred into fresh 1.5ml eppendorf tubes with lids cut off to allow tubes fit 
the centrifuge. Lids were kept sterile. DNase/RNase-Free Water of 50µl was added to 
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columns matrix and after centrifugation for 1min (12000 rpm, at 4ºC), RNA was eluted and 
kept on ice for immediate complement DNA (cDNA) preparation and the rest stored at -
80ºC. 
2.6.2. RNA concentration and quality 
The concentration and quality of RNA samples were determined using an NanoDrop™ ND-
1000 Spectrophotometer (NanoDrop Technology, Delaware, USA) and/or by Agilent 2100 
Bioanalyser electrophoresis system using the Agilent RNA 6000 Pico Chips (Agilent 
Technologies, USA).  
2.6.3. NanoDrop™ ND-1000 Sectrophotometer 
The concentration and purity of extracted RNA was first measured using NanoDrop™ ND-
1000 Spectrophotometer. After selecting NanoDrop program, machine pedestal was 
vigorously wiped and initialised using sterile MilliQ water (1µl). Aliquot of each sample (1µl) 
being kept on ice was sequentially analysed at 260 wavelength. The ratio of absorbances at 
260nm and 280nm and at 260 and 230 was used to determine the purity of RNA 
(A260/A280>1.8; A260/A230>1.8). 
2.6.4. Agilent 2100 Bioanalyser 
Prior analysis of RNA quality and integrity, sample aliquots were diluted in sterile MilliQ 
water to final RNA concentration of 5ng/µl and kept on ice. Agilent RNA 6000 Pico reagents 
were left on bench to equilibrate to RT for 30mins before assay. The electrodes on the 
bioanalyser were decontaminated before starting and after an assay using electrode cleaner 
chips filled with RNaseZAP or RNAse-free distilled water, accordingly. Stock of gel matrix 
was prepared by filtering 550µl in filter column, centrifuged (4000rpm, 10mins), splitted into 
65µl aliquots in RNAse-free tubes to be kept on ice for immediate use and the rest stored at 
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4 ºC. Stock of dye concentrate was vortexed for 10secs, centrifuged (1200rpm, 2mins), and 
1µl was added to a 65µl gel-matrix aliquot which was then vortexed, centrifuged (12000rpm, 
10mins) and kept on ice covered in foil. Samples and RNA 6000 Ladder (1.2µl) were 
denatured at 70ºC for 2mins in a heating block and placed on ice. RNA Chip was placed 
into Chip Priming Station being set at position C and the syringe clip at the top position. 
Aliquot of 9µl gel-dye mix was gently added into bottom G well, priming station was closed, 
syringe plunger (1ml location) was push down for 30secs and slowly released. Additional 
9µl of gel-dye mix was added to other well marked G and 5µl of RNA 6000 Pico Marker was 
loaded into the 13 remaining wells of the chip. Denatured samples and ladder aliquots of 1µl 
were added to assigned wells, vortexed for 1min within vortex mixer, placed in Bioanalyser 
and run for 30mins using Eukaryote Total Nano Series II assay settings. The observation of 
the distinct 18s and 28s ribosomal peaks, their ratio (28s/18s) and the degradation in the 
peaks was used to assess RNA purity of samples. Representative picture of total RNA from 
cultured HT-29-AK cells upon drug treatment is shown in figure 9.  
 
 
Figure 9: Electrophoretic separation of HT-29-AK cells total RNA upon drug treatment 
with the Agilent 2100 Bioanalyser using RNA 6000 Pico Chip. 
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2.6.5. cDNA synthesis 
First-strand cDNA was synthesised using Tetro cDNA Synthesis Kit (Bioline, UK) according 
to the manufacturer’s protocol (www.bioline.com). Total RNA for cells untreated and treated 
with the drug was prepared at 1µg in MilliQ sterile dH20 to a final volume of 12µl in an 
RNase-free reaction tube and kept on ice. In a separate tube, the priming premix was 
prepared on ice containing 4µl Random Hexamer, 4µl  dNTP mix (10mM), 4µl Ribosafe 
RNase Inhibitor, 4µl Tetro Reverse Transcriptase (200U/µl) and 16µl of 5x RT Buffer. Total 
volume of primer premix (32µl) was gently mixed by pipetting up and down. Primer premix 
(8µl) was added to each of 4 experimental tubes with 12µl of total RNA from each sample 
and gently mixed. The final reaction mixture of 20µl in each tube resulted in dilution of RNA 
to a final concentration of 50ng. The mixture was heated in a Gradient PCR machine 
(Eppendorf Mastercycler Gradient, UK) to 25ºC for 10mins, 45ºC for 30mins and to 85ºC for 
5 mins to denature the reverse transcriptase. The resulting cDNA samples were chilled on 
ice, proceed to qPCR immediately or stored at -20ºC for long term storage. 
2.6.6. qRT-PCR 
The generated cDNA was then used as template for qPCR with the 2x SensiFAST™ SYBR 
Hi-ROX Mix (Bioline, UK) containing the SYBR® Green I dye, dNTPs, stabilizers, enhancers 
and hot-start Taq polymerase to avoid primer-dimer formation. Reaction primer pairs 
(forward and reverse) for genomic DNA targets are presented in table 2. ß-actin was used 
as an internal control for normalisation. Amplification condition for qPCR was performed 
using Hard-Shell® 96-Well Semi-Skirted PCR plate (Bio-Rad, UK) with a 10µl total reaction 
volume per each well composed of 5µl SYBR Mix, 0.4µl of each primer (10µM), 1µl cDNA 
template and 3.2µl MilliQ dH2O. For each sample, the gene of interest ‘target’ and gene 
used for normalisation ‘reference’ which was β-actin, together with included no template 
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negative control (MilliQ sterile dH20 instead of template cDNA) was measured in triplicate. 
PCR plate was sealed using Microseal® ‘B’ Adhesive film (Bio-Rad, UK), centrifuged 
(1200rpm, 30secs, 4ºC) and run on a BioRad CFX Connect Real Time System (Bio-Rad, 
UK). PCR thermocycling included an initial denaturation step at 95°C for 2mins, followed by 
39 cycles of 95°C for 10s, annealing at 55°C for 30s and elongation for at 72°C for 60s. The 
melting curves of PCR amplicons were obtained with temparatures ranging from 65°C to 
95°C with a 0.5°C increase in temperature for 0.05s.  
Table 2: Primer sequences for qPCR and expected PCR products (bp).  
Gene  Primer sequence (5'→3') Product (bp) 
β-actin 
Forward: CTG GAA CGG TGA AGG TGA CA 
Reverse: AAG GGA CTT CCT GTA AAC AAT GCA 
168 
CLDN-1 
Forward: CTG TCA TTG GGG GTG CGA TA 
Reverse: CTG GCA TTG ACT GGG GTC AT 
118 
E-cadherin 
Forward: GGT GCT CTT CCA GGA ACC TC 
Reverse: GAA ACT CTC TCG GTC CAG CC 
195 
HIF-1α 
Forward: AAG GTG TGG CCA TTG TAA AAA CTC 
Reverse: GCA TCA GTA GTT TCT TTA TGT ATG 
167 
Survivin 
Forward: GTT CTT TGA AAG CAG TCG AG 
Reverse: GCC AGT TCT TGA ATG TAG AG  
341 
VEGF-α 
Forward: GAG ATG AGC TTC CTA CAG CAC  
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2.6.7. Quality determination of qRT-PCR products 
The results of the qRT-PCR amplifications were analysed by a melt curve observation 
and/or by individual DNA band visualisation on a 2µl ethydium bromide (5mg/ml) stained 
2% agarose gel in 50ml sterilised TBE buffer (0.1M Tris base, 0.1M Boric acid and 2.55mM 
EDTA Na2 2H2O, pH 8). Briefly, 0.7g of agarose powder (Sigma Aldrich, UK) in 35ml TBE 
buffer was heated carefully in microwave for 1mins and transferred to water bath (at 55ºC) 
for 10mins. Resulting 2% agarose gel was impregnated with 2µl ethidium bromide and 
poured into the gel tank to settle down for 20 mins. Combs forming 8 wells were removed 
and 50ml of TBE buffer was poured to a tank. The wells were loaded with 10µl of PCR 
product mixed with 2µl loading dye (6x) and with 3µl of molecular marker GeneRuler 1kb 
Plus DNA Ladder (Thermo Scientific, Hampshire, UK) in a separate well. DNA bands were 
separated on a Power-Pac (Bio-Rad, UK) at 50mA for 25 mins and visualised under a UV-
light in GEL-DOC Imager (Bio-Rad Laboratories, USA). 
2.6.8. mRNA concentration calculations 
The mean threshold cycle values (Ct) determined for target genes and reference β-actin 
were used to calculate ΔCt (ΔCt = Ct of the target gene - Ct of the reference gene). The fold 
change in mRNA expression levels of target genes in drug treated cells as compared to 
untreated cells were determined using the 2ˉΔΔCt method in the following formula 2-(ΔCt of 
drug treated group – ΔCt of control group). The normalised quantification values were 
ultimately expressed as relative fluorescence units (RFU) with a normalisation of the relative 
quantities of all target (gene) expression to the control quantity representing a value of 1.  
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2.7. IMMUNOCYTOCHEMISTRY STAINING 
Immunocytochemistry was performed against adherent HT-29-AK cells to determine the 
effects of the drug treatment on the cellular localisation and intensity staining of CA-9,         
E-cadherin and CLDN-1. Cells (4x104cells/well) were seeded on 19mm glass coverslips in 
sterile 24-well tissue culture plates (Thermo Fisher Scientific, UK), and immediately treated 
without or with ART and DHA at specific concentrations before being incubated for 24 and  
72h at 37°C in normoxia (20% O2), respectively. At the end of the incubation periods, cells 
were fixed using paraformaldehyde method (for CA-9) or ice-cold methanol method           
(for E-cadherin and CLDN-1).  
2.7.1. Paraformaldehyde fixation method and primary antibody staining 
In CA-9 staining, cells were fixed by adding 100µl of 37% paraformaldehyde (Sigma Aldrich, 
UK) to cells with growth medium for 30mins. Thereafter, growth medium-paraformaldehyde 
mixture was removed and each cover slip was incubated in 500ul of blocking buffer (0.5% 
BSA and 0.1% saponin in PBS) for 1h at RT followed by incubation with 150µl of CA-9 
primary antibody (5µg/1000µl) overnight at 4ºC, in the dark.  
2.7.2. Methanol fixation method and primary antibody staining 
In E-cadherin and CLDN-1 staining, the growth medium was removed from the wells and 
cells were washed three times with PBS, fixed in 500µl of 100% ice-cold methanol for 
5mins, and incubated in 500µl blocking buffer (0.5% BSA and 0.1% saponin in PBS) for 1h 
at RT. Coverslips were bound in 250µl of primary antibody (E-cadherin and CLDN-1 
antibodies; dilution 1:1000) overnight at 4ºC, in the dark. 
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2.7.3. Secondary antibody staining and confocal microscopic analysis 
After incubation with primary antibodies in paraformaldehyde and methanol fixation 
methods, cells were washed three times in PBS and incubated with  250µl of the Alexa goat 
anti-mouse IgG conjugated secondary antibody (Invitrogen, UK) diluted 1:1000 with 
blocking buffer (0.5% BSA and 0.1% saponin in PBS) for 1h at RT, covered in foil. 
Coverslips were transferred into glass slides, mounted using DPX Mounting Medium (Fisher 
Scientific, Loughborough, Leicestershire, UK), and visualised on a confocal microscope 
(Zeiss LSM 510 META, Germany) at x 200 magnification using green argon laser at 488mn 
wavelength. Additionally, a He-Ne laser set to 543nm was used for phase contrast pictures 
acquisition. The objective used was EC Plan-Neofluar 20x/0.50 M27 and the pinhole 
channel set at 76µm.   
2.7.4. Data analysis 
The experiments were repeated at least two times and the representative images (from at 
least 10 images per coverslips) shows the localisation of specific protein in the majority of 
the cells being analysed by Zeiss laser scanning confocal microscope AIM Software 
(version 4,2,0,0). The scoring of target protein staining, localisation and intensity frequency 
was performed first by AIM Software settings optimisation for each fluorescent protein to 
obtain the highest signal-to-noise ratio followed by stack imaging (x- y- z- axis) and by using 
intensity frequency tools of AIM Software.  
2.8. IN VITRO CELL SCRATCH WOUND ASSAY 
2.8.1. Scratch wound assay of confluent HT-29-AK cells 
For the in vitro wound healing assay, HT-29-AK cells (2x106/well) were seeded in 12-well 
flat bottomed plates (Thermo Fisher Scientific, UK) and grown for 3-4 days in normoxia 
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(20%  O2, 5% CO2, at 37°C) until confluency was reached. At the appropriate time, a wound 
was created in some, but not all of the wells of the plates, by scrapping across the 
monolayer using the tip of a sterile 10µl Gilson pipette. The non-adherent cells were 
carefully removed by washing the wells three times with MEM medium supplemented with 
10% FBS.  Before cells were treated without or with ART and DHA, the diameter of the 
wounds of each well was monitored using a light microscope with a digital camera (3.0 
Mega CMOS; Resolution 640x480; Premire® Texas, USA), photographed and analysed at 
four marked field of view per well using the TS view image analysis package (TS View 
Version 6.12.9). Cells were then incubated (at 37°C, 72h) with 2ml of fresh MEM medium 
and were treated with the drugs concentrations estimated on confluent cells (ART: 95.31µM, 
190.62µM, 381.24 and 953.10µM; DHA 54.27µM, 108.53µM, 217.06 and 434.12µM). After 
incubation, the number of viable cells was assessed using the tryptan blue dye exclusion 
assay. Briefly, 50µl of the incubation medium was mixed with 50µl tryptan blue (Sigma 
Aldrich, UK) composed of 0.4% tryptan blue solution in 0.85% NaCl. An aliquot (~10µl) of 
this suspension was loaded onto a haemacytometer and counted using a light microscope 
at 10x magnification (Mazurek, Medilux-12, Southam, Warwickshire, UK). The average of 
viable cells were counted from four 1mm2 squares of a haemocytometer chamber, 
multiplied by the dilution factor of 2 and multiplied by 104 to estimate cell number in 1ml. 
The rest of the incubation medium containing the non-adherent/dead cells was removed 
and discarded before the wells were washed three times in fresh drug-free medium, with the 
wound diameter measured after the second wash. Assays were further incubated for 96h 
(20% O2, 5% CO2, 37°C) in fresh media without or with the test agents in the appropriate 
wells as before. The viable cell count was repeated using the tryptan blue exclusion assay 
and the diameter of the wound of each well also measured as described.  
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2.8.2. Data analysis 
The mean number of dead cells and wound diameter were estimated from 2 independent 
experiments for each drug treatment and plotted against the concentrations of ART and 
DHA using Grafit Software. 
2.9. FLOW CYTOMETRIC ANALYSIS OF PROTEIN LEVELS                                                               
2.9.1. Intracellular protein staining 
2.9.1.1. Intracellular expression levels of COX-2, CLDN-1, catalytically active caspase-3, 
phospho-Akt, MMP-2 and MMP-9 
To investigate the effects of drug treatment on the intracellular expression levels of proteins, 
the fluorescence activated cell sorter (FACS) analysis was performed. Cells 
(5x106cells/flask) were incubated without or with the drugs alone or in combination with ASA 
at concentrations described previously for 72h at 37°C in normoxia (20% O2). After 
incubation, cells were collected and washed three times in PBS (5ml) by centrifugation 
(1200rpm for 5min). Cell pellets were fixed by being re-suspended in 250µl of PBS and 
250µl of 6% formaldehyde, and incubated for 10mins at 37°C. Samples were then placed 
on ice for 1 min before being centrifuged (1200rpm, 5min). The cell pellets were blocked for 
30 mins in 1ml of ice-cold 90% methanol and later stored at -20ºC for batch analyses. 
Thereafter, thawed cells were centrifuged at 1200rpm for 5min and the supernatant 
discarded. The pellets were washed twice in 200µl of incubation buffer (0.5% BSA and 
0.1% saponin in PBS; stored at 4ºC) by centrifugation (at 1200rpm for 5min) and blocked for 
10min in 100µl of incubation buffer. The cell pellets were collected by centrifugation and re-
suspended in 100µl of following antibodies: CLDN-1 (dilution 1:1000), caspase-3 (dilution 
1:100), phospho-Akt (dilution 1:100), COX-2 (dilution 1:80), MMP-2 (dilution 1:14) and 
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MMP-9 (dilution 1:14) and incubated in the dark for 1h. Thereafter, cells were washed in 
100µl of incubation buffer and re-suspended in 0.5ml PBS. Finally the cells were transferred 
into Falcon™ round-bottom polystyrene tubes (Fisher Scientific, UK) and analysed on BD 
FACS Calibur ® flow cytometer (Becton Dickinson) using the FL-1 channel with an excitation 
wavelength of 488nm.  
2.9.1.2. Intracellular levels of HIF-1α 
In order to investigate intracellular levels of HIF-1α, the thawed cell pellets were washed 
twice in 300µl of Hanks’ Balanced Salt Salution (HBSS) by centrifugation (1200rpm, 5min). 
The pelleted cells were then re-suspended in 0.8 ml of SAP buffer (0.1% saponin, 0.05% 
NaN3 in HBSS), centrifuged (1200rpm, 5min) followed by discarding of 600µl of the 
supernatant from each eppendorf tube. To remaining 200µl of SAP buffer, 10µl of antibody 
conjugate was added and the samples were incubated in the dark for 45min at 37°C. 
Subsequently, the samples were washed twice in 0.8 ml of SAP buffer by centrifugation 
(1200rpm, 5min) before the samples were finally re-suspended in 800µl of PBS samples 
and analysed by flow cytometer as above.  
2.9.2. Cell surface protein staining 
2.9.2.1. Cell surface levels of E-cadherin and CA-9 
The fluorescence levels of E-cadherin and CA-9 on cell surfaces were measured by 
terminating the flasks after incubation with/without ART and DHA (as described above) by 
transferring the content of flasks to labelled universal bottles, centrifugation (1200rpm, 5min) 
and discarding the supernatant. The cell pellets were then washed three times in 250µl of 
incubation buffer (PBS supplemented with 0.5% BSA; stored at 4ºC) by centrifugation 
(1200rpm, 5min) and Fc-blocked using 1µg of anti-human IgG-Fc antibody (abcam®, UK) in 
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100µl of incubation buffer for 15mins at RT. The pellets were collected by centrifugation (at 
1200rpm for 5min), re-suspended in 30µl of E-cadherin and CA-9 antibodies (1:3 dilution) 
prior to incubation for 45mins at 4ºC. Following incubation, un-reacted antibodies were 
removed by washing the cells twice in 250 µl of incubation buffer by centrifugation 
(1200rpm, 5min) and finally the cells were re-suspended in 0.5ml PBS for flow cytometric 
analysis using 488nm wavelength laser excitation as described previously. 
2.9.3. Data analysis 
Data were analysed with the CellQuestTM software (Becton Dickinson, USA). The 
fluorescence of the cells was plotted against a total of 10 000 events and the results were 
expressed on a logarithmic scale from which relative fluorescence units were measured 
(RFU). RFU of analysed samples were ultimately normalised where ART, DHA and ASA 
treated cells were expressed relative to untreated cells (control) representing a value of 1. 
2.10. WESTERN BLOTTING      
Cells were seeded at a density of 5x106cells into 75cm2 tissue culture flasks and treated 
with ART and DHA for 24h or 72h at 37ºC in normoxia (20% O2). After incubation, cells 
were collected by centrifugation (1200rpm, 5mins), washed three times in PBS and proceed 
to protein extraction.  
2.10.1. Extraction of protein from cultured cells 
2.10.1.1. Extraction of protein using syringe with a 27-gauge hypodermic needle 
The pelleted cells in plastic universal bottles were re-suspended in ice-cold 150µl of protein 
lysis buffer (100 mM NaCl, 10 mM (pH 7.6) Tris, 1 mM (pH 8) EDTA, 2 mM sodium 
pyrophosphate, 2 mM sodium fluoride, 2 mM β-glycerophosphate supplemented with 
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protease inhibitors of phenylmethylsulfonyl fluoride (0.1 mg/ml), 0.1 μg/ml aprotinin and 0.1 
μg/ml leupeptin) and placed on ice to prevent denaturation of proteins. Samples were 
triturated on ice using syringe with a 27-gauge hypodermic needle (Becton Dickinson BD, 
UK) by pumping twenty times the mixture slowly into the syringe and ejecting with a single 
vigorous stroke. Samples were incubated on ice for 30 mins. The cell lysates were clarified 
of cell debris by centrifugation (14000rpm, 30mins, at 4ºC) and supernatant was transferred 
into new labelled eppendorf tubes. Protein concentration in lysates was measured at 280nm 
using a Nano-Drop Spectrophotometer (ND-1000 3.3 software, Labtech International, UK). 
In ratio 1:1, 100µl of cell lysates was mixed with 100µl of sample buffer (100mM Tris-Cl, (pH 
6.8), 20% glycerol, DTT 200mM, 0.2% bromophenol blue in 2.5% SDS) and denatured at 
95ºC for 10mins  before being centrifuged at 4000rpm for 30 sec. Samples were chilled on 
ice prior electrophoretic separation or stored at -20ºC. 
2.10.1.2. Extraction of protein using sonicator 
To improve quality and quantity of extracted proteins, collected cells were sonicated with an 
ultrasonic probe. The procedure was normalised first by preparing the pellet of untreated 
HL-60 cells in a universal bottle, re-suspending with 900µl of ice-cold lysis buffer and 
dividing into 6 tubes with equal volume of 150µl cell-lysis buffer mixture and were kept on 
ice. Tubes were analysed either under earlier established homogenisation method with 
syringe or under different test conditions prepared for sonication procedure. The optimal 
procedure of sonication resulted in increased the concentration of proteins by about 3-fold 
without compromising its quality as compared to extraction using the syringe. Here, tube 
with cells was placed in a backer with ice and sonicated using an ultrasonic probe for 3 
cycles lasting 5secs each with 30secs intervals. Homogenised cells were clarified by 
centrifugation (14000rpm, 30mins, at 4ºC) and lysates were transferred into new eppendorf 
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tubes to be quanified as described previously, used in SDS-PAGE electrophoresis or stored 
at -20ºC. 
2.10.2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Equal amounts of sample protein lysates (60µg/well) prepared in total 20µl volume with 
sample buffer were separated by SDS-PAGE. 12-well Mini-Protean® TGX Stain-FreeTM Any 
kD™ Precast Gels (Bio-Rad, UK) were placed into an Mini-PROTEAN® electrophoresis 
tank (Bio-Rad, UK). Approximately 150ml and 500ml of 1x running buffer composed of 
glycine 14.42g/l, SDS 1.0g/l and Tris 3.0 g/l was poured into the inner and outer chambers 
of tank, respectively and the gel combs were carefully removed. Samples were loaded to 
the wells alongside the protein molecular markers, 5µl (10-250kD) Precision Plus Protein™ 
Kaleidoscope™ (Bio-Rad, UK) and 5µl (9-200kDa) Biotylated Protein Ladder (Cell 
Signalling Technology, UK). The gel was run for 90min at 130V using Power-Pac 3000 (Bio-
Rad, UK). 
2.10.3. Transfer to PVDF membrane 
Following electrophoresis, gels were removed from glass plates and placed into stain-free 
tray for Coomassie-like stain-free gel imaging on a Gel Doc™ EZ imaging system (Bio-Rad, 
UK) to visualise protein separation, ensure equal protein loading across samples and to 
verify protein transfer before immunoblotting (figure 10A). Transfer stack compromised of 7 
layers of filter pads was placed on the bottom of transfer cassette electrode (anode) 
followed by polyvinylidene fluoride (PVDF) membrane (Trans-Blot® Turbo™ 0.2µm Midi 
PVDF Transfer Packs,Bio-Rad, UK), gel and second transfer stack on the top of cassette. 
During the procedure the air bubbles were removed using blot roller, cassette was closed 
using cassette lid (cathode) and placed into Trans-Blot® Turbo™ Transfer System          
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(Bio-Rad, UK). Protein bands transfer was conducted for mixed molecular weight settings of 
7mins at 55V, 1.3A. Membranes were verified again for quality of protein transfer under Gel 
Doc™ EZ imaging system (Bio-Rad, UK) with stain-free tray for Ponceau-like stain-free 
membrane imaging (figure 10 B). 
 
Figure 10: Representative Images of protein transfer and separation using a stain-
free Gel Doc™ EZ imaging system (Bio-Rad, UK). Pictures showing A) total protein 
smears with estimated location of investigated proteins and B) PVDF membrane after 
protein transfer. MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9;    
p-Akt, phospho-Akt; t-Akt, total-Akt. 
2.10.4. Immunolabelling and detection 
To avoid non-specific binding, membranes were blocked with 25ml of 5% fat-free dry milk in 
Tris-buffered saline + 0.1% Tween®-20 (TBS/T) and placed on an orbital shaker for 1h at 
RT. Subsequently, membranes were probed 5ml of pre-titrated primary antibodies (1:1000 
dilution) in antibody dilution buffer (0.25g BSA (5%), 0.25g dehydrated Marvel milk in 
TBS/T), placed on a roller mixer and incubated at 4ºC overnight. Unbound primary 
antibodies were removed by washing the membrane three times for 5 mins in 10ml TBS/T 
on an orbital shaker for 1h at RT. Membranes were then probed with 15ml of infra-red goat 
anti-rabbit IgG and infra-green anti-biotin HRP-conjugated secondary antibody dilutions 
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(1:7500 dilution), incubated on an orbital shaker for 1h at RT and excess of secondary 
antibodies was removed were through three washes (5mins/wash) in 10ml TBS/T. 
Immunodetection was performed using Super Signal® West Femto Maximum Sensitivity 
Substate chemiluminescent kit (Thermo Scientific Pierce, UK) according manufacturer’s 
instructions and analysed under a UV-light in Chemi-Doc™ MP Imaging System (Bio-Rad, 
UK). 
2.10.5. Membrane stripping and re-probing 
Membrane stripping allowed detection of the next protein through removing initially bound 
antibody without losing the target protein. For total antibody detection, membrane previously 
probed with phospho antibody were always stripped by boiling the membrane for 5 mins in a 
glass backer with distilled water, re-blocking in 5% fat-free dry milk in Tris-buffered saline + 
0.1% Tween®-20 (TBS/T) for 1h at RT and incubating with the different primary antibody.  
2.10.6. Densitometry 
The band intensity of samples from at least one experiment was quantified using 
densitometry software (Quantity One, Version 4.6.3, Bio-Rad Laboratories). β-actin was 
used as an internal control to ensure equal loading of proteins and additional normalisation 
between the samples. The procedure involved calculation of ratio between experimental 
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2.11. APO-BrdU™ TUNEL ASSAY 
APO-BrdUTM terminal deoxynucleotidyl transferase-mediated nick end labelling (TUNEL) 
Assay (Life Technologies, UK) was used to determine whether ART- and DHA-induced cell 
death is incorporated with BrdU (5-bromo-2-deoxyuridine), a structural analog of thymidine 
being present at 3’-OH DNA break sites of apoptotic cells. Cells (5x106 cells/flask) were 
incubated in the absence or presence of ART and DHA for 24h or 72h in normoxia (20% O2) 
at concentrations stated previously. Following the manufacturer’s instructions, culture flasks 
were terminated and collected cells were re-suspended in 250µl of PBS, fixed in 250µl of 
6% formaldehyde at 37°C for 10 minutes and placed immediately on ice for 2 mins. 
Samples were centrifuged at 1200 rpm for 2mins, before being permeabilised in 1ml of ice-
cold methanol (90%) and left on ice for 30 mins. Samples were centrifuged (1200 rpm, 
2mins), methanol was aspirated and cells washed twice in 1ml of wash buffer. DNA-
labelling solution (50µl) was added and samples were incubated at 37°C for 1h. Samples 
were rinsed twice in 1ml of rinse buffer and centrifuged (1200 rpm, 2mins). The supernatant 
was discarded and cells were re-suspended in 100µl of antibody staining solution and 
incubated in the dark for 30 mins. Propidium iodine/RNase staining buffer (0.5ml) was 
added to samples and incubated in the dark for 30 mins before the samples were analysed 
on BD FACS Calibur ® flow cytometer (Becton Dickinson) at 488nm wavelength laser 
excitation. The principle of APO-BrdU™ TUNEL Assay is presented in figure 11.  
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Figure 11: The principle of APO-BrdU™ TUNEL Assay. The determination whereby the 
drugs-induced cell death is linked with BrdU (5-bromo-2-deoxyuridine), a structural analog 
of thymidine being present at 3’-OH DNA break sites of apoptotic cells was investigated by 
flow cytometric analysis. To fixed samples the deoxythymidine analog 5-bromo-2’-
deoxyurdine 5’-triphosphate (BrdUTP) and deoxynucleotidyl transferase (TdT) were added 
resulting in labelling DNA break sites which were detected by staining with anti-BrdU 
antibody (modified from www.phnxflow.com and www.lifetechnologies.com). 
2.12. AGAROSE GEL ELECTROPHORESIS OF DNA 
Agarose gel electrophoresis is a method used to separate DNA fragments based on their 
molecular size. It was performed to evaluate the effects of ART and DHA on DNA 
fragmentation. Cells (5x10⁶cells/flask) were treated without or with the drugs and incubated 
for 72h in normoxia (20% O2). Cells were collected and re-suspended in 200µl medium and 
DNA was isolated from samples using the Qiagen kit (Crawley, UK), according to 
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manufacturer’s instructions. The DNA concentration in each sample was measured using 
Nano-Drop™ ND-1000 Spectrophotometer (ND-1000 3.3 software, Labtech International, 
UK). Equal amounts of purified DNA (50ng/µl or 70ng/µl) were prepared in total volume of 
25µl mixed with 5µl of 6x DNA loading dye. Agarose  gel buffer was composed of Tris Base 
10.8g, Boric acid 5.5g, EDTA Na2 H2O 0.95g filled to 1l with dH2O; pH 8.0 and sterilised. 
Agarose powder (Sigma Aldrich, UK) at 0.28g was added to agarose gel buffer aliquots of 
35ml and the mixture was heated carefully in microwave oven for 1mins then transferred to 
water bath (at 55ºC) for 10mins. Agarose gel (0.8%) was impregnated with 2µl ethidium 
bromide (5mg/ml in dH2O) and poured into the gel tank to settle down. Combs forming 8 
wells were removed and 50ml of agarose gel buffer was additionally poured to a tank. The 
molecular marker used for DNA fragments size assessment being a α/ Eco 1301 16 or 
GeneRuler 1kb Plus DNA Ladder (Thermo Scientific, Hampshire, UK) alongside samples 
were loaded to wells. As a positive control, 50ng/µl or 70ng/µl DNA from a heat-treated 
control (at 95°C for 20 mins) was used. Samples were separated on a Power-Pac (Bio-Rad, 
UK) at 50mA for 25 mins and visualised under a UV-light in GEL-DOC apparatus at 366nm. 
2.13. STATISTICAL ANALYSIS 
Data were expressed as mean ± SD of at least three independent experiments and 
analysed for normality of distribution using the Shapiro-Wilk test. Statistically significant 
differences between control and appropriate drug treated samples were determined by the 
non-parametric Mann-Whitney-U-test and parametric Paired T- test or One Way Anova 
(Turkey test with multiple comparison or Dunnett test for comparison with control).  P ≤ 0.05 
was considered as statistically significant.   





PART I: THE ANTI-CANCER ACTIVITY AND MOLECULAR MECHANISMS OF ACTION 
OF ART AND DHA AGAINST HT-29-AK AND HL-60 CELLS UNDER NORMOXIC 
CONDITIONS   (20% O2) 
3.1. ART and DHA display growth inhibitory activities against HL-60, HT-29-AK and 
Caco-2 cells in vitro under standard normoxic conditions. 
The aim of this study was to investigate the anti-cancer effects of ART and DHA, which are 
two main pharmacologically active metabolites of artemisinin derivatives, against human 
leukaemia HL-60 and CRC HT-29-AK and Caco-2 cells. Previous reports demonstrate that 
ART and DHA show anti-cancer effects against different cancer cell types both in vitro and 
in vivo (Efferth et al. 2002 and 2003; Lu et al. 2008). Therefore, the cytotoxicity of ART and 
DHA was first evaluated against all cell lines in normoxia (20% O2, 5% CO2, at 37°C) to 
identify agreement or to challenge previous experimental reports and to establish ART and 
DHA concentrations needed in subsequent mechanistic studies. As it was widely reported 
that 1,2,4-trioxanes exhibit their inhibitory activities in a time- and concentration dependent-
manner (Lu et al. 2008; Zhou and Wang 2008; Lijuan et al. 2010), the cells were exposed to 
varying concentrations of ART and DHA (HL-60cells at 0-100µM; HT-29-AK and Caco-2 
cells at 0-750µM ) for 24, 48, 72h. The percentage of viable cells for each drug derived for 
specific cell line and time point was determined by thiazolyl blue MTT cytotoxicity assay as 
described in Materials & Methods (Sections 2.4.1. and 2.4.2) The results were then 
expressed as IC50 values (the 50% growth-inhibition concentrations) from sigmoidal-
concentration-response curves by the 4-parametric logistic analysis via Grafit Software and 
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used in the subsequent experimental settings (Materials & Methods, Sections 2.4.1. and 
2.4.2).  
The results presented in table 3 show that ART and DHA inhibited the growth of all cell lines 
in a time-dependent manner, with cells being differentially susceptible to the drugs. From 
IC50 values in table 3, it is evident that HL-60, HT-29-AK and Caco-2 cells are most 
susceptible to the inhibitory effects of the drugs following 72h incubation and are least 
susceptible to the agents at 24h. Consistently with previous reports (Mercer et al. 2007; Hou 
et al. 2008; Lu et al. 2008; Zhou and Wang 2008; Lijuan et al. 2010), the study shows that 
ART and DHA are potent but show different inhibitory effects against the different tissue 
types (leukaemia vs. CRC) (table 3). Human leukaemia HL-60 cells were the most sensitive 
to ART and DHA while both HT-29-AK and Caco-2 colon cancer cell lines showed reduced 
susceptibility to drugs (table 3). Moreover, ART and DHA displayed distinct cytotoxic effects 
not only against different cancer types but also against different malignant differentiation 
state between cell lines derived from the same origin, gastrointestinal tract. Thus, ART     
and DHA were more cytotoxic at all incubation time points against well-differentiated CRC       
HT-29-AK cells in comparison to poorly-differentiated CRC Caco-2 cells (table 3). Prutki et 
al. (2006) reported previously that well-differentiated CRC cells had higher levels of TfR1 
(responsible for iron endocytosis), as compared to poorly-differentiated cells. The findings 
indicate that the TfR1 diversity exhibited by well- and poorly-differentiated cancer cell lines 
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Table 3: The effect of ART and DHA against HL-60, HT-29-AK and Caco-2 cells for 24h, 
48h or 72h cultured in normoxia. Data points are means ± SD of at least three 






Cell lines  
HL-60 HT-29-AK Caco-2 
IC₅₀ (µM, Mean±SD) 
24 
ART 1.96 ± 0.28  165.06 ± 24.25    448.34 ± 59.49    
DHA 0.70 ± 0.12  58.02 ± 4.09  213.04 ± 24.47 
48 
ART 0.71 ± 0.15*** 64.61 ± 6.61*** 319.45  ± 62.10***  
DHA 0.65 ± 0.09  38.28 ± 2.44***  167.69± 17.72*** 
72 
ART 0.60 ± 0.08***  14.44 ± 2.64*** 42.13 ± 9.61*** 
DHA 0.49 ± 0.03** 19.75 ± 1.07*** 76.42 ± 8.14*** 
 
The inhibitory effects against cancer cells were further drug specific. DHA displayed the 
most potent activity against HL60 cells with IC50 values of 0.70 ± 0.12µM, 0.65 ± 0.09µM 
and 0.49 ± 0.03µM, as compared to ART values of 1.96 ± 0.28µM, 0.71 ± 0.15µM and 0.60 
± 0.08µM for 24, 48 and 72h incubations, respectively (table 3). After 72h where both drugs 
were most potent, DHA with an IC50 value of 0.49 ± 0.03µM was ~1.22 fold more potent 
(P<0.001), as compared to ART with an IC50 value of 0.70 ± 0.124µM (table 3). The 
concentration-response survival curves in figure 12 show that the cells are most susceptible 
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Figure 12: Concentration- and time-response effects of ART and DHA on the growth 
of HL-60 leukaemia cancer cells cultured in normoxia for 24-72h. The MTT assay was 
performed by treating HL-60 cells with varying concentrations (0-100µM) of A) ART and B) 
DHA for 24, 48, and 72h in normoxia (20% O2) as described in Materials & Methods 
(Sections 2.4.1. and 2.4.2). Data points are means ± SD of at least three independent 
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Similar observations were reported between ART and DHA against HT-29-AK and Caco-2 
cells (table 3). The inhibitory profile of the agents against well-differentiated HT-29-AK cells 
over the incubation periods were as follows: ART, 165.06 ± 24.25µM, 64.61 ± 6.61µM and 
14.44 ± 2.64µM at 24h, 48h and 72h, respectively (table 3). DHA significantly inhibited the 
growth of the cells resulting in IC50 values of 58.02 ± 4.09µM, 38.28 ± 2.44µM and 19.75 ± 
1.07µM for 24, 48 and 72h incubation, respectively (table 3). DHA displayed a significant 
(P< 0.001) cytotoxic activity against HT-29-AK cells over ART for 24h (58.02 ± 4.09µM vs. 
165.06 ± 24.25µM) and 48h (1.69~fold; 38.28 ± 2.44µM vs. 64.61 ± 6.61µM). In contrast, 
ART after 72h incubation was significantly (P< 0.001) more cytotoxic as compared to DHA 
(14.44 ± 2.64µM vs. 19.75 ± 1.07µM. The concentration-response curves for ART and DHA 
against HT-29-AK cells after 24, 48 and 72h incubation are shown in figures 13A and 13B.  
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Figure 13: Concentration- and time-response effects of ART and DHA on the growth 
of HT-29-AK CRC cells cultured in normoxia for 24-72h. The MTT assay was performed 
by treating HT-29-AK cells with varying concentrations (0-750µM) of A) ART and B) DHA for 
24, 48 or 72h in normoxia (20% O2) as described in Materials & Methods (Sections 2.4.1. 
and 2.4.2). Data points are means ±SD of at least three independent experiments with 18 
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In poorly-differentiated Caco-2 cells, ART inhibitory activities were as follows:               
448.34 ± 59.49µM, 319.45 ± 62.10µM and 42.13 ± 9.61µM after 24h, 48h and 72h, 
respectively (table 3). DHA was more potent over ART after 24h and 48h resulting in IC50 
values of 213.04 ± 24.47µM, 167.69 ± 17.72µM respectively (table 3). Following 72h, DHA 
was less potent than ART with cytotoxic activity against Caco-2 cells of 76.42 ± 8.14µM     
(table 3). The concentration-response curves for ART and DHA against Caco-2 cells after 
24, 48 and 72h incubation are shown in figures 14A and 14B.  
Due to relatively low activity of ART and DHA against Caco-2 cells, in the subsequent 
experiments HL60 cells and HT-29-AK cells were investigated. Having acquired the IC50 of 
the agents alone, the mechanistic basis of the effects of the drugs were evaluated at three 
selected concentrations based on their ½IC50, IC50 and 2xIC50 obtained under that 
experimental condition. 
 
104 | P a g e  
 
 
Figure 14: Concentration- and time-response effects of ART and DHA on the growth 
of Caco-2 CRC cells cultured in normoxia for 24-72h. The MTT assay was performed by 
treating the cells with varying concentrations (0-750µM) of A) ART and B) DHA for 24, 48 or 
72h in normoxia (20% O2) as described in Materials & Methods (Sections 2.4.1 and 2.4.2). 
Data points are means ±SD of at least three independent experiments with 18 replicates; 
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3.2. Cytotoxicity of ART and DHA against HT-29-AK is dependent on the proliferation 
state of the cells. 
ART and DHA are reported to gain selectivity by targeting cancer cells, which have a high 
expression of TfR1 for iron absorption (Jiao et al. 2007; Zhao et al. 2013). Cellular iron is 
required to sustain unlimited and fast proliferation of cancer cells (Mercer et al. 2007; Oh et 
al. 2009; O’Neill et al. 2010). In addition, ART and DHA contain an endoperoxide bridge, 
which reductive cleavage by iron is a necessary prerequisite in their cytotoxicity (Mercer et 
al. 2007). It was reported previously that the effectiveness of some chemotherapeutic 
agents, which target highly proliferating cancer cells is decreased at highly hypoxic regions 
of tumour (Rustum et al. 2010). This is linked with the disproportional and incomplete 
vasculature in hypoxic tumours (Bhattacharya et al. 2004; Rustum et al. 2010; Goel et al. 
2011). Disfunctional vasculature results in areas of lower rate of cancer cell proliferation, 
therefore, decreased effectiveness of some anti-cancer agents which target only highly 
proliferating cancer cells (Bhattacharya et al. 2004; Rustum et al. 2010; Goel et al. 2011). 
Remaining alive hypoxic cells enhance tumour aggressiveness through inhibition of cancer 
cell death which has been shown experimentally to be associated with development of 
therapeutic resistance and cancer recurrence (Milosevic et al. 2012; bCho et al. 2013; Chen 
et al. 2014; Dekervel et al. 2014). Therefore, the potential of ART and DHA to preferentially 
kill rapidly proliferating cancer cells led to a question whether ART and DHA have the ability 
to target the relatively slow-proliferating cancer cells, which might cause treatment failure.   
In this experiment, we explored the effects of ART and DHA against well-differentiated       
HT-29-AK cells (1x104cells/well) which were seeded first in 96-well flat-bottomed microtitre 
plates for 72h allowing the cells to reach ~80% confluency. Culture media was discarded and 
fresh media without/with ART and DHA (0-750µM) was added for 24h and the plates were 
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terminated and analysed as described in Materials & Methods (Section 2.4.3). As shown in 
table 4, the cytotoxicity of ART and DHA might be partly dependent on the proliferation state 
of cells at the time of the experiment. The confluent cells were less susceptible to the 
cytotoxic effects of ART and DHA compared to cells treated at t0 (table 4). Treatment of 
confluent cells with DHA significantly (P<0.001) decreased the IC50 of DHA compared to their 
counterparts treated at t0 (~1.87-folds; 108.53 ± 19.68 µM vs. 58.02 ± 4.09µM). In contrast to 
DHA, the cytotoxicity of ART was less affected by confluent HT-29-AK cells when compared 
to highly proliferating cells at t0 (~1.15-folds;190.62µM vs. 165.06 ± 24.25µM; table 4). These 
results suggest that ART might more selectively and effectively target quiescent cancer cells 
within heterogeneic tumour interior as compared to DHA. The ability of ART to selectively kill 
the rapidly proliferating and the relatively slow dividing cells may be a promising therapeutic 
approach to improving survival of CRC patients. However, there were insufficient repeats 
done under confluent cell conditions to allow statistical analyses. 
Table 4: The effect of ART and DHA against HT-29-AK cells, at time 0h and confluent 
cells, cultured in normoxia for 24h. Data points are means ± SD of at least three 





State of cells used 
for experiments 
HT-29-AK 
IC₅₀ (µM, Mean±SD) 
ART highly proliferating 
cells at 0h 
165.06 ± 24.25 
DHA 58.02 ± 4.09 
ART confluent cells 
at 72h 
190.62 
DHA 108.53 ± 19.68*** 
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3.3. Cytotoxicity of ART and DHA against HL-60 and HT-29-AK cells is iron-
dependent. 
As iron is central to the activity of 1,2,4-trioxanes (Efferth 2005; O’Neill et al. 2010; Handrick 
et al. 2010; Rasheed et al. 2010; Ba et al. 2012), the role of iron (at 1 and 3µM haemin) and 
iron chelator DFO (at 60µM) in the anti-cancer activity of the drugs was evaluated. Data 
presented in table 5 show that DFO antagonised the activity of ART and DHA in both cell 
lines. ART in the presence of DFO was significantly (P<0.001) less cytotoxic against HL-60 
cells compared to ART alone (IC50 of 29.5 ± 5.56 µM vs. 1.96 ± 0.28µM). Similarly, ART in 
the presence of DFO was significantly (P<0.001) less cytotoxic against HT-29-AK cells 
compared to ART alone (IC50 of 271.63 ± 10.49µM vs. 165.06 ± 24.25µM). DHA in the 
presence of DFO showed a significant (P<0.001) reduction in cytotoxicity against cells, 
respectively as compared to DHA alone (table 5). In contrast, haemin enhanced the 
cytotoxicity of the agents against both cell lines (table 5). HL-60 cells treated with ART and 
DHA in the presence of 1µM haemin showed a 60% (P<0.001) and 12.86% increase in 
cytotoxicity as compared to the drugs alone, respectively. Haemin (at 3µM) significantly 
(P<0.001) enhanced the activity of ART and DHA against HL-60 cells by 67% and 40%, 
respectively. A similar effect was observed against HT-29-AK cells where 1µM haemin 
increased the anti-cancer effects of ART by ~7.8% and DHA by ~24% (P<0.001). Haemin 
(at 3µM) increased cytotoxicity of ART by ~17.5% (P<0.01) and DHA by ~42% (P<0.001), 
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Table 5: The effect of ART and DHA alone and in the presence of deferiprone, DFO 
(60µM) and haemin (1µM or 3µM) against HL-60 and HT-29-AK cells for 24h cultured in 
normoxia. Data points are means ± SD of at least three independent experiments with 18 
replicates. ART, artesunate; DHA, dihydroartemisinin; DFO, deferiprone. **P<0.01; 
***P<0.001 
Incubation time  
24h 
Test agents 
HL-60  HT-29-AK 
IC₅₀ (µM, Mean±SD) 
ART 1.96 ± 0.28  165.06 ± 24.25    
DHA 0.70 ± 0.12 58.02 ± 4.09  
ART + DFO (60µM) 29.50 ± 5.56***  271.63 ± 10.49***  
DHA + DFO (60µM) 9.25 ± 1.20***  294.88 ± 31.97***  
ART + 1µM haemin  0.78 ± 0.08***  152.16 ± 12.75   
DHA + 1µM haemin 0.61 ± 0.04  43.90 ± 4.65 *** 
ART + 3µM haemin 0.65 ± 0.03***  133.49 ± 12.02** 
DHA + 3µM haemin 0.42 ± 0.03***  33.43 ± 1.61*** 
3.4. ART and DHA altered the secretion of sTfR1 in HL-60 and HT-29-AK cells in 
normoxia 
Our previous experiments indicate that the availability of iron plays a pivotal role in the 
cytotoxicity of ART and DHA (table 5). Numerous reports demonstrate that ARTand DHA 
target selectively cancer cells, which have a high expression of the membrane TfR1 for 
enocytosis-mediated iron uptake (Jiao et al. 2007; Zhao et al. 2013). There are increasing 
reports showing that ART and DHA decrease expression of TfR1, thus resulting in 
diminished iron homeostasis through inhibiting iron endocytosis needed by cells to 
proliferate (Zhou et al. 2008; Ba et al. 2012 Zhao et al. 2013).  TfR1 protein is proteolytically 
released from the surface of cells as a soluble protein through a highly regulated process 
known as ectodomain shedding (Hayashida et al. 2010). As a soluble form of TfR1 (sTfR1) 
in the incubation media is a quantitive marker of cell surface TfR1 in vitro (R’zik and Beguin 
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2001). Here, ELISA was performed to analyse the effect of ART and DHA treatment on 
sTfR1 concentrations in cell culture supernatants collected from HT-29-AK and HL-60 cells. 
For comparison purposes, culture supernatants from DHA-treated cells were collected at 
two different incubation time points (24h vs. 72h) and analysed as described in Materials & 
Methods (Section 2.5.1).  
As can be seen in figure 15 A, there were measurable levels of sTfR1 equivalent to 3.40 
nmol/L in ART-untreated HT-29-AK cells after 72h incubation. As compared to control 
(3.40nmol/L), sTfR1 levels in HT-29-AK cells treated at 7.22µM ART were increased by 
~18.24% (4.02nmol/L). The levels of sTfR1 for ART-treated cells at 14.44µM and 28.88µM 
were lower than the lowest concentration of standard (< 3nmol/L). 
DHA (at 29.01µM) upon 24h incubation resulted in a marked decrease in sTfR1 levels by 
~75.66% (1.76nmol/L vs. control with 7.23 nmol/L) (figure 15A). High concentrations of DHA 
at 58.02µM and 116.04µM resulted in increased sTfR1 levels by ~2.15-fold (~114.52%, 
15.51nmol/L) and ~2.87-fold (~186.86%, 20.74 nmol/L), respectively, as compared to 
control (7.23 nmol/L) (figure 15A). After 72h incubation, DHA-untreated cells showed a 
sTfR1 concentration of 1.84 nmol/L, which was increased by ~8.15% (1.99nmol/L) upon 
treating the cells with 9.88µM DHA. In contrast, the levels of sTfR1 for DHA-treated cells at 
19.75µM were decreased by ~59.78% (0.74 nmol/L) and below limit of detection at 39.50µM 
DHA, respectively, as compared to control (figure 15A). 
 
 




Figure 15: The secretion levels of sTfR1 in cancer cells upon ART and DHA 
treatments in normoxia. A) HT-29-AK and B) HL-60 cells were treated with the test 
compounds for 24h and 72h under normoxic conditions (20% O2), before the cell-free 
incubation media were analysed for sTfR1 secretions by ELISA (Materials & Methods, 
Section 2.5.1). The histograms for ART-treated cells for 72h (black bars), DHA for 24h (grey 
bars) and DHA for 72h (purple bars) represent 2 independent experiments which are not 
powered to perform statistical analysis. Blue arrow indicates sTfR1 secretions below the 
limit of detection (< 3 nmol/L). ART, artesunate; DHA, dihydroartemisinin. 
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For comparison purposes similar investigations were performed for HL-60 cells treated with 
ART and DHA (figure 15B). Following 72h of incubation, ART-untreated HL-60 cells 
displayed sTfR1 concentration of 4.49 nmol/L which was decreased by ~15.37%            
(3.79 nmol/L) upon treating the cells at 0.30µM ART (figure 15B). HL-60 cells treated with 
0.60µM and 1.20µM ART increased sTfR1 concentrations by 59.24% (7.15nmol/L) and 
~2.50-folds (~149.67%; 11.21 nmol/L), as compared to control (4.49 nmol/L) (figure 15B).  
As depicted in figure 15B, DHA-untreated cells following 24h incubation showed a sTfR1 
concentration of 0.89nmol/L, which was increased slightly by ~3.37% (0.92nmol/L) at 
0.35µM DHA. HL-60 cells treated with DHA at higher concentrations of 0.70µM and 1.40µM 
DHA resulted in sTfR1 concentrations being below the limit of detection. Inhibition of sTfR1 
continued with prolonged incubation of HL-60 cells with DHA. This led to a 30% reduction 
(2.38 nmol/L) in sTfR1 with 0.25µM DHA and observed sTfR1 levels below the limit of 
detection with 0.50µM and 1.00µM DHA, respectively, as compared to control (3.40 nmol/L) 
(figure 15B).   
Overall, ART and DHA have the ability to decrease sTfR1 secretions in HL-60 and            
HT-29-AK cells but this inhibition is strongly compound- and cell line- dependent (figure 15). 
When ART-treated HT-29-AK cells for 72h decreased sTfR1 secretions, ART against       
HL-60 cells for 72h increased sTfR1 concentration levels (figure 15). Similarly, DHA-treated 
HT-29-AK cells after 24h incubation markedly up-regulated the secretions of sTfR1 while 
DHA-treated HL-60 cells for 24h decreased sTfR1 levels (figure 15). 
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 3.5. DHA altered the secretion of IL-6 in HL-60 and HT-29 cells in normoxia. 
There is evidence that TfR1 expression is regulated by pro-inflammatory cytokines, 
including IL-6, which is strongly associated with CRC development and progression          
(Han et al. 1997; Chalaris et al. 2011; Harel et al. 2011). Experimental reports show that 
ART and DHA exert potent anti-inflammatory properties through the inhibition of pro-
inflammatory cytokines, including IL-8 and IL-1β (Xu et al. 2007; Wu et al. 2010; Wang et al. 
2011). Additionally, high IC50 values for ART and arteether correlated with high IL-6 signal 
transducer expression (P<0.05), thus showing potential impact of IL-6 on anti-cancer effects 
of 1,2,4-trioxanes (Anfosso et al. 2006).  
Here, we wanted to evaluate if the effects of DHA on IL-6 secretion levels in HT-29-AK and 
HL-60 cells are time-dependent. Investigations were carried out at 24h and 72h using 
ELISA (Materials & Methods, Section 2.5.2).  
As compared to control (0.16pg/mL), DHA at 29.01µM following 24h incubation in HT-29-AK 
cells did not alter IL-6 secretion levels (~0.30 fold; 0.18pg/mL) whereas the highest DHA 
concentration at 116.04µM had increased IL-6 secretions (~0.85 fold; 0.51pg/mL) (figure 
16A). In contrast, middle DHA concentration (58.02µM) representing DHA IC50 value at this 
time point resulted in IL-6 secretions being below than the lowest concentration of standard 
(< 0.039pg/mL) (figure 16A). Similar pattern was observed with HT-29-AK cells after 72h 
(figure 16A). There was a ~1.6-fold (0.16pg/mL) and ~4.4-fold (0.44pg/mL) increase in IL-6 
secretions upon treating the cells with 9.88µM, and 39.50µM of DHA, as compared to 
control (0.1pg/mL), respectively (figure 16A). However, IL-6 secretion with 19.75µM DHA 
(DHA IC50 value at this time point) was below the limit of detection (figure 16A). 
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In HL-60 cells after 24h, DHA (0.35µM) significantly (P<0.001) decreased IL-6 levels by 
~2.75-fold (0.04pg/mL), as compared to control (0.11pg/mL; figure 16B). The levels of IL-6 
concentrations were undetected with 0.70µM DHA (< 0.039pg/mL) and up-regulated with 
1.40µM DHA (~7.55-fold, 0.83pg/mL), as compared to control (0.11pg/mL; figure 16B). 
Similar pattern was observed against HL-60 cells treated for 72h (figure 16B). DHA (at 
0.25µM) markedly decreased IL-6 levels by ~2.38 fold (0.08pg/mL) whereas the levels of IL-
6 were below the limit of assay detection (< 0.039pg/mL) with 0.50µM of DHA (figure 16B). 
An increased (~2.42-fold) secretion of IL-6 was observed with highest concentration of DHA 
(at 1.00 µM), as compared to control (0.19pg/mL) (figure 16B). 
The results show that DHA exhibited a dual response on IL-6 secretion levels in HT-29-AK 
and HL-60 cancer cells, i.e. the levels of IL-6 were below limit of detection at the middle 
DHA concentrations and an increase of IL-6 was measured at the highest DHA 
concentrations. The undetected levels of IL-6 with DHA at IC50 (middle) concentrations might 
possibly relate to the specific unknown mechanisms of action of DHA in both cell lines. 
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Figure 16: The secretion levels of pro-inflammatory cytokine IL-6 in cancer cells upon 
DHA treatment at 24h and 72h in normoxia. A) HT-29-AK and B) HL-60 cells were 
treated with DHA for 24h (black bars) and 72h (grey bars) under normoxic conditions     
(20% O2), before IL-6 secreted into the culture media was measured by ELISA as described 
in Materials and Methods (Section 2.5.2). Blue arrow indicates IL-6 secretions below the 
limit of detection (< 0.039pg/mL). Data for DHA-treated HL-60 cells for 24h represent the 
mean ± S.D. of three independent experiments. ***P<0.001 as tested by Paired T test. 
Other results represent 2 independent experiments and are not powered to perform 
statistical analysis. DHA, dihydroartemisinin. 
3.6. ART and DHA down-regulated intracellular protein levels of COX-2 in HT-29-AK 
cells in normoxia 
Increasing reports show that the anti-cancer effects of ART and DHA in solid tumours are 
attributed to the inhibition of pro-inflammatory COX-2 protein, which is  implicated clinically 
in enhanced mortality rates in patients and the development of chemo-resistance (Wang et 
al. 2011; Rahman et al. 2012; Roelofs et al. 2014; Zuo et al. 2014; Zhang et al. 2015). Due 
to limited reports of the effects of ART and DHA on COX-2 protein levels in haematological 
cancers, we initially aimed to evaluate and compare the effects of ART and DHA on COX-2 
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protein levels in HT-29-AK cells and HL-60 cells. However, due to COX-2 antibody 
limitations the experiments were only performed against HT-29-AK cells to challenge 
current reports on COX-2 expression in solid tumours. With prepared samples for flow 
cytometric analysis as described in Materials & Methods (Section 2.9.1.1), there was a 
concentration-dependent decrease in COX-2 protein levels by ~7% (0.93 ± 0.08 RFU), 15%   
(0.85 ± 0.07 RFU; P<0.001), 23% (0.77 ± 0.06 RFU; P<0.001) upon treating HT-29-AK cells 
with 7.22µM, 14.44µM and 28.88µM ART, respectively, as compared to control (1.00 ± 0.11 
RFU) (figure 17A). Similarly, as shown in figure 17B, DHA-treated HT-29-AK cells for 72h 
significantly down-regulated COX-2 protein levels in a concentration-dependent manner by 
~4.00% (0.96 ± 0.10 RFU; P<0.01), ~22% (0.78 ± 0.02 RFU; P<0.001) and ~33% (0.67 ± 
0.002 RFU; P<0.001) with 9.88 µM, 19.75 µM and 39.50 µM DHA, respectively, as 
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Figure 17: ART and DHA decreases the intracellular protein levels of COX-2 in HT-29-
AK cells at 72h in normoxia. Cells were treated without or with A) ART (at 0µM, 7.22µM, 
14.44µM and 28.88µM) and B) DHA (at 0µM, 9.88µM, 19.75µM and 39.50µM) for 72h in 
normoxia (20% O2), stained with COX-2 antibody and analysed on flow cytometer (Materials 
and Methods, Section 2.9). Results are expressed as mean ± SD of three independent 
experiments. ***P<0.001 and **P<0.01 vs. control as tested by one-way Anova (Dunnett 
test for comparison with control). ART, artesunate; DHA, dihydroartemisinin. 
3.7. Effect of ART and DHA on mRNA and protein expression levels of E-cadherin and 
its localisation. 
Experimental reports show that ART and artemisinin inhibit invasion of cancer cells through 
restoring cell adhesion by increasing E-cadherin expression (Li et al. 2008; Lijuan et al. 
2010; Weifeng et al. 2011). Therefore, in present study it was of interest to investigate the 
effect of ART and DHA on cell-cell adhesion molecule E-cadherin in both cell lines.  
ART-mediated effect on E-cadherin was investigated in HT-29-AK cells using qPCR 
analysis as described in Materials and Methods (Section 2.6). For comparison purposes, 
HT-29-AK cells were exposed to ART for 24h and 72h. Treatment with 82.53 µM ART of 
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HT-29-AK cells for 24h had a minimal effect on mRNA E-cadherin levels with resulting a 
10% decrease in E-cadherin levels as compared to control (ΔΔCt= 1.10 ± 0.13 vs. ΔΔCt= 
1.00 ± 0.09, respectively; figure 18A). When HT-29-AK cells were incubated for 24h with 
high ART concentrations, E-cadherin mRNA levels increased by 94% at 165.06µM ART 
(ΔΔCt= 1.94 ± 0.37; P<0.001) and maximum increase by ~2.94-fold (ΔΔCt= 2.94 ± 0.61; 
P<0.001) was observed at 330.12µM ART, as compared to untreated cells (ΔΔCt= 1.00 ± 
0.09), respectively (figure 18A). When compared to control group (ΔΔCt= 1.00 ± 0.03),      
E-cadherin mRNA levels were significantly (P<0.001) down-regulated in all ART-treated 
samples for 72h incubation by 2.27-fold (ΔΔCt= 0.44 ± 0.03 with 7.22µM ART and ΔΔCt= 
0.44 ± 0.01 with 14.44µM ART P<0.001) and by 2.17-fold (ΔΔCt= 0.46 ± 0.10) with 28.88µM 
ART (figure 18B).  
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Figure 18: The effect of ART on E-cadherin mRNA expression in HT-29-AK cells at 
24h and 72h in normoxia. qPCR analysis of E-cadherin gene expression was assessed in 
ART untreated and treated cells for (A) 24h (at 0µM, 82.53µM, 165.06µM, 330.12µM) and 
(B) 72h (at 0µM, 7.22µM, 14.44µM and 28.88µM) in normoxia (20% O2) as described in 
Materials and Methods (Section 2.6). The results indicate means ± SD of three independent 
experiments. ***P<0.001 vs. control as tested by one-way Anova (Dunnett test for 
comparison with control). ART, artesunate. 
The increase in E-cadherin mRNA levels upon ART treatment for 24h and subsequent down-
regulation after 72h was considered provocative as E-cadherin plays a fundamental role in 
maintaining cell-cell contacts (Pećina-Šlaus 2003; Fujii et al. 2014). Therefore, it was 
hypothesized that triggered changes in E-cadherin mRNA levels upon ART treatments at 
both time points were associated with a disruption of cell epithelial integrity. To investigate 
this possibility, HT-29-AK cells were incubated with increasing concentrations of ART for 24h 
and 72h and immunocytochemical staining patterns for E-cadherin was analysed using Zeiss 
confocal microscope. As presented in a representative set of images in figure 19, for 
normalisation purposes some HT-29-AK cells were stained with secondary antibody only 
(figure 19i) to visualise any not specific signal. He-Ne laser set to 543nm was performed to 
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obtain cell surface phase contrast imaging of cells untreated and treated with compounds 
(figure 19ii). The background signal was removed (figure 19iii) using confocal microscope 
AIM software settings and all samples incubated with E-cadherin primary and secondary 
antibodies (complete staining) were further analysed. This step was repeated for every 
antibody used in next experiments and settings were constant for each sample set analysis. 
 
Figure 19: Normalisation of immunocytochemistry staining method for E-cadherin 
localisation in HT-29-AK cells. Cells were fixed, i) incubated with anti-mouse Alexa 488 
secondary antibody (non-complete staining) prior analysis on confocal Zeiss LSM 510 META 
microscope with the objective used EC Plan-Neofluar 20x/0.50 M27 and the pinhole channel 
set at 76µm; ii) taking phase contrast image using He-Ne laser set to 543nm; and removing 
the background (iii) using confocal microscope Zeiss LSM 510 META settings tools 
(Materials & Methods, Section 2.7). 
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It was observed that an increase of mRNA E-cadherin levels upon ART for 24h resulted in 
mis-localisation of E-cadherin protein expressions (figure 20A). ART control cells had weak, 
diffusely distributed basal and lateral membranous staining of E-cadherin protein, while ART 
treatment resulted in concentration-dependent increase in E-cadherin lateral membrane 
staining and no changes in basal membranous staining, respectively (figure 20). 
Representative linear-profile histograms further confirm increase in intensity staining of       
E-cadherin at cell lateral area (blue marker) with 165.06µM ART as compared to weak and 
evenly distributed  E-cadherin proteins over the membrane (red and blue markers)  in ART 
control cells.  
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Figure 20: The effect of ART on E-cadherin cellular protein localisation in HT-29-AK 
cells at 24h in normoxia.  Evaluation of E-cadherin localisation without/with ART treatment 
after 24h incubation: A) control, B) 82.53µM ART, C) 165.06µM ART, and D) 330.12µM 
ART. Cells were fixed, incubated with anti-E-cadherin and a) E-cadherin complete staining 
for each ART concentration was visualised using anti-mouse Alexa 488 secondary antibody 
prior analysis on confocal Zeiss microscope as described in Materials and Methods (Section 
2.7). The objective used was EC Plan-Neofluar 20x/0.50 M27 and the pinhole channel set at 
76µm. The representative images show the localisation and the staining intensity of           
E-cadherin in the majority of the cells analysed by AIM Software from 3 independent 
experiments. High-magnification images are located in upper right corner of representative 
picture whereas (b) phase contrast images are located on the left. Representative linear-
profile histograms are indicated by white line upon ART treatment for 24h (control and 
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In contrast, the membranous localisation of E-cadherin after 72h in all ART-untreated and 
treated cells was evenly distributed at baso-lateral level across all samples with 
representative images being shown for control and IC50 concentration at 14.44µM (figure 21 
B and C). 3D side view of cells was obtained by Z-section scanning for control cells and 
ART-treated cells (at 14.44µM) in positions a, b and c (figure 21 B and C) and showed no 









Figure 21: The effect of ART on E-cadherin cellular protein localisation in HT-29-AK cells at 72h in normoxia. Cells 
were fixed, incubated with anti-E-cadherin and visualised using anti-mouse Alexa 488 secondary antibody (complete staining) 
prior analysis on confocal Zeiss microscope. The objective used was EC Plan-Neofluar 20x/0.50 M27 and the pinhole channel 
set at 76µm. Representative 3D side view obtained by Z-section scanning of cells in positions a, b and c (as shown in A 
image).The representative images show the localisation of E-cadherin in the majority of the cells derived for B) ART-untreated 
cells (control) and C) at 14.44µM ART as analysed by AIM Software from 3 independent experiments. ART, artesunate. 
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In terms of DHA, E-cadherin expressions were only investigated using immunocytochemistry 
staining where HT-29-AK cells were treated with DHA for 24h and 72h incubations prior 
analysis (figures 22 and 23). Imaging of stained cells with E-cadherin antibody upon DHA 
treatment for 24h showed that untreated cells and cells treated with 29.01µM and 58.02 µM 
DHA had equally distributed basal and lateral membranous localisation of E-cadherin protein 
(figure 22). Interestingly, DHA treatment at 116.04µM in addition to baso-lateral membranous 
staining of cells also showed staining of cell nuclei (figure 22). Z-section imaging of all DHA 
untreated and treated cells in positions a, b, and c (figure 22a) was performed to evaluate 
potential changes in E-cadherin localisation at three different depths across the cells. 
Representative Z-section images are presented in figure 22 for DHA-untreated cells and 
treated with 116.04µM. 
As illustrated in figure 23, treatment with DHA for 72h showed baso-lateral localisation of     
E-cadherin in all untreated and DHA-treated samples with not observed changes in             
E-cadherin localisation at different depths in cells while performing Z-section scanning (data 
not shown).  
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Figure 22: The effect of DHA on E-cadherin cellular 
protein localisation in HT-29-AK cells at 24h in 
normoxia. Evaluation of E-cadherin localisation using 
immunocytochemical staining was performed by seeding 
cells on glass coverslips with/without DHA at b) control, 
c) 29.01µM, d) 58.02µM, e) 116.04µM for 24h. Cells 
were then fixed, incubated with anti-E-cadherin and 
visualised using anti-mouse Alexa 488 secondary 
antibody on confocal microscope (Zeiss LSM 510 
META) as described in Materials and Methods (Section 
2.7). The objective used was EC Plan-Neofluar 20x/0.50 
M27 and the pinhole channel set at 76µm. The 
representative images show the localisation and the 
staining intensity of E-cadherin in the majority of the 
cells analysed by AIM Software. Representative           
Z-section images of E-cadherin staining intensity were 
taken in i, ii and iii positions as shown in picture a) and 
represent DHA treatment for 24h with b) control and e) 
116.04µM). The results represent 3 independent 
experiments.  DHA, dihydroartemisin. 
 




Figure 23: The effect of DHA on E-cadherin cellular protein localisation in HT-29-AK cells at 72h in normoxia. 
Evaluation of E-cadherin localisation using immunocytochemical staining was performed by seeding cells on glass coverslips 
with/without DHA at a) 0µM, b) 9.88µM, c) 19.75µM and d) 39.50µM for 72h in normoxia (20% O2). Cells were then fixed, 
incubated with anti-E-cadherin and visualised using anti-mouse Alexa 488 secondary antibody on confocal microscope (Zeiss 
LSM 510 META as described in Materials and Methods (Section 2.7). The objective used was EC Plan-Neofluar 20x/0.50 
M27 and the pinhole channel set at 76µm. The representative images show the localisation and the staining intensity of         
E-cadherin in the majority of the cells analysed by AIM Software. The results represent 3 independent experiments. DHA, 
dihydroartemisin.
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To investigate whether ART and DHA modulate E-cadherin protein expression levels in    
HL-60 cells, cells were treated with drugs for 72h and stained with E-cadherin antibody prior 
flow cytometric analysis as described in Materials & Methods (Section 2.9.2.1). Figure 24A 
shows that ART treatment resulted in a significant (P<0.001) concentration-dependent 
increase in E-cadherin cell surface protein levels by ~52% (1.52 ± 0.10 RFU), ~65% (1.65 ± 
0.13 RFU) and ~2.19-fold (2.19 ± 0.23 RFU) upon treating the cells with 0.30µM, 0.60µM 
and 1.20µM of ART for 72h, respectively, as compared to control (1.00 ± 0.05 RFU). In 
contrast, analysis of protein levels in DHA-treated cells for 72h resulted in E-cadherin 
protein expression levels to be decreasing with higher concentrations (figure 24B). 
Compared to control, treatment of cells with 0.25µM DHA caused no significant changes in 
E-cadherin protein expression (by 1%; 1.00 ± 0.09 RFU vs. 1.01 ± 0.09 RFU). Significantly 
down-regulated levels of E-cadherin protein secretions were observed with increasing 
concentrations of DHA by 11% (0.89 ± 0.05 RFU; P<0.01) and 12% (0.88 ± 3.88 RFU; 
P<0.01) with 0.49 µM and 0.98 µM DHA, respectively when compared to control (1.00 ± 
0.09 RFU). 
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Figure 24:  The effect of ART and DHA on surface E-cadherin protein expression 
levels in HL-60 cells at 72h in normoxia. Cells were treated without or with A) ART (at 
0µM, 0.30µM, 0.60µM and 1.20µM) and B) DHA (at 0µM, 0.25µM, 0.50µM and 1.00µM) for 
72h in normoxia (20% O2), stained with E-cadherin antibody and analysed on flow 
cytometer as described in Materials & Methods (Section 2.9.2.1). Results are expressed as 
mean ± SD of three independent experiments. ***P<0.001 and **P<0.01 vs. control as 
tested by one-way Anova (Dunnett test for comparison with control). ART, artesunate; DHA, 
dihydroartemisinin. 
3.8. Effect of ART and DHA on protein, mRNA and cellular localisation of CLDN-1 
The up-regulation of CLDN-1 protein which maintains cell-cell integrity has been reported to 
enhance EMT and metastatic potential (Dhawan et al. 2005; Bezdekova et al. 2012). 
Besides, inverse relation between E-cadherin and CLDN-1 reported previously led us to 
evaluate the potential mechanisms of the cell death induced by ART and DHA by measuring 
CLDN-1 expressions at protein and mRNA levels together with its cell localisation using flow 
cytometric analyses, qPCR and immunocytochemisrty staining, respectively as described in 
Materials & Methods (Sections 2.6; 2.7 and 2.9.1.1).  
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To assess the role of ART-mediated expression change in CLDN-1mRNA levels and 
localisation, HT-29-AK cells were exposed to ART for 72h and for comparison purposes for 
24h. Flow cytometric and immunocytochemistry analyses were only performed for 72h 
incubation with ART-treated HT-29-AK cells. qPCR analysis showed first that after 24h, 
measured CLDN-1 mRNA levels in samples treated with 82.53µM ART were highly            
up-regulated by ~6.97-fold, as compared to control (ΔΔCt= 6.97 ± 1.04 vs. ΔΔCt= 1.00 ± 
0.03, P<0.001; figure 25A). These up-regulated mRNA CLDN-1 levels were decreasing with 
increasing concentrations of ART with resulting a fold change of ~ 2.66- (ΔΔCt= 2.66 ± 0.45, 
P<0.01) and ~2.65-fold (ΔΔCt= 6.95 ± 0.45, P<0.01) upon treating the cells with 165.06µM 
and 330.12µM ART for 24h respectively, as compared to control (ΔΔCt= 1.00 ± 0.03) (figure 
25A). In contrast, mRNA CLDN-1 expression levels after 72h were significantly (P<0.001) 
decreased with increasing concentrations of ART and resulted in ~2.00- (ΔΔCt= 0.50 ± 0.06), 
~2.13- (ΔΔCt= 0.47 ± 0.02) and ~1.92- (ΔΔCt= 0.52 ± 0.12) down-regulation with 7.22µM, 
14.44µM and 28.88µM ART, respectively, as compared to untreated cells (ΔΔCt= 1.00 ± 
0.04; figure 25B).  
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Figure 25:  The effect of ART on CLDN-1 mRNA expression in HT-29-AK cells at 24h 
and 72h in normoxia. Cells were treated without or with A) ART (at 0µM, 82.53µM, 
165.06µM and 330.12µM) for 24h and B) ART (at 0µM, 7.22µM, 14.44µM and 28.88µM) for 
72h in normoxia (20% O2) and mRNA CLDN-1 levels were measured by qPCR (Materials & 
Methods, Section 2.6). Results are expressed as mean ± SD of three independent 
experiments. **P<0.01 and ***P<0.001 vs. control as tested by one-way Anova (Dunnett 
test for comparison with control). ART, artesunate. 
It was further investigated if CLDN1 suppression at the mRNA after 72hh treatment with ART 
was affected by any post-translational mechanisms. Therefore, the intracellular protein 
expression levels of CLDN-1 were measured by flow cytometry upon ART treatment for 72h 
as described in Materials & Methods (Section 2.9.1.1). Up-regulation of CLDN-1 protein 
levels were observed to be decreasing with increasing concentrations of ART (figure 26). As 
compared to control (1.00 ± 0.21 RFU), there was 80% (1.80 ± 0.18 RFU; P<0.001), 59% 
(1.59 ± 0.17 RFU; P<0.001) and 41% (1.41 ± 0.10 RFU; P<0.001) change in CLDN-1 protein 
levels upon treating the cells with 7.22µM, 14.44µM and 28.88µM ART, respectively (figure 
26). Immunocytochemistry staining conducted as described in Materials & Methods (Section 
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2.7) showed membranous and cytoplasmic distribution of CLDN-1 in ART untreated cells 
(figure 27). In ART-treated cells at 7.22µM, 14.44µM and 28.88µM, re-location of CLDN-1 
was observed from cytoplasm to the baso-lateral structures of the membrane (figure 27). 
 
Figure 26: The effect of ART on intracellular CLDN-1 protein levels in HT-29-AK cells 
at 72h in normoxia. Cells were treated without or with ART (at 0 µM, 7.22µM, 14.44µM and 
28.88µM) for 72h in normoxia (20% O2) and CLDN-1 levels were measured on flow 
cytometer (Materials & Methods, Section 2.9.1.1). Results are expressed as mean ± SD of 
three independent experiments. ***P<0.001 vs. control as tested by one-way Anova 
(Dunnett test for comparison with control). ART, artesunate. 
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Figure 27: The effect of ART on CLDN-1 cellular protein localisatin in HT-29-AK cells at 72h in normoxia. Evaluation of 
CLDN-1 localisation using immunocytochemical staining was performed by seeding cells on glass coverslips with/without 
ART at a) 0µM, b) 7.22µM, c) 14.44µM and d) 28.88µM for 72h in normoxia (20% O2). Cells were then fixed, incubated with 
anti-CLDN-1 and visualised using anti-mouse Alexa 488 secondary antibody on confocal microscope (Zeiss LSM 510 
META). The objective used was EC Plan-Neofluar 20x/0.50 M27 and the pinhole channel set at 76µm. The representative 
images derived from 2 independent experiments show the localisation and the staining intensity of CLDN-1 in the majority of 
the cells analysed by AIM Software. High-magnification images are located next to respective sample. ART, artesunate. 
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As shown in figure 28, similar flow cytometric analysis was performed in HT-29-AK cells 
treated with DHA for 72h. The protein expression levels of CLDN-1 were up-regulated 
significantly (P<0.001) upon DHA treatment resulting in a 3.98-fold (3.98 ± 0.72 RFU) 
increase with a low DHA concentration (9.88µM), as compared to control (1.00 ± 0.31; 
figure 28). The higher concentrations of DHA at 19.75 µM and 39.50 µM lead to a steady 
decrease in CLDN-1 fold changes of ~3.79- (3.79 ± 0.56 RFU) and ~3.22-fold                  
(3.22 ± 0.36 RFU), respectively, as compared to control (figure 28). DHA treated and 
untreated samples analysed by confocal microscope did not work properly and 
investigations should be repeated in the future (data not shown).  
 
Figure 28:  DHA decreases up-regulated levels of intracellular CLDN-1 in HT-29-AK 
cells at 72h in normoxia. Cells were treated without or with DHA (at 0 µM, 9.88µM, 
19.75µM and 39.50µM) for 72h in normoxia (20% O2), labelled with CLDN-1 antibody and 
analysed on flow cytometer as described in Materials & Methods (Section 2.9.2.1). Results 
are expressed as mean ± SD of three independent experiments. ***P<0.001 vs. control as 
tested by one-way Anova (Dunnett test for comparison with control).                                               
DHA, dihydroartemisinin. 
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With promising inhibitory activities of ART and DHA on CLDN-1 levels observed against   
HT-29-AK cells, flow cytometric analysis was performed to evaluate the effects of 
compounds on CLDN-1 protein levels in HL-60 cells (figure 29). ART treatment in HL-60 
cells caused a significant (P<0.001) concentration-dependent increase in CLDN-1 protein 
expression levels by ~2.42-fold (2.42 ± 0.36 RFU), ~3.50-fold (3.50 ± 0.25 RFU) and    
~4.40-fold (4.40 ± 0.50 RFU) upon treating the cells with 0.30µM, 0.60µM and 1.20µM of 
ART, respectively, as compared to control (1.00 ± 0.10 RFU) (figure 29A). Increase in 
CLDN-1 expression was also observed while treating HL-60 cells with DHA but CLDN-1 
protein fold changes in all DHA-treated cells were not that high as compared to ART (figure 
29A vs. 29B). As compared to control (1.00 ± 0.07 RFU), there was a marked but not 
significant increase in intracellular CLDN-1 levels by 13% (1.13 ± 0.08 RFU) upon treating 
HL-60 cells with 0.25µM DHA (figure 29B). Significantly (P<0.001), DHA-treated cells had 
up-regulated levels of CLDN-1 protein by 40% (1.40 ± 0.09 RFU) and 37%                      
(1.37 ± 0.03 RFU) with 0.49 µM and 0.98 µM of DHA, respectively, as compared to control                  
(1.00 ± 0.07 RFU) (figure 29B).  
Overall, data show opposite activities of ART and DHA on CLDN-1 protein expression 
arising between HT-29-AK and HL-60 cells which could be due to cancer type differences 









Figure 29: ART and DHA increase production of CLDN-1 intracellular protein in HL-60 
cells at 72h in normoxia. Cells were treated for 72h without or with A) ART (at 0µM, 
0.30µM, 0.60µM and 1.20µM) and B) DHA (at 0µM, 0.25µM, 0.50µM and 1.00µM) in 
normoxia (20% O2), labelled with CLDN-1 antibody and analysed on flow cytometer as 
described in Materials and Methods (Section 2.9.2.1). Results are expressed as mean ± SD 
of three independent experiments. ***P<0.001 vs. control as tested by one-way Anova 
(Dunnett test for comparison with control). ART, artesunate; DHA, dihydroartemisinin. 
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3.9. ART and DHA reduced the wound healing capacity of HT-29-AK cells under 
normoxic conditions 
The results have shown that ART and DHA display potent anti-cancer effects against highly 
proliferating HT-29-AK cells with reduced activity observed towards confluent cells (table 4). 
Reduced activity was more evident for DHA as compared to ART, hypothesizeng that ART 
is more likely to target slow proliferating cells within heterogeneic tumour mass. Therefore, 
using the concentrations of compounds derivered against confluent cells, in vitro wound 
healing assay was performed to assess the ability of ART and DHA to closure the wound 
gap made in HT-29-AK cells, as described in Matarials & Methods (Section 2.8). 
 The results displayed in figure 30 show representative photographs captured by light 
microscope at 10x (and x4) magnification. With an initial control wound diameter of 
623.51µm (figure 30A ii), the wound diameter had reduced to 521.08µm after 3 days    
(figure 30 A iii) and the diameter further reduced to 45.06µm after 7 days of continuous 
culture (figure 30 A iiii). The monolayer of untreated ART cells throughout 7 days of the 
study was characterised by high cell-cell contact without changes in cell morphology (green 
arrows; figure 30 A). However, the capacity of the wound to close upon treating the cells 
with 95.31µM, 190.62µM, 381.24 µM and 953.10µM of ART for 72h was markedly reduced 
in a concentration-dependent manner as evidenced by the corresponding widening of the 
wound diameter to 833.68µm, 853.41µm, 966.05µm and ~1025.20µm, respectively      
(figure 30 B α, C α, D α, E α). 
Further incubation for 96h with 95.31µM, 190.62µM, 381.24 µM and 953.10µM of ART 
resulted in an additional concentration-dependent widening of the wound to 1050µm, 
1150µm, ~2000µm and ~4000µm, respectively (figure 30 B β, C β, D β, E β). The migration 
of the cells after this time was markedly reduced upon treating the cells with 95.31µM, 
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190.62µM of ART, with most of the cells killed by the higher concentrations of ART (381.24 
µM and 953.10µM; figure 30 B β, C β, D β, E β).  Single cancer cells observed at these high 
concentrations could mean that some cells had decreased ART susceptibility due to 
heterogeneic characteristics. Reduced sensitivity by some cells to ART could be also due to 
very high concentrations of ART being above concentrations used clinically which might 
contribute to the development of resistance. Furthermore, ART- treated exhibited a 
concentration-dependent manner inability to form cell-cell contact which might be linked with 
decreased E-cadherin mRNA levels observed previously (figure 18B). These characteristics 
might be linked with the induction of programmed cell death as there were changes in 
cancer cell morphology including cell shrinkage and formed balls of cell debris being typical 
features of apoptosis (figure 30, red arrows). These findings led to investigate in subsequent 
experiments the effect of ART on cleaved caspase-3 intracellular levels which is required for 
the execution of apoptosis. 
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Figure 30: Wound healing capacity of HT-29-AK monolayers after treatment with ART 
in normoxia. Cells were seeded onto 24-well plate and grown in MEM growth media  in 
normoxia (20% O2) till confluency was reached (figure 30A i). An initial wound was created  
using a sterile 10µl Pasteur pipette (figure 30A ii) before the cells  were treated without or 
with ART at A) 0µM, B) 95.31µM, C) 190.62µM and D) 381.24µM and E) 953.10 µM for 72h 
as described in Materials & Methods (Section 2.8). For each ART concentration (B-E), the 
wound diameter was measured after the first treatment with ART for 3 days which is 
represented as respective ‘α’ picture. After additional 96h (7 days in total) with ART, the 
wound diameter  was measured again and is indicated as a respective ‘β’ picture for each 
ART concentration (B-E). Green arrows, normal cells; red arrows, damaged cells, dotted red 
arrows indicate wound healing diameter greater than 1100µm. ART, artesunate. 
 
Due to the cytotoxic ability of ART (table 4) against HT-29-AK cells and its ability to increase 
the diameter of the wound (figure 30), it was of interest to determine whether the unattached 
cells in the vicinity of the wounds (which was visible under the microscope prior to the 
washing) were dead or alive. After 72h incubation with ART, the cells were collected from 
the wounds and counted using tryptan blue exclusion assay (Materials & Methods, Section, 
2.8). The rest of the incubation media containing the non-adherent/dead cells was removed. 
The cells were washed three times in fresh ART-free media and the wound diameter was 
measured. The plates were incubated for additional 96h (7 days in total) in fresh media, in 
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the presence or absence of ART, as described in Materials & Methods (Section 2.8). The 
viable cell count was repeated using the tryptan blue exclusion assay and the diameter of 
the wound of each well was measures as before. The results after 72h and additional 96h 
were summarised (total 7 days) and the wound diameter and the mean number of dead 
cells was plotted against the concentrations of ART as shown in figure 31.  As illustrated in 
figure 31, there was a concentration-dependent increase in the number of dead cells, which 
correlated with an increase in the wound diameter, as compared to initial control.  
 
Figure 31: ART increases the diamater of the wound and the number of dead cells in 
HT-29-AK monolayers in normoxia. Following confluency, a wound was created and the 
cells were incubated in normoxia (20% O2) without or with ART (at 0µM, 95.31µM, 
190.62µM, 381.24 µM and 953.1µM) as described in Materials & Methods (Section 2.8). 
The results dead cells were estimated by tryptan blue exclusion assay. Data represent 
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Similar in vitro wound healing assay was performed for DHA-treated HT-29-AK cells. The 
results presented in figure 31 show the initial control wound (figure 32 Ai) with a diameter of 
714.17µm which decreased in diameter to 374.76µm upon incubating the cells for 3 days 
without drug treatment (figure 32 A iii). There was complete closure of the wound after 7 
days of incubation without drug treatment (figure 32 Aiiii). As with ART-untreated cells, it 
was observed that DHA-untreated cells had a high cell-cell contact and normal cell 
morphology (green arrows, figure 32 A) whereas DHA-treated cells were notably smaller, 
had shrunk and shown marked inhibition of cell-cell contact (red arrow head; figure 32 B, C, 
D, E). The results after 7 days of incubation show that upon treating the cells with 54.27µM, 
108.53µM, 217.06 542.65µM of DHA, there was notable a concentration-dependent 
widening of the wound diameter to 984.74µm, 1278.24µm ~1600µm and ~3500µm, 















A) Control   HT-29-AK cells 
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Figure 32: Wound healing capacity of HT-29-AK monolayers after treatment with DHA 
in normoxia. Cells were seeded onto 24-well plate and grown in MEM growth media  in 
normoxia (20% O2) till confluency was reached (figure 32A i). An initial wound was created  
using a sterile 10µl Pasteur pipette (figure 32A ii) before the cells  were treated without or 
with DHA at A) 0µM, B) 54.27µM, C) 108.53µM and D) 217.06µM and E) 542.65µM as 
described in Materials & Methods (Section 2.8). For each DHA concentration (B-E), the 
wound diameter was measured after total 7 days of incubation with DHA. Green arrows, 
normal cells; red arrows, damaged cells, dotted red arrows indicate wound healing diameter 
greater than 1100µm. DHA, dihydroartemisinin. 
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Figure 33 shows that the number of dead cells in the incubation media correlated with an 
increase in the wound diameter, as compared to initial control.  
Overall, ART and DHA exhibited comparable activity profiles in the inability of the wound to 
heal with observed increasing number of dead cells with ART and DHA increasing 
concentrations (figures 31 and 33).  
 
 
Figure 33: DHA increases the diamater of the wound and the number of dead cells in 
HT-29-AK monolayers in normoxia. Following confluency, a wound was created and the 
cells were incubated in normoxia (20% O2) without or with DHA (at 0µM, 54.27µM, 
108.53µM, 217.06 and 542.65µM) as described in Materials & Methods (Section 2.8). The 
results dead cells were estimated by tryptan blue exclusion assay. Data represent mean of 
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3.10. Effect of ART and DHA on irreversibility of cell growth in normoxia 
As the results of the wound healing assay indicate ART and DHA might inhibit 
migration/invasion of cancer cells through the inhibition of wound gap to heal, it was of 
interest to investigate if the agents inhibit the ability of cells to re-grow post drug treatment. 
For these experiments, MTT assay was performed as described in Materials & Methods 
(Section 2.4.6). 
As illustrated in figure 34 A, cells treated with ART (at 7.22µM, 14.44µM, and 28.88µM) 
showed a significant (P<0.001) concentration-dependent inhibition of cell growth by ~38% 
(62.19 ± 0.34%), ~49% (51.19 ± 0.28%) and ~57% (43.09 ± 1.00%), respectively, as 
compared to control (100 ± 0.49%). There was a significant (P<0.001) concentration-
dependent re-growth of the cells post-wash by ~44% (105.87 ± 4.04%) and ~43% (94.01 ± 
6.79%) as compared to their matched pre-washed ART-treated samples. However, 
28.88µM ART-treated cells showed a significant (P<0.001) inhibition of cells re-growth by 
~19% (62.01 ± 11.49%). The initial treatment of cells with 9.88µM, 19.75µM, and 39.50µM 
of DHA resulted in a significant (P<0.001) concentration-dependent inhibition of cell 
proliferation by ~30% (69.69 ± 1.84%), ~51% (48.97 ± 1.11%) and ~ 66% (34.02 ± 1.38%), 
as compared to control (100 ± 0.67%). After wash, as compared to part 1, DHA (at 9.88µM) 
did not inhibit re-growth of cells whereas cells treated with 19.75µM of DHA demonstrated a 
~43% (P<0.001; 48.97 ± 1.11% vs. 91.47 ± 5.64%) re-growth of the cells. The greatest 
inhibitory effect of DHA against HT-29-AK cells was observed when the cells were treated 
with 39.50µM of DHA. Here, the cells re-grew by 22.04% (P<0.001; 34.02 ± 1.38% vs. 
56.06 ± 4.38%) post-wash (figure 34 B). 
 
 




Figure 34: ART and DHA inhibit the re-growth of HT-29-AK cells cultured in normoxia. 
Initially (light grey bars), HT-29-AK cells were treated without or with (A) ART (at 0, 7.22, 
14.44 and 28.88µM) and (B) DHA (at 0, 9.88, 19.75 and 39.50 µM) for 72h in normoxia 
(20% O2) and terminated as described in Materials & Methods (Section 2.4.6). In the re-
growth assay, the treated cells were washed and further incubated for 72h in drug-free 
media before the assay was terminated (Materials and Methods, Section 2.4.6). Data 
represent the mean ± S.D of 3 independent experiments. ***P<0.001 as tested by Paired T 
test. ART, artesunate; DHA, dihydroartemisinin.  
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For comparison purposes, similar investigations using MTT assay were performed with 
ART- and DHA-treated HL-60 cells (figure 35). As presented in figure 35 A, initial treatment 
without or with ART at 0.98µM, 1.96µM, and 3.92µM resulted in a significant (P<0.001) 
reduction in the growth of HL-60 cells by 37%, 70% and 91%, respectively as compared to 
control (100 ± 2.19%). Subsequent incubation of the cells, post wash for a further 72h in 
drug-free media revealed a significant (P<0.001) reduction in the ability of the cells to re-
grow, i.e., none of the drug treated cells were able to re-grow to the levels observed in 
control samples (figure 35A). Nevertheless, there was significant (P<0.001) re-growth of the 
cells by 26% and 35%, as compared to the results of initial treatment with 0.98µM and 
1.96µM ART, respectively (figure 35A). Interestingly, cells initially treated with ART (at 
3.92µM) showed a re-growth of only 17% after the wash step (P<0.001; 9.5 ± 2.43% vs. 
25.66 ± 3.28%) (figure 35A). Cells treated with DHA (at 0.70µM, 1.40 µM and 2.80µM) also 
showed significant inhibitory effect on cell growth by 2%, 76.1% (P<0.001) and 93.2% 
(P<0.001), respectively as compared to their corresponding control (figure 35 B). After the 
wash step, there was a significant (P<0.001) re-growth of the cells by 39% and 20% as 
compared with the pre-wash samples treated with DHA at 1.40µM and 2.80µM, 
respectively. Interestingly, data acquired from samples treated with 0.70µM of DHA post 
wash revealed a further reduction (~10%) in the ability of the cells to re-growth as compared 
to the corresponding pre-wash data (P<0.001; 3.55 ± 0.31% vs. 26.83 ± 5.45%) (figure 35 
B). 




Figure 35: ART and DHA inhibit the re-growth of HL-60 cells cultured in normoxia. 
Initially (dark grey bars), HL-60 cells were treated without or with (A) ART (at 0, 0.98, 1.96, 
and 3.92µM) and (B) DHA (at 0, 0.70, 1.40 and 2.80µM) for 72h in normoxia (20% O2) and 
the plates were terminated as described in Materials & Methods (Section 2.4.6). Some of 
the plates were washed and incubated in drug-free media for a further 72h (light grey bars) 
before the plates were terminated (Materials and Methods, Section 2.4.6). Data represent 
the mean ± S.D of 3 independent experiments. ***P<0.001 as tested by Paired T- test. ART, 
artesunate DHA, dihydroartemisinin.  
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3.11. Effect of ART and DHA on the expression of MMP-2 and MMP-9 proteins 
The 2D wound healing assay showed that ART and DHA markedly reduced the capacity of 
the wound to heal/close (figures 30-33). In addition, MTT assay indicated the ability of ART 
and DHA to inhibit the re-growth of cancer cells after finishing drug therapy (figures 34 and 
35).  To investigate a possible molecular basis of these observations, the ability of ART and 
DHA to inhibit intracellular proteins MMP-2 and MMP-9 were investigated. Both proteins are 
associated with enhancing cancer cell migration, invasion, and metastatic abilities through 
decresing cell-EM interactions and were measured as described in Materials & Methods 
(Section 2.9.1.1) (Kim et al. 2012).  
The protein levels of MMP-2 and MMP-9 were evaluated first upon ART and DHA treatment 
in HT-29-AK cells. Figure 36A shows that treatment with ART (at 7.22µM, 14.44µM and 
28.88µM) caused an up-regulation in MMP-2 expressions with the highest observed at 
14.44µM ART (~1.52-fold, 1.52 ± 0.17 RFU; P<0.001) and the lowest MMP-2 levels were 
observed with the highest concentration at 28.88µM ART (~1.09-fold, 1.09 ± 8.11 RFU), as 
compared to control (1.00 ± 0.13 RFU), respectively. The up-regulation of MMP-9 protein 
levels was decreasing with higher ART concentrations, resulting in a change in fold 
difference by ~3.35 (3.35 ± 0.31 RFU; P<0.001), ~3.12 (3.12 ± 0.27 RFU; P<0.001) and 
~2.75 (2.75 ± 0.37 RFU; P<0.001) upon treating HT-29-AK cells with 7.22µM, 14.44µM and 
28.88µM of ART, as compared with control (1.00 ± 0.03 RFU), respectively (figure 36B).  
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Figure 36: The effect of ART on intracellular MMP-2 and MMP-9 protein levels in      
HT-29-AK cells at 72h in normoxia. Cells were treated without or with ART (at 0µM, 
7.22µM, 14.44µM and 28.88µM) for 72h in normoxia (20% O2), labelled with either               
A) MMP-2 or B) MMP-9 antibodies and analysed on flow cytometer. C) Representative 
histograms showing changes in MMP-2 protein levels upon ART treatment as compared to 
untreated HT-29-AK cells as analysed by CellQueast Software on flow cytometer. Results 
are expressed as mean ± SD of three independent experiments. **P<0.01 and ***P<0.001 
vs. control as tested by one-way Anova (Dunnett test for comparison with control).           
ART, artesunate. 
MMP-2 intracellular protein expression levels were higher upon DHA treatment of HT-29-AK 
cells for 72h as compared to MMP-2 levels observed upon treating the cells with ART for 
72h (figure 36A vs. figure 37A). Compared to control (0.99 ± 0.08 RFU), the up-regulated 
protein levels of MMP-2 in HT-29-AK cells were decreasing with increasing concentrations 
of DHA resulting in MMP-2 fold differerence of 2.45-fold (2.45 ± 0.30 RFU; P<0.001), 2.20-
fold (2.20 ± 0.13 RFU; P<0.001) and 2.15-fold (2.15 ± 0.12 RFU; P<0.001) upon treating the 
cells with 9.88µM, 19.75µM and 39.50µM DHA, respectively (figure 37A). 
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The up-regulated levels of MMP-9 in HT-29-AK cells had steady lowering trend upon DHA 
treatment with increasing concentrations for 72h (figure 37B). Thus, compared to control 
(1.00 ± 0.21 RFU), there was 2.49-fold (2.49 ± 0.15 RFU; P<0.001), 2.39-fold (2.39 ± 0.17 
RFU; P<0.001) and 2.03-fold (2.03 ± 0.08 RFU; P<0.001) increase in MMP-9 release upon 
treating HT-29-AK cells with DHA treatment at 9.88µM, 19.75µM and 39.50µM, respectively 


































































Figure 37: The effect of DHA on the protein expression of MMP-2 and MMP-9 in        
HT-29-AK cells at 72h in normoxia. Cells were treated without or with DHA (at 0µM, 
9.88µM, 19.75µM and 39.50µM) for 72h under normoxic conditions, labelled with either A) 
MMP-2 or B) MMP-9 antibody and analysed on flow cytometer.  In similar experiments, 
proteins were isolated from cells after DHA treatment, separated by SDS-PAGE and stained 
with C) MMP-2 and D) MMP-9 for Western blotting analysis as described in Materials and 
Methods (Section 2.10). Flow cytometry results represent the mean ± SD of three 
independent experiments where ***P<0.001 vs. control as tested by one-way ANOVA 
(Dunnett test for comparison with control). Western blotting data show results of 1 
independent experiment. DHA, dihydroartemisinin. 
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The protein expression levels of MMP-2 and MMP-9 were additionally investigated for DHA-
treated HT-29-AK cells for 72h using Western blotting performed as described in Materials 
& Methods (Section 2.10). Representative pictures show similar pattern in MMP-2 and 
MMP-9 protein expressions as compared with the results derived from flow cytometric  
analysis (figures 37 C and D). The dark bands at corresponding picture indicate high protein 
levels whereas light bands show low protein levels in those samples (figures 37 C and D).   
MMP-2 and MMP-9 investigations in HL-60 cells treated with ART for 72h showed opposite 
results as compared to data on both proteins in HT-29-AK cells. As illustrated in figure 38A, 
HL-60 untreated cells showed MMP-2 intracellular protein levels of 1.00 ± 0.06 RFU which 
was increased in a concentration-dependent manner by 35% (1.35 ± 0.04 RFU; P<0.05), 
45% (1.45 ± 0.18 RFU; P<0.01) and 63% (1.63 ± 0.15 RFU; P<0.001) upon treating         
HL-60 leukaemia cells with 0.30µM, 0.60µM and 1.20µM ART, respectively. It was further 
observed that expression of MMP-9 with ART after 72h was higher as compared to MMP-2 
results (figures 38 A and B). ART-untreated cells demonstrated MMP-9 protein levels of 
1.00 ± 0.02 RFU which was increased ~1.97- (1.97 ± 0.15 RFU; P<0.001), ~2.55-             
(2.55 ± 0.10 RFU; P<0.001) and ~3.06-fold (3.06 ± 0.25 RFU; P<0.001) upon ART 
treatment at 0.30µM, 0.60µM and 1.20µM, respectively (figure 38B). 




Figure 38: The effect of ART on the intracellular MMP-2 and MMP-9 protein 
expression in HL-60 cells at 72h in normoxia. Cells were treated without or with ART (at 
0µM, 0.30µM, 0.60µM and 1.20µM) for 72h in normoxia (20% O2), labelled with either A) 
MMP-2 or B) MMP-9 antibodies and analysed on flow cytometer as described in Materials 
and Methods (Section 2.9.1). Results are expressed as mean ± SD of three independent 
experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. control as tested by one-way Anova 
(Dunnett test for comparison with control). ART, artesunate. 
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In comparison to the effects of ART in HL-60 cells, DHA-treated HL-60 cells at 0.25µM, 
0.50µM and 1.00µM for 72h demonstrated not significant decreasing trend in MMP-2 protein 
levels by 1% (0.99 ± 0.03 RFU), 3% (0.97 ± 0.09 RFU) and 7% (0.93 ± 0.06 RFU), 
respectively, as compared to control (1.00 ± 0.02 RFU) (figure 39A). In addition, the 
expression levels of MMP-9 were increasing with increasing concentrations of DHA 
resulting in a percentage increase of 6% (1.06 ± 0.06 RFU), 13% (1.13 ± 0.03 RFU) and 
22% (1.22 ± 0.04 RFU) upon treating the cells with 0.25µM, 0.50µM and 1.00µM of DHA, 
respectively, as compared with untreated cells (1.00 ± 0.07 RFU, figure 39B). 
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Figure 39: The effect of DHA on the intracellular MMP-2 and MMP-9 protein 
expression in HL-60 cells at 72h in normoxia. Cells were treated without or with DHA (at 
0µM, 0.25µM, 0.50µM and 1.00µM) for 72h in normoxia (20% O2), labelled with either A) 
MMP-2 or B) MMP-9 antibodies and analysed on flow cytometer as described in Materials 
and Methods (Section 2.9.1). Results are expressed as mean ± SD of three independent 
experiments. *P<0.05 vs. control as tested by one-way Anova (Dunnett test for comparison 
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3.12. ART and DHA alter secretions and mRNA levels of pro-angiogenic VEGF-α in 
HT-29-AK and HL-60 cells 
VEGF-α isoform is a key pro-angiogenic modulator, which has been demonstrated to have 
a central role in cancer metastasis through promoting angiogenesis (Niki et al. 2000). 
Increasing evidence indicates that ART and DHA inhibit two main pro-angiogenic factors, 
VEGF-α and HIF-1α in several cancer cell lines (Anfosso et al. 2006; Huang et al. 2007; 
Zhou et al. 2007; Aung et al. 2011; Wang et al. 2011). Therefore, to further study the cellular 
effects of action of ART and DHA against HT-29-AK and HL-60 cells, mRNA and protein 
levels of VEGF-α were investigated to identify agreement or to challenge previous reports 
(Materials & Methods, Sections 2.5.3 and 2.6). 
In HT-29-AK cells, the mRNA expression levels of VEGF-α for 24h and 72h incubations with 
ART treatments were first measured by qPCR (figures 40A and B). HT-29-AK cells treated 
with ART for 24h showed increasing concentration levels of VEGF-α by 8.20-fold (ΔΔCt of 
8.20 ± 1.10), 8.82-fold (ΔΔCt of 8.82 ± 0.69) and 9.13-fold (ΔΔCt of 9.13 ± 1.16) in a ART 
concentration-increasing manner with 82.53µM, 165.06µM and 330.12µM ART, 
respectively, as compared to control (ΔΔCt of 1.00 ± 00; P<0.001) (figure 40 A). In contrast, 
ART treatment for 72h significantly (P<0.001) inhibited VEGF-α mRNA expression in all 
samples by ~1.56 fold (ΔΔCt of 0.64 ± 0.04), ~1.45 fold (ΔΔCt of 0.69 ± 0.03) and ~1.64 fold 
(ΔΔCt of 0.61 ± 0.03) with 7.22µM, 14.44µM and 28.88µM ART, as compared to control 
(ΔΔCt of 1.00 ± 0.03, figure 40B), respectively.  
ELISA investigating of the cellular VEGF-α165 secretions after 72h with ART in HT-29-AK 
cells was performed to evaluate if VEGF-α is modulated post-transcriptionaly by other 
mediators (figure 40C). VEGF-α165 protein levels in cell culture supernates from all ART-
untreated and treated samples showed that ART treatment had variable effect on        
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VEGF-α165 secretion (figure 40C). Control cells showed VEGF-α165 secretion levels of 
515.14pg/mL, which was decreased by ~1.20-fold (430.18pg/ml) upon treating the cells with 
7.22µM of ART, followed by an increase by ~1.07-fold (551.27pg/mL) with 14.44µM ART. 
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Figure 40: The effect of ART on VEGF-α mRNA expression levels and cellular     
VEGF-α165 secretion in HT-29-AK cells in normoxia. Cells were treated without or with 
ART (at 0µM, 82.53µM, 165.06µM and 330.12µM) for 24h and without or with ART (at 0µM, 
7.22µM, 14.44µM and 28.88µM) for 72h in normoxia (20% O2). After incubations cells were 
analysed for VEGF-α mRNA using qPCR analysis (A and B). In separate investigations 
culture media was collected and analysed for VEGF-α165 levels by ELISA (C). Results are 
expressed as mean ± SD of three independent experiments. ***P<0.001 vs. control as 
tested by one-way Anova (Dunnett test for comparison with control). VEGF- α165 protein 
levels represent 2 independent experiments which are not powered to perform statistical 
analysis. ART, artesunate. 
Figure 41 shows that similar variable effects on VEGF-α165 protein secretions were 
observed in HT-29-AK samples treated with DHA for 24h. There was an increase by     
~1.06-fold (189.94pg/mL) in samples treated with 29.01µM of DHA, followed by a decrease 
by ~1.32- (136.23pg/mL) and ~1.29-fold (139.16pg/mL) when the cells were treated with 
DHA at 58.02µM and 116.04µM, as compared to control (139.16pg/mL), respectively. 
However, HT-29-AK cells treated for 72h at 9.88µM, 19.75µM and 39.50µM DHA showed a 
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reduction in VEGF-α165 secretion by ~1.27- (511.23pg/mL), ~1.26- (513.18pg/mL) and   
~1.4-fold (464.36pg/mL), respectively, as compared to control (648.93 pg/mL) (figure 41).  
 
Figure 41: The effect of DHA on VEGF-α165 cellular secretion in HT-29-AK cells at 24h 
and 72h in normoxia. Cells were exposed to DHA for 24 h (striped bars) and 72h (dotted 
bars) with DHA concentrations shown under normoxic conditions (20% O2). Following 
incubation cell-free culture media were analysed by ELISA as described in Materials & 
Methods (Section 2.5.3). The histograms represent the mean of 2 independent experiments 
which are not powered for statistical analysis. DHA, dihydroartemisinin.  
Overall, data indicate that DHA treatment for 72h caused a decreased secretion of      
VEGF-α165 as compared to control at all concentrations tested. ART treatment for 72h and 
DHA for 24h produced some notable reductions in VEGF-α165 levels, but only at certain 
concentrations (ART at 7.22µM and 28.88µN; DHA at 58.02µM and 116.04µM; figures 40 
and 41). In addition, we observed similar data patterns for mRNA and VEGF-α165 for ART-
treated HT-29-AK cells for 72h, suggesting lack of other mediators affecting VEGF-α 
expression post-transcriptionaly (figure 41).  
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Similar investigations were performed to investigate the effects of ART and DHA on     
VEGF-α165 in HL-60 cells (figure 42). HL-60 cells showed measurable levels of VEGF-α165, 
with more VEGF-α165 found in cells cultured for 72h with DHA, as compared to those 
cultured for 24h (figure 42). After 24h, DHA-untreated cells displayed the lowest VEGF-α165 
secretions of 92.29 pg/ml, which was increased by ~22.21% (112.79) at 0.35µM and 
0.70µM DHA, and by ~25.39% (115.72pg/mL) at 1.40µM DHA (figure 42). VEGF-α165 
secretions in samples treated for 72h with 0.25µM. 0.49µM and 0.98µM DHA decreased 
with increasing DHA concentrations by ~1.25% (386.23pg/mL), ~9.24% (354.98pg/mL) and 
~9.49% (354.00pg/mL), as compared to control (391.11pg/ml), respectively (figure 42). 
Similarly, as shown in figure 42, ART-untreated HL-60 cells for 72h showed a VEGF-α165 
secretion of 490.72pg/mL which was decreased by ~15.52% (414.55pg/mL), ~5.37% 
(464.36pg/mL) and ~12.74% (428.22pg/mL) upon treating the cells with 0.30µM, 0.60µM, 
1.20µM ART, respectively. Taken together, while DHA-treated HL-60 cells for 24h showed 
an increase in VEGF-α165 protein secretions, HL-60 cells treated with  ART or DHA for 72h 
showed the ability to effectively decrease secretions of VEGF-α165 protein. The findings 
indicate anti-angiogenetic activity of both compounds against leukaemia HL-60 cells after 
72h incubation. However, due to resources limitations presented results represent only 2 
independent experiments which are not powered for statistical analysis. 
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Figure 42: The effect of ART and DHA on VEGF-α165 cellular secretion in HL-60 cells 
in normoxia. Cells were exposed to ART for 72h (black bars), DHA for 24 h (grey bars) and 
72h (purple bars) with the drug concentrations shown under normoxic conditions (20% O2). 
Following incubation cell-free culture media were analysed by ELISA as described in 
Materials & Methods (Section 2.5.3). The histograms represent the mean of 2 independent 
experiments which are not powered for statistical analysis. ART, artesunate; DHA, 
dihydroartemisinin. 
3.13. Effect of ART and DHA on HIF-1α protein and mRNA expression levels 
The results indicate the ability of ART and DHA to produce variable effects on VEGF-α in 
cancer cells (figures 40-42). The expression of HIF-1α upon treatment with 1,2,4,-trioxanes 
in different experimental settings was variable and led to conflicting data regarding the 
effects of compounds on HIF-1α (Anfosso et al. 2006; Huang et al. 2007; Ba et al. 2012). 
Therefore, the effect of ART and DHA was evaluated in present study towards pro-
angiogenic protein, HIF-1α. qPCR and flow cytometric analyses were performed to evaluate 
the effect of ART and DHA on expression change in HIF-1α mRNA and intracellular proteins 
levels, respectively, as described in Materials & Methods (Section 2.6 and 2.9.2).  
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Measured mRNA levels of HIF-1α upon treating HT-29-AK cells with ART for 24h were 
markedly up-regulated in a concentration-dependent manner by 10.12- (ΔΔCt= 10.12), 
10.79- (ΔΔCt= 10.79) and 36.93-fold (ΔΔCt= 36.93) with 82.53µM, 165.06µM and 330.12µM 
ART, as compared to control (ΔΔCt=1.00), respectively (figure 43A). In contrast, HT-29-AK 
cells treated with ART for 72h showed HIF-1α mRNA levels to be significantly (P<0.001) 
decreased (figure 43B). There was a down-regulation of HIF-1α mRNA levels by 1.59-fold 
(ΔΔCt= 0.63 ± 0.05; P<0.001), 2.00-fold (ΔΔCt= 0.50 ± 0.03; P<0.001) and 6.25-fold (ΔΔCt= 
0.16 ± 0.03; P<0.001) upon treating HT-29-AK cells with increasing concentrations of ART 
at 7.22µM, 14.44µM and 28.88µM, as compared to control (ΔΔCt= 1.00 ± 10), respectively 
(figure 43B). The protein expression of HIF-1α at intracellular level in HT-29-AK cells as 
measured by flow cytometric analysis was up-regulated upon ART treatment for 72h with 
levels to be decreasing with higher ART concentrations (figure 43C). This resulted in a 
significant (P<0.001) change in fold difference by ~2.81 (2.81 ± 0.17 RFU), ~2.52 (2.52 ± 
0.12 RFU) and ~2.32 (2.32 ± 0.16 RFU) while treating HT-29-AK cells with 7.22µM, 
14.44µM and 28.88µM ART for 72h, as compared to control (1.00 ± 0.11 RFU), respectively 
(figure 43C).   
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Figure 43: The effect of ART on HIF-1α mRNA expression and intracellular protein 
HIF-1α levels in HT-29-AK cells in normoxia. Cells were treated without or with ART for 
A) 24h (at 0µM, 82.53µM, 165.06µM and 330.12µM) and B) 72h (at 0µM, 7.22µM, 14.44µM 
and 28.88µM) in normoxia (20% O2) and after incubations HIF-1α mRNA levels were 
analysed by qPCR as described in Materials & Methods (Section 2.6). C) In separate 
investigations after treating HT-29-AK cells for 72h with ART, cells were labelled with HIF-
1α antibody and analysed for protein levels on flow cytometer (Materials & Methods 
2.9.1.2). Results are expressed as mean ± SD of three independent experiments. 
***P<0.001 vs. control as tested by one-way Anova. The mRNA HIF-1α expressions after 
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There was observed opposite effect in HIF-1α mRNA levels upon treating HT-29-AK cells 
for 24h and 72h with DHA as compared to results gathered for ART for the same time 
points, respectively (figures 43A and B vs. 44A and B). After 24h, variable effect on HIF-1α 
gene expression levels led to a significant down-regulation with 29.01µM DHA (by 42%, 
ΔΔCt=0.58 ± 0.08; P<0.001), up-regulation with 58.02µM DHA (by 33%, ΔΔCt=1.33 ± 0.10; 
P<0.001) and followed by down-regulation with 116.04µM DHA (by 15%, ΔΔCt=0.85 ± 0.11; 
P<0.05), as compared to untreated cells (ΔΔCt=1.00 ± 0.03; figure 44A), respectively. In 
contrast, qPCR analysis after 72h showed up-regulation in mRNA HIF-1α levels in all 
samples treated with DHA with the greatest increase observed at 39.50µM (~8.30-fold; 
ΔΔCt= 8.30  vs. ΔΔCt of 1.00) (figure 44B). Treating HT-29-AK cells for 72h with DHA at 
9.88µM, 19.75µM and 39.50µM resulted in a decreasing trend of up-regulated levels of      
HIF-1α protein as investigated on flow cytometer by ~2.34-fold (2.34 ± 0.08 RFU), ~2.07-
fold (2.07 ± 0.05 RFU) and ~1.77-fold (1.77 ± 0.19 RFU) as compared to control (1.00 ± 
0.15 RFU; P<0.001), respectively (figure 44C).  
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Figure 44:  The effect of DHA on the mRNA expression and intracellular protein levels 
of HIF-1α in HT-29-AK cells in normoxia. Cells were treated without or with DHA for A) 
24h (at 0µM, 29.01µM, 58.02µM and 116.04µM) and B) 72h (at 0µM, 9.88µM, 19.75µM and 
39.50µM) in normoxia (20% O2) and after incubations HIF-1α mRNA levels were analysed 
by qPCR as described in Materials & Methods (Section 2.6). C) In separate investigations 
after treating HT-29-AK cells for 72 with DHA, cells were labelled with HIF-1α antibody and 
analysed for protein secretions on flow cytometer (Materials & Methods, Section 2.9.1.2). 
Results are expressed as mean ± SD of three independent experiments. *P<0.05 and 
***P<0.001 vs. control as tested by one-way Anova. The mRNA HIF-1α expressions after 
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The results show that mRNA HIF-1α levels in HL-60 cells treated with ART were markedly 
grater after 72h as compared to 24h (figure 45). The HIF-1α mRNA levels were viariable in 
ART-treated HL-60 cells for 24h resulting in a 2.33-fold (ΔΔCt= 0.43) decrease upon 
treating the cells with 0.98 µM ART, as compared to control (ΔΔCt= 1.00). In contrast,     
HIF-1α mRNA expressions increased by 7.23-fold (ΔΔCt= 7.23) and 3.24-fold (ΔΔCt= 3.24) 
upon treating the cells with 1.96 µM and 3.92 µM ART for 24h, as compared to control 
(ΔΔCt= 1.00), respectively (figure 45 A). After 72h, HIF-1α mRNA levels increased by 
10.38-fold (ΔΔCt= 10.38) and 27.00-fold (ΔΔCt= 27.00) upon treating the cells with 0.30 µM 
and 0.60 µM ART as compared to control (ΔΔCt= 1.00), respectively (figure 45 B). The 
highest concentration at 1.20µM ART had the lowest HIF-1α mRNA expressions of ΔΔCt = 
2.25 as compared to control (ΔΔCt= 1.00) (figure 45 B). At protein levels measured using 
flow cytometric analysis, HL-60 cells treated with ART at 0.30µM, 0.60µM and 1.20µM had 
a significant (P<0.001) concentration-dependent increase in HIF-1α protein activity by 
~1.34- (1.34 ± 0.10 RFU), ~1.59- (1.59 ± 0.14 RFU) and ~1.71-fold (1.71 ± 0.27 RFU), 
respectively as compared to control (1.00 ± 0.17 RFU; figure 45C). 
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Figure 45: The effect of ART on the mRNA expression and intracellular protein levels 
of HIF-1α in HL-60 cells in normoxia. Cells were treated without or with ART for A) 24h (at 
0µM, 0.98µM, 1.96µM and 3.92µM) and B) 72h (at 0µM, 0.30µM, 0.60µM and 1.20µM) in 
normoxia (20% O2) and after incubations HIF-1α mRNA levels were analysed by qPCR as 
described in Materials & Methods (Section 2.6). In separate investigations after treating the 
cells for 72 with ART, cells were labelled with HIF-1α antibody and analysed for C) protein 
levels on flow cytometer (Materials & Methods 2.9.1.2). The results are expressed as mean 
± SD of three independent experiments. ***P<0.001 vs. control as tested by one-way Anova 
(Dunnett test for comparison with control). The mRNA HIF-1α expressions represent 2 
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There were variable effects of DHA treatment in HL-60 cells observed after 24h, with HIF-1α 
mRNA levels to be down-regulated markedly with 0.35µM and 1.40µM DHA by ~5-fold 
(ΔΔCt= 0.20)  and ~1.12-fold (ΔΔCt= 0.89), as compared to control (ΔΔCt= 1.00), 
respectively (figure 46A). There was a 1.21-fold (ΔΔCt= 1.21) increase in HIF-1α mRNA 
levels in HL-60 cells when treated with DHA at 0.70µM, as compared to control (ΔΔCt= 
1.00, figure 46B). In contrast, HIF-1α mRNA levels after 72h DHA treatment were increasing 
in a concentration-dependent manner with the peak observed at 1.00µM (ΔΔCt= 1.64 ± 0.17 
vs. control of ΔΔCt= 1.00 ± 0.02; ~1.64-fold, P<0.001; figure 46B). There was a measured 
difference between mRNA and intracellular protein levels of HIF-1α upon treating             
HL-60 cells for 72h with DHA, which might indicate the involvement of post-transcriptional 
mediators or dalay in cellular response. Flow cytometric analysis showed noticeable but not 
significant increase in HIF-1α intracellular protein levels by 8.25% with 0.25µM DHA when 
compared to control (1.08 ± 0.11RFU vs. 1.00 ± 0.08 RFU; figure 46C). The significant 
(P<0.01) down-regulation was observed with increasing concentrations of DHA and led to 
12.88% and 13.72% fall in HIF-1α levels upon treating the cells with 0.50µM and 1.00µM of 
DHA as compared to control, respectively (figure 46C). 
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Figure 46: The effect of DHA on the mRNA expression and intracellular protein levels 
of HIF-1α in HL-60 cells in normoxia. Cells were treated without or with ART for A) 24h 
(0µM, 0.35µM, 0.70µM and 1.40µM) and B) 72h (0µM, 0.25µM, 0.50µM and 1.00µM) in 
normoxia (20% O2) and after incubations HIF-1α mRNA levels were analysed by qPCR as 
described in Materials & Methods (Section 2.6). In separate investigations after treating the 
cells for 72 with DHA, cells were labelled with HIF-1α antibody and analysed for C) protein 
levels on flow cytometer (Materials & Methods 2.9.1.2). Results are expressed as mean ± 
SD of three independent experiments. ***P<0.001 and **P<0.01 vs. control as tested by 
one-way Anova. The mRNA HIF-1α expressions after 24h represent 2 independent 
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3.14. Effect of ART and DHA on CA-9 localisation in HT-29-AK cells 
As the changes in HIF-1α mRNA and protein levels in HT-29-AK and HL-60 cells upon ART 
and DHA treatments were observed (figures 43-46), further attention was directed towards 
HIF-1α down-stream protein, CA-9. Epidemiological reports correlate CA-9 high protein 
expression and immunohistochemical staining with poor prognosis in solid tumours, 
including CRC (Saarnio et al. 1998; Rasheed et al. 2009; IIie et al. 2010; Lock et al. 2013; 
Cheng et al. 2015; de Martino et al. 2015). Together with some reports of CA-9 involvement 
in enhancing EMT transformation and metastatic potential in cancers (Švastová et al. 2003), 
we focused on determining the localisation and possible changes of CA9 staining in        
HT-29-AK cells upon ART and DHA treatment for 24h and 72h incubations, respectively. 
Immunocytochemical staining of cell was performed as described in Materials & Methods 
(Section 2.7). As presented in figure 47, it was shown that CA-9 protein localisation in all 
samples untreated and treated with ART and DHA for both time points was membranous, 
equally distributed at basal and lateral levels. The findings indicate the lack of impact of 
ART and DHA on CA-9 protein localisation. However, additional studies are needed to verify 
the CA-9 expression at protein and mRNA levels. 
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Figure 47: The effect of ART and DHA treatment on CA-9 intracellular protein 
localisation in HT-29-AK cells at 24h and 72h in normoxia. Evaluation of CA-9 
localisation using immunocytochemical staining was performed by seeding cells on glass 
coverslips with/without ART for A) 24h (at 0µM, 82.53µM, 165.06µM and 330.12µM) and B) 
72h (at 0µM, 7.22µM, 14.44µM and 28.88µM); with/without DHA for C) 24h (at 0µM, 
29.01µM, 58.02µM and 116.04µM) and D) 72h (0µM, 9.88µM, 19.75µM and 39.50µM) as 
described in Materials & Methods (Section 2.7). Cells were fixed, incubated with anti-CA-9 
and visualised using anti-mouse Alexa 488 secondary antibody on confocal microscope 
(Zeiss LSM 510 META) at x 200 magnification. The objective used was EC Plan-Neofluar 
20x/0.50 M27 and the pinhole channel set at 76µm. The representative images show the 
localisation and the staining intensity of CA-9 in the majority of the cells analysed by AIM 
Software. ART, artesunate; DHA, dihydroartemisinin. 
3.15. ART and DHA treatment altered the cellular and mRNA survivin levels in HL-60 
and HT-29-AK cells 
The anti-cancer effects of ART and DHA in CRC SW480 cells and leukaemia KBM-5 cells in 
vitro and in vivo were reported previously to be linked with the inhibition of survivin (Shao et 
al. 2008; Kim et al. 2015). Survivin is a protein responsible for promoting motility and 
angiogenesis abilities of malignant cells, and the inhibition of cell apoptosis (Shin et al. 
2001; Shao et al. 2008; Ye et al. 2014; Kim et al. 2015). Here, the effect of ART and DHA 
against HT-29-AK and HL-60 cells on mRNA  and protein levels of survivin were measured 
by qPCR and ELISA as described in Materials & Methods (Sections 2.5.4 and 2.6). The aim 
of this investigation was to compare the results with previous reports and to provide 
additional knowledge of ART and DHA mode of action by evaluating 2 different time points 
(24h vs. 72h) at transcriptional level using qPCR and following 72h incubation to evaluate 
cellular protein survivin levels as analysed by ELISA. 
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The gene expression levels of survivin upon ART treatments in HT-29-AK cells were 
decreasing with increasing incubation time lengths (24h vs. 72h) (figure 48A and B). HT-29-
AK cells treated with ART at 82.53µM, 165.06µM and 330.12µM for 24h had increased 
mRNA expressions of survivin by ~30.84-fold (ΔΔCt= 30.84 ± 10.53; P<0.001), ~8.33-fold 
(ΔΔCt= 8.33 ± 5.10), and a maximum fold change of ~39.64-fold (ΔΔCt= 39.64 ± 14.67; 
P<0.001), as compared to control (ΔΔCt= 1 ± 0.05), respectively (figure 48A). After 72, 
survivin mRNA levels increased by 1.90- (ΔΔCt= 1.90 ± 0.90), 6.83- (ΔΔCt= 6.83± 1.52) and 
2.86-fold (ΔΔCt= 2.86 ± 1.20) upon treating the cells with 7.22µM, 14.44µM and 28.88µM 
ART, as compared to control (ΔΔCt= 1.00 ± 0.11), respectively (figure 48B).  
Levels of survivin mRNA in ART-treated HL-60 cells were decreasing over a period of time 
between 24h and 72h (figure 48C vs. D). After 24h, there was up-regulation of survivin gene 
expression with ART at 0.98µM, 1.96µM, and 3.92µM by ~7.35-fold (ΔΔCt= 7.35 ± 1.62), 
~15.64-fold (ΔΔCt= 15.64 ± 4.73; P<0.001), and the greatest up-regulation resulting in a 
fold change of ~36.02-fold (ΔΔCt= 36.02 ± 10.72; P<0.001), respectively, as compared to 
control (ΔΔCt= 1 ± 00; figure 48C). These survivin mRNA levels were still up-regulated after 
72h but difference in survivin fold change decreased as compared to 24h. There was a 
~5.51-fold (ΔΔCt= 5.51 ± 0.54; P<0.05), ~10.97-fold (ΔΔCt= 10.97 ± 2.70; P<0.001) and 
~6.73-fold (ΔΔCt= 6.73 ± 1.04; P<0.01) increase upon treating HL-60 cells with ART at 
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Figure 48: The effect of ART on the mRNA expression levels of survivin in HT-29-AK 
and HL-60 cells at 24h and 72h in normoxia. HT-29-AK cells were treated with ART for A) 
24h (at 0 µM, 82.53µM, 165.06µM and 330.12µM) and B) 72h (at 0 µM, 7.22µM, 14.44µM 
and 28.88µM) whereas HL-60 cells were treated with ART for 24h C) (at 0 µM, 0.98µM, 
1.96µM and 3.92µM) and 72h D) (at 0 µM, 0.30µM, 0.60µM and 1.20µM) and survivin 
mRNA levels were measured by qPCR as described in Materials and Methods (Section 
2.6). Data for HT-29-AK cells treated with ART for 72h represent the mean of 2 independent 
experiments and is not powered for statistical analysis. *P<0.05, **P<0.01 and ***P<0.001 
as tested by one-way ANOVA (Dunnett test). ART, artesunate. 
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Cell lysates analysed by ELISA showed that ART (at 7.22µM, 14.44µM and 28.88µM) after 
72h treatment in HT-29-AK cells induced a slight decrease in survivin protein levels with the 
most noticeable of 16.39% (996.09pg/ml) at the highest concentration of  ART (at 28.88µM), 
as compared to control (1191.41pg/ml; figure 49). ART-treated HL-60 cells for 72h at 
0.30µM, 0.60µM, and 1.20µM had a slight decrease in survivin protein expressions with the 
highest decrease observed at 1.20µM ART (1824.22pg/ml), as compared to control 
(1957.03 pg/ml; figure 49).  
 
Figure 49: The effect of ART on cellular protein levels of survivin in HT-29-AK and HL-
60 cells at 24h and 72h in normoxia. Survivin cellular protein levels from cell lysates were 
investigated by ELISA from ART-treated HT-29-AK cells for 72h (at 0µM, 7.22µM, 14.44µM 
and 28.88µM; grey bars) and ART-treated HL-60 cells for 72h (at 0µM, 0.30µM, 0.60µM and 
1.20µM; black bars) as described in Materials and Methods (Section 2.5.4). Data for cells 
treated with ART for 72h represent the mean of 2 independent experiments and is not 
powered for statistical analysis. ART, artesunate. 
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The mRNA survivin levels upon DHA treatments at 29.01µM, 58.02µM and 116.04µM for 
24h were significantly (P<0.001) decreased by 3.03- (ΔΔCt= 0.33 ± 0.23), 2.17- (ΔΔCt= 
0.46 ± 0.21) and the same 2.17-fold (ΔΔCt= 0.45 ± 0.23), as compared to control (ΔΔCt= 
1.00 ± 0.04), respectively (figure 50A). In contrast, survivin mRNA levels in HT-29-AK cells 
treated with DHA for 72h were all significantly (P<0.001) increased with the highest levels 
measured at 39.50µM (~35.33-fold; ΔΔCt= 35.33 ± 5.28) (figure 50B). In accordance with 
decreased survivin mRNA levels observed after 24h with DHA, treatment of HT-29-AK cells 
with 29.01µM, 58.02µM and 116.04µM of DHA for 24h caused a 2.05% (1871.10pg/ml), 
19.63% (1535.16pg/ml) and 31.08% (1316.41pg/ml) decrease in survivin levels as analysed 
by ELISA as compared to control (1910.16pg/ml), respectively (figure 50C). In opposite to 
increased survivin mRNA levels observed after 72h using qPCR, treatment of HT-29-AK 
cells for 72h at 9.88µM DHA decreased survivin levels by ~6.95% (1699.22 pg/ml), as 
compared to control (1826.17pg/ml) (figure 50C). DHA treatment at 19.75µM and 39.50µM 
decreased survivin protein levels by 14.22% (1566.41 pg/ml) and 15.94% (1535.16 pg/ml) 
as compared to control (1826.17pg/ml), respectively (figure 50C). The differences between 
survivin at mRNA and protein levels might indicate delay in response at transcriptional and 
post-transcriptional level or activity of other regulators modulating survivin protein 
expression (figure 50C). 
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Figure 50:  The effect of DHA on the mRNA expression and cellular protein levels of 
survivin in HT-29-AK cells at 24h and 72h in normoxia.  Survivin mRNA levels measured 
for DHA-treated HT-29-AK cells for A) 24h (at 0 µM, 29.01µM, 58.02µM and 116.04µM) and 
B) for 72h (at 0 µM, 9.88µM, 19.75µM and 39.50µM) as analysed by qPCR as described in 
Materials & Methods (Section 2.6). C) A two-site sandwich ELISA was performed on the cell 
lysates upon treating HT-29-AK cells for 24h (black bars) and 72h (grey bars) (Materials & 
Methods, Section 2.5.4). The results derived from ELISA were not powered for statistical 
analysis. The results derived from qPCR represent 3 independent experiments where 
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The results from qPCR analysis showed that the survivin mRNA levels from DHA-treated 
HL-60 cells for 24h were down-regulated (figure 51A). These resulted in a ~1.27- (ΔΔCt= 
0.79 ± 0.21), ~1.79- (ΔΔCt= 0.56 ± 0.28; P<0.05) and ~1.82-fold (ΔΔCt= 0.55 ± 0.19; 
P<0.01) decrease upon treated HL-60 cells for 24h with DHA at 0.30 µM, 0.70 µM and 1.40 
µM, as compared to control of ΔΔCt equal to 1.00 ± 0.00, respectively (figure 51A). In 
contrast, as compared to control (ΔΔCt= 1.00), DHA treatment for 72h resulted in             
up-regulation of survivin mRNA levels at 0.25 µM (~19%; ΔΔCt= 1.19), 0.50µM (~85%; 
ΔΔCt= 1.85) and 1.00µM (~67%; ΔΔCt= 1.67), respectively (figure 51B). 
Treatment of HL-60 cells for 24h with 0.35µM DHA did not alter the cellular protein level of 
survivin, as compared to control (1832.031pg/ml vs. 1832.31pg/ml; figure 51C). However, 
treatment of HL-60 cells with 0.70µM and 1.40µM caused a decrease in survivin 
concentrations by 9.38% (1660.16pg/ml) and 18.34% (1496.09 pg/ml), as compared to 
control (1832.031pg/ml), respectively (figure 51C). More noticeable decrease in protein 
survivin levels was observed at 72h incubation at 0.25µM DHA (by ~22.57%; 1527.34pg/ml) 
and 1.00µM (by ~32.48%; 1332.03pg/ml), as compared to untreated cells (1972.66pg/ml), 
respectively. The IC50 concentration of DHA representing 0.50µM resulted in un-changed 
survivin levels when compared to untreated cells (by 2%; 1933.60pg/ml vs. 1972.66pg/ml) 
(figure 51C). 
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Figure 51: The effect of DHA on the mRNA expression and cellular protein levels of 
survivin in HL-60 cells at 24h and 72h in normoxia.  Survivin mRNA levels measured for 
DHA-treated HL-60 cells for A) 24h (at 0 µM, 0.35µM, 0.70µM and 1.40µM) and B) for 72h 
(at 0 µM, 0.25µM, 0.50µM and 1.00µM) before being analysed by qPCR as describe in 
Materials & Methods (Section 2.6).  C) A two-site sandwich ELISA was performed on the 
cell lysates upon treating HL-60 cells for 24h (black bars) and 72h (grey bars) (Materials & 
Methods, Section 2.5.4). The results derived from ELISA were not powered for statistical 
analysis. qPCR results for DHA-treated HL-60 cells for 24h represents 3 independent 
experiments where *P<0.05 and **P<0.01 as tested by one-way ANOVA (Dunnett test). 
DHA, dihydroartemisinin. 
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3.16. Effect of ART and DHA on phospho-Akt expression levels 
Akt, is a serine/threonine-specific protein that plays a pivotal role in apoptosis 
inhibition by promoting malignant cell survival, proliferation and angiogenesis (Bortul 
et al. 2003; Altomare and Testa 2005; Stegeman et al. 2012). In colorectal HCT116 
cells, TNF-α-activated Akt pathway contributed to inflammation-induced EMT, 
enhanced invasion and metastasis of cells (Wang et al. 2013). Previous reports 
demonstrated that ART in human cervical carcinoma cells and DHA in human 
prostate cancer cells promoted TRAIL-induced apoptosis through inhibition of the 
NF-κB and PI3K/Akt signaling pathways (He et al. 2010; Thanaketpaisarn et al. 
2011). These observations show that ART and DHA have the ability to inhibit Akt, 
which could represent promising therapeutic approach for cancer therapy. Therefore, 
to further study the mode of action of ART and DHA in cancer cells, activated Akt 
(phosphorylated at Ser473) was investigated using flow cytometric and Western 
blotting analyses as described in Materials and Methods (Sections 2.9 and 2.10). It 
was hypothesized that ART and DHA in HT-29-AK and HL-60 cells would decrease 
expression of phoshorylated (phospho) Akt.  
The findings derived from flow cytometic analysis showed that HT-29-AK cells 
treated with 7.22µM, 14.44µM and 28.88µM of ART had increased significantly      
(P< 0.001) phospho-Akt levels by ~3.31- (3.31 ± 0.53 RFU), ~3.47- (3.47± 0.32 RFU) 
and ~3.64-fold (3.64 ± 0.58 RFU), respectively, as compared to control (1.00 ± 0.04 
RFU) (figure 52A).  
 
 




Figure 52: ART increases the protein levels of phospho-Akt in HT-29-AK cells 
at 72h in normoxia. Cells were exposed to ART (at 0µM, 7.22µM, 14.44µM and 
28.88µM) for 72h in normoxia (20% O2) and A) analysed for the presence of 
phospho-Akt on flow cytometer (Materials & Methods, Section 2.9). B) 
Representative dot plots derived from flow cytometer show (in arrow) an increase in 
phospho-Akt labelled cells between ART-treated and control cells. The results 
represent the mean ± SD of three independent experiments. ***P<0.001 vs. control 
as tested by one-way ANOVA (Dunnett test). ART, artesunate. 
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Interestingly, DHA treatment increased the levels of phospho-Akt protein in HT-29-
AK cells in a time- and concentration-dependent manner (figures 53 A and B).       
HT-29-AK cells treated for 24h with DHA at 29.01µM, 58.02µM and 116.04µM 
showed a marked increase in phospho-Akt by ~1.26- (1.26 RFU), ~2.33- (2.33 RFU) 
and ~2.51-fold (2.51 RFU), as compared to control (1.00 RFU), respectively (figure 
53 A). In contrast, DHA-treated HT-29-AK cells for 72h at 9.88µM and 19.75µM had 
increased the release of phosho-Akt by ~1.15-fold (1.15 RFU) and ~1.03-fold (1.03 
RFU), as compared to control (1.00 RFU), respectively (figure 53 B). However, DHA 
at 39.50µM decreased the levels of phospho-Akt levels by ~1.11 fold (0.90 RFU), as 
compared to DHA untreated cells (1.00 RFU) (figure 53 B).  
In order to validate flow cytometric results of DHA-mediated changes in phospho-Akt 
expression levels, Western blot analysis was performed for these two time points 
(figure 53 C and D). The results of Western blotting analysis are in accordance with 
flow cytometric observations and the dark bands correspond to the high protein 
levels of phospho-Akt whereas the lighter bands show the low protein phospho-Akt 
(figure 53). 
 
































































Figure 53: The effect of DHA on phospho-Akt intracellular protein levels in HT-
29-AK cells at 24h and 72h in normoxia. Cells were exposed to A) DHA (at 0, 
29.01µM. 58.02 µM and 116.04µM) for 24h and B) DHA (at 0, 9.88µM. 19.75µM and 
39.50µM) for 72h in normoxia (20% O2) and analysed for the presence of 
phospho(p)-Akt by flow cytometric analysis (Materials & Methods, Section 2.9). In 
similar experiments, proteins isolated from DHA-treated and control samples were 
separated by SDS-PAGE and Western blotting analysis was performed as described 
in Materials & Methods (Section 2.10). Re-probing of membrane for total (t)-Akt 
levels in cells treated for 24h with DHA confirmed equal loading of protein into all of 
the wells (lower panel of D). The results derived from flow cytometric and Western 
blotting analyses represent 2 independent experiments which are not powered for 
statistical analysis. DHA, dihydroartemisinin. 
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For comparison purposes similar flow cytometric investigations were performed in 
HL-60 cells treated with ART and DHA accordingly. As shown in figure 54 A, HL-60 
cells treated with ART at 0.30µM, 0.60µM and 1.00µM had up-regulated phospho-
Akt levels in a concentration-dependent manner by ~2.22-fold (2.22 ± 0.64 RFU; 
P<0.001), ~2.79-fold (2.79 ± 0.74 RFU; P<0.001) and ~3.16-fold (3.16 ± 0.51 RFU; 
P<0.001), as compared to control (1.01 ± 0.15 RFU), respectively. The 
phosphorylation of Akt protein increased in a concentration-dependent manner by 
~5% (1.05 ± 0.17 RFU), ~10% (1.10 ± 0.18 RFU) and ~16% (1.16 ± 0.19 RFU) upon 
treating HL-60 cells for 72h with DHA at 0.25µM, 0.50µM and 1.00µM, as compared 
to control (1.00 ± 0.18 RFU), respectively but these changes were not significant 
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Figure 54: The effect of ART and DHA on phospho-Akt intracellular protein 
levels in HL-60 cells at 72h in normoxia. Cells were treated without or with A) ART 
(at 0.30µM, 0.60µM and 1.20µM) and B) DHA (at 0.25µM, 0.50µM and 1.00µM) for 
72h under normoxic conditions (20% O2), labelled with phospho-Akt antibody and 
analysed on flow cytometer (Materials & Methods, Section 2.9). The results 
represent the mean ± SD of three independent experiments where ***P<0.001 vs. 
control as tested by one-way ANOVA (Dunnett test). ART, artesunate; DHA, 
dihydroartemisinin. 
3.17. ART and DHA increased caspase-3-dependent apoptosis of HT-29-AK 
and HL-60 cells 
Since several studies have demonstrated that 1,2,4-trioxanes induce cell death via 
apoptosis (Mercer et al. 2007; Lu et al. 2008; Hamacher-Brady et al. 2010), the 
effects of ART and DHA was investigated on pro-apoptotic cleaved caspase-3 in   
HT-29-AK and HL-60 cells.  
As presented in figure 55A, HT-29-AK cells treated with 7.22µM (3.09 ± 0.38), 
14.44µM (3.24 ± 0.39 RFU) and 28.88µM (3.30 ± 0.27 RFU) of ART showed a 
significant (P<0.001) concentration-dependent increase in cellular level of caspase-3 
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as compared to control (1.00 ± 0.13), which was further presented as dots plots 
using flow cytometric analysis tools (figure 55B). Similarly, cells treated with DHA 
demonstrated a significant (P< 0.01) concentration-dependent increase of caspase-3 
activity with the highest levels observed of 2.53 ± 0.73 RFU (at 39.5µM DHA) as 
compared to untreated samples (1.00 ± 0.10 RFU; figure 55C). 
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Figure 55: The effect of ART and DHA on the activity of cellular cleaved 
caspase-3 in HT-29-AK cells at 72h in normoxia. Cells were treated with A) ART 
(at 0µM, 7.22µM, 14.44µM and 28.88µM) and C) DHA (at 0µM, 9.88µM, 19.75µM 
and 39.50µM) for 72h in normoxia (20% O2) and analysed for catalytically active 
caspase-3 by flow cytometry as described in Materials & Methods (Section 2.9). B) 
Representative dot plots derived from flow cytometer show (in arrow) an increase in 
cleaved caspase-3 labelled cells between ART-treated and control cells. The results 
represent the mean ± SD of three independent experiments. **P<0.01 and 
***P<0.001 vs. control as tested by one-way Anova (Dunnett test). ART, artesunate; 
DHA, dihydroartemisinin. 
As shown in figure 56 A, HL-60 cells treated with ART (at 0.30µM, 0.60µM and 
1.00µM) had a significant (P<0.001) concentration-dependent increase in cleaved 
caspase-3 activity by ~1.48-fold (1.48 ± 0.13 RFU), ~2.04-fold (2.04 ± 0.18 RFU) and 
~2.77-fold (2.77 ± 0.24 RFU), as compared to control (1.00 ± 0.14 RFU), 
respectively. Similarly, DHA-untreated cells showed a caspase-3 secretion of 1.00 ± 
0.11 RFU which increased by ~1.06-fold (1.06 ± 0.11 RFU; P<0.05), ~1.07-fold (1.07 
± 0.13 RFU), ~1.12-fold (1.12 ± 0.13 RFU; P<0.05) upon treating the cells with 
0.25µM, 0.50µM and 1.00µM DHA, respectively (figure 56 B). 

































































Figure 56: The effect of ART and DHA on the activity of cellular cleaved 
caspase-3 in HL-60 cells at 72h in normoxia. Cells were treated with A) ART (at 0, 
0.30µM, 0.60µM and 1.00µM) and B) DHA (at 0, 0.25µM, 0.50µM and 1.00µM) for 
72h in normoxia (20% O2) and analysed for the presence of cleaved caspase-3 by 
flow cytometry as described in Materials & Methods (Section 2.9). The results 
represent the mean ± SD of three independent experiments. *P<0.05 and 
***P<0.001 vs. control as tested by one-way ANOVA (Dunnett test). ART, 
artesunate; DHA, dihydroartemisinin. 
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3.18. DHA induces DNA strand breaks in treated HL-60 and HT-29-AK cells as 
measured by 5-bromo-2'-deoxyuridine (BrdU) assay under normoxic 
conditions 
The results of previous study show that the anti-cancer effects of ART and DHA are 
linked with the induction of caspase-3 dependent apoptosis (figures 55 and 56). In 
order to further evaluate these observations, APO-BrdUTM TUNEL Assay was used 
to  determine whether  DHA-induced cell death is incorporated with BrdU (5-bromo-
2-deoxyuridine), a structural analog of thymidine being present at 3’-OH DNA break 
sites of apoptotic cells (Materials & Methods, Section 2.11). 
As depicted in figure 57, there was a concentration-dependent increase in labelled 
BrdU levels upon treating HT-29-AK cells for 24h with the different concentrations of 
DHA. The BrdU levels increased by ~1.18-fold (1.18 RFU), ~1.36-fold (1.36 RFU), 
and ~1.65-fold (1.65 RFU) upon treating the cells with 9.88µM, 19.75µM and 
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Figure 57: The effect of DHA on the presence of BrdU-labelled nicks in DNA in 
HT-29-AK cells at 24h and 72h in normoxia. Full bars represent cells treated for 
24h with DHA (at 0µM, 29.01µM, 58.02µM and 116.04µM; black bars) and the grey 
bars represent cells treated with DHA for 72h (at 0µM, 9.88µM. 19.75µM and 
39.50µM). The samples were analysed for the presence of BrdU-labelled DNA by 
flow cytometric analysis as described in Materials & Methods (Section 2.11). The 
results represent 1 independent experiment which is not powered for statistical 
analysis. DHA, dihydroartemisinin.  
The results presented in figure 58 show that HL-60 cells treated for 24h with DHA at 
0.35µM, 0.70µM and 1.40µM resulted in a marked concentration-dependent 
incorporation of BrdU into the nicked DNA strands by ~1.58-fold (1.58 RFU),     
~1.97-fold (1.96 RFU) and ~2.47-fold (2.47 RFU), as compared to control (1.00 
RFU), respectively. HL-60 cells treated for 72h with all of the concentrations tested of 
DHA (0.25µM, 0.49µM and 0.98µM) showed elevated BrdU levels, as compared to 
control (figure 58).  
 




























































                           
HT-29-AK cells
206 | P a g e  
 
 
Figure 58: The effect of DHA on the presence of BrdU-labelled nicks in DNA in 
HL-60 cells at 24h and 72h in normoxia. Black bars represent cells treated for 24h 
with DHA (at 0, 0.35µM, 0.70µM and 1.40µM) and the grey bars represent cells 
treated with DHA for 72h with DHA (at 0, 0.25µM, 0.50µM and 1.00µM). The 
samples were analysed for the presence of incorporated BrdU by flow cytometric 
analysis as described in Materials & Methods (Section 2.11). The results represent 1 
independent experiment which is not powered for statistical analysis. DHA, 
dihydroartemisinin. 
3.19. ART and DHA induced DNA fragmentation in HT-29-AK and HL-60 cells in 
normoxia 
In previous experiments, it was found that ART and DHA induced a concentration-
dependent increase of pro-apoptotic caspase-3 in HT-29-AK and HL-60 cells (figures 
55 and 56). DHA-treated HL-60 cells and HT-29-AK cells have also shown that DHA 
promote apoptosis by inducing DNA strand breaks, and observation which comes 
from an increase in BrdU-stained cells (figures 57 and 58). To investigate whether 
these results correlate with the presence of fragmented DNA in treated cells, HT-29-
AK and HL-60 cells were treated with ART and DHA for varying incubation periods 
between 24h and 72h before the DNA was isolated and analysed using agarose gel 
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electrophoresis (Materials & Methods, Section 2.12).  In order to validate the results, 
a positive control (heat-treated sample) was used. DNA damage was induced upon 
incubation of the isolated non-drug treated sample for 20min at 95°C (figure 59). This 
manipulation resulted in DNA smearing pattern which was compared to untreated 
and treated samples (figure 59).  
As shown in figure 59, treatment of HT-29-AK cells for 72h with A) ART (at 7.22µM, 
14.44µM, and 28.88µM) and B) DHA (at 9.88µM, 19.75µM and 39.50µM) led to the 
detection of ≥ 20 000 basepairs (bp) DNA fragments accumulated in all 
concentrations tested (red arrows). These DNA fragments represent the break-up of 
the large genomic DNA upon drug treatment into smaller, low molecular weight 
fragments being signs accompanying apoptosis.  
The DNA damage upon ART treatment was not concentration-dependent, as 
compared to untreated cells [figure 59 A; lanes 3, 4, 5 (red arrows) vs. lane 2 (purple 
arrows)]. The heated samples (positive control) resulted in DNA smearing pattern 
ranging from ~20000-5000 bp (figure 59 A, lane 1, blue curly bracket). DNA isolated 
from DHA-treated cells (figure 59 B, lane 3, 4, 5) appeared to result in a greater DNA 
damage (more visible, lighter packed areas) at all concentrations tested as 
compared to negative control (barely visible; lane 2). DNA smearing pattern starting 
from 21226 bp and being lower than 4268 bp (figure 59 B, lane 1, blue curly 
bracket).  
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Figure 59: HT-29-AK cells DNA fragmentation analysis upon ART and DHA 
treatment for 72h in normoxia. Cells (5x10⁶cells/flask) were treated without/with 
ART and DHA for 72h in normoxia (20% O2), before the DNA was isolated from cells 
and analysed using agarose gel electrophoresis (Materials & Methods, Section 
2.12). Representative pictures: A) 72h, ART at 7.22 µM [lane 3], 14.44µM [lane 4], 
28.88µM [lane 5]; B) 72h, DHA at 9.88µM [lane 3], 19.75 µM [lane 4], 39.50 µM [lane 
5]. Positive controls (control DNA heated at 95°C for 20 mins) were used for both 
drugs for 72h (figure 58 A and B) [lane 1] and revealed DNA smearing (blue curly 
bracket). The drug untreated samples (negative control) are shown in lane 2 (figure 
58 A and B). Purified DNA from ART and DHA untreated and treated cells at 
50ng/µL were separated on 0.8% agarose gel and visualised under UV light. Gene 
Ruler 1kb (A; 20000-5000 bp) or Lambda DNA/Eco 1301 16 (B; 21226- 4268 bp) 
molecular markers (Thermo Scientific, Hampshire, UK) were used to determine DNA 
bands. ART, artesunate; DHA, dihydroartemisinin. 
As presented in figure 60, HL-60 cells treated with A) ART (at 0.98µM, 1.96µM, 
3.92µM) for 24h; B) ART (at 0.36µM, 0.71µM, 1.42µM) for 48h; and 72h C) ART (at 
0.30µM, 0.60µM and 1.20µM) for 72h resulted in the production of damaged DNA 
fragments (red arrows). Molecular weights of DNA fragments for all ART treated cells 
are ≥ 21226 bp (figure 60 A and B, lanes 3, 4, 5; and 60 C lanes 1-3). However, as 
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presented in figure 60 A and B (lane 2) and 60 C (lane 4) by purple arrows only a 
small appearance of DNA fragmentation is present in the DNA extracted from ART-
untreated cells (negative control). As illustrated in lane 1 for 24h (A) and 48h (B), the 
heated controls also showed a small appearance of DNA fragmentation. Overall, 
cells treated with ART for 24h (lane 3, 4, 5) resulted in more visible DNA damage as 
compared to heated control (lane 1). For the 48h incubation, cells treated with 
1.42µM ART appeared to result in greater DNA damage, as compared to the 
respective heated control (figure 60 B, lane 5 vs. lane 1). A heated control sample for 
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Figure 60: HL-60 cells DNA fragmentation analysis upon ART treatment for 24-
72h in normoxia. Cells (5x10⁶cells/flask) were treated without or with ART for 24, 48 
or 72h in normoxia (20% O2), before the DNA was isolated and assayed using 
agarose gel electrophoresis (Materials & Methods, Section 2.12). Representative 
pictures: A) 24h, ART at 0.98 µM [lane 3], 1.96 µM [lane 4], 3.92 µM [lane 5]; B) 48h, 
ART at 0.36 µM [lane 3], 0.71 µM [lane 4], 1.42 µM [lane 5]; C) 72h, ART at 0.30 µM 
[lane 1], 0.60 µM [lane 2], 1.20 µM [lane 3]. In this study, ART untreated samples 
(negative control) were used for all incubation periods (lane 1 for 24h and 48h  and 
lane 4 for 72h). For data validation, positive control (DNA isolated from untreated 
samples which were heated at 95°C for 20 mins) was used for 24h (A) and 48h (B) 
incubations [lane 1]. Purified DNA from control and ART-treated cells at 70ng/µL 
were separated on 0.8% agarose gel and visualised under UV light. The Lambda 
DNA/Eco 1301 16 molecular marker (Thermo Scientific, Hampshire, UK) was used 
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As presented in figure 61A and B, the results obtained for HL-60 cells treated with 
DHA for 24h (at 0.35µM, 0.70µM,1.40µM) and 72h (at 0.25µM, 0.50µM, 1.00µM) 
show a concentration-dependent increase in amount of smaller DNA fragmentation 
of ≥ 20 000 bp (more lighter, packed areas). DNA damage upon DHA treatment was 
indicated by red arrows (figure 61 A and B, lanes 3,4,5) whereas DHA untreated 
cells with almost undetectable DNA damage with purple arrows (figure 61 A and B, 
lanes 2). Positive controls for both incubations time points (figure 61 A and B, blue 
curly brackets) showed DNA damage with the appearance of smearing pattern 
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Figure 61: HL-60 cells DNA fragmentation analysis upon DHA treatment at 24h 
and 72h in normoxia. Cells (5x10⁶cells/flask) were treated without or with DHA for 
24 or 72h under normoxic conditions (20% O2), before the DNA was isolated and 
assayed using agarose gel electrophoresis (Materials & Methods, Section 2.12). 
Representative pictures: A) 24h, DHA at 0.35 µM [lane 3], 0.70 µM [lane 4], 1.4 µM 
[lane 5]; B) 72h, DHA at 0.25 µM [lane 3], 0.50 µM [lane 4], 1.00 µM [lane 5]. Here, 
positive control (non-drug treated isolated DNA which was heated at 95°C for 20 
mins) used for the 24h (A) and 72h (B) [lane 1] incubations which show DNA 
smearing (blue curly bracket). DHA-untreated samples (negative control) were used 
for both incubation periods (lane 2 for 24h and 72h). Purified DNA from control and 
DHA-treated cells at 70ng/µL were separatedon 0.8% agarose gel and visualised 
under UV light. The Lambda DNA/Eco 1301 16 molecular marker (Thermo Scientific, 










PART II: THE ANTI-CANCER ACTIVITY AND MOLECULAR MECHANISMS OF 
ART AND DHA AGAINST HT-29-AK AND HL-60 CELLS UNDER HYPOXIC 
CONDITIONS (1% O2) 
4.1. ART and DHA inhibit the growth of HL-60 and HT-29-AK cells in low 
oxygen tension 
Since our previous study in normoxia (20% O2, 5% CO2, 75% N2 at 37°C) has shown 
that ART and DHA exhibit profound cytotoxic activity (Section 3.1, table 3), the main 
focus of this study was to investigate whether low oxygen tension (1% O2, 5% CO2, 
94% N2 at 37°C) affected the sensitivity of HL-60 and HT-29-AK cells to ART and 
DHA. Similar to data acquired under normoxic conditions, it was revealed that 
treatment of HL-60 and HT-29-AK cells with ART and DHA under hypoxic conditions 
inhibited the growth of the cells in a time-dependent manner (tables 3 and 6).          
The 50% growth-inhibition concentration for ART-treated HL-60 cells for 24h was 
equal to IC50 value of 0.92 ± 0.23µM (table 6). There was a significant improvement 
in the activity of ART against leukaemic HL-60 cells with increase in incubation time, 
resulting in measured IC50 values of 0.73 ± 0.03µM (IC50 value of 0.92 ± 0.23µM vs. 
IC50 value of 0.73 ± 0.03µM ART; 1.26-fold enhancement; P<0.05), and 0.51 ± 
0.06µM (IC50 value of 0.92 ± 0.23µM vs. IC50 value of 0.51 ± 0.06µM ART; 1.80-fold 
enhancement; P<0.001) after 48h and 72h, respectively (table 6).  
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There was a significant increase in the cytotoxicity of ART in hypoxia, as compared 
to normoxia after 24h incubation (hypoxia: IC50 value of 0.92 ± 0.23µM vs. normoxia: 
IC50 value of 1.96 ± 0.28µM, 2.13-fold enhancement; P<0.001) and after 72h 
incubation (hypoxia: IC50 value of 0.51 ± 0.06 µM vs.normoxia: IC50 value of 0.60 ± 
0.08 µM, 1.18-fold enhancement; P<0.05) (tables 3 and 6). The cytotoxicity of ART 
in hypoxia for 48h, as compared normoxia was unchanged (hypoxia: IC50 value of                   
0.73 ± 0.03 µM vs. IC50 value of 0.71 ± 0.15 µM, P>0.05) (tables 3 and 6). These 
observations show the influence of low oxygen tumour microenvironment on ART 
response. ART was more potent against HL-60 cells after 24h and 72h in hypoxia, 
as compared to normoxia (tables 3 and 6).The cytotoxicity of ART after 48h 
incubation against HL-60 cells was unaffected by low oxygen microenvironment 
(tables 3 and 6). The findings show potential applications of ART for leukaemia 
therapy, especially towards leukaemic cells within hypoxic BM areas. In addition, the 
results show the importance of modeling the tumour microenvironment when 
developing novel therapeutic drug applications. 
 As compared to IC50 value of 1.10 ± 0.08µM for DHA-treated HL-60 cells for 24h in 
hypoxia, the cytotoxicity of DHA in low oxygen microenvironment significantly 
(P<0.001) increased with prolonged incubation (48h: IC50 value of 0.60 ± 0.09µM, 
1.83-fold enhancement; 72h: IC50 value of 0.53 ± 0.07µM, 2.08-fold enhancement) 
(table 6). The inhibitory action of DHA for 24h in hypoxia was reduced by ~1.57-fold 
as compared to 24h in normoxia (hypoxia: IC50 value of 0.70 ± 0.12µM vs. normoxia: 
IC50 value of 1.10 ± 0.08µM) with a level of statistical significance of P<0.001 (tables 
3 and 6). The changes in the cytotoxicity of DHA against HL-60 cells for 48h and 72h 
incubations under hypoxic conditions were too minimal to be considered significant 
(48h; hypoxia: IC50 value of 0.60 ± 0.09µM vs. normoxia: IC50 value of 0.65 ± 
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0.09µM, 72h; hypoxia: IC50 value of 0.53 ± 0.07µM vs. normoxia: IC50 value of 0.49 ± 
0.03µM) (tables 3 and 6). 
The findings show that DHA treatment of HL-60 cells in normoxia effectively inhibited 
the growth of both cell lines and this inhibition was decreased by hypoxia only for 
24h treatment with DHA. The results show similar potency profiles of DHA in 
normoxia and hypoxia against leukaemic cells after 48h and 72h incubation, thus 
indicating potential applications of DHA to target leukaemia clinically. However, 
further studies are needed to support these observations. 
After 72h incubation in low oxygen microenvironment (1% O2) where ART and DHA 
were most potent against HL-60 cells, there was no significant difference in the 
cytotoxicity of compounds (ART with IC50 value of 0.51 ± 0.06µM vs. DHA with IC50 
value of 0.53 ± 0.07µM; P>0.05, table 6). These results show similar potency profiles 
of ART and DHA against leukaemic cells after 72h incubation in hypoxia.  
Table 6: The cytotoxic effect of ART and DHA alone at 24h, 48h or 72h 
incubation in hypoxia. The results for the drugs alone at each incubation point are 
expressed as the mean IC₅₀ ± SD of at least three independent experiments with 18 





HL-60 cells HT-29-AK cells 
IC₅₀ (µM, Mean±SD) 
ART 0.92 ± 0.23  269.86 ± 84.41 
DHA 1.10 ± 0.08  84.97 ± 2.72 
48 
ART 0.73 ± 0.03* 132.99 ± 31.83*** 
DHA 0.60 ± 0.09*** 50.36 ± 2.47*** 
72 
ART 0.51 ± 0.06*** 46.51 ± 4.74*** 
DHA 0.53 ± 0.07*** 27.10 ± 2.73*** 
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As compared to the growth-inhibitory effect of ART with IC50 value of                  
269.86 ± 84.41µM against colorectal HT-29-AK cells after 24h incubation in hypoxia, 
the cytotoxic activity of ART against HT-29-AK cells in hypoxia significantly (P<0.001) 
increased with prolonged incubation, resulting in measured IC50 values of 132.99 ± 
31.83µM (2.03-fold enhancement), and 46.51± 4.74µM (5.80-fold enhancement) after 
48h and 72h, respectively (table 6). 
When comparing the cytotoxic activity of ART against HT-29-AK cells under normoxic 
and hypoxic conditions, it was found that low oxygen microenvironment (1% O2) 
reduced the cytotoxcity of ART at all time tested (tables 3 and 6). After 24h,            
HT-29-AK cells were 1.63-fold less susceptible to the cytotoxic effects of ART, as 
compared to normoxia (hypoxia: IC50 value of 269.86 ± 84.41µM vs. normoxia: IC50 
value of 165.06 ± 24.25µM; P<0.01) (tables 3 and 6). After 48h, HT-29-AK cells were 
2.06-fold less susceptible to the cytotoxic effects of ART, as compared to normoxia 
(hypoxia: IC50 value of 132.99 ± 31.83µM vs. normoxia: IC50 value of 64.61 ± 6.61µM; 
P<0.001) (tables 3 and 6). After 72h where ART was most potent against HT-29-AK 
cells under both tested conditions, the cytotoxicity of ART against the cells in hypoxia 
was reduced by 3.22-fold, as compared to normoxia (hypoxia: IC50 value of 46.51 ± 
4.73µM vs. normoxia: IC50 value of 14.44 ± 2.64µM; P<0.001) (tables 3 and 6).  
As compared to the growth-inhibitory effect of DHA with IC50 value of                   
84.97 ± 2.72µM against colorectal HT-29-AK cells after 24h incubation in hypoxia, the 
cytotoxic activity of DHA against HT-29-AK cells in hypoxia significantly (P<0.001) 
increased with prolonged incubation, resulting in measured IC50 values of 50.36 ± 
2.47µM (1.69-fold enhancement), and 27.10 ± 2.73 µM (3.14-fold enhancement) after 
48h and 72h, respectively (table 6). 
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When comparing the cytotoxicity of DHA against HT-29-AK cells under normoxic and 
hypoxic conditions, low oxygen microenvironment (1% O2) was shown to antagonise 
growth-inhibitory effect of DHA at all time tested (tables 3 and 6). After 24h,            
HT-29-AK cells were 1.46-fold less susceptible to the cytotoxic effects of DHA, as 
compared to normoxia (hypoxia: IC50 value of 84.97 ± 2.72µM vs. normoxia:          
IC50 value of 58.02 ± 4.09µM; P<0.001) (tables 3 and 6). After 48h, HT-29-AK cells 
were 1.32-fold less susceptible to the cytotoxic effects of DHA, as compared to 
normoxia (hypoxia: IC50 value of 50.36 ± 2.47µM vs. normoxia: IC50 value of        
38.28 ± 2.44µM; P<0.001) (tables 3 and 6). After 72h where DHA was most potent 
against HT-29-AK cells under both tested conditions, the cytotoxicity of DHA against 
the cells in hypoxia was reduced by 1.37-fold, as compared to normoxia (hypoxia: 
IC50 value of 27.10 ± 2.73µM vs. normoxia: IC50 value of 19.75 ± 1.07µM; P<0.001) 
(tables 3 and 6).  
After 72h incubation in low oxygen microenvironment (1% O2) where ART and DHA 
had the highest growth-inhibitory effects against HT-29-AK cells, DHA was more 
cytotoxic as compared to ART (DHA with IC50 value of 27.10 ± 2.73µM vs. ART with 
IC50 value of 45.70 ± 3.84µM; table 6) with a level of statistical significance of 
P<0.001.  
The results show that  the low oxygen microenvironment (1% O2) is a major factor 
that decreases the cytotoxicity of ART and DHA against human colorectal HT-29-AK 
cells. These data indicate the importance of developing novel therapeutic drug 
applications, including combination therapies to enhance the anti-cancer effects of 
ART and DHA for CRC treatment 
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4.2. Cytotoxicity of ART and DHA in hypoxia against HL-60 and HT-29-AK cells 
was affected by the presence of DFO and haemin. 
As previous experiments in normoxia have shown that the cytotoxicity of ART and 
DHA in HL-60 and HT-29-AK cells is enhanced by the presence of 1µM and 3µM 
haemin and antagonised by the ferric iron chelator DFO at 60µM (table 5), it was of 
interest to evaluate whether hypoxia modulates these effects. Interestingly, the results 
obtained by MTT cytotoxicity assay under hypoxic conditions (table 7) showed that 
the presence of haemin antagonised the cytotoxic effects of ART and DHA. Lower 
haemin concentration (1µM) decreased the cytotoxicity of ART by ~5.03-fold        
(ART alone with IC50 value of 0.92 ± 0.23µM vs. ART+ 1µM haemin with IC50 value of     
4.63µM; table 7). Haemin at 3µM further decreased the cytotoxicity of ART by   
~18.42-fold (ART alone with IC50 value of 0.92 ± 0.23µM vs. ART+ 3µM haemin with 
IC50 value of 16.95µM). The cytotoxicity of DHA was antagonised by haemin (1µM) 
(IC50 value of 3.65µM) being a 3.32-fold increase in DHA IC50 value of 1.10 ± 0.08µM 
(table 7). Haemin at 3µM further decreased the cytotoxicity of DHA by ~4.98-fold (IC50 
value of 5.48µM), as compared to DHA alone with IC50 value of 1.10 ± 0.08µM (table 
7). 
Similarly to normoxia (table 5), the presence of DFO (60µM) antagonised the 
cytotoxicity of ART and DHA against HL-60 cells under hypoxic conditions (table 7). 
The cytotoxicity of ART was antagonised the most in the presence of DFO (60µM) 
resulting in a ~58.90-fold increase in IC50 value of ART (0.92 ± 0.23 µM vs. 54.18µM; 
table 7). The cytotoxicity of DHA was also diminished by DFO (at 60µM) (IC50 value of 
11.12µM) being a 10.11-fold increase in DHA IC50 value of 1.10 ± 0.08µM (table 7). 
As in normoxia (table 5), the results derived for HT-29-AK cells after 24h incubation 
showed that lower haemin concentration (1µM) increased the cytotoxicity of ART     
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by ~1.58-fold (ART alone with IC50 value of 269.86 ± 84.41µM vs. ART+ 1µM haemin 
with IC50 value of 170.5 ± 18.56µM). The anti-cancer properties of DHA against      
HT-29-AK cells were also enhanced by haemin (1µM) (IC50 value of 63.26µM) being a 
1.34-fold increase in DHA IC50 value of 84.97 ± 2.72µM (table 7). Haemin at 3µM 
further increased the cytotoxicity of ART and DHA by ~1.72- (IC50 value of 156.52µM) 
and 1.64-fold (IC50 value of 51.91µM) when compared to ART IC50 value of 269.86 ± 
84.41µM and DHA IC50 value of 84.97 ± 2.72µM alone, respectively (table 7). In 
addition, treatment of HT-29-AK cells with ART in combination with DFO (60µM) 
antagonised the activity of ART by at least ~2.78- fold (IC50 value of ≤ 750µM) when 
compared to ART alone (269.86 ± 84.41µM) (table 7). Similar effects were observed 
for DHA (IC50 value of 84.97 ± 2.72µM) where the presence of DFO (60µM) inhibited 
the cytotoxicity by ~7.78-fold (IC50 value of 660.68µM) (table 7). 
Table 7: The cytotoxic effect of ART and DHA alone and in the presence of 
deferiprone (60µM) and haemin (1µM and 3µM) against HL-60 and HT-29-AK 
cells at 24h incubation in hypoxia. The results for the drugs alone at each 
incubation point are expressed as the mean IC₅₀ ± SD of at least three independent 
experiments with 18 replicates. Data for the drugs in the presence of DFO and 
haemin (1µM and 3µM) represent 1 independent experiment with 18 replicates. ART, 




HL-60 cells HT-29-AK cells 
IC₅₀ (µM, Mean±SD) 
ART 0.92 ± 0.23  269.86 ± 84.41 
DHA 1.10 ± 0.08  84.97 ± 2.72 
ART + DFO (60µM) 54.18  ≤ 750 
DHA + DFO (60µM)  11.12  660.68  
ART + 1µM haemin 4.63  170.50  
DHA + 1µM haemin 3.65  63.25  
ART + 3µM haemin 16.95  156.52  
DHA + 3µM haemin 5.48  51.91  
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Under normoxic conditions, it was shown that ART and DHA had increased 
cytotoxicity towards HL-60 and HT-29-AK cells in the presence of haemin (1µM and 
3µM) (table 5). As presented in table 7, enhanced ART and DHA cytotoxicity in the 
presence of haemin (1µM and 3µM) was observed only towards CRC HT-29-AK cells 
which was in accordance with the results derived from normoxia (table 5 vs table 7). 
The lower anti-cancer activities of ART and DHA against HL-60 cells under hypoxic 
conditions in the presence of haemin (1µM and 3µM) might be resulted from different 
mechanisms by which iron is utilised by cancer cells in hypoxia, as compared to 
normoxia. The molecular regulation of iron up-take by malignant cells to sustain cell 
growth is mediated by the cell surface TfR1. Therefore, it was of interest to 
investigate wheather decreased activity of ART and DHA in the presence of haemin 
(1µM and 3µM) is associated with the changes of secreted levels of TfR1 upon the 
drugs treatment in hypoxia as compared to normoxia. Based on these considerations, 
ELISA to measure sTfR1 was performed in subsequent study. 
4.3. Hypoxia modulates the effects of ART and DHA on the cellular secretion of 
sTfR1 in HL-60 and HT-29-AK cells 
Data shown in table 7 demonstrate that the presence of haemin (1µM and 3µM) has 
variable effects on ART and DHA in both cell lines in hypoxia. Therefore, it was of 
interest to investigate the effects of ART and DHA on the levels of sTfR1 in cancer 
cells under hypoxia.  
With prepared samples for ELISA as described in Materials & Methods (Section 
2.5.1), we measured concentration-dependent increase in sTfR1 secretion levels by       
~1.89-fold (4.34 nmol/L), ~3.28-fold   (7.54 nmol/L), ~4.37-fold (10.04 nmol/L) upon 
treating HL-60 cells with 0.26µM, 0.52µM and 1.04µM ART, respectively, as 
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compared to control (2.30 nmol/L) (figure 62). In contrast, measured sTfR1 levels in 
samples treated with 0.27µM DHA were highly up-regulated by ~2.30-fold, as 
compared to control (2.07nmol/L vs. 0.90nmol/L, figure 62). These up-regulated 
sTfR1 secretions were decreasing with increasing concentrations of DHA. There was 
a fold change of ~ 1.51- (1.36 nmol/L) and ~1.36-fold (0.66 nmol/L) upon treating    
HL-60 cells with 0.54µM and 1.08µM DHA for 72h respectively, as compared to 
control (0.90nmol/L) (figure 62).  
The findings show that ART and DHA exhibit distinct mechanisms towards TfR1 
levels in HL-60 cells under hypoxic conditions. While ART increased TfR1 levels, 
DHA decreased TfR1 levels in HL-60 cells after 72h in hypoxia. The profile of activity 
of ART and DHA on TfR1 levels in HL-60 cells is similar to the observations in 
normoxia (figures 15 vs. 62), suggesting lack of influence of hypoxia on TfR1 levels in 
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Figure 62: The secretion levels of sTfR1 in HL-60 cells upon ART and DHA 
treatments in hypoxia. Cells were exposed to ART (at 0µM, 0.26µM, 0.52µM and 
1.04µM) and DHA (at 0µM, 0.27µM, 0.54µM and 1.08µM) for 72h under hypoxic 
conditions (1% O2). After 72h incubation cell-free conditional media (from untreated 
and ART- and DHA-treated HL-60 cells) were analysed by ELISA for sTfR1 levels as 
described in Materials & Methods (Section 2.5.1). The histograms for ART treated 
cells (black bars) and DHA (grey bars) for 72h represent mean of 2 independent 
experiments which are not powered for statistical analysis. ART, artesunate; DHA, 
dihydroartemisinin. 
The results displayed in figure 63 indicate that ART and DHA in hypoxia elicit 
opposite effects on sTfR1 secretions in HT-29-AK cells, as compared to the effects 
of compounds observed against HL-60 cells (figure 62 vs. figure 63).  
Low concentration of ART (at 22.85µM) resulted in an increase of sTfR1 secretion 
levels by ~1.13-fold (5.43nmol/L), as compared to ART untreated cells (4.80nmol/L) 
(figure 63). These up-regulated sTfR1 secretions were decreasing with increasing 
concentrations of ART with resulting a fold change of ~ 2.15- (2.23nmol/L) and ~2.86-
fold (1.68 nmol/L) upon treating HT-29-AK cells with 45.70µM and 91.40µM ART 
respectively, as compared to control (4.80 nmol/L) (figure 63). HT-29-AK cells treated 
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with 13.55µM, 27.10µM and 54.20µM DHA resulted in a concentration-dependent 
increase in sTfR1 concentrations by ~ 2.06- (3.79 nmol/L), ~ 2.48- (4.57 nmol/L) and 
~9.66-folds (17.77 nmol/L), as compared to control (1.84nmol/L), respectively (figure 
63). 
Similarly to the observations in HL-60 cells, ART and DHA showed distinct 
mechanisms towards TfR1 levels in HT-29-AK cells under hypoxic conditions. While 
ART decreased TfR1 levels, DHA increased TfR1 levels in HT-29-AK cells after 72h 
in hypoxia. The profile of activity of ART on TfR1 levels in HT-29-AK cells is similar to 
the observations in normoxia (figures 15 and 63), suggesting lack of influence of 
hypoxia on TfR1 levels in ART and DHA-treated HL-60 cells for 72h. In contrast, DHA 
decreased TfR1 in HT-29-AK cells after 72h in normoxia but the TfR1 levels upon 
DHA treatment were increased in hypoxia, indicating the involvement of hypoxia in 
anti-cancer effects of DHA.  
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Figure 63:  The secretion levels of sTfR1 in HT-29-AK cells upon ART and DHA 
treatments in hypoxia. Cells were exposed to ART (0, 22.85µM, 45.70µM and 
91.40µM) and DHA (0µM, 13.55µM, 27.10µM and 54.20µM) for 72h under hypoxic 
conditions (1% O2). After 72h incubation cell-free conditional media (from untreated 
and ART- and DHA-treated HL-60 cells) were analysed by ELISA for sTfR1 levels as 
described in Materials & Methods (Section 2.5.1). The histograms for ART treated 
cells (black bars) and DHA (grey bars) for 72h represent mean of 2 independent 
experiments which are not powered for statistical analysis. ART, artesunate; DHA, 
dihydroartemisinin. 
4.4. The proliferation rate of HL-60 and HT-29-AK cells is affected by oxygen 
availabilty 
In order to better understand the mode of action of ART and DHA,  the proliferation 
rate of HL-60 and HT-29-AK cells at 0, 24, 48, 72 and 96h incubation was 
investigated under normoxic (20% O2) and hypoxic (1% O2) conditions as described 
in Materials & Methods (Section 2.4.5). As presented in figure 64, HL-60 and HT-29-
AK cells in the first 24h were not proliferating rapidly (lag phase); there was no 
significant difference in the growth rate under both conditions. However, after 24h    
HL-60 and HT-29-AK cells under normoxia have turned into logarithmic growth 
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phase, followed by the plateau phase after 48h and again into logarithmic phase after 
72h (figure 64). In contrast, the growth of HL-60 cells under hypoxia was slowly 
increasing from 0h to 72h, turning into death phase after 72h (figure 64A). The growth 
rate of HT-29- AK cells under hypoxia was linear up to 72h with a sharp decline 
(death phase) after 72h (figure 64B). Overall, the growth rate of HL-60 and HT-29-AK 
cells in normoxia after 48h was significantly (P<0.001) faster, as compared to the 
proliferation rate of the cells under hypoxia after 48h (figure 64).   
 
Figure 64: The growth kinetics of A) HL-60 and B) HT-29-AK cells cultured in 
normoxia and hypoxia. Cells (1x104cells/well) were plated in 96-well flat-bottomed 
microtitre plates and incubated for 0, 24, 48, 72 and 96h in normoxia (20% O2) or 
hypoxia (1% O2). Following incubation, the absorbance associated with viable cells 
following MTT assay was estimated as described in Materials & Methods (Section 
2.4.5). The values are means± S.D. of at least 3 independent experiments, with 6 
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4.5. DHA treatment altered the secretion of cytokine IL-6 in HL-60 and HT-29-
AK cells in hypoxia 
In HL-60 cells after 24h, DHA at 0.27µM increased slightly IL-6 levels by ~1.11-fold 
(0.20pg/mL), as compared to control (0.18pg/mL; figure 65). The levels of IL-6 
secretions were undetected with 0.53µM DHA (< 0.039pg/mL) and up-regulated with 
1.06µM DHA (~2.94-fold, 0.53pg/mL), as compared to control (0.18pg/mL; figure 65). 
Similar pattern was observed against HT-29-AK cells treated with DHA for 72h 
(figure 65). As compared to control (0.17pg/mL), DHA (at 13.55µM) increased IL-6 
levels by ~1.59- fold (0.27pg/mL) whereas the levels of IL-6 were below the limit of 
assay detection (< 0.039pg/mL) with 27.10µM of DHA (figure 65). Most detactable 
IL-6 secretion (~2.18-fold, 0.37pg/mL) was observed with the highest concentration 
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Figure 65: The secretion levels of pro-inflammatory cytokine IL-6 in HL-60 and 
HT-29-AK cells upon DHA treatment for 72h in hypoxia. HL-60 cells (black bars) 
were treated with 0µM, 0.27µM, 0.53µM and 1.06µM of DHA and HT-29-AK cells 
(grey bars) were treated with 0µM, 13.55µM, 27.10µM and 54.20µM of DHA for 72h 
before the incubation media was measured for secreted IL-6 levels by ELISA 
following manufacturer’s instructions (www.rndsystems.com) (Materials & Methods, 
Section 2.5.2). As shown in arrow, the level of IL-6 secretions with DHA at 0.53µM 
and 27.10µM was below the limit of detection (< 0.039pg/mL). Data represent mean 
of 2 independent experiments and is not powered for statistical analysis. DHA, 
dihydroartemisinin. 
4.6. ART and DHA reduced the levels of VEGFα165 in HL-60 and HT-29-AK cells 
in hypoxia  
As in normoxia, the effect of ART and DHA on the level of VEGF-α165 secretion in 
HL-60 and HT-29-AK cells in hypoxia was investigated (figure 66). With measurable 
levels of VEGF-α165 in all samples, ART at 0.26µM, 0.51µM, and 1.02µM produced 
identical levels of reduction in VEGF-α165 secretions of 82.52 pg/mL, 81.54 pg/mL 
and 82.52 pg/mL, as compared to control (93.26pg/mL), respectively (figure 66). In 
contrast, measured VEGF-α165 secretions in cells treated with 0.27µM and 0.54µM 
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DHA were slightly up-regulated by ~1.07-fold (89.36 pg/mL) and 1.01-fold (84.47 
pg/mL), respectively, as compared to control (83.50 pg/mL) (figure 66). The levels of 
VEGF-α165 secretions were decreased with 1.06µM DHA (~1.08-fold, 77.64 pg/mL), 
as compared to control (83.50 pg/mL; figure 66). 
 
Figure 66: The effect of ART and DHA on VEGF-α165 cellular secretion in HL-
60 cells at 72h in hypoxia. Cells were exposed to ART (at 0µM, 0.26µM, 0.51µM 
and 1.02µM) or DHA (at 0µM, 0.27µM, 0.53µM and 1.06µM) for 72 h under hypoxic 
conditions (1% O2) before the cell-free culture media were analysed by ELISA as 
described in Materials & Methods (Section 2.5.2). The histograms for ART treated 
cells (black bars), DHA for 72h (grey bars) represent 2 independent experiments 
which are not powered for statistical analysis. ART, artesunate; DHA, 
dihydroartemisinin. 
The results displayed in figure 67, show that HT-29-AK cells treated with 22.85 µM 
and 91.40µM ART resulted in a minimal reduction of VEGF-α165 secretion by ~1.03-
fold (433.11 pg/mL) and ~1.06-fold (424.32pg/mL), as compared to control         
(447.75 pg/mL), respectively. The levels of VEGF-α165 were minimally increased with 
45.70µM ART (461.43 pg/mL) as compared to control (447.75 pg/mL; figure 67). 
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DHA-treated HT-29-AK cells for 72h down-regulated VEGF-α165 secretions in a 
concentration-dependent manner by ~1.19-fold (453.61 pg/mL), ~1.23-fold (438.96 
pg/mL) and ~1.30-fold (415.53 pg/mL) with 13.55 µM, 27.10 µM and 54.20 µM DHA, 
respectively when compared to untreated cells (541.50 pg/mL) (figure 67). 
 
Figure 67:  The effect of ART and DHA on VEGF-α165 cellular secretion in HT-
29-AK cells under hypoxia. Cells were exposed to ART (at 0µM, 22.85µM, 
45.70µM and 91.40µM) or DHA (at 0µM, 13.55µM, 27.10µM and 54.20µM) for 72 h 
under hypoxic conditions (1% O2). Thereafter, cell-free incubation media were 
analysed by sandwich ELISA as described in Materials & Methods (Section 2.5.2). 
The histograms for ART treated cells (black bars) and DHA (grey bars) represent 
mean of 2 independent experiments which are not powered for statistical analysis. 
ART, artesunate; DHA, dihydroartemisinin. 
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4.7. ART and DHA treatment altered cellular survivin levels in HL-60 and HT-29-
AK cells in hypoxia  
To investigate whether hypoxia modulates the expression of survivin, HL-60 and   
HT-29-AK cells were incubated without or with the test agents for 72h in low oxygen 
tension (1% O2). As shown in figure 68, cellular survivin concentration was            
up-regulated in a concentration-dependent manner with 0.26µM and 0.51µM ART 
against HL-60 cells by ~1.04- (910.16 pg/mL) and ~1.13-fold, (988.28 pg/mL), as 
compared to control (871.09 pg/mL), respectively. However, as compared with 
control (871.09pg/mL), ART at 1.02µM resulted in a reduction in survivin 
concentration by ~1.11-fold (785.16 pg/mL) (figure 68). Moreover, as compared to 
control (339.84pg/mL), there was a marked increase in survivin concentrations by 
~2.98- (1011.72pg/mL), ~2.77- (941.41pg/mL) and ~4.08-fold (1386.72pg/mL) upon 
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Figure 68: The effect of ART and DHA on cellular survivin levels in HL-60 cells 
at 72h in hypoxia. Cells were exposed to ART (at 0µM, 0.26µM, 0.51µM and 
1.02µM) or DHA (at 0µM, 0.27µM, 0.53µM and 1.06µM) for 72 h under hypoxic 
conditions (1% O2) before the cell-free culture media were analysed by ELISA as 
described in Materials & Methods (Section 2.5.4). The histograms for ART treated 
cells (black bars), DHA for 72h (grey bars) represent 2 independent experiments 
which are not powered for statistical analysis.. ART, artesunate; DHA, 
dihydroartemisinin. 
In addition, HT-29-AK cells treated with 22.85µM of ART showed decreased survivin 
levels by ~1.34-fold (746.09 pg/mL), as compared to control (996.09 pg/mL)       
(figure 69). Compared to control (996.09 pg/mL), there was a marked increase by 
~1.79– (1785.16 pg/mL) and ~1.59-fold (1582.03 pg/mL) when the cells were treated 
with 45.70µM and 91.40µM of ART, respectively (figure 69). DHA at 13.55µM 
(1433.59 pg/mL) and 54.20µM (1441.41 pg/mL) had no effect on survivin levels in 
HT-29-AK cells, as compared to control (1433.59pg/mL) (figure 69). However, DHA 
at 27.10µM markedly decreased the concentration of survivin by ~1.42-fold 
(1011.719pg/mL) as compared to control (1433.59pg/mL) (figure 69).  
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Figure 69: The effect of ART and DHA  on cellular survivin levels in HT-29-AK 
cells in hypoxia. Cells were incubated without or with ART at 0µM, 22.85µM, 
45.70µM and 91.40µM (black bars) or DHA at 0µM, 13.55µM, 27.10µM, 54.20µM 
(grey bars) for 72h under hypoxic conditions (1% O2). A two-site sandwich ELISA 
was used to measure survivin in cell lysates as described in Materials and Methods 
(Section 2.5.4). The results represent 2 independent experiments which are not 
powered for statistical analysis. ART, artesunate, DHA, dihydroartemisinin.  
4.8. ART and DHA induced the release of phospho-Akt in HT-29-AK cells in 
hypoxia 
To determine the effect of ART and DHA on phospho-Akt secretion against           
HT-29-AK cells in hypoxia, a flow cytometric analysis was performed as described in 
Materials & Methods (Section 2.9.1). The treatment of HT-29-AK cells for 72h with 
22.85µM, 45.70µM and 91.40µM of ART induced a significant (p< 0.001) increase in 
phospho-Akt levels by ~2.9- (2.90 ± 0.04 RFU), ~2.74- (2.74 ± 0.13 RFU) and ~3.01-
fold (3.01 ± 0.03 RFU), as compared to control (1.00 ± 0.01 RFU), respectively         
(figure 70). ART-mediated increase in phosho-Akt in HT-29-AK cells under hypoxia 
after 72h was not in a concentration-dependent manner, as compared to the results 
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obtained in normoxia (figure 52 A vs. figure 70). As in normoxia, HT-29-AK cells 
treated with DHA under hypoxia induced a concentration-dependent increase in 
phospho-Akt protein levels by ~1.42- (1.42 ± 0.37 RFU), ~2.01- (2.01 ± 0.48 RFU) 
and ~2.39-fold (2.39 ± 0.35 RFU; P<0.01), as compared to control (1.00 ± 0.26 
RFU), respectively (figure 70). 
 
Figure 70: ART and DHA increase the protein levels of phospho-Akt in HT-29-
AK cells at 72h in hypoxia. Cells were exposed to ART (0µM, 22.85µM, 45.70µM 
and 91.40µM) and DHA (0µM, 13.55µM. 27.10µM and 54.20µM) for 72h in hypoxia 
(1% O2) and analysed for the presence of phosho-Akt by flow cytometric analysis as 
described in Materials & Methods (Section 2.9.1). The results for ART and DHA 
treated cells represent the mean ± SD of three independent experiments. **P<0.01 
***P<0.001 vs. control as tested by the Mann-Whitney test. 
4.9. ART and DHA induced the release of cleaved caspase-3 in HL-60 and HT-
29-AK cells under hypoxic conditions  
It was observed that ART and DHA induced a concentration-dependent increase of 
caspase-3 in HL-60 and HT-29-AK cells under normoxic conditions (figures 55 and 
56). To further investigate whether apoptosis of cancer cells upon ART and DHA 
































































72h         HT-29-AK cells
*** *** *** **
234 | P a g e  
 
treatment is affected by oxygen availability, caspase-3 activity was measured in cells 
treated without or with the test agents under hypoxic conditions. As shown in figure 
71, treatment of HL-60 cells with ART and DHA for 72h increased not-significantly 
cellular levels of caspase-3. 
 
Figure 71: The effect of ART and DHA on the activity of cellular cleaved 
caspase-3 in HL-60 cells at 72h in hypoxia. Cells were treated with ART (at 0µM, 
0.25µM, 0.52µM and 1.04µM; black bars) and DHA (at 0µM, 0.27µM, 0.54µM and 
1.08µM; grey bars) for 72h under hypoxic conditions (1% O2) and analysed for the 
presence of caspase-3 by flow cytometry as described in Materials & Methods 
(Section 2.9.1). The histograms represent the mean ± SD of three independent 
experiments. ART, artesunate; DHA, dihydroartemisinin. 
As shown in figure 72, treatment of the HT-29-AK cells at 22.85µM, 45.70µM, and 
91.40µM ART showed a marked ~2.86- (2.86 ± 0.09 RFU), ~2.68-                       
(2.69 ± 0.09 RFU) and ~2.96-fold (2.96 ± 0.16 RFU) increase in the cellular levels of 
caspase-3, as compared to control (1.00 ± 0.03 RFU),  respectively. HT-29-AK cells 
treated at 13.55µM, 27.10µM, and 54.20µM DHA had a noticeable increase in 
caspase-3 levels by ~1.36- (1.36 ± 0.17 RFU), ~1.38- (1.38 ± 0.29 RFU) and ~1.63-
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fold (1.63 ± 0.24 RFU), as compared to control (1.00 ± 0.07 RFU), respectively 
(figure 72).   
 
Figure 72: The effect of ART  and DHA on the activity of cellular cleaved 
caspase-3 in HT-29-AK cells in hypoxia. Cells were treated with ART (at 0µM, 
22.85µM, 45.7µM, and 91.4µM) and DHA (at 0µM, 13.55µM, 27.10µM, and 
54.20µM) for 72h under hypoxic conditions (1% O2) and analysed for the presence of 
caspase-3 activity by flow cytometry as described in Materials & Methods (Section 
2.9.1). The results represent the mean ± SD of three independent experiments. ART, 
artesunate, DHA, dihydroartemisinin.  
4.10. DHA induced DNA damage as measured by BrdU staining in HL-60 and 
HT-29-AK cells under hypoxia 
To further investigate the effect of DHA under hypoxic conditions, the levels of BrdU-
labelled cells were determined by flow cytometry (Materials & Methods, Section 
2.11). HT-29-AK cells treated for 72h with DHA resulted in an increase in BrdU 
staining as compared to control (figure 73). As depicted in figure 73A, HL-60 cells 
treated with 1.06µM DHA unchanged the level of BrdU stained cells, as compared to 
untreated cells (1.00 RFU vs. 1.01 RFU). DHA-treated HT-29-AK cells increased 
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BrdU levels by ~1.16- (1.16 RFU), ~1.13- (1.13 RFU) and ~1.28-fold (1.28 RFU) 
upon treating the cells with 13.55µM, 27.10µM and 54.20µM, as compared to 
untreated cells (1.00 RFU), respectively (figure 73B). 
 
Figure 73: The effect of DHA on the presence of BrdU-stained cells as a marker 
of DNA damage in HL-60 and HT-29-AK cells in hypoxia. Representative 
histograms: A) DHA treated HL-60 cells at 0µM and 1.06µM and B) DHA treated        
HT-29-AK cells at 0µM, 13.55µM, 27.10µM and 54.20µM for 72h under hypoxic 
conditions (1% O2). The samples were analysed for the presence of BrdU-labelled 
cells by flow cytometric analysis as described in Materials & Methods (Section 2.11). 
The results represent 1 independent experiment. DHA, dihydroartemisinin.  
4.11. DHA induced DNA fragmentation in HL-60 cells in hypoxia 
To determine whether DHA treatment induced DNA damage in HL-60 cells, a DNA 
isolated from untreated and treated samples were separated on an agarose gel. As 
depicted in figure 74, HL-60 cells treated without (negative control) or with 0.27µM, 
0.54µM and 1.08µM of DHA for 72h under hypoxia resulted in a DNA damage with 
DNA fragments of ≥ 20 000 bp in all concentrations tested (red arrows). DHA- 
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lighter smeared areas as compared to negative control (lane 2, purple arrow). 
Heating of control sample led to a DNA smear pattern ranging from 20000 to 1500 
bp (lane 1, blue curly bracket).  
 
Figure 74: A representative DNA fragmentation analysis of DHA-treated HL-60 
cells for 72h  in hypoxia using agarose gel electrophoresis. HL-60 cells (5x10⁶ 
cells/flask) were treated with 0.27µM [lane 3], 0.54µM [lane 4] and 1.08µM [lane 5] 
DHA for 72h under hypoxic conditions (1% O2). In this study, two controls were used: 
DHA untreated sample (negative control) [lane 2] and DHA untreated sample which 
were heated at 95°C for 20 mins (positive control). DNA damage observed in heated 
control led to a DNA smearing pattern ranging from 20000 to 1500kDa (blue curly 
bracket). Purified DNA from control and DHA-treated cells at 70ng/µL were loaded 
separated on 0.8% agarose gel and visualised under UV light. The GeneRuler 1kb 
Plus DNA molecular marker (Thermo Scientific, Hampshire, UK) was used to 












PART III: THE ANTI-CANCER EFFECTS OF ART AND DHA (ALONE AND IN 
COMBINATION WITH ASA) AGAINST HT-29-AK AND HL-60 CELLS UNDER 
NORMOXIC AND HYPOXIC CONDITIONS 
5.1. Cytotoxicity of ASA against HT-29-AK and HL-60 cells is dependent on 
oxygen availability 
It was established that ART and DHA inhibit the growth of HL-60 and HT-29-AK cells 
in time and concentration manners, both under normoxic (standard 20% O2) and 
hypoxic (1% O2) conditions (tables 3 and 6). Here, to explore whether ART and DHA 
exhibit synergy with ASA, both cell lines were initially treated with ASA to screen its 
cytotoxic activities through MTT assay as described in Materials & Methods (Section 
2.4.7). Similar experiments were performed in normoxia and hypoxia to evaluate 
whether different oxygen levels influenced the sensitivity of HL-60 and HT-29-AK 
cells to ASA (Materials & Methods, Section 2.4.7). The cells were exposed to ASA 
(0- 60mM) for 24, 48 and 72h under either normoxic (20% O2) or hypoxic (1% O2) 
conditions.    
As compared to the growth-inhibitory effect of ASA against HL-60 cells in normoxia 
after 24h incubation with an IC50 value of 16.89 ± 2.5mM, the cytotoxicity of ASA 
against HL-60 cells in normoxia significantly (P<0.001) increased with prolonged 
incubation, resulting in IC50 values of 3.12 ± 0.46mM (~5.41-fold enhancement) and 
2.50 ± 0.18mM (~6.76-fold enhancement) after 48h and 72h, respectively (table 8). 
When HL-60 cells were treated with ASA under hypoxic conditions at 24, 48 and 
72h, IC50 values  increased, as compared to normoxia by at least ~3.55-fold (>60mM 
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vs. 16.89 ± .5mM), ~19.23fold (>60mM vs. 3.12 ± 0.46mM), and ~8.82-fold        
(22.05 ± 2.7mM vs. 2.5 ± 0.18mM; P<0.001), respectively. Treatment of HT-29-AK 
cells with ASA for 24h in normoxia resulted in ASA IC50 value of 21.35 ± 2.12mM 
with a significant (P < 0.001) drop of cell viability in a time-dependent manner, thus 
enhanced ASA cytotoxic activities with IC50 values as follow: 13.25 ± 0.79mM 
(~1.61-fold enhancement) and 6.15 ± 0.83mM (~3.47-fold enhancement) after 48h 
and 72h, respectively (table 8). When comparing the cytotoxicity of ASA against    
HT-29-AK cells under normoxic and hypoxic conditions, low oxygen 
microenvironment (1% O2) was shown to antagonise growth-inhibitory effect of ASA 
at all time tested (table 8). After 24h, HT-29-AK cells were 1.50-fold less susceptible 
to the cytotoxic effects of ASA, as compared to normoxia (hypoxia: IC50 value of 
31.95 ± 2.59mM vs. normoxia: IC50 value of 21.35 ± 2.12mM; P<0.001) (table 8). 
After 48h, HT-29-AK cells were 1.34-fold less susceptible to the cytotoxic effects of 
ASA, as compared to normoxia (hypoxia: IC50 value of 17.73 ± 1.64mM vs. 
normoxia: IC50 value of 13.25 ± 0.79mM; P<0.001) (table 8). After 72h where ASA 
was most potent against HT-29-AK cells under both tested conditions, the 
cytotoxicity of ASA against the cells in hypoxia was reduced by 1.38-fold, as 
compared to normoxia (hypoxia: IC50 value of 8.47 ± 2.18mM vs. normoxia: IC50 
value of 6.15 ± 0.83mM; P<0.01) (table 8). Overall, low oxygen tension (1% O2) 
reduced the sensitivity of HL-60 cells and HT-29-AK cells to ASA, as compared to 
normoxic conditions (table 8). 
ASA was dissolved in DMSO at stock concentrations of 1mM and 10mM. In order to 
exclude any cytotoxic effects of DMSO on cancer cells, the cells were treated with 
equivalent concentrations of DMSO (positive control) as present in drug treated 
samples (under both test conditions of hypoxia and normoxia). The final 
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concentration of DMSO in culture media was less than 0.5% and the results showed 
that DMSO did not produce any cytotoxic effects against the cells (data not shown). 
Table 8: The effect of ASA on the growth of HL-60 and HT-29-AK cells cultured 
for 24h, 48h or 72h under normoxic or hypoxic conditions. The cells were 
seeded in 96-well flat-bottomed microtitre plates and treated with graded 
concentrations of ASA (0-60mM) against HL-60 and HT-29-AK cells  for 24, 48 or 
72h in a) top table: normoxia (20% O2, 5% CO2, 75% N2; 37°C,) or b) bottom table: 
hypoxia (1% O2, 5% CO2, 94% N2;  37°C) as described in Materials & Methods 
(Section 2.4.7). Cell growth upon ASA treatment at each time point was measured 
by the MTT colorimetric assay and IC50 values were derived via Grafit Software. All 
results are expressed as the mean IC₅₀ ± SD of at least three independent 
experiments. ***P<0.001 vs. 24h as tested by Paired-T test.  
Incubation 
condition Incubation (hrs) 
HL-60 cells HT-29-AK cells 
ASA IC50 (mM, Mean ± SD) 
Normoxia 
 
24 16.89 ± 2.5  21.35 ± 2.12  
48 3.12 ± 0.46*** 13.25 ± 0.79 *** 
72 2.50 ± 0.18*** 6.15 ± 0.83 *** 
Hypoxia 
24 > 60  31.95 ± 2.59  
48 > 60  17.73 ± 1.64 *** 
72 22.05 ± 2.70*** 8.47  ± 2.18 *** 
 
5.2. ASA modulates the cytotoxicity of ART and DHA against cancer cells 
To investigate whether a fixed concentration of ASA, equivalent to their IC50 
concentrations as estimated under specific test condition (HL-60 cells: normoxia: 
2.50mM ASA; HT-29-AK cells: normoxia: 6.15mM ASA; hypoxia: 8.47mM ASA), has 
any effects on ART and DHA cytotoxicity against HL-60 and HT-29-AK cells, the 
combination studies were performed using MTT assay as described in Materials & 
Methods (Section 2.4.7). During investigations under hypoxic conditions with HL-60 
a) 
b) 
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cells, ASA IC50 value used for combination studies resulted in cancer cells to be all 
dead. Therefore, 1/10 of ASA IC50 value (2.21mM) estimated in hypoxia was used in 
further combination studies. For HL-60 cells in normoxia, combination of 2.50mM 
ASA significantly (P<0.001) increased the cytotoxicity of ART (IC50 value of 0.48 ±        
0.02 µM) as compared to ART alone (IC50 value of 0.59 ± 0.08 µM) whereas the 
cytotoxicity of DHA was not affected (DHA IC50 value of 0.49 ± 0.03 µM vs. DHA 
combined with ASA with IC50 value of 0.49 ± 0.04 µM; table 9). For HT-29-AK cells 
treated under normoxic conditions, the presence of 6.15mM ASA significantly       
(P< 0.001) improved the cytotoxicity of DHA (IC50 value of 5.93 ± 0.58 µM) and ART 
(IC50 value of 6.67± 0.73 µM) resulting in a 3.33-fold and 2.16-fold greater activity as 
compared to DHA (IC50 value of 19.75 ± 1.07µM) and ART (IC50 value of 14.44 ± 
2.64 µM) alone, respectively (table 9).  
Table 9: The effect of ART and DHA alone and in the presence of fixed 
concentrations of ASA against HT-29-AK and HL-60 cells in normoxic 
conditions. The results are expressed as the mean IC50 ± SD of three independent 
experiments. ART, artesunate; ASA; aspirin; DHA, dihydroartemisinin. ***P<0.001 as 
tested by Paired-T test. 
 
Normoxia 
  HL-60 cells HT-29-AK cells 
Test agents IC50 (µM ± SD) 
ART 0.59 ± 0.08 14.44 ± 2.64 
DHA 0.49 ± 0.03 19.75 ± 1.07 
                                                      Test agents + 2.50mM ASA Test agents +6.15mM ASA 
ART 0.48 ± 0.02*** 6.67 ± 1.73*** 
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Table 10: The effect of ART and DHA alone and in the presence of fixed 
concentrations of ASA against HT-29-AK and HL-60 cells in hypoxic 
conditions. The results are expressed as the mean IC50 ± SD of three independent 
experiments. The results (z) are derived from 1 independent experiment. ART, 




  HL-60 cells HT-29-AK cells 
Test agents IC50 (µM ± SD) 
ART 0.51 ± 0.06 46.51 ± 4.74 
DHA 0.53 ± 0.07 27.10 ± 2.73 
                                                      Test agents + 2.21mM ASA Test agents +8.47mM ASA 
ART 0.46z 1.63 ± 0.50*** 
DHA 0.23z 7.90 ± 0.99*** 
 
For HL-60 cells in hypoxia, the presence of 2.21mM of ASA led to a marked 
improvement in the activity of ART (IC50 value of 0.46µM) and DHA (IC50 value of 
0.23µM), increasing their cytotoxicity by ~11% and ~43% as compared to ART     
(IC50 value of 0.51 ± 0.06 µM) and DHA (IC50 value of 0.53 ± 0.07µM) alone, 
respectively (table 10). The results obtained from HT-29-AK cells show that the 
presence of 8.47mM ASA significantly increased the cytotoxicity of ART (IC50 of 
value 1.63 ±   0.50 µM; P<0.001) and DHA (IC50 value of 7.90 ± 0.99µM; P< 0.001) 
resulting in a 28.53- and 3.43-folds greater activity, as compared to the measured 
IC50 values for ART (IC50 value of 46.51 ± 4.74 µM) and DHA (IC50 value of           
27.10 ± 2.73 µM) alone, respectively (table 10).  
Overall, the results show that a fixed concentrations of ASA in combination with DHA 
and ART (except ASA combined with DHA against HL-60 cells in normoxia) in both 
243 | P a g e  
 
conditions tested pharmaco-enhanced DHA and ART. The enhancement effect was 
more marked for HT-29-AK cells than for HL-60 cells. 
5.3. Effect of ART and DHA (alone and in combination with ASA) on COX-2 
protein 
The expression levels of pro-inflammatory COX-2 protein in HT-29-AK cells of either, 
ASA, ART and DHA alone or ASA in combination with drugs is presented in       
figure 75. As compared to control group (1.00 ± 0.08 RFU), treatment of cells with 
ART (at 14.44 µM) and DHA (at 19.75 µM) for 72h significantly (P<0.001) enhanced 
the protein levels of COX-2 by 3.36-fold (3.36 ± 0.45 RFU) and 3.05-fold (3.05 ± 0.29 
RFU), respectively (figure 75). There was an average increase in the percentage of 
COX-2 protein levels by ~40% (1.40 ± 0.15 RFU) upon ASA treatment (at 6.15mM) 
compared to control, however these changes were not found to be significant. COX-
2 expressions levels in the ASA combined groups with ART (3.61 ± 0.40 RFU) or 
DHA (3.72 ± 0.50 RFU) were significantly (P<0.001) up-regulated when compared to 
control but not statistically increased when compared to ART (by ~6.93%, 3.36 ± 
0.45 RFU) and DHA (by ~18.01%, 3.05 ± 0.29 RFU) alone (figure 75).  
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Figure 75:  The effect of ART, DHA and ASA (alone and in combination) on 
cellular COX-2 protein levels in HT-29-AK cells. Cells were treated without or with 
the test agents for 72h in normoxia (20% O2), harvested, incubated with COX-2 
antibody and analysed on flow cytometer as described in Materials & Methods 
(Section 2.9). The results represent 3 independent experiments were ***P<0.001 vs. 
control as tested by one-way ANOVA (Turkey test with multiple comparison). ART, 
artesunate; ASA, aspirin; DHA, dihydroartemisinin.  
5.4. Effect of ART and DHA (alone and in combination with ASA) on survivin 
cellular and mRNA levels 
Survivin is a pro-survival protein associated with the development of drug resistance, 
thus favouring the progression and metastasis of cancer (Shin et al. 2001; Shao et 
al. 2008; Ye et al. 2014; Kim et al. 2015). This led to investigate whether ASA co-
treatment modulates survivin mRNA expression in HT-29-AK cells (figure 76). 
Compared to control (ΔΔCt= 1.00± 0.02), qPCR analysis showed significant increase 
of survivin mRNA levels in samples treated with ART, DHA and ASA by ~1.58-fold 
(ΔΔCt= 1.58 ± 0.37; P<0.01), ~1.78-fold (ΔΔCt= 1.78 ± 0.43; P<0.001) and ~1.62-
fold (ΔΔCt= 1.62 ± 0.29; P<0.01), respectively (figure 76). When HT-29-AK cells 
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were incubated with ART and ASA combination, survivin mRNA levels increased by 
22% (ΔΔCt= 1.92 ± 0.49), as compared to ART alone but these protein changes 
were not significant (figure 76). Interestingly, combination of DHA with ASA reduced 
the increase in survivin mRNA by 18% caused by DHA alone (ΔΔCt= 1.46 ± 0.15 vs. 
ΔΔCt= 1.78 ± 0.43, respectively; P>0.05; figure 76).  
 
Figure 76: The effect of ART, DHA and ASA (alone and in combination) on 
survivin mRNA levels in HT-29-AK cells. Cells were exposed to the test agents in 
normoxia (20% O2) as shown and as described in Materials and Methods (Section 
2.6). The results represent the mean ± SD of three independent experiments.  
***P<0.001, **P<0.01 and *P<0.01 vs. control as tested by one-way ANOVA (Turkey 
test with multiple comparison). ART, artesunate; ASA, aspirin; DHA, 
dihydroartemisinin. 
5.5. Effect of ART and DHA (alone and in combination with ASA) on HIF-1α 
mRNA levels 
qPCR analysis of HIF-1α mRNA levels showed that HT-29-AK-treated cells for 72h 
with ASA not significantly reduced levels of HIF-1α (by 8.08%), as compared to 
control cells (ΔΔCt= 0.91 ± 0.14 vs. ΔΔCt= 0.99 ± 0.04, respectively) (figure 77). 
Treatment with ART led to a significant decrease of HIF-1α gene expression levels 
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by ~16.16%, as compared to control (ΔΔCt= 0.83 ± 0.08 vs. ΔΔCt= 0.99 ± 0.04, 
respectively; P<0.01) whereas treatment with DHA alone did not have any effect on 
HIF-1α levels (ΔΔCt= 1.00 ± 0.11) (figure 77). Combining ASA with ART further 
enhanced the reduction effect of ART alone in the expressions of HIF-1α mRNA in 
cancer cells by 14.46% (ΔΔCt= 0.71 ± 0.05 vs. ΔΔCt= 0.83 ± 0.08, respectively) and 
by 28.28%, compared to control group alone (ΔΔCt= 0.71 ± 0.05 vs. ΔΔCt= 0.99 ± 
0.04; P<0.001, respectively) (figure 77). Co-treatment of DHA with ASA reduced the 
mRNA levels of HIF-1α by 9%, as compared to DHA alone (ΔΔCt= 0.91 ± 0.07 vs. 
ΔΔCt= 1.00 ± 0.11, respectively) but the difference was not statistically significant 
(figure 77). 
 
Figure 77:  The effect of ART, DHA and ASA (alone and in combination) on HIF-
1α mRNA levels in HT-29-AK cells. Cells were exposed to the test agents in 
normoxia (20% O2) as shown and as described in Materials and Methods (Section 
2.6). The result histograms represent the mean ± SD of three independent 
experiments.  ***P<0.001 and **P<0.01 vs. control as tested by one-way ANOVA 
(Turkey test with multiple comparison). ART, artesunate; ASA, aspirin; DHA, 
dihydroartemisinin. 
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5.6. Effect of ART and DHA (alone and in combination with ASA) on VEGF-α 
mRNA levels 
VEGF-α is a key mediator contributing to cancer angiogenesis and metastasis 
(Schneider et al. 2011; Yoshioka et al. 2012; Panoilia et al. 2015). Therefore, the 
effects of ART and DHA in combination with ASA against HT-29-AK cells under 72h 
incubations were examined on possible changes in VEGF-α transcriptional stability 
(figure 78). As compare to control cells, the expression pattern of VEGF-α mRNA 
was slightly decreased by ART (by 4%, ΔΔCt= 0.96 ± 0.15 vs. ΔΔCt= 1.00 ± 0.09, 
respectively) and ASA (by 7%, ΔΔCt= 0.93 ± 0.13 vs. ΔΔCt= 1.00 ± 0.09, 
respectively) as single agents but increased by DHA (by 6%, ΔΔCt= 1.06 ± 0.21 vs. 
ΔΔCt= 1.00 ± 0.09, respectively) (figure 78). However, these VEGF-α mRNA 
expression changes were not statistically significant. Cells treatment with DHA and 
ASA combination did not alter markedly VEGF-α transcriptional levels, as compared 
to DHA alone (ΔΔCt= 1.04 ± 0.10 vs. ΔΔCt= 1.06 ± 0.21 vs. respectively). 
Interestingly, combination of ART with ASA attenuated the decrease in VEGF-α 
mRNA levels measured with ART alone by additional 17.71% (ΔΔCt= 0.79 ± 0.06 vs. 
ΔΔCt= 0.96 ± 0.15 vs. respectively) and by 21%, as compared to control (ΔΔCt= 
0.79 ± 0.06 vs. ΔΔCt= 1.00 ± 0.09, P<0.05, respectively) (figure 78). 
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Figure 78: The effect of ART, DHA and ASA (alone and in combination) on 
VEGF-α mRNA levels in HT-29-AK cells. Cells were exposed to the test agents in 
normoxia (20% O2) as shown and as described in Materials and Methods (Section 
2.6). The result histograms represent the mean ± SD of three independent 
experiments.  *P<0.05 vs. control as tested by one-way ANOVA (Turkey test with 
multiple comparison). ART, artesunate; ASA, aspirin; DHA, dihydroartemisinin. 
5.7. ASA combination with ART and DHA increased cellular phospho-Akt 
levels 
The cellular expression levels of anti-apoptotic phosho-Akt upon treatment of HT-29-
AK cells with ART, DHA and ASA (alone and in combination) were measured by flow 
cytometric analyses and are presented in figure 79. Data acquired show significant 
(P<0.001) increase in phosho-Akt levels by ~2.62-fold (2.62 ± 0.24 RFU) and ~2.28-
fold (2.28 ± 0.78 RFU) upon treating the cells with ART and DHA alone, respectively, 
as compared to control (1.00 ± 0.31 RFU). Cellular levels of phosho-Akt increased 
by 11% when treated with ASA alone, as compared to control (1.11 ± 0.07 RFU            
vs. 1.00 ± 0.31 RFU, respectively) but these changes were not significant. The 
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combination of ART with ASA up-regulated levels of phospho-Akt to 3.06 ± 0.73 
RFU, which led to a fold difference of ~1.17, as compared to ART alone (2.62 ± 0.24 
RFU) and by 3.06-fold increase as compared to control (3.06 ± 0.73 RFU vs. 1.00 ± 
0.31 RFU; P<0.001, respectively). Similarly, co-treatment of DHA with ASA caused 
an increase in phospho-Akt levels by 1.43-fold as compared to DHA alone (3.27 ± 
0.87 RFU vs. 2.28 ± 0.78 RFU, respectively) and significant up-regulation by 3.27-
fold as compared to untreated cells (P<0.001; 3.27 ± 0.87 RFU vs. 1.00 ± 0.31 RFU, 
respectively). 
 
Figure 79: The effect of ART, DHA and ASA (alone and in combination) on 
cellular phospho-Akt levels in HT-29-AK cells in normoxia. HT-29-AK cells were 
exposed to the test agents in normoxia (20% O2) as shown and as described in 
Materials and Methods (Section 2.9). The results for ART and DHA treated cells 
represent the mean ± SD of three independent experiments. ***P<0.001, vs. control 
as tested by one-way ANOVA (Turkey test with multiple comparison). ART, 
artesunate; ASA, aspirin; DHA, dihydroartemisinin. 
 
 

















































250 | P a g e  
 
5.8. ASA enhanced ART- and DHA- caspase-3-dependent apoptosis  
As ART and DHA were shown in vast number of reports, including in our previous 
studies to induce cancer cells apoptosis (Kim et al. 2015; Zhang et al. 2015; Zhao et 
al. 2015; figures 55 and 56), we examined whether ASA can enhance ART- and 
DHA-mediated cell death. Expression of cleaved caspase-3 protein levels measured 
by flow cytometric analysis following treatment of cells with ART, DHA or ASA (alone 
and in combination) for 72h is shown in figures 80 and 81. Significantly (P<0.001),            
HL-60 cells treated with ART, DHA and ASA increased levels of cleaved caspase-3 
to 3.10 ± 0.16 RFU, 1.79 ± 0.06 RFU and 2.02 ± 0.04 RFU, as compared to control 
cells  (1.00 ± 0.01 RFU), respectively (figure 80).  Used in combination, ART and 
ASA significantly (P<0.001) up-regulated levels of caspase-3 to 9.88 ± 0.51 RFU, 
which resulted in a fold difference of ~3.19, as compared to ART alone (3.10 ± 0.16 
RFU) (figure 80). Alongside this, co-treatment of DHA with ASA caused a significant 
increase (~7.59-fold; 13.59 ± 0.42 RFU; P<0.001) in the levels of cleaved caspase-3, 
as compared to DHA alone (1.79 ± 0.06 RFU) (figure 80). 
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Figure 80: The effect of ART, DHA and ASA (alone and in combination) on 
cellular cleaved caspase-3 levels in HL-60 cells. HL-60 cells were exposed to the 
test agents in normoxia (20% O2) as shown and as described in Materials and 
Methods (Section 2.9). The result histograms represent the mean ± SD of three 
independent experiments.  ***P<0.001, vs. control; ###P<0.001 vs. DHA; &&&P<0.001 
vs. ART as tested by one-way ANOVA (Turkey test with multiple comparison). ART, 
artesunate; ASA, aspirin; DHA, dihydroartemisinin. 
As shown in figure 81 cleaved caspase-3 release in HT-29-AK cells was activated by 
a single agent of ART (3.28 ± 0.20 RFU; ~3.28-fold; P<0.001), DHA                     
(3.05 ± 0.09 RFU; ~3.04-fold; P<0.001) and ASA (1.66 ± 0.11 RFU; ~1.66-fold; 
P<0.01), as compared to control (1.00 ± 0.05 RFU). Combination treatment of ASA 
with either, ART and DHA significantly increased caspase-3 protein levels in cells, as 
compared to ART alone (by 81.65%; 4.10 ± 0.49 RFU; vs. 3.28 ± 0.20 RFU; P<0.01) 
and DHA alone (by ~125%; 4.30 ± 0.74 RFU vs. 3.05 ± 0.09 RFU; P<0.001), 
respectively (figure 81).  
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Figure 81: The effect of ART, DHA and ASA (alone and in combination) on 
cellular cleaved caspase-3 levels in HT-29-AK cells. HT-29-AK cells were 
exposed to the test agents in normoxia (20% O2) as shown and as described in 
Materials and Methods (Section 2.9). The result histograms represent the mean ± 
SD of three independent experiments.  ***P<0.001, vs. control; **P<0.01, vs. control; 
###P<0.001 vs. DHA; &&P<0.01 vs. ART as tested by one-way ANOVA (Turkey test 
with multiple comparison). ART, artesunate; ASA, aspirin; DHA, dihydroartemisinin. 
  
































































Part 1: THE MOLECULAR BASIS OF THE ANTI-CANCER EFFECTS OF ART 
AND DHA AGAINST HT-29-AK AND HL-60 CELLS IN NORMOXIA AND HYPOXIA 
6.1. Cytotoxicity of ART and DHA under normoxic and hypoxic conditions 
Extensive anti-cancer effects of ART and DHA have been reported in multiple cancer 
types of human tumour including leukaemia and CRC (Lu et al. 2008; Zhou et al. 
2008; Jones et al. 2009; Lu et al. 2011; Zhao et al. 2015). However, the molecular 
activity of ART and DHA against cancer cells remains still incompletely understood. 
As increasing reports are describing the potential clinical utility of ART and DHA 
(Singh and Verma 2002; Singh and Panwar 2006; Jansen et al. 2011; Krishna et al. 
2015), further studies are needed to provide additional molecular basis of their action 
to enhance greater understanding of the fundamental cellular processes targeted by 
the agents.  
Non-adherent human leukaemia HL-60 cells and adherent human CRC HT-29-AK 
cells are highly-proliferating cells, extensively reported to be very sensitive to ART 
and DHA and for these properties were selected for in vitro experimental settings in 
the present study (Anfosso et al. 2006; Mercer et al. 2007; Li et al. 2008; Lu et al. 
2008; Zhou et al.2008; Zhao et al. 2015). Second gastrointestinal cell Caco-2 line 
was used to compare the effects of ART and DHA between cells of the same tissue 
origin but characterised by different differentiation state of cells (well-differentiated 
HT-29-AK cells vs. non-differentiated Caco-2 cells) (Li et al. 2008; Bourseau-
Guilmain et al. 2011). 
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Under standard normoxic experimental conditions (20% O2), ART and DHA inhibited 
the growth of leukaemia HL-60 cells and CRC HT-29-AK and Caco-2 cells in a time-
dependent manner (table 3; figures 12, 13 and 14). These results were in 
accordance with several previous studies, such as Lu et al. (2008), Zhou and Wang 
(2008), Buommino et al. (2009), Li et al. (2009) and Lijuan et al. (2010). Our results 
also showed that leukaemia HL-60 cells were the most sensitive to ART and DHA 
followed by CRC HT-29-AK and Caco-2 cells (table 3). The distinct anti-cancer effect 
of ART and DHA against different cancer cell lines and malignant phenotypes was 
found in several previous studies (Efferth et al. 2001; Mercer et al. 2007; Hou et al. 
2008; Lu et al. 2008). Prolonged incubation of the cells with the drugs enhanced their 
activity, with the following rank order, 72h>48h>24h. After 72h, DHA was more 
potent than ART against HL-60 cells (0.60 ± 0.08µM vs. 0.49 ± 0.03µM) whereas 
ART was more potent than DHA against HT-29-AK cells (14.44 ± 2.64µM vs. 19.75 ± 
1.07µM) and against Caco-2 cells (42.13 ± 9.61µM vs. 76.42 ± 8.14µM) (table 3).  
Distinct profiles of anti-cancer effect of ART and DHA between cells of the same 
origin such as gastric and bladder cancers but different sub-types (gastric BGC-823, 
HGC-27 and MGC-803 cell lines; bladder T24 and RT4 cell lines) were determined 
previously (Hou et al. 2008; Zuo et al. 2014; Zhang et al. 2015). The differences 
arising between HT-29-AK and Caco-2 colorectal cell lines could be linked with 
different status of TfR1 receptors which are needed for endocytosis-mediated iron 
and drug intake (Dautry-Varsat et al. 1983; Eckenroth et al. 2011). Further support 
for the latter comes from numerous reports which demonstrate the ability of 1,2,4-
trioxanes to conjugate with TfR1-transferrin complex at the cell membrane (Zhou et 
al. 2008; Ba et al. 2012 Zhao et al. 2013). The complex is then internalised into the 
cell through endocytosis and released iron within an endosome result in the 
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cleavage of 1,2,4-trioxanes’ endoperoxide bridge leading to the formation of free 
radicals which kill cancer cells (Mercer et al. 2007; Lai et al. 2005; Oh et al. 2009). 
In previous studies, well-differentiated carcinoma tissues were characterised by high 
distribution of TfR1 (15; P<0.05) whereas poor-differentiated samples had low 
distribution of TfR1 (1; P<0.05) (Prutki et al. 2006). It could be postulated that ART 
and DHA in well-differentiated HT-29-AK cells are more rapidly internalised by the 
highly distributed TfR1 on cell surface whereas in poorly-differentiated Caco-2 cells 
the transport of the drugs was limited due to lower numbers of TfR1. In addition, 
Caco-2 cells over-express a pentaspan stem cell marker CD133, which was shown 
to inhibit endocytosis of iron carrying transferrin molecule, which could further result 
in decreased activation of ART and DHA through iron-mediated cleavage of 
endoperoxide bond within the cell (Bourseau-Guilmain et al. 2011). However, in 
cancer cell line xenografts it has been reported that well-differentiated cells have 
features of poorly distributed microvessels within the tumour biomass, which limit 
transport and distribution of chemotherapeutic agents (Rustum et al. 2010). In 
contrast, poorly-differentiated human tumour xenografts were characterised by a 
well-vascularised tumour biomass featuring more developed blood vessels (Rustum 
et al. 2010). This allows a better drug transport and penetration within the tumour, 
thus a better therapeutic response (Rustum et al. 2010). Therefore, it is important to 
develop xenografts model of ART and DHA activity against both gastrointestinal cell 
lines as current in vitro study may not reflect completely their response in vivo.  
The changes in cytotoxicity of ART and DHA against HT-29-AK cells were further 
linked with different proliferation status of the cells (table 4). Highly proliferative     
HT-29-AK cells treated with ART and DHA for 24h immediately after seeding (t0) 
were more susceptible to drugs as compared to confluent cells  (80% confluency) 
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treated with drugs for 24h (t0 : ART IC50 of 165.06 ± 24.25µM, DHA IC50 of 58.02 ± 
4.09µM vs. 80% confluent cells: ART IC50 of 190.62µM, DHA IC50 of 108.53 ± 
19.69µM). It could be explained by the fact that confluent cells have lower 
requirements for iron, thus reduced cytotoxicity of ART and DHA as compared to 
highly proliferative HT-29-AK cells at t0 with greater requirement for iron. ART and 
DHA might have decreased access to TfR1 in confluent cells due to tight cell-cell 
interactions as compared to ‘loosely’ growing cells at t0.   
As in normoxia (20% O2), ART and DHA in hypoxia (1%O2) inhibited the growth of 
HL-60 and HT-29-AK cells in a time-dependent manner (table 6). In HL-60 cells, 
after 72h when the drugs were most potent, ART was more potent in hypoxia than 
normoxia (normoxia: IC50 of 0.60± 0.08µM vs. hypoxia: IC50 of 0.51 ± 0.06µM;     
1.18-fold enhancement; P<0.05); while cytotoxicity of DHA was not affected by 
different oxygen tensions (normoxia: IC50 of 0.49± 0.03µM vs. hypoxia: IC50 of 0.53 ± 
0.07µM; P>0.05). These results suggest that ART and DHA in HL-60 cells effectively 
overcome unfavourable hypoxic environment to exert their cytotoxic activities and 
from the clinical point of view may decrease risk of cancer therapy failure and the 
development of chemo-resistance.   
In contrast, the cytotoxicity of ART and DHA against HT-29-AK cells was significantly 
(P<0.01) inhibited in hypoxia (1% O2) compared to normoxia (20% O2) at all time 
point tested. The findings suggest reduced sensitivity of the cells towards ART and 
DHA and the impact of hypoxic condition on the drugs-mediated cytotoxicity (table 3 
vs. table 6). Encouragingly, the reduced sensitivity to ART and DHA against HT-29-
AK cells was decreasing with longer incubations, showing enhanced killing 
mechanisms of ART and DHA over a period of time (table 6). The hypoxia-
dependent anti-cancer effect of DHA against cancer cells was investigated in 
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previous experimental studies (Aung et al. 2011; Ontikatze et al. 2014). In human 
CRC cells (HCT15, HCT116, and Coco 205), hypoxic microenvironment (0.2% O2) 
was induced 2h before DHA (0-80µM) was added for 48h and showed the effective 
inhibition of all cell lines in both normoxic and hypoxic conditions (Ontikatze et al. 
2014). It could be possible that incubation of cells for 2h in hypoxic chamber was not 
enough to effectively induce hypoxic environment in cancer cells, thereby to observe 
decreased sensitivity of cells towards ART and DHA as it was observed in our study 
(table 3 vs. table 6). Before each treatment in the investigations, cells were grown in 
hypoxia (1% O2) for 72h to effectively induce hypoxia. In addition, into account 
should be taken different CRC types used in the studies. Here, HT-29-AK cells were 
selected to study the anti-cancer effects of ART and DHA. In contrast, Ontikatze et 
al. (2014) investigated the anti-cancer effect of DHA against a panel of human CRC 
lines, including HCT15, HCT116, and Coco 205 cancer cells but not HT-29-AK cells. 
According to the literature, Ontikatze et al. (2014) studied DHA against a panel of 
CRC cell lines at low oxygen tension of 0.2%. In the present study, the oxygen 
tension of 1% was investigated, which might further result in different effects of DHA 
between the studies. Other parameters which could affect the results between 
different laboratory settings include length of cell incubations with DHA (24-48-72h 
vs. 48h) and composition of culture media.  
6.2. Cytotoxicity of ART and DHA in cancer cells is iron-dependent 
It is reported that the endoperoxide bridge of 1,2,4-trioxanes requires activation by 
an iron (II) species to produce ROS and CCR to exert their cytotoxicity (Efferth et al. 
2004; Mercer et al. 2007). In normoxia (20% O2), it was found that haemin, an iron 
carrying molecule (at 1µM and 3µM) enhanced the activity of ART and DHA in HL-60 
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and HT-29-AK cells following 24h incubation. The findings support the importance of 
iron in ART- and DHA-mediated activity and are consistent with previous reports 
(Smith et al. 1997; Efferth et al. 2004; Singh and Lai 2004; Lai et al. 2005; Kelter et 
al. 2007; Zhang and Gerhard 2008; Zhang and Gerhard 2009). As shown in table 5, 
iron chelating molecule, DFO (60µM) antagonised ART and DHA cytotoxicity in both 
cell lines after 24h by mopping out available iron needed to activate their 
endoperoxide bridge. These observations were consistent with previous studies 
where iron chelators or compounds without the endoperoxide bridge were used and 
this resulted in decreased or loss of cytotoxic effects of the agents (Mercer et al. 
2007; Zhao et al. 2015).  
In hypoxia (1% O2), surprisingly, the cytotoxicity of ART and DHA against HL-60 cells 
was antagonised by the presence of haemin at 1µM, and further at 3µM haemin 
(compounds+1µM haemin: DHA IC50 of 3.65µM, ART IC50 of 4.63µM; 
compounds+3µM haemin: DHA IC50 of 5.48µM, ART IC50 of 16.95µM vs. DHA IC50 
of 1.10 ± 0.08µM and ART IC50 of 0.92 ± 0.23µM alone; table 7). The results indicate 
that adaptive responses of HL-60 cells to hypoxia are mediated by haemin where 
increasing haemin concentrations at 1µM and 3µM decreased ART and DHA 
cytotoxicity. The molecular mechanisms responsible for antagonised effects of ART 
and DHA to cancer cells upon haemin co-adminstration are unknown and require 
further investigations. In addition, decreased cytotoxicity of ART was reported when 
co-adminstrated with Ferrosanol® (10µg/ml) in normoxia (20% O2) against breast 
cancer MCF7 cells, suggesting that TfR1 on cell surfaces of some cell lines under 
specific experimental conditions do not react with drug-iron complex which could 
inhibit endocytosis-mediated drug-iron complex internalisation within the cells and 
activation of drug (Kelter et al. 2007). 
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 In contrast, the cytotoxicity of ART and DHA in HT-29-AK cells was increased in the 
presence of haemin (at 1µM and 3µM)  and was antagonised in the presence of 
DFO, thus showing similar molecular mechanisms of action of the drugs as in 
normoxia (20% O2) (table 7 vs. table 5).  
However, the inhibition of cytotoxicity of ART and DHA with DFO was much greater 
in hypoxia (1% O2) than in normoxia (20% O2), suggesting additional inhibitory 
mechanisms involved (table 5 vs. table 7). It was reported that HIF-1α in normoxia is 
rapidly degraded in an O2 and Fe2+- dependent manner, resulting in a no detectable 
HIF-1α secretion (Ke and Costa 2006; Romney et al. 2011). Other studies showed 
that at low oxygen levels, HIF-1α is more stable and detectable which result in the 
up-regulation of genes involved in angiogenesis and drug resistance (Ke and Costa 
2006; Romney et al. 2011). It can be hypothesized that DFO by diminishing the 
availability of Fe2+ in culture media lead to further stabilization of HIF-1α, thus 
resulting in decreased inhibitory effects of the drug.  
A high expression of TfR1 has been implicated with tumour stage and poor 
prognostic subsets in breast cancer (Habashy et al. 2010). In addition, the over-
expression of TfR1 in a panel of in vitro cell models of acquired resistance to 
tamoxifen indicated TfR1 as a candidate marker of tamoxifen resistance (Habashy et 
al. 2010). The concentration of sTfR1 in the incubation media is a quantitative 
marker of cellular TfR1 levels (R’zik and Beguin, 2001). In the present study, DHA- 
treated HT-29-AK cells under normoxic conditions for 24h resulted in overall up-
regulated levels of sTfR1 whereas after 72h there was observed down-regulation of 
sTfR1 upon DHA treatment (figure 15). When comparing results from hypoxia, sTfR1 
in DHA-treated HT-29-AK cells for 72h increased in a concentration-dependent 
manner, showing the involvement of low oxygen microenvironment as compared to 
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normoxia (figure 15 vs. figure 63). In contrast, under both conditions, ART-treated 
HT-29-AK cells for 72h decreased levels of sTfR1 as compared to control, thus 
indicating that hypoxic environment did not have impact on ART-mediated sTfR1 
levels (figures 15 and 61). ART-mediated sTfR1 decrease is in agreement with data 
reported by others (Zhou et al. 2008; Ba et al. 2012). Therefore, ART-mediated 
decrease in sTfR secretion may be a consequence of the deleterious effects of ART 
on the cells. This might be linked with inhibited recycling of TfR1 to the cell surface 
and decreased cell iron uptake capacity as triggered by ART. The cells depleted in 
iron, which is required for continous cell proliferation and DNA synthesis have 
reduced stability of intracellular proteins, thus resulting ultimately in cell death. For 
HL-60 cells, DHA-treated cells for 24h and 72h in normoxia resulted in a decrease of 
sTfR1 and this was consistent with down-regulation of sTfR1 in hypoxia with DHA-
treated cells for 72h (figures 15 and 62). The different mode of action was reported 
with ART against HL-60 cells. Here, sTfR1 levels in normoxia and hypoxia increased 
after ART treatment for 72h (figures 15 and 62). The results of these studies indicate 
that ART and DHA may exhibit different mechanisms of action against different cell 
lines and different time point tested (figures 15 and 62). ART- and DHA-mediated 
effect on sTfR1 might be also dependent on the availability of oxygen (figures 15 and 
62). Unfortunately, due to resources limitations presented data represent only 2 
independent experiments and further studies are needed to confirm these findings 
and allow statistical analysis. 
The results of growth kinetics of HL-60 and HT-20-AK cells further suggest that the 
cytotoxicity of ART and DHA is not related with proliferation rates observed in both 
conditions (figure 64).  
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6.3. Effect of ART and DHA on IL-6 and COX-2 levels 
IL-6 is a pro-tumourigenic cytokine, involved in tumour cell proliferation, survival and 
invasiveness (Grivennkov et al. 2009; Nagasaki et al. 2014; Rokavec et al. 2014). 
The higher levels of TfR1 in gut mucosal and leukaemic cells were reported to be 
stimulated and regulated by a number of pro-inflammatory cytokines, including    
TNF-α, IL-6 and IL-1β (Nezu et al. 1994; Han et al. 1997; Chalaris et al. 2011; Harel 
et al. 2011). Previous studies showed that 1,2,4-trioxanes exert anti-inflammatory 
activities through inhibition of interleukins, including IL-8 and IL-1β (He et al. 2011; 
Wang et al. 2011). The cytotoxicity of ART and arteether also correlated with high   
IL-6 signal transducer expression (P<0.05), thus potentially affecting their anti-cancer 
effects (Anfosso et al. 2006). Therefore, the next step of this study was focused on 
investigating IL-6 secretion levels in media collected following the treatment of      
HT-29-AK and HL-60 cells with DHA. 
HT-29-AK and HL-60 cells treated with DHA for 24h and 72h showed a dual 
response on IL-6 expression (figure 16). In both cell lines, there were undetectable 
levels of IL-6 expression (below the lowest concentration of standard 0.039pg/mL) 
with concentrations representing IC50 value of DHA followed by increased levels of 
IL-6 with concentrations representing 2xIC50 value of DHA at 24h and 72h, 
respectively (figure 16). 
Hypoxia is reported to stimulate IL-6 over-expression which further may enhance 
expression of HIF-1α via STAT-3 signaling pathway (Anglesio et al. 2011). In the 
present study, as in normoxia, HT-29-AK and HL-60 cells treated with DHA for 72h 
incubation showed a dual response on IL-6 expression (figures 16 and 65) with 
secretions levels of IL-6 being unchanged by hypoxic microenvironment when 
compared to normoxia. Overall, despite limited number of repeats, the results may 
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indicate that DHA-mediated IL-6 changes are independent from oxygen tension 
levels but strictly dependent on the concentrations tested of DHA. 
Increasing invasive and the migratory potential of cells in cancer progression require 
the up-regulation of many pro-inflammatory mediators including COX-2 (Jang et al. 
2009). COX-2, an inducible isoform of COX enzyme, induces the release of 
prostaglandins (PGs) involved in inflammatory, wound healing, and malignancy 
processes (Jang et al. 2009). 1,2,4-trioxanes were reported to exert potent anti-
inflammatory activities through COX-2 inhibition in cancer cells (Wang et al. 2011; 
Zhang et al. 2014; Zuo et al. 2014) and non-cancer studies (Okorji and Olajide 
2014). These previous reports are similar to our observations were DHA- and ART-
treated HT-29-AK cells for 72h down-regulated the COX-2 protein levels in a 
concentration-dependent manner, thus confirming their anti-inflammatory effects in 
both cell lines (figure 17).  
6.4. Effect of ART and DHA on expression and localisation of E-cadherin and   
CLDN-1 in cancer cells 
Enhanced inflammation within tumour microenvironment contributes to EMT, a 
differentiation cascade which promotes the breakdown of the epithelial integrity and 
facilitates cell motility and invasiveness (Jang et al. 2009; Imbert et al. 2012; 
Rokavec et al. 2014; Gu et al. 2015). One of the major steps enabling EMT through 
invasion of cancer cells is dysregulation of the epithelial marker E-cadherin (Ca2+-
binding transmembrane molecule), which is pivotal in cell-cell adhesion (Li et al. 
2008). Previous reports showed that E-cadherin levels increased upon treatment 
with ART and artemisinin in some cancer cell types, including colorectal poorly-
differentiated CLY and moderately-differentiated Lovo cells, endometrial HEC-1B 
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cells and hepatocarcinoma HepG2 cells (Li et al. 2008; Lijuan et al. 2010; Weifeng et 
al. 2011). In the same study of Li et al. 2008, ART treatment (0-200µM for 72h) in 
well-differentiated HT-29 cells demonstrated a decreasing E-cadherin protein 
expression as analysed by a Western blotting technique and with membranous 
localisation of E-cadherin detected by immunofluorescence. The significant 
observation of our study was that ART treatment for 24h incubation resulted in up-
regulation in E-cadherin mRNA levels in HT-29-AK cells while treatment with ART for 
72h resulted in E-cadherin mRNA down-regulation, suggesting that ART modulates 
E-cadherin mRNA levels in a time-dependent manner (figure 18). The localisation of                  
E-cadherin within the cells upon ART treatment was further explored by 
immunocytochemical staining (figures 20 and 21). After 24h treatment with ART, 
control cells had equally distributed membranous E-cadherin localisation whereas 
ART-treated cells had minimal basal localisation and ART-mediated increase in 
lateral membranous staining (figure 20). It was reported previously that a biological 
response modifier and anti-cancer agent, ubenimex enhanced cell-cell adhesion 
through aggregation of E-cadherin at cell-cell contact sites in a human breast YMB-S 
cancer cell line (Fujioka et al. 1995). The results of a present study might indicate 
that ART through increasing the localisation of E-cadherin at cell-cell contact sites 
enhanced cell-cell adhesion in HT-29-AK cells after 24h treatment with ART. 
Nevertheless, Doki et al. (1993) demonstrated that cell clones from human 
esophageal cancer TE-2 cells with negative E-cadherin expression were relatively 
more invasive than cell clones with positive E-cadherin expression. This absent or 
down-regulated expression of E-cadherin was frequently reported in diverse 
metastatic and invasive cancers, including CRC, breast, pancreatic, hepatocellular 
carcinoma, ovarian and endometrial cancers (Deep et al. 2014; He et al. 2013; Zhou 
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et al. 2013; Kashiwagi et al. 2010; Jang et al. 2009; Sawada et al. 2008;  Mell et al. 
2003). It has also been shown clinically that decreased expression of E-cadherin 
correlated with worse survival rate in patients with CRC (Elzagheid et al. 2012; He et 
al. 2013). Therefore, the results of this study might indicate that ART by enhancing 
the aggregation of E-cadherin at cell-cell contacts is contributing to the inhibition of 
migration and invasiveness in HT-29-AK cells.  
Despite it was not investigated in the present study, we further postulate E-cadherin 
localisation to be associated with enhanced activity of ankyrin-G. Ankyrin-G (gene 
ank3) is a scaffolding protein being required for protein trafficking of various 
membrane domains, including epithelial lateral membranes (Durak et al. 2014). The 
results from the study of Kizhatil and colleagues (2007) on human bronchial 
epithelial cells may suggest that ankyrin-G binds to the cytoplasmic domain of         
E-cadherin and simultaneously recruits β-2-spectrin, resulting in accumulation of      
E-cadherin at lateral membranes, thus increasing cell-cell interactions and inhibiting 
the process of EMT. However, further studies are needed to confirm this hypothesis. 
The down-regulation of E-cadherin mRNA levels in all samples with ART-treated   
HT-29-AK cells for 72h treatment was linked with equally distributed E-cadherin at 
basal and lateral membranous sites as analysed with immunocytochemical staining 
(figure 18 vs. 21), and this was in agreement with previous observations of Li et al. 
(2008). The treatment of HT-29-AK cells with ART for 24h resulted in an inverse 
relationship between increased levels of E-cadherin and decreased levels of CLDN-1 
(figure 18A and 25A). CLDN-1 is a tight junction protein which regulates normal 
epithelial physiology and its dysfunction is implicated with tumorigenesis and EMT 
(Dhawan et al. 2005; Bezdekova et al. 2012; Blanchard et al. 2013; Huang et al. 
2015). Singh et al. (2011) showed that increased levels of CLDN-1 mediated down-
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regulation of E-cadherin by up-regulating the expression of Zeb-1. This resulted in 
progression from normal colonic epithelium to colon adenocarcinoma (Singh et al. 
2011). It could be possible that augmented mRNA levels of E-cadherin had negative 
impact on CLDN-1 mRNA levels but further studies are needed to exactly analyse 
this association. Quantitative PCR results of our study showed that HT-29-AK cells 
treated for 72hrs with ART showed decreased CLDN-1mRNA expression (figure 25). 
At protein level, flow cytometric analysis showed increased CLDN-1 protein levels 
upon treating HT-29-AK cells with ART for 72 (figure 26). However, these increased 
CLDN-1 levels were decreasing with higher ART, suggesting delay in transcription 
response mediated by ART (figure 26). Conflicting results have been published with 
respect to CLDN-1 expression in colon cancer and its clinical outcome (Dhawan et 
al. 2005; Shibutani et al. 2013). Analysis of CLDN-1 expression in tissue samples 
from healthy and CRC patients showed loss of CLDN-1 expression in normal colon 
tissues, increased CLDN-1 levels in 3 patients with primary colon cancer and marked 
over-expression in CLDN-1 protein levels in 2 patients with metastatic CRC (Dhawan 
et al. 2005). Under investigation is also localisation of CLDN-1 within CRC cells and 
their potential importance in CRC progression (Dhawan et al. 2005; Bezdekova et al. 
2012).  CLDN-1 in normal colonic epithelium typically is localised at cell membrane, 
altered mislocalisation stained as membranous/cytoplasmic is observed in 
adenomacarcinoma (p=0.0001) and adenomas (p=0.0002) where cytoplasmic 
localisation was linked with a higher degree of dysplastic lesions (Bezdekova et al. 
2012). In CRC tissue samples membranous/cytoplasmic is more frequent when 
compared to adenomas (87% vs. 51%, respectively; p=0.001), thus suggesting the 
importance of CLDN-1 localisation in CRC progression (Bezdekova et al. 2012).  Our 
data of the effects of ART-untreated and -treated HT-29-AK cells for 72h indicate 
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that CLDN-1 in untreated cells has membranous and cytoplasmic localisation, 
whereas ART-treated cells shows re-localisation of CLDN-1 from cytosolic  
structures to the membrane, thus possibly reversing EMT and inhibiting CRC 
progression (figure 27).  
For comparison purposes, we performed some studies investigating the effect of 
DHA treatment on the localisation of E-cadherin in HT-29-AK cells. DHA-treatment 
for 24h resulted in basolateral-E-cadherin localisation at 29.01µM and 58.02µM, 
whereas the highest DHA concentration (at 116.04µM) resulted in a partly 
membranous and nuclear accumulation (figure 22).  It can be hypothesized that DHA 
at a highest concentration of 116.04µM reached a threshold of E-cadherin up-
regulation, possibly resulting in its gene-regulatory activities. Treatment of HT-29-AK 
cells for 72h was consistent with previous results with ART and showed baso/lateral 
membranous localisation in all DHA-untreated and –treated cells and with 
concomitant decreasing pattern of CLDN-1 protein levels analysed using flow 
cytometric analyses (figures 23 and 28). 
Similar investigations of ART and DHA were performed against HL-60 cells. Flow 
cytometric analysis showed that ART-treated cells for 72h had a concentration-
dependent increase in E-cadherin protein surface levels and augmented CLDN-1 
levels (figures 24 and 28). In contrast, DHA treated HL-60 cells for 72h had down-
regulated E-cadherin levels and concentration-dependent increase in CLDN-1 levels 
(figures 24 and 29). These results show that the effects of ART and DHA could differ 
between each drug and cell line used. However, the associated clinical meaning and 
the basis molecular mechanisms of these changes require further studies.  
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6.5. Inhibition of cell migration and invasion by ART and DHA 
The ability of cancer cells to invade and metastasise is related with high mortality 
and morbidity in patients (Steeg et al. 2006; Shapiro et al. 2007). The anti-invasive 
and anti-metastatic activities of ART and DHA were evaluated previously by various 
techniques, including 2D wound healing assay, 3D transwell chamber invasion 
assays and in vivo metastasis settings (Hwang et al. 2010; Rasheed et al. 2010; 
Weifeng et al. 2011; aChen et al. 2013). In 2D wound-healing assay, artemisinin 
treatment (0-75µM) for 24-48-72h resulted in a concentration- and time- dependent 
inhibition of hepatoma cells (HepG2 and SMMC-7721) migration and invasion which 
was linked with blocking the ability of cells to close the wound gap (Weifeng et al. 
2011). Consistent with these findings, it was observed here using a crude invasion 
assay that ART and DHA inhibited the capacity of HT-29-AK cells to heal the wound 
(figures 30-32). Together with concentration-dependent wound diameter inhibition, 
there were increasing numbers of floating dead cells (non-viable cells) (figures 31-
33). ART- and DHA- treated HT-29-AK cells which remained attached to the well 
looked small and had noticeable damaged membranes under microscope, as 
compared to healthy control cells. It was hypothesized that ART and DHA-induced 
genotoxicity marked these cells to undergo a programmed cell death, apoptosis, 
were some of these typical cell features to apoptosis were observed (figures 30 and 
32).  
To determine the potential molecular basis of these findings, the ability of DHA and 
ART to suppress MMPs, which are responsible for enhancing invasion and 
metastasis of tumour cells, was investigated. In the present study, ART-treated     
HT-29-AK cells for 72h decreased up-regulated protein levels of MMP-2 with the 
highest concentration used (at 28.88µM) resulting in MMP-2 levels being comparable 
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with untreated cells (1.09 ± 0.08RFU vs. 1.00 ± 0.13RFU, figure 36A). The 
expression levels of MMP-9 upon ART treatment for 72h resulted in a concentration-
dependent decrease of up-regulated MMP-9 levels, as compared to control (figure 
36B). The results from flow cytometric and Western blotting analyses further showed 
that DHA treatment for 72h decreased the up-regulated MMP-2 and MMP-9 levels in 
a concentration-dependent manner (figure 37 A-D). For comparison purposes, we 
performed flow cytometric studies for the effects of ART and DHA on MMP-2 and 
MMP-9 levels against HL-60 cells (figure 38). It was observed that ART treatment 
following 72h incubation resulted in a concentration-dependent increase in MMP-2 
and MMP-9 levels as compared to control (figure 38). Whereas treatment with DHA 
for 72h unchanged MMP-2 levels in all DHA untreated and treated cells but resulted 
in a slight increase of MMP-9, as compared to control cells (figure 39). There are 
various previous studies describing the potent inhibitory effects of ART and DHA 
towards several MMPs, including MMP-2 and MMP-9 (Buommino et al. 2009; 
Rasheed et al. 2010; Wang et al. 2011; Weifeng et al. 2011). Here, ART and DHA 
showed their inhibitory properties against MMP-2 and MMP-9 in adherent HT-29-AK 
cells whereas unfavorable effects of the compounds against both MMPs were 
observed against suspension HL-60 cells. These observations warrant further 
investigations to better understand the biological meaning of these results and 
possible clinical outcomes.   
A major clinical problem is associated with the ability of tumour cells to re-grow, 
causing local re-currence of cancer even after surgery and the threat of the 
development of resistance to anti-cancer agents (Abulafi and Williams 1994). The 
results of ART and DHA in a wound healing/migration assay and their ability to alter 
MMP-2 and MMP-9 expression levels indicate that ART and DHA might inhibit 
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migration and invasion of HT-29-AK cells in our study. Therefore, it was of interest to 
further determine the effect of the drugs on HT-29-AK cells capacity to re-grow. The 
initial treatment of HT-29-AK cells with either ART (at 7.22, 14.44, 28.88µM) or DHA 
(at 9.88, 19.75 and 39.50µM) for 72h showed a concentration-dependent growth-
inhibition by the agents (figure 34). After washing the cells following 72h incubation, 
the ability of ART and DHA to inhibit the re-growth of cells was noticed, with the most 
prominent inhibition observed with the highest concentrations of ART (28.88µM) and 
DHA (39.50µM) (figure 34).  For comparison purposes, similar experiments with ART 
and DHA were performed for HL-60 cells (figure 35). We observed that none of ART 
and DHA treated HL-60 cells were able to re-grow to the levels observed in control 
samples (figure 35). The re-growth inhibition abilities of ART and DHA were more 
marked in HL-60 cells as compared to HT-29-AK cells (figure 34 vs. figure 35), with 
the exact molecular mechanisms of these observations required to be further 
determined. The results indicate a promising potential of ART and DHA to inhibit 
cancer cell re-growth, thus contributing to better therapeutic effects in patients 
through decreasing the risk of cancer re-currence and the development of 
resistance.  
6.6. ART and DHA to modulate VEGF-α and HIF-1α levels 
Angiogenesis, a process of new blood vessel formation is associated with 
uncontrolled tumour growth, metastasis and cancer cell resistance to anti-cancer 
agents (Zhou et al. 2007; Mohammadi-Motlagh et al. 2010; Schneider et al. 2011). 
The secretion of the main cancer pro-angiogenic factor VEGF-α and cytokines is 
enhanced during angiogenesis and occurs via multiple processes, including hypoxia-
mediated activation of HIF-1α (Duffy et al. 2003). There is evidence that ART and 
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DHA inhibit two main pro-angiogenic factors VEGF-α and HIF-1α in several cancer 
cell lines (Anfosso et al. 2006; Huang et al. 2007; Zhou et al. 2007; Aung et al. 2011; 
Wang et al. 2011). In normoxic conditions of the present study, ART-treated HT-29-
AK cells for 24h resulted in a significant (P<0.001) increase of VEGF-α mRNA levels 
with concomitant decrease of VEGF-α mRNA levels observed after 72h (figure 40 A 
and B). The measurement of VEGF-α165 secretion levels from collected media after 
ART treatment for 72h showed decrease in its expression with the lowest ART 
concentration of 7.22µM and the highest 28.88µM while unchanged levels with 
14.44µM ART (figure 40 C). The VEGF-α165 secretion levels were decreasing with 
increasing concentrations of DHA (at 58.02µM and 116.04µM) following treatment 
for 24h and decreased with DHA treatment (at 9.88µM, 19.75µM and 39.50µM) for 
72h when compared to their respective controls (figure 41). The secretion levels of 
VEGF-α165 were also measured in HL-60 cells, where DHA treatment for 24h 
showed no change in VEGF-α165 levels in all sample treated and un-treated cells 
whereas decreased secretion levels of VEGF-α165 were measured for DHA and 
ART treated HL-60 cells for 72h (figure 41). Despite of some limitations of these 
studies, including not enough repeats to allow statistical analysis we can conclude 
that ART and DHA show the ability to decrease VEGF-α levels. Thus, the results 
might indicate a crucial role of ART and DHA in angiogenesis inhibition but further 
experiments are needed to clarify the exact mechanisms of their effects. 
Hypoxia has been reported to be a major stimulus for the up-regulation of VEGF-α 
and HIF-1α (Ankoma-Sey et al. 2000; Hendriksen et al. 2009). In addition, 
knockdown of HIF-1α or survivin in the ovarian cancer cell lines suppressed VEGF-α 
expression, thus showing the correlation between VEGF-α expression and other 
proteins (Huang et al. 2008). Under hypoxic conditions in the present study, ART- 
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and DHA-treated HL-60 and HT-29-AK cells for 72h had variable effects on VEGF-α 
which were specific for the drug used and cell line tested (figures 66 and 67). The 
secretion levels of VEGF-α165 were similar to those obtained in normoxia, suggesting 
that the anti-cancer effects of ART and DHA towards VEGF-α165 are not affected by 
hypoxic microenvironment (figures 40-42 vs. figures 64 and 65).   
Previous studies have shown that DHA (5-25µM) inhibited the expression of HIF-1α 
in rat C6 glioma cells (Huang et al. 2007). Similar observations with the ability of 
artesunate and artemisinin to inhibit HIF-1α  were reported in human rheumatoid 
arthritis fibroblast-like syniviocytes and in mouse embryonic stem cell-derived 
embryoid bodies, respectively (Wartenberg et al. 2003; He et al. 2011). More 
recently Ba et al. (2012) demonstrated that the treatment with DHA (0-25µM) for 24h 
or with 25µM DHA for different times from 0h to 24h increased HIF-1α levels in a 
human hepatoma HepG2 cancer cell line.The aim of our further investigations was to 
investigate the effect of ART and DHA on HIF-α mRNA and intracellular protein 
levels in both cell lines. Due to time and resources limitations, the studies were 
performed under normoxic conditions only. ART-treated HT-29-AK cells for 24h 
showed increased HIF-α mRNA at all concentrations tested (at 82.53µM, 165.06µM 
and 330.12µM) while 72h incubation resulted in a concentration-dependent 
significant (p<0.001) decrease of HIF-α mRNA (figure 43 A and B). At protein level, 
investigated using flow cytometric analysis, ART-treated cells for 72h resulted in 
decreasing levels of HIF-α with increasing concentrations of ART (at 7.22µM, 
14.44µM and 28.88µM) (figure 43 C). These results indicate that ART effect on 
mRNA HIF-α expression levels is time-dependent and can be modulated post-
transcriptionally. Variable results for HIF-α mRNA levels between 24h and 72h 
incubation together with variations in HIF-α protein expression were observed for 
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ART against HL-60 cells and for DHA against HT-29-AK and HL-60 cells (figures 44, 
44 and 46). The molecular mechanisms responsible for the different expression of 
HIF-α in cancer cells are unknown and need to be better clarify.  
The observed changes in HIF-1α expressions upon ART and DHA treatments 
resulted in further investigations of CA-9, another hypoxia marker directly regulated 
by HIF-1α (Li et al. 2014). In squamous cell head and neck SSCHNC cancer cells, 
CA-9 had strong membrane and cytoplasmic expression (26.6%) seen mainly in 
areas of focal necrosis and was related with resistance to radiotherapy (Koukourakis 
et al. 2001). Here, it was observed that  CA-9 protein localisation in all  ART and 
DHA untreated and treated cells for both time points was membranous, without signs 
of mislocalisation to cytoplasm and without changes in CA-9 intensity (figure 47). 
The findings indicate the lack of impact of ART and DHA on CA-9 protein localisation 
in HT-29-AK cells (figure 47). It would be beneficial to investigate CA-9 at mRNA and 
protein levels stimulatenously to determine any potential variations in their levels and 
to compare these effects to CA-9 main regulator, HIF-1α. 
6.7. ART and DHA modulate the expression of proteins which are responsible 
for caspase-dependent cell death 
Protection against apoptosis is a key mechanism implicated in malignant 
transformation by enhanced cell survival, avoidance of immune surveillance and 
development of resistance to chemotherapeutic agents (Yang et al. 2001; Hector 
and Prehn 2009).  Akt plays a pivotal role in apoptosis inhibition by promoting 
malignant cell survival, proliferation and angiogenesis through a number of 
downstream effectors (Bortul et al. 2003; Altomare and Testa 2005; Stegeman et al. 
2012). ART in human cervical carcinoma cells and DHA in human prostate cancer 
cells have been shown to enhance TRAIL- mediated apoptosis through inhibition of 
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the NF-κB and PI3K/Akt signaling pathways (He et al. 2010; Thanaketpaisarn et al. 
2011). These events were accompanied by inhibition of pro-survival proteins, such 
as survivin, XIAP, and Bcl-XL (Thanaketpaisarn et al. 2011). In human rheumatoid 
arthritis fibroblast–like synoviocytes, ART inhibited the PI3K/Akt activation and 
secretion of VEGF and IL-8 which were stimulated in synoviocytes by TNF-α or 
hypoxia (He et al. 2011). The observations of He and collegues (2011) demonstrated 
that ART has the ability to inhibit the expression of angiogenic factors in 
synoviocytes which could represent promising therapeutic approach for Rheumatoid 
arthritis. 
In this study, incubation of HT-29-AK cells with DHA for the first 24h resulted in a 
transient, concentration-dependent increase in protein levels of anti-apoptotic 
phospho-Akt concentrations followed by a concentration-dependent decrease in 
phospho-Akt after 72h (figure 53). In contrast, HT-29-AK cells treated with ART for 
72h resulted in a concentration-dependent increase in phospho-Akt levels (figure 
52). We also noted  increasing proteins levels of phosho-Akt upon ART and DHA 
treatment for 72h of HL-60 cells which stand  in contrast with majority of  previous 
reports (figure 54) (Ma et al. 2011; Thanaketpaisarn et al. 2011; Kim et al. 2015). It 
suggests that the compounds may activate other pathways implicated in inhibition of 
apoptosis. These observations are important from clinical point of view, as even 
short activation of phospho-Akt may be associated with enhanced inflammatory 
responses and induction of resistance to chemotherapy (Bortul et al. 2003; Wang et 
al. 2013). Further studies of ART and DHA alone and in the presence of allosteric 
Akt inhibitors may clarify the effects of the drugs on phospho-Akt levels. Up-
regulated levels of Akt were reported in ART and DHA-treated HT-29-AK cells in 
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hypoxia, thus indicating similar profiles of activities of compounds in both conditions 
(figure 70).  
To investigate the mechanistic basis of anti-cancer effects of ART and DHA, a 
suppressor of apoptosis, survivin protein was evaluated (Shin et al. 2001; Ye et al. 
2014). Previous studies have shown that 1,2,4-trioxanes induce apoptosis by 
causing significant decreases in cellular survivin levels (Mu et al. 2007; Shao et al. 
2008). Here, the cellular levels of survivin measured upon drug treatment were 
dependent on the incubation length and cell line-specific (figures 48-50). Survivin 
expression can be regulated by several stimuli, such as Akt, HIF-α, IL-6 and IL-4 
(through activation of the STAT-6 signaling pathway). For HT-29-AK cells treated 
with ART, we noted decreasing levels of survivin at the level of mRNA with the 
length of incubation (24h vs. 72h) while protein levels also showed decreasing trend 
after 72h, suggesting that post-transcriptionally survivin is not affected significantly 
by other mediators (figure 48). In contrast, DHA-treated HT-29-AK cells showed 
increasing expressions of survivin mRNA with prolonged incubations (24h vs. 72h) 
whereas protein levels measured by ELISA showed concentration-dependent 
decrease in survivin, indicating that survivin is modulated post-transcriptionally 
(figure 50). For comparison purposes, studies of ART against HL-60 cells 
demonstrated decreasing mRNA levels of survivin with longer incubation (24h vs. 
72h) while at protein survivin levels were unchanged at all ART treatments (figure 
49). DHA-treated HL-60 cells for 24h had decreased survivin mRNA expressions as 
investigated by qPCR, whereas after 72h the levels of survivin mRNA were only low 
with the highest concentration of DHA at1.00µM (figure 49). ELISA analysis showed 
decreasing protein levels of survivin after treating HL-60 cells for 24 and 72h with 
DHA (figure 49). Further studies are needed to clarify the role of survivin and other 
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mediators of survivin in the cytotoxicity of ART and DHA against HL-60 and HT-29-
AK cells. 
Survivn levels in hypoxia upon treating the both cell lines with ART and DHA were 
variable and distinctive from those effects observed in normoxia (figures 67 and 68). 
The results might indicate the influence of low oxygen tension and presumable other 
mediators on the effects of ART and DHA in HL-60 and HT-29-AK cells (figures 67 
and 68). Data for the effects of ART and DHA in both cell lines under hypoxic 
conditions represent 2 independent experiments and requires additional repeats for 
statistical analysis (figures 68 and 69).  
There is ample data which suggest that 1,2,4-trioxanes exert their anti-tumour 
activities via apoptosis by its primary effecter  molecule, caspase-3 (Lu et al. 2008; 
Kong et al. 2012; Dong and Wang 2014; Zuo et al. 2014; Kim et al. 2015). These 
observations are consistent with our own data in which ART and DHA treatment for 
72h increased catalytically cleaved caspase-3 in HL-60 and HT-29-AK cells, 
suggesting that these agents promote cancer cell apoptosis (figures 55 and 56). 
These observations were accompanied by morphological changes observed in ART- 
and DHA-treated HT-29-AK cells under light microscope  showing characteristic cell 
shrinkage, blebbing and “a mass of cell debris”, being typical hallmarks of apoptosis 
(Coelho et al. 2000; Bestwick et al. 2006; Sanmartin et al. 2012). The DHA-induced 
caspase-3 production was consistent with elevated or concentration-dependent 
increased levels of BrdU-labelled nicks in DNA strands which are present in 
apoptotic cells only (figure 57 and 58). Together with the drug-induced increase in 
caspase-3 and BrdU-labelled DNA levels, there were accumulated DNA fragments in 
samples treated with the test agents upon separating the DNA on agarose gel 
electrophoresis as compared to respective controls (figures 59-61). The results have 
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not showed small DNA fragments or features of smear ladder as compared to 
previous studies (Li et al. 2009; Yang et al. 2009). This could be due to technical 
problem related with a too high the percentage of agarose gel resulting in inhibited 
separation of damaged DNA and this should be checked in the future.  
As in normoxia, cells treated for 72h with ART and DHA under low oxygen (1%) 
showed up-regulated secretions of caspase-3 (figures 71 and 72), suggesting that 
these agents promote cancer cell apoptosis even in hypoxia. DHA mediated 
caspase-3 secretion was consistent with elevated levels of BrdU-labelled nicks in 
DNA strands, which are present in apoptotic cells only (figure 73). Together with 
DHA-induced increased caspase-3 and BrdU-labelled DNA levels in HL-60 cells, 
there were observable presence of fragmented DNA in samples treated with DHA 
upon separating on agarose gel electrophoresis (figure 74), which is consistent with 
previous reports in normoxia but was not investigated previously in hypoxia (Li et al. 
2009; Yang et al. 2009).  
6.8. Conclusions and future studies 
Overall, despite of some limitations (e.g. small sample size, selection of DHA only for 
some experiments) the results of this study indicate that ART and DHA in standard 
normoxic experimental settings (20% O2) effectively induced a time-dependent 
growth inhibition in HL-60, HT-29-AK and Caco-2 cells. The importance of modelling 
tumour microenvironment in drug discovery and development is becoming more 
popular due to the potential benefits for cancer therapy through reducing the risk of 
chemo-resistance. Therefore, the cytotoxicity of ART and DHA was additionally 
investigated under low oxygen tension (1% O2) to mimic tumour hypoxia. Hypoxic 
environment reduced the susceptibility of the cells to ART and DHA, as compared to 
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normoxia. The anti-cancer activity of ART and DHA was iron-dependent in normoxia 
while low oxygen tension (1%) showed that ART and DHA against HL-60 cells was 
not exclusively dependent on their interaction with iron. Given the broad spectrum of 
mediators involved in ART and DHA anti-cancer effects showed from data collected,  
further studies are required to validate our observations and translate them into 
significance for cancer therapy. 
CHAPTER 7 
DISCUSSION 2 
Part 2: THE MOLECULAR BASIS OF THE ANTI-CANCER EFFECTS OF ART 
AND DHA COMBINED WITH ASA AGAINST HT-29-AK AND HL-60 CELLS IN 
NORMOXIA AND HYPOXIA 
7.1. Anti-cancer effects of ART and DHA (alone and in combination with ASA) 
against HL-60 and HT-29-AK cells under normoxic and hypoxic conditions 
This study investigated ART and DHA in combination with ASA, as a chemo-
sensitizing agent on the growth of human HT-29-AK colorectal and human HL-60 
leukaemic cancer cells. Specifically, we have shown that ART and DHA in 
combination with ASA had improved inhibitory effects on the growth in cultured 
cancer cells under normoxic (in ART and ASA combination) and hypoxic conditions. 
The combination regimen with ASA in HT-29-AK cells under normoxic conditions 
enhanced the caspase-3-dependent apoptotic effects of ART and DHA at least in 
part through down-regulation of tumour angiogenesis-stimulating growth factors, 
including survivin, HIF-1α and VEGF-α. 
Due to the anti-inflammatory properties of ASA, its ability to inhibit cancer cell growth 
and induce apoptosis, ASA has become an attractive agent to investigate in 
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combination with currently used chemo-therapeutic compounds (Bellosillo et al. 
1998; Gao et al. 2004; Pathi et al. 2012; Li et al. 2013). It was reported previously 
that ASA successfully potentiated the inhibitory effects of troglitazone (aYan et al. 
2010), doxorubicin (Hossain et al. 2012), cisplatin (Kumar and Singh 2012), valproic 
acid (Li et al. 2013) and reversine (Qin et al. 2013) in cancer cells. ART and DHA 
have shown to enhance anti-cancer effect of several anti-cancer compounds in 
cultured cells (including cisplatin-resistant ovarian cancer cells and doxorubicin-
resistant T leukaemia cells) and carcinoma xenografts (Efferth et al. 2007; Wang et 
al. 2010; Liu and Cui 2013; Zhang et al. 2013; Feng et al. 2014). Because the 
primary mechanisms of action of 1,2,4-trioxanes (ART, DHA, artemisinin) and ASA 
are linked with the inhibition of crucial cell signaling factors, including survivin, COX-
2, HIF-1α and VEGF-α involved in angiogenesis and the induction of apoptosis 
through similar intermediates (caspase-3), it was hypothesized that ASA would 
enhance the cytotoxic effects of ART and DHA. 
Before investigating ASA in combination with ART and DHA our first studies aimed 
to evaluate the effects of ASA under normoxic and hypoxic conditions in HL-60 and 
HT-29-AK cells to allow determination of ASA fixed concentrations which were used 
in further experimental settings. In initial normoxic (20% O2) studies, it was found 
that ASA inhibited the growth of HL-60 and HT-29-AK cells in a time-dependent 
manner (table 8). These results are consistent with the observations previously 
reported in several other cancers in vitro, including B-cell chronic lymphocytic human 
leukaemic cells (Bellosillo et al. 1998), human colon cancer SW480, RKO, HT-29, 
and HCT116 cell lines (Zhou et al. 2011; Pathi et al. 2012), YD8 human oral 
squamous cancer cells (Park et al. 2010), human HeLa and mouse U14 cervical 
carcinoma (Qin et al. 2013). The mean ASA IC50 values determined by Bellosillo et 
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al. (1998) in leukaemic cells under 48h were in the range between 4.4 and 7.3mM/L 
and were comparable to ASA IC50 value of 3.12 ± 0.46mM calculated in our study 
when treating HL-60 cells for 48h (table 8). The ASA IC50 value after 72h in present 
study was 2.50 ± 0.18mM and was within the range of effective concentrations of 
ASA against leukaemic cancer cells reported previously (Bellosillo et al. 1998). In 
cultured HT-29-AK cells, the inhibitory effect of ASA observed in present 
investigation was also time-dependent, resulting in IC50 values as follow:  21.35 ± 
2.12mM, 13.25 ± 0.79mM and 6.15 ± 0.83mM after 24, 48 and 72h incubations, 
respectively (table 8). ASA IC50 value of 6.15 ± 0.83mM was similar with IC50 values 
observed upon ASA treatment of 4 colon cancer cell lines (SW480, RKO, HT-29, and 
HCT116) for 72h with resulted IC50 values ranging from 2.5mM to 5mM in all cell 
lines (Pathi et al. 2012).  
In previous chapters we have shown the importance of the oxygen concentration in 
ART- and DHA-mediated cytotoxicity (table 3 vs. table 6). Therefore, we further 
investigated the effect of low oxygen levels (1%) on ASA-mediated anti-cancer 
effects in both cell lines. HL-60 and HT-29-AK cells were less susceptible to ASA 
under each time point tested (24, 48h and 72h) in hypoxia as compared to respective 
time points in normoxia (table 8). Interestingly, HL-60 cells were far less sensitive to 
ASA in hypoxia as compared to HT-29-AK cells (ASA HL-60 cells IC50 values of 
>60mM at 24 and 48h; and 22.05 ± 2.7mM at 72h; ASA HT-29-AK cells IC50 values 
of 31.95 ± 2.59mM, 17.73 ± 1.63mM and 8.47 ± 2.18mM after 24, 48 and 72h, 
respectively; figure 8). The findings are unexpected in view of the fact that in 
previous our studies, ART and DHA were more cytotoxic towards HL-60 cells in both 
normoxic and hypoxic conditions as compared to HT-29-AK cells (reduced sensitivity 
of cells in hypoxia). These discrepancies might arise from different contribution of 
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hypoxic signaling mediators on ASA-mediated cytotoxicity in cancer cells of different 
line and cell state (suspension vs. attached cells).  
We further wished to determine whether ASA fixed concentrations derived for HL-60 
cells (normoxia: 2.50mM) and HT-29-AK cells (normoxia: 6.25mM; hypoxia: 8.47mM) 
after 72h can synergistically enhance anti-cancer effects of ART and DHA. We have 
chosen these fixed ASA concentrations after 72h for two reasons. First, they are 
most potent against each cell line and secondly, there are in the range of ASA serum 
concentrations achievable in humans, thus being most practical for therapeutic use 
(Juárez et al. 2004). Because ASA IC50 concentration of 22.05mM derived from 
hypoxia in HL-60 cells at 72h was resulting in dead of all cells during MTT 
experiments (data not shown), we decided to use 1/10 of this concentration equal to 
2.21mM. MTT combination studies demonstrated a synergistic interaction between 
fixed concentration of ASA (2.50mM) when co-treated with ART but not with DHA in 
HL-60 cells under normoxic conditions (ASA+ART IC50 value of 0.48 ± 0.02µM vs. 
ART alone with IC50 of 0.59 ± 0.08µM, P<0.001; ASA+DHA IC50 value of 0.49 ± 
0.03µM vs. DHA alone with IC50 of 0.49 ± 0.04µM; table 9). Hypoxia enhanced the 
cytotoxicity of ART and DHA in HL-60 cells when combined with ASA (2.21mM) but 
there was not enough repeats to perform statistical analyses (ASA+ART IC50 value 
of 0.46mM vs. ART alone with IC50 of 0.51 ± 0.06mM; ASA+DHA IC50 value of 
0.23mM vs. DHA alone with IC50 of 0.53 ± 0.07mM; table 10). ASA (6.15mM) in 
normoxia significantly (P<0.001) enhanced the cytotoxic effects of ART and DHA on 
the inhibition of CRC growth and proliferation (ASA+ART IC50 value of 6.67 ± 1.73µM 
vs. ART alone with IC50 of 14.44 ± 2.64µM; ASA+DHA IC50 value of 5.93 ± 0.58µM 
vs. DHA alone with IC50 of 19.75 ± 1.07µM; table 9). However, even greater 
enhancement of ART and DHA-mediated anti-cancer effects when combined with 
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ASA was seen in hypoxic microenvironment, suggesting high selectivity of 
combination regimen towards hypoxic cells (ASA+ART IC50 value of 1.63 ± 0.50µM 
vs. ART alone with IC50 of 46.51 ± 4.74µM; ASA+DHA IC50 value of 7.90 ± 0.99µM 
vs. DHA alone with IC50 of 27.10 ± 12.73µM; P<0.001; table 10). This data indicate 
that ART and DHA combination with ASA could reverse decreased susceptibility of 
cells under hypoxic conditions to ART and DHA alone. Thus, ART and DHA in 
combination with ASA might be an effective combination regimen to enhance 
efficacy of chemotherapy in cancer cells. Due to time and resources limitations 
further studies were concentrated on possible mechanisms of action of ART and 
DHA combined with ASA under normoxic conditions.  
A pleiotropic enzyme COX-2 belongs to the COX membrane-bound haemo- and 
glycol-proteins family (COX-1, COX-2 and COX-3 isoforms) (Thun et al. 2002; 
Grrenhough et al. 2009). COX-2 is implicated in carcinogenesis by promoting the 
proliferation, survival, angiogenesis, migration and the invasiveness of malignant 
cells (Thun et al. 2002; Grrenhough et al. 2009). The mechanisms of action 
responsible for the inhibitory effects of ASA on cancer cells, including colorectal 
carcinoma is reported to stem in part from its ability to directly suppress the 
expression of COX-1 and COX-2 enzymes (Thun et al. 2002; Vane and Botting 2003; 
Weiss et al. 2006; Yoo and Lee 2007; Rahman et al. 2012; aCho et al. 2013). In 
addition, it has been reported by others (Wang et al. 2011; Zuo et al. 2014; Zhang et 
al. 2015) and us (figure 17) that ART and DHA decrease COX-2 expression in 
cancers. Therefore, we hypothesized that ART and DHA combination with ASA 
would synergistically decrease COX-2 protein expression in HT-29-AK cells. In 
contrast, it was observed using flow cytometric analyses that COX-2 levels in all 
single drug treatments were increased, with the highest changes observed when 
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cells were treated with ART and DHA combined to ASA (figure 75). This suggests 
that the anti-cancer mechanisms of ART and DHA combinations with ASA are 
independent of COX-2 inhibition. Our observations are consistent with some other 
ASA studies, including in B-cell chronic lymphocytic leukaemic cells, colon cancer 
cells and COX-null mouse embryo fibroblasts where ASA-dependent inhibitory and 
apoptotic effects were postulated to be COX-independent (Hanif et al. 1996; 
Bellosillo et al. 1998; Zhang et al. 1999). aCho et al. 2013 indicated important 
function of COX-1 in carcinogenesis, therefore we cannot rule out possibility that 
enhanced cytotoxicity effects of ART and DHA when combined with ASA are 
mediated through down-regulation of COX-1 isoform which require further 
investigations. Considering the mechanisms of the drugs combinations inhibitory 
effects cannot be explained by COX-2 protein expression, we decided to investigate 
survivin mRNA levels.  
Previous studies showed that 1,2,4-trioxanes-induced apoptosis in single drug 
treatments was accompanied by a significant decrease or loss in a key apoptosis 
inhibitor survivin protein or mRNA levels (Shao et al. 2008; Odaka et al. 2014; Kim et 
al. 2015).  In human myeloid leukaemic KBM-5 cells investigated by Kim et al. 2015, 
combination of ART (10µM) with doxorubicin (30µM), paclitaxel (1.50nM) and 
docetaxel (1.50nM) for 24h potentiated the inhibitory effect in survivin down-
regulation in these cells more effectively as compared to single agents. The anti-
cancer effects of ASA (alone or in combination) were also reported to be associated 
with survivin mRNA and protein levels down-regulation (Yang et al. 2011; Li et al. 
2013; Dong et al. 2014). Combination of ASA (3mM/l) with cisplatin (10µg/ml) was  
reported in gastric SGC7901/cisplatin cell cultures to significantly reduce mRNA and 
protein levels of survivin when compared to ASA (3mM/l) or cisplatin (10µg/ml) alone 
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(Dong et al. 2014). In the current study, ASA combination with ART resulted in a 
marked increase of survivin mRNA levels as compared to single drugs (figure 76). 
However, ASA was shown to markedly decrease survivin mRNA levels in HT-29-AK 
cells when combined with DHA (figure 76). Survivin down-regulation of ASA and 
DHA combination was further confirmed in preliminary ELISA cellular survivin levels 
(data not shown) but repetition of experiments is necessary to allow statistical 
analysis. Our observations indicate that synergistic effect of ART and DHA with ASA 
on colon cancer inhibition might be drug specific were different mechanistic 
mechanisms are involved. It can be postulated that survivin over-expression in ART 
and ASA combination might contribute to the development of drug resistance and/or 
the inhibition of cell sensitivity towards drug treatment. In contrast, combined 
treatment with DHA and ASA resulting in survivin down-regulation might inhibit the 
process of angiogenesis more effectively and enhance cell sensitivity towards drug 
combination, thus reducing the risk of chemo-resistance. It is possible that 
combination of ART and ASA which resulted in increased of survivin mRNA is linked 
with lower fold difference in inhibitory effects against HT-29-AK cells, as compared to 
inhibitory effects of DHA co-treatment with ASA and their respective single agents 
(ART IC50 value of 14.44  ± 2.64µM vs. ART combined with ASA IC50 value of 6.67  ± 
1.73µM, 2.16-fold enhancement; DHA IC50 value of 19.75  ± 1.07µM vs. DHA 
combined with ASA IC50 value of 5.93 ± 0.58µM, 3.33-fold enhancement; table 9).  
Survivin down-regulation as a strategy to increase the cytotoxic effects of 
chemotharapy agents was evidenced by Ghanbari et al. (2014). Ghanbari et al. 
(2014) showed that combination of docetaxel with vinblasite lowered the expression 
of survivin and decreased the IC50 value of docetaxel (from 70 to 5nM; P<0.05). 
However, similar studies of docetaxel with vinblasite combination in the presence of 
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survivin inhibitor deguelin resulted in significant (P<0.05) enhancement in synergistic 
efficacy of docetaxel and vinblastine (Ghanbari et al. 2014). We can hypothesize that 
the enhancement of sensitivity of HT-29-AK cells by ASA and DHA combination 
therapy and down-regulation of the same cellular pathway mediator survivin 
simultaneously is resulting in drugs synergistic cytotoxic effects, therefore better anti-
cancer efficacy and higher target selectivity. The enhanced therapeutic effects and 
selectivity of the artemisinins would lead to lower concentrations of drugs used 
clinically and decrease potential side effects in humans. Furthermore, highly effective 
and selective drug combinations could be used against already resistant cancer cells 
lines for superior clinical outcome and prolonging survival times for patients with 
colorectal cancer. Further studies using survivin inhibitors could help to confirm this 
hypothesis.  
HIF-1 is a heterodimeric transcription factor which has been demonstrated to play an 
important role in promoting the expression of pro-angiogenesis and pro-resistance 
proteins in carcinogenesis (Tacchini et al. 1999; Švastová et al. 2003; Jeong et al. 
2005; aCho et al. 2013; Chen et al. 2014; Li et al. 2014). Therefore, the inhibition of 
this protein by chemotherapeutic agents alone or in combinations is an attractive 
therapeutic approach. A number of preclinical reports in cancer cells, such as rat C6 
glioma cells treated with DHA (5-25µM) (Huang et al. 2007) and non-cancer settings 
(Wartenberg et al. 2003; He et al. 2011) have shown that the 1,2,4-trioxanes inhibit   
HIF-1α expression. There are also some reports showing induction of HIF-1α in 
cancers, including human hepatoma cell line HepG2 treated with DHA (0-25µM) for 
24h or with 25µM DHA for different times from 0h to 24h (Ba et al. 2012). Our 
previous experiments showed that the effects of ART and DHA on HIF-1α were 
linked with used compound and cancer type (human leukaemic HL-60 cells vs. 
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human colorectal HT-29-AK cells) (figures 43-46). Other factors were associated 
with investigated target (mRNA or protein levels) and incubation time (24h vs. 72h) 
(figures 43-46). In current study, it has been reported that mRNA HIF-1α levels in 
ASA and ART-treated samples were decreased whereas in DHA-treated samples 
were unchanged as compared to control (figure 77). The pronounced down-
regulation of mRNA HIF-1α levels was observed in ART and DHA combination with 
ASA, suggesting synergistic effect of drugs to be due to inhibition of HIF-1α levels 
(figure 77). This data further suggest that by combining ASA with ART or DHA we 
can enhance the inhibition of drug resistance and angiogenesis of HT-29-AK cells 
more effectively as compared with single agents and achieve better efficacy of 
chemotherapy in these cells.  
According to numerous studies, the VEGF family members and their receptors have 
shown to play various biological functions, including in vasculogenesis (Krusche et 
al. 2013), angiogenesis (Niki et al. 2000), metastasis and tumour survival 
(Jayasinghe et al. 2013).  The expression and concentration of soluble VEGFR-1 as 
investigated by a Western blot analysis and ELISA in samples of patients with CRC 
were significantly (P<0.001) increased as compared to those in controls (Abbasi et 
al. 2015). The observations of Abbasi et al. (2015) indicated soluble VEGFR-1 as a 
useful indicator of the malignant potential and tumour progression (Abbasi et al. 
2015). Especially, VEGF-α isoform has been demonstrated to have a crucial role in 
cancer metastasis through promoting angiogenesis (Niki et al. 2000).  Mechanistic 
studies on ASA (5 and 10mM) inhibitory effects against colon cancer cells (RKO, 
SW480, HT-29 and HCT-116) were reported to be associated with the down-
regulation of pro-angiogenic mediators VEGF-α and its receptor VEGFR1 (Pathi et 
al. 2012). Furthermore, ASA (100mg/kg, twice a day orally) administrated to male 
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mice injected with a solution containing Lewis lung carcinoma cells led to reduction 
in lung cancer metastasis to regional lymph nodes and significantly (P<0.0001)  
reduced mice mortality (Ogawa et al. 2014). There is much evidence that 1,2,4-
trioxanes  inhibit angiogenesis through VEGF-α suppression or decrease in cultured 
cancer cells and non-cancer studies in vitro; and in vivo using xenograft tumours 
(Wartenberg et al. 2003; Aung et al. 2011; Wang et al. 2011; Zhang et al. 2013). 
Zhang et al. (2013) demonstrated that a synergistic anti-proliferative effect in human 
lung carcinoma (A549 and A549/DDP cells) of DHA combined with cisplatin was 
attributed to reduced tumour microvessel density and suppression of angiogenesis-
related proteins HIF-1α and VEGF-α both in vitro and in vivo. Krusche et al. (2013) 
also demonstrated synergistic inhibition of angiogenesis by ART and captopril 
(angiotensin-I-converting enzyme inhibitor) of human umbilical vein endothelial cells 
(HUVEC) in vitro using wound healing assay and vascularisation processes in vivo 
using a chorioallantoic membrane (CAM) assay of quail embryos. In our study, 
examination of mRNA levels of VEGF-α in HT-29-AK cells showed down-regulation 
of their transcriptional stability upon combination of ART with ASA, as compared to 
ART alone, and significantly (P<0.05) as compared to control (figure 78). These 
results are further showing that ART and DHA-mediated synergistic effects in HT-29-
AK cells might be due to the inhibition of angiogenesis through down-regulation of 
VEGF-α mRNA levels. 
Previous studies showed that ART and DHA decreased the levels of phosho-Akt 
in cultured cancer cells and xenograft tumor model (He et al. 2010; Ma et al. 2011; 
Thanaketpaisarn et al. 2011; Lee et al. 2013; Odaka et al. 2014). aCho et al. 2013 
demonstrated that the inhibitory effect of ASA (1mM) on EGFR-activated cell viability 
in ovarian OVCAR-3 cancer cells was associated with blocking phospho-Akt and 
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phospho-Erk protein expressions. The phosphorylation of Akt in present study was 
showed to be up-regulated upon combination of ASA with ART and DHA in           
HT-29-AK cells (figure 79). Uddin et al. 2010 showed that clinically activated 
phospho-Akt was associated with over-expressed COX-2 levels and not linked with 
COX-1 in epithelial ovarian cancer (EOC). In vitro studies using EOC cells of Uddin 
and colleagues (2010), further showed that the inhibition of COX-2 using ASA 
selective inhibitor NS398 and gene silencing impaired phospho-Akt levels and 
resulted in cell growth inhibition and induction of apoptosis. These results might 
indicate link between COX-2 and phospho-Akt up-regulation observed in our study 
when combining ASA with ART and DHA. Future experiments with using COX-2 
selective inhibitor NS398 or gene silencing would clarify the signaling mechanisms 
involved in the up-regulation of phospho-Akt expression in our study.  
Key proteins involved in the process of apoptosis include caspases, where      
caspase-3 is an executor protein activated by extrinsic and intrinsic signaling 
cascades (Hector et al. 2009). Anti-cancer effects of ASA (alone or in combination) 
treatment regimen has been reported to be attributed with the activation of caspase-
dependent apoptosis, especially caspases-3,7,8 and 9 (Gao et al. 2004; Hossain et 
al. 2012; Pathi et al. 2012; Li et al. 2013; Qin et al. 2013; Thakkar et al. 2013). 
Similarly, ART and DHA-induced apoptosis (alone and in combination with other 
chemotherapeutic agents) against cell lines, including colorectal and leukaemia cells 
is reported with intrinsic and extrinsic dependent activation of caspases (Jiang et al. 
2013; Liu and Cui 2013; Feng et al. 2014; Wang et al. 2014; Zhang et al. 2015). 
Here, studies using flow cytometic analyses (figure 80 and 81) showed that ASA co-
treatment significantly enhanced caspase-3-dependent apoptotic effect of ART and 
DHA in cultured leukaemic HL-60 and colorectal HT-29-AK cells in vitro as compared 
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to monotherapy drugs effect. The findings further support our previous results of the 
drugs combinatorial synergistic effects in cancer cells.  
7.2. Conclusions and future directions 
In conclusion, we presented evidence showing better anti-cancer activity of ART and 
DHA when combined with ASA against HT-29-AK cells under normoxic and hypoxic 
conditions in vitro. The inhibitory effect of combination treatments against HL-60 cells 
was improved in normoxia (in ART and ASA combination) but hypoxic 
microenvironment was showed to enhance the efficacy of ART and DHA when 
combined with ASA. However, more repeats are needed to perform statistical 
analyses for ART and DHA combined with ASA against HL-60 cells in hypoxia. As 
presented in simplified diagram of drugs combinations mechanisms of action     
(figure 82), we found that synergistic activity of combinations in colorectal cancer HT-
29-AK cells was COX-2 independent and potentially correlated with up-regulation of 
survivin mRNA (in ART and ASA combination) and phospho-Akt protein expressions, 
which might unfavourably decrease combinational cytotoxicity effects. Most 
importantly, we observed combination treatments efficacy in HT-29-AK cells to be 
associated with enhanced anti-angiogenic effects in HT-29-AK cells via survivin (in 
DHA and ASA combination), HIF-1α, and VEGF-α (in ART and ASA combination) 
inhibition as well as the induction of caspase-3-dependent apoptosis (figure 82). 
Therefore, by inhibiting cancer cell growth, restricting angiogenesis and promoting 
apoptosis of HT-29-AK cells, ART and DHA combination with ASA may potentially 
be of great value in the treatment of CRC. MTT cytotoxicity assay showed that the 
cytotoxicity of DHA in combination with ASA against HL-60 cells was not enhanced 
under normoxic conditions (table 9). However, there was a significant enhancement 
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in the production of caspase-3 in HL-60 cells when DHA was combined with ASA in 
normoxia (figure 81). The mechanisms involved are not clear and further 
investigations are needed. Other future studies might include investigation of the 
effect of combinations on mediators implicated in angiogenesis, migration and 
invasion in both cell lines. Additional cancer cell lines to study the effects of ART and 
DHA in combination with ASA under normoxic and hypoxic conditions would 
increase further the understanding of their effects. These studies should be 
performed to clearly answer the question whether the effects of these combinations 
are at pre- or post-transcriptional level. Determination of mechanistic basis of the 
combined treatments on the tumour inhibition, metastasis and vasculogenesis in vivo 
experiments in rodents is also needed.  
  





Figure 82: The proposed shema of the mechanisms of action of ART and DHA 
combined with  ASA in induced apostosis in human colorectal HT-29-AK 
cancer cells under normoxic conditions. Symbol     means decrease and the          
arrow    means increase. 
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